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Abstract 
Critically ill patients often require mechanical ventilation (MV) to facilitate 
treatment for respiratory failure or airway protection when consciousness is 
impaired. Whilst the endotracheal tube (ETT) is an essential interface 
between the patient and ventilator, it may promote VAP by impeding host 
defence mechanisms and by translocating microorganisms from dental 
plaque to the lower airways. Ventilator-associated pneumonia (VAP), which 
may be challenging to diagnose, is the most frequent hospital-acquired 
infection in critical care. It has been reported that when patients receive MV 
the composition of dental plaque changes to include respiratory pathogens 
such as Meticillin-Resistant Staphylococcus aureus (MRSA) and 
Pseudomonas aeruginosa. 
 
The primary aim of this research was to confirm that dental plaque 
communities altered during MV and to identify the potential causes of these 
changes. A combination of culture-based microbiology, community profiling 
molecular techniques and proteomic analysis of saliva was performed to 
analyse the microbiological content of the oral cavity, and to also quantify 
changes in dental plaque composition and saliva.  
 
For the first time, this study comprehensively analysed the dental plaque of 
mechanically ventilated patients and documented considerable species 
richness and diversity. Numerous potential respiratory pathogens were 
detected including Staphylococcus aureus, P. aeruginosa and Streptococcus 
pneumoniae in approximately one-third of mechanically ventilated patients. In 
addition, salivary flow rate was decreased and both the salivary pH and 
concentration of pro-inflammatory cytokines were significantly elevated 
during intubation.  
 
Dental plaque is a reservoir for VAP, and preventing or reducing respiratory 
colonisation may play a role in the management of ventilated patients. 
Interventions to prevent colonisation could include the modulation of salivary 
parameters such as pH and volume and further work may lead to the 
identification of specific proteins that are significant.  Reducing the incidence 
of VAP will not only reduce mortality in the ICU, but will also have a great 
impact on hospital economics by reducing inpatient stay. 
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Chapter 1 
Literature review 
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1.1 The role of oral microbiome in systemic infection 
The oral microbiome, the community of microorganisms and associated 
genetic material in the oral cavity, is extremely diverse with over 1000 
microbial species currently identified (Wade, 2013a; Wade 2013b). Previous 
research has shown systemic infections can originate from microorganisms 
frequently isolated from the oral cavity (Yip & Smales, 2012).  Infection 
mediated by oral microorganisms may occur once the number of potentially 
pathogenic bacteria increases to a level that can cause damage either to the 
tooth (e.g. dental caries), local tissues (e.g. periodontal disease) or distant 
sites (pneumonia or endocarditis), as highlighted in table 1.1 (Gomes-Filho et 
al., 2010).  
	
Table 1.1 – The association between oral microorganisms and systemic 
infections (Desvarieux, 2005; Ohara-Nemoto et al., 2008; Lockhart et al., 
2009; Gomes-Filho et al., 2010; Preshaw et al., 2012; Welte et al., 2012). 
 
Systemic infection Association with oral microbiota 
  Community-acquired 
pneumonia 
Periodontal pathogens: Porphyromonas gingivalis, 
Fusobacterium nucleatum, Prevotella oralis 
  Hospital-acquired 
pneumonia 
Periodontal pathogens: Porphyromonas gingivalis, 
Fusobacterium nucleatum, Prevotella oralis 
  
Diabetes 
Oral anaerobic community can influence glycaemic 
control, diabetes increases risk of periodontitis  
  Cardiac atherosclerosis Correlation with oral infection and intimal thickening 
  Infective endocarditis Gingivitis and periodontitis inflammation, dental procedures and toothbrushing - route of entry for 
 
 Streptococcus mutans and Streptococcus mitis 
bacteraemia, staphylococci (oral and nasal origin) 
  Pre-term birth and low 
weight birth 
 
High abundance of Porphyromonas gingivalis, 
Prevotella intermedia and Tannerella forsythia 
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The oral cavity represents a primary route of entry for microorganisms into 
the body and harbours microorganisms that can consequently translocate to 
other areas of the body. It should not be a surprise, given the contiguity of 
the aerodigestive tract, that bacteria within the oral cavity have been 
associated with pneumonia in individuals in community, nursing home, 
hospital or critical care settings. Dental pain or the wearing of a dental 
prosthesis have been identified as risk factors for community-acquired 
pneumonia (CAP) (Almirall et al., 2008). Community-acquired pneumonia 
(CAP) is defined as an acute infection of the lung occurring in an individual 
anywhere in the community (Raghavendran et al., 2000).  A study by 
Rodriguez et al., 2014 enrolling 1,336 individuals with CAP and 1,326 cases 
of control, related the onset of CAP with oral health parameters (Rodriguez et 
al., 2014). In the CAP group, there was a significantly higher prevalence of 
dental dysaesthesia and the use of dental prosthesis. Further analysis within 
their study also revealed that a recent visit to the dentist (within the last 
month) was seen as a preventative measure for CAP.  
 
1.2 Ventilator-associated pneumonia (VAP) 
1.2.1. VAP prevalence 
Critically ill patients often require mechanical ventilation (MV), to treat 
respiratory failure or protect the airway where conscious level is impaired. An 
endotracheal tube (ETT) facilitates the flow of gases from the ventilator to the 
lower airways, providing adequate gaseous exchange. However, whilst the 
ETT is an essential conduit between patient and ventilator, the placement of 
the ETT has been suggested to be a key factor in the development of 
ventilator-associated pneumonia (VAP) (Gibbs & Holzman, 2012). The 
placement of the ETT can impair the cough reflex, allow the pooling of 
secretions (contaminated with bacteria), and provides a surface for biofilm 
formation. VAP is a hospital-acquired infection (HAI) with reported incidences 
of up to 67% (Joseph et al., 2010). Recent studies suggesting the global 
incidence of VAP is 15% of mechanically ventilated patients (Kollef, 2015) 
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and attributed mortality rates are reported to be between 33-50% of cases 
(Nicasio et al., 2010). VAP is a bacterial pneumonia developing 48 h after 
intubation (Lin et al., 2013) and is the most prevalent HAI in critical care units 
(Joseph et al., 2010; Raad et al., 2011). There is some dispute as to the 
precise definition of VAP, and this leads to challenges in accurate diagnosis 
(Klompas et al., 2012). Correspondingly, the lack of standardisation of 
diagnosis can make the study of the effects of interventions difficult (Tejerina 
et al., 2010). Previous studies investigating prevalence rates of VAP in 
critical care units have highlighted the difficulties in diagnosing VAP, many 
features of VAP have other causes which are common in critical illness (e.g. 
fever, abnormal radiographs) (Grap et al., 2011). Given these issues, VAP 
prevalence rates from as low as 5% to as high as 67% have been reported 
(Brennan et al., 2004; Sundar et al., 2012). Guidelines have been generated 
to facilitate the reporting of VAP cases (NHSN, 2015). Reporting VAP, 
especially in the US, has been affected by remuneration. Cases were subject 
to extra billing as VAP is seen as an avoidable infection, which has 
undoubtedly affected reporting incidences. Although studies have shown 
large differences in VAP rates in intensive care units (ICUs), it is well 
established that pneumonia in the context of mechanical ventilation 
contributes significantly to the rates of HAIs. A number of risk factors have 
been associated with VAP development (Figure 1.1).  
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Figure 1.1 – Several factors associated with the development of VAP a; ETT 
b; lower airways compromised, c; aerosols, d; equipment used in critical care 
medicine, e; transference of organisms from biotic and abiotic sites (Joseph 
et al., 2010). 
1.3 The Oral microbiota  	
1.3.1 Composition of the oral cavity  
The oral cavity supports a diverse array of microorganisms with over 1000 
cultivable species currently recognised (Faran Ali & Tanwir, 2012). The 
diversity of the oral microbiota reflects the range of microbial habitats that are 
present, including keratinised and non-keratinised oral mucosa, teeth, 
protected periodontal pockets and any existing oral prostheses (Aas et al., 
2005). Environmental conditions in the oral cavity, including different oral 
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tissues and proteinaceous conditioning of surfaces, temperature, and pH all 
contribute to such microbial variety (Faran Ali & Tanwir, 2012). 
The rapid development of molecular technologies has allowed relatively 
inexpensive high-throughput sequencing and profiling of the oral microbiome. 
Utilising community profiling, more than 1000 bacterial taxa have now been 
identified within the oral cavity, many of which coexist within polymicrobial 
biofilms (Kawamura & Kamiya, 2012). Microbial metabolism from diverse 
communities (the metabolome) is considered a key virulence factor, by way 
of acidic end products which may alter the local pH (Takahashi, Washio, & 
Mayanagi, 2012). Whilst the oral microbiome is thought to be relatively stable 
in terms of microbial species during adult lifetime, there can be shifts in the 
population dynamics, and changes to the local oral environment can lead to 
dental plaque-mediated diseases such as dental caries and periodontal 
disease (Marsh, 1994). These local perturbations can occur through 
alteration in diet (for example, high sugar or carbohydrate diets), 
accompanied by poor oral hygiene which can lead to an increase in both acid 
tolerant streptococci and the anaerobic community within dental plaque and 
other areas of the oral cavity (Kawamura & Kamiya, 2012). Medications and 
the disruption of local immune responses due to underlying illness may also 
cause changes to the dynamics of the oral microbiota (Zarco et al., 2011).  
The complexity of the oral microbiome extends to the inclusion of fungi such 
as the yeast of the genus Candida. Candida species have been isolated from 
up to 60% of healthy adults, and are frequent colonisers of mucous 
membranes, with the most prevalent species being Candida albicans (Thein 
et al., 2006). C. albicans’ ability to interact with bacteria adds to the diversity 
of the oral microbiome (Dongari-Bagtzoglou et al., 2009). C. albicans is an 
opportunistic pathogen that undergoes morphological transformation 
between yeast and hyphae, ultimately enhancing virulence. Although 
Candida normally colonises the human mouth harmlessly, in the presence of 
certain risk factors, including smoking, old age and medications, infection can 
occur (Gantner et al., 2005; Loyola et al., 2012).  
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The host tightly regulates the balance and extent of microbial colonisation. If 
this balance changes, for example when health declines, there is the 
capacity for the microenvironment to change. The oral cavity has been 
shown to offer a habitat to potentially pathogenic species (Zuanazzi et al., 
2010). Commensal microorganisms within the oral microbiota have the ability 
to modulate the local environment, and in the healthy individual, such 
commensal oral microorganisms may therefore inhibit secondary pathogen 
colonisation (Wade, 2013a). 
 
1.4 Saliva  
1.4.1 Composition of saliva 
Whole saliva, originates from major (submandibular, parotid and sublingual) 
and minor salivary glands (Huang, 2004). Saliva is a complex mixture of 
biomolecules including lipids, carbohydrates and proteins (Schipper et al., 
2007) in addition to components from gingival crevicular fluid, epithelial cells, 
oral and mucosal tissues, blood components and microorganisms (Table 1.2) 
(Humphrey & Williamson, 2001). Protection of the oral cavity is enhanced by 
oral fluids such as saliva as it contains an arsenal of antimicrobial peptides 
(Subrahmanyam & Sangeetha, 2003). In healthy adults, up to 1500 ml of 
saliva is produced per day, however, physiological and pathological factors 
can severely alter production (Yamamoto et al., 2009).  
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Table 1.2 – Constituents of saliva (Humphrey & Williamson, 2001; 
Amerongen & Veerman, 2002). 
 
Saliva constituent  Proportion (%) 
 
Water  99.5 
Electrolytes  <0.5% 
Mucus <0.5% 
Glycoproteins <0.5% 
Antibacterial proteins <0.5% 
Enzymes (amylase) <0.5% 
Epithelial cells <0.5% 
White blood cells 
 
<0.5% 
 
 
 
Currently, over 2,000 proteins have been identified in saliva (Yan et al., 2009; 
Amado et al., 2013). Some salivary proteins have been found to adhere to 
the enamel surfaces of teeth (1.3). Early microbial colonisers within dental 
plaque, predominantly members of the Streptococcus genus including 
Streptococcus mitis and Streptococcus salivarius, can adhere to immobilised 
proteins such as statherin and glycoproteins anchored on the enamel surface 
which form the pellicle layer (Rudney et al., 2003; Kolenbrander et al., 2005; 
Chaudhuri et al., 2007). Salivary components therefore select for initial 
bacterial colonisation of the tooth surface and effect the composition of 
dental plaque (Sekine et al., 2004).  
 
1.4.2 Functions of saliva  
The functions of saliva include, but are not limited to, molecular transport, 
lubrication, antibacterial defense, and pH homeostasis (Tabak et al., 1982; 
Rudney, 2000). In healthy individuals, salivary flow rates vary between 0.2-2 
ml/min, with a salivary pH range between 6.2-7.4 (Fenoll-Palomares et al., 
2004; Dodds et al., 2005). The composition of saliva, in particular free 
calcium and phosphate serve as buffering agents which help maintain the 
integrity of the tooth under cariogenic conditions (Amerongen & Veerman, 
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2002; Lamkin & Oppenheim 1993). Saliva provides a transport medium for 
microorganisms in the oral cavity (Rudney, 2000).  
 
1.4.3 Antimicrobial activity of saliva 
Antibacterial peptides such as lysozyme and lacotransferrin provide 
protection and interactions against organisms and foreign debris entering the 
oral cavity (Table 1.3) (Silva et al., 2012; Gorr & Abdolhosseini, 2011).  
 
 
Table 1.3 – Antimicrobial activity of salivary proteins 
 
Antimicrobial protein Main function 
 
Lysozyme Anti-bacterial 
Lactotransferrin Anti-bacterial 
Lactoperoxidase Anti-bacterial 
Mucins Anti-bacterial, Anti-viral 
Cystatins Anti-bacterial, Anti-viral 
Histatins Anti-fungal, Anti-bacterial 
IgA Anti-bacterial 
Cytokines Anti-bacterial 
Immunoglobulins Anti-bacterial, Anti-viral 
Proline-rich glycoproteins Anti-bacterial 
Defensins Anti-bacterial 
Calprotectin Anti-fungal, Anti-bacterial 
Chromogranin A 
 
Anti-fungal, Anti-bacterial 
 
 	
Salivary proteins have co-evolved with the diversity of the oral microbiome 
(Gorr & Abdolhosseini, 2011). Four of the most well-known antimicrobial 
peptides are lactotransferrin, lysozyme, salivary peroxidase and secretory 
IgA (Rudney et al., 1991). Lysozyme is an enzyme with antimicrobial 
properties, which lyses bacterial cells and limits bacterial overgrowth in the 
oral cavity (Pfaffe et al., 2011). However, alongside the major salivary 
proteins, are over 1,000 less abundant protein types present, often with 
poorly understood biological functions (Huang, 2004).  
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1.4.4 Salivary proteomics  
Proteomics (the research of proteins within a ‘proteome’, which is a complete 
set of proteins expressed within a cell or organism at a certain time) focuses 
on protein structure and function, and is a clinically important and expanding 
discipline in the post-genomic era (Chevalier, 2010). With over 2,000 
identified proteins in saliva, advances in proteomic platforms have enabled 
the study of such complex fluids (Amado et al., 2013; Jágr et al., 2014). The 
most abundant salivary proteins are amylase, acidic and basic proline rich 
proteins (PRPs) and mucin, which together make up ~75% of the salivary 
proteome (Figure 1.2) (Scarano et al., 2010).  
 
 
 
Figure 1.2 – Major protein groups in human whole saliva, adapted from 
(Scarano et al., 2010).  
There are two main strategies to analyse the salivary proteome. Firstly, a gel 
based approach can separate peptides within saliva and which can be 
coupled with peptide-spot identification using MALDI MS. Whilst such 2D gel 
electrophoresis (2DE) allows separation of multiple proteins, the subsequent 
downstream applications, including mass protein identification are labour-
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intensive compared to gel-free workflows (Chevalier, 2010). Gel-free 
workflows involving chromatography followed by MS can be employed for 
high-throughput global protein identification (Aebersold & Mann, 2003; 
Scarano et al., 2010; Yao et al., 2003). Gel-free proteomic workflows have 
the capacity to identify hundreds of peptides simultaneously, although bias 
can occur with the focus on specific and targeted proteins (Jehmlich et al., 
2013). At each step in a proteomics workflow there are several options 
available, therefore, a mixed proteomic approach utilising gel-based and 
high-through put analysis is often used when analysing complex fluids (Shen 
et al., 2010).  
 
Salivary proteins including PRPs and statherin which make up over one-third 
of the salivary proteome, provide a binding site for early oral colonisers and 
thus play an important role in modulating dental plaque formation (1.5) 
(Rudney, Krig, & Neuvar, 1993; Rudney, 2000). 
 
1.5 Dental plaque an archetypal biofilm 
Dental plaque was considered to be a microbial construct (i.e. a biofilm) in 
the 1970s (Costerton et al., 1978). Dental plaque specifically harbours an 
estimated 500 different bacterial species with differences in microbial 
composition occurring between (the interproximal spaces) and along the 
teeth, indicating that the microbial structure is not uniform, but dynamic in 
nature (Rosan & Lamont, 2000). Streptococcus species are recognised as 
primary pioneer colonisers of teeth and the initiators of dental plaque 
development (Denepitiya & Kleinberg, 1982).  
 
Lazarevic et al., 2009 analysed the oral microbiome using molecular 
methods and reported that up to 70% of sequences belong to the 
Streptococcus and Neisseria genera. Dental plaque formation begins almost 
instantaneously after a tooth is mechanically cleaned via brushing (Rosan & 
Lamont, 2000). Largely composed of streptococci, dental plaque biofilms can 
be acid tolerant to a pH as low as pH 2.5 (Ritz, 1967; Mcneill & Hamilton, 
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2003;). The binding of Streptococcus species such as Streptococcus mitis 
and Streptococcus gordonii promotes colonisation by a range of different 
species including Fusobacteria. Fusobacteria species are considered 
‘bridging bacteria’ as they co-adhere to other microbial species including 
anaerobic bacteria such as Prevotella intermedia and Porphyromonas 
gingivalis leading to polymicrobial biofilm development (Marsh, 2010), as 
highlighted in figure 1.3.  
 
 
 
Figure 1.3 - Coaggregation between oral bacteria on the tooth surface 
adapted from Rickard et al 2003, with blocks representing a variety of 
receptors between species. Species such as Fusobacterium can effectively 
act as a ‘bridge’ between the early and late colonisers (Toole et al., 2000). 
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1.6 Biofilms 
1.6.1 Biofilm composition 
The term ‘biofilm’ describes a community of microorganisms that can be 
attached to living and non-living surfaces and/or to each other (Reid, 1999). 
Biofilms are ubiquitous in all ecosystems, forming on a variety of surfaces 
and within the most extreme environments including acidic and extremely hot 
environments (Davey & O’Toole, 2000). 
Biofilm formation can be regarded as a key virulence factor, partly because 
of the phenotypic differences between biofilm organisms and those in 
planktonic (free swimming) form. Biofilm- mediated infections are difficult to 
treat as the cells are physically protected by the biofilm structure (Ma et al., 
2009). Biofilm cells are embedded in complex matrices of extracellular 
polymeric substances (EPS), which enhances biofilm stability, table 1.4 (Ma 
et al., 2009; Kim et al., 2012; Muszanska et al., 2012).  
 
Table 1.4 – Comparison of planktonic and biofilm cell characteristics (Ma et 
al., 2009). 	
 
Planktonic cells Biofilm cells 
 
Free floating Attached to surface/each other 
Increased sensitivity to antimicrobials Increased virulence factor expression 
 
Rate of growth: Cell proliferation 
 Cell production of EPS 
 
Production of ECM - structural layer 
  
Enhanced resistance to antimicrobials 
 
 
 
EPS constituents can include polysaccharides, proteins, extracellular DNA 
(eDNA), lipids, inorganic salts and water, and the production of EPS is 
variable depending on the microbial species. EPS effectively provides a 
hydrated barrier between the cells and their external environment. Gristina et 
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al., 1985 documented thick adherent biofilms to both biomaterials (including 
catheters) and tissue. 
Within the complex network of the biofilm, microchannels develop allowing 
fluid flow within the structure and the transfer of nutrients, chemical signals 
and removal of waste products through the community (Stoodley, 1999).  
In addition, if biofilm microorganisms become starved of nutrients or oxygen 
(if required), then they can enter a ‘stationary growth phase’, which is 
protective until improved conditions arise (Fricks-Lima et al., 2011). A 
complex biofilm has an inherent ability to adapt to external changes, 
ultimately enhancing the biofilm and therefore microbial survival.  
 
1.6.2 Biofilm development 
Whilst the extent of biofilm development can vary depending upon the 
microbial species, a typical formation can be summarised in three universal 
stages (Figure 1.4). The initial phase of a biofilm development involves 
reversible attachment to a surface and each other (Halan et al., 2012). The 
adhesion of microorganisms in aqueous solutions can be explained by the 
Derjaguin-Landau-Verwey-Overbeek (DVLO) theory of colloidal stability to 
model interactions, including physical forces such as van der Waals forces 
(Hermansson, 1999; Garrett et al., 2008). Planktonic cells, in the initial first 
phase of attachment invariably become attached to a surface previously 
conditioned by organic and inorganic nutrients. This initial reversible 
attachment is the critical first step for biofilm growth (Lazar, 2011). Once cells 
have ‘loosely’ attached to the surface via available energy for adsorption 
specific ligand interactions (adhesins and receptors), microbial species 
generate covalent bonds rendering stronger and permanent adhesion. 
Bacterial adhesins along with pellicle receptors facilitate the process of 
bacterial adherence. Structurally, adhesins are either associated with fibrillar 
appendages or surface proteins (Rosan & Lamont, 2000). Coupled with 
surface colonisation, is active microbial metabolism, which uses surrounding 
nutrients and generates an array of by-products. This results not only in 
irreversible binding, but also continuous replication forming several micro-
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colonies in certain niches of the body for example in between the teeth 
(Roger et al., 2008). Ultimately, this encourages EPS production enhancing 
the overall biofilm structure further anchoring the microorganisms to the 
attachment site (Rickard et al., 2003).  
 
Along with communication via signaling molecules and chemical mediators, 
microbial cells can coaggregate together. Bacterial coaggregation is the 
binding of two cells via specific adhesins and receptor molecules (Rickard et 
al., 2003). Coaggregation is a common attribute of oral bacteria, and most 
notably apparent with Fusobacterium nucleatum and Prevotella species 
(Okuda et al., 2012). Streptococcus species have numerous partner-species 
including Actinomyces naeslundii and C. albicans, and such coaggregation 
willl facilitate polymicrobial biofilm development and enhancement (Bamford 
et al., 2009). 
 
 
 
 
Figure 1.4 - A diagrammatic representation of biofilm formation on the tooth 
surface adapted from Hojo et al., 2009. 	 	
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1.6.3 Biofilm detachment and dispersal 
Once a biofilm has fully developed, cells can disperse to colonise 
neighboring and distal sites within the body. Biofilm detachment often 
considered a virulence factor (and sometimes referred to as the fourth stage 
of biofilm development), can occur as a result of either environmental forces 
or chemical signalling. In many cases, biofilm detachment arises due to 
forces from fluid or gaseous flow (Koerner, 1997). Such environmental forces 
can cause cellular erosion whereby small biofilm matter is sheared away 
from the formed biofilm, consequently moving with the direction of the flow 
(Morgenroth & Wilderer, 2000). Biofilm cells can also detach from the total 
biofilm mass via abrasion, where collisions occur between biofilm cells and 
particles within the surrounding materials and fluid (Gjaltema et al., 1997). In 
addition, biofilm sloughing can occur with increasing shear forces, resulting in 
big aggregates of cells detaching from the larger biofilm encased within EPS 
and moving as a formed biofilm (Morgenroth & Wilderer, 2000; Telgmann et 
al., 2004). 
Biofilm dispersal or detachment can also be a virulence mechanism 
associated with biofilm-related infections (Kaplan, 2010), whereby 
detachment is regulated at a molecular and quorum sensing level and this 
offers a controlled strategy for biofilm survival (Lindsay & Von Holy, 2006; 
Boles & Horswill, 2011). 
 
1.6.4 Quorum Sensing (QS) 
With the identification of more than 1000 taxa of bacteria identified in the oral 
cavity, (many within close proximity to each other), it is not surprising that 
cell-to-cell communication and intercellular coordination occurs (Galloway et 
al., 2012). Quorum sensing (QS) is an umbrella term used to describe 
bacterial communication, mediated by chemical signaling molecules. QS is 
important for species survival, growth (He et al., 2012) and successful biofilm 
organisation (Kolenbrander et al., 2005). The subsequent microbial 
interactions can be mutually beneficial or antagonistic (Stacy et al., 2012).  
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Small species-specific diffusible molecules often mediate cellular 
communication. Quorum sensing (QS) molecules can directly bind to 
receptors on bacteria and trigger the modulation of a number of factors 
including virulence and biofilm regulation (Karlsson et al., 2012). Classes of 
QS molecules include autoinducer (AI) molecules and N-acyl homoserine 
lactones (AHLs). The concentration of QS molecules directly relates to the 
number of producing cells and when threshold concentrations are reached, 
signaling effects are manifested. Hence QS is a cell density based signaling 
process.  AIs are continuously released into the EPS, and allow bacterial 
cells to ‘monitor’ their surroundings and modulate gene expression, thus 
contributing to biofilm survival, adaptation and competitiveness (Lazar, 
2011). AHLs are more commonly produced by Gram-negative bacteria whilst 
Gram-positive bacteria employ peptide based systems including AIs (Waters 
& Bassler, 2005).   
 
Bacteria QS signal molecules can mimic host hormones and in some 
situations influence and control eukaryotic expression (Pacheco & 
Sperandio, 2009). Studies by Telford et al., 1998 and Karlsson et al., 2012 
have evaluated the role of AHLs produced by P. aeruginosa to modulate the 
behaviour in human cells. Telford et al., 1998 emphasised the role of AHL 
molecules in influencing Th1 and Th2 host cell responses, whereby P. 
aeruginosa AHL molecules can subsequently down regulate the production 
of bactericidal IL-12, thus mimicking host responses.  
 
Studies have reported antibiotics including macrolides inhibiting QS systems. 
Burr et al., 2016 reported in vitro inhibition of P. aeruginosa QS by macrolide 
antibiotics, for example erythromycin. Burr et al., 2016 further investigated 
these findings in a clinical trial of P. aeruginosa positive sputum from non-
cystic fibrosis bronchiectasis patients. Following exposure to low doses of 
macrolide antibiotics, they found a down regulation of P. aeruginosa QS 
gene expression, without an accompanying reduction in bacterial load.chapt 
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Although contributing to biofilm development, metabolic signaling via various 
QS systems are not the only factors controlling biofilm development.  In 
nature, sessile polymicrobial communities need to be adaptable to external 
environmental conditions (Kellerberg & Molin 2002).  
There are many complex and overlapping interactions within polymicrobial 
biofilms, where survival, growth and competitiveness thrives. Dental plaque 
is known for its microbial diversity and therefore, consideration of 
interspecies interactions is vital in determining the impact oral biofilms have 
in both localised and systemic infections.  
 
1.6.5 Biofilm associated infections 
Biofilm mediated infections cause up to 60% of medical and hospital 
associated infections (Lazar, 2011), some of which are highlighted in table 
1.5. Furthermore, biofilms are recognised as leading causes for the vast 
majority of hospital infections requiring medical treatment (Anderson et al., 
2013).  		
Table 1.5 – Biofilm associated-infections and causative pathogens (Otto, 
2008; Toté et al., 2010; Majumdar & Padiglione, 2012; Tarquinio et al., 2014) 
 
Bacterial species Biofilm infections 
Pseudomonas  
aeruginosa 
Cystic fibrosis lung infection, respiratory infection, 
chronic wound, otitis media, catheter-associated urinary 
tract infections 
  
Staphylococcus 
 aureus 
Endocarditis, respiratory infection, chronic osteomyelitis, 
orthopaedic implants 
  
Escherichia 
 coli 
Urinary tract infection, catheter related urinary tract 
infection, biliary tract infection 
  
Streptococcus pneumoniae Chronic otitis media, chronic rhinosinusitis, chronic obstructive pulmonary disease 
  
Staphylococcus epidermidis 
Catheter related infections, prosthetic cardiac valve 
infections, joint replacement infections 
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Two clinically relevant examples of biofilm organisms are Staphylococcus 
aureus, a Gram-positive cocci, and Pseudomonas aeruginosa, a Gram-
negative organism frequently producing complex biofilms within the 
respiratory tract. 
S. aureus can form complex multi-layered biofilms both within the body and 
on medical devices, especially those exposed to proteinaceous fluids (Otto, 
2009). Essential in S. aureus biofilm formation is the genetic regulator SarA, 
responsible for controlling key initial adhesions and promoting biofilm 
maturation (Abee et al., 2011). Surface components such as phenol-soluble 
modulin (PSM) (surfactant peptides) and Microbial Surface Components 
Recognising Adhesive Matrix Molecules (MSCRAMMS) are key in adhering 
biofilm cells to surface molecules found in the enamel pellicle conditioning 
film (Otto, 2009).  
In biofilm-associated infections, the ability of selective de-attachment is 
crucial for pathogenesis, survival and competitiveness, allowing cells to 
‘travel’ through the body (fluid, medical devices) and colonise other sites. 
Staphylococcus aureus biofilm detachment is a multi-step process, where 
biofilm cells are prepared for survival outside the EPS (Otto, 2009; Boles & 
Horswill, 2011). The accessory-gene regulator (Agr) system is a regulatory 
mechanism responsible for producing enzymes that degrade EPS (Mirani et 
al., 2013). EPS degradation allows S. aureus to detach from the biofilm 
complex (Boles & Horswill, 2011).  
 
Pseudomonas aeruginosa an opportunistic pathogen, is often involved in 
respiratory infections, hospital acquired infections (HAIs) and cystic fibrosis 
(CF) related respiratory infections (Ma et al., 2009; Mulcahy et al., 2013). 
Pseudomonas aeruginosa forms biofilms on environmental, medical, and 
various surfaces within the body (Høiby et al., 2001; Fricks-Lima et al., 
2011). Pseudomonas aeruginosa flagella enable motility, attachment and 
formation of bacterial monolayers (O’Toole & Kolter, 1998; Høiby et al., 
2001). Type IV pili further support these initial attachments by stabilising and 
anchoring reactions, furthermore increasing cell to cell communications and 
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forming micro colonies of P. aeruginosa, either monomicrobial, or within a 
polymicrobial biofilm (O’Toole & Kolter, 1998; Barken et al., 2008).   
The P. aeruginosa genome has a high number of regulatory genes and 
multiple chemotaxis systems, regulating and constantly adapting biofilm 
formation (Whiteley et al., 2001; Mulcahy et al., 2013). Pseudomonas 
aeruginosa can display different phenotypic forms, most notably the so-called 
mucoidal and non-mucoidal forms. The mucoidal phenotype exhibits 
increased virulence and is particularly associated with CF/respiratory 
infections (Sauer et al., 2002; Wiens et al., 2014). Mucoidal and virulent 
strains of P. aeruginosa demonstrate high capacity to produce alginate, 
which is an exopolysaccharide acting as a supporting structure within P. 
aeruginosa biofilms (Boyd & Chakrabarty, 1995).  
Following bacterial adherence, and up-regulation in expression of algC, the 
gene responsible for the synthesis of alginate and EPS composition occurs 
(O’Toole & Kolter, 1998). Key genes involved in EPS production are those 
involved in alginate production, the Pel genes and polysaccharide synthesis 
locus (Psl). Psl is a cluster of 15 genes and promotes biofilm construction 
and P. aeruginosa cell interactions (Ma, 2007). Expression of Pel genes 
protects against antimicrobial agents via the production of a glucose-rich 
matrix extracellular matrix (Vasseur et al., 2005; Colvin et al., 2011). P. 
aeruginosa can also produce pyocyanin (a virulence factor), which attaches 
directly to eDNA within the matrix, providing cellular respiration through the 
biofilm matrix via electron transfer (Das et al., 2015). The ability of P. 
aeruginosa to lyse and detach from the biofilm is considered a virulence 
factor. Once P. aeruginosa cells detach from the biofilm as a response to the 
external environment, cells revert back to the planktonic form to disperse and 
colonise other areas of the body (Webb et al., 2003).   
 
1.6.6 Biofilm imaging  
Biofilm imaging can provide information about its structure and to a certain 
extent the microbial composition. With a magnification limit up to 100,000x 
and the ability to construct accurate and 3-dimensional images, biofilm 
	 21 
structures can be imaged using scanning electron microscopy (SEM) 
(Vernon-Parry, 2000). Electron beams are focused onto the sample surface 
to create an image using released scattered electrons. SEM micrographs are 
invaluable when imaging the structure and extent of microbial biofilms (Gil-
Perotin et al., 2012). In order to generate images, specimens have to be 
electrically conductive at the surface and fixed through the process of sputter 
coating, to ensure the entire sample is coated with a thin layer of conductive 
material, usually gold (Hill et al., 2010). 
A second form of microscopy used to analyse biofilms is confocal laser 
scanning microscopy (CLSM). In confocal microscopy, light is emitted by the 
laser source, reflecting off a dichromatic mirror scanning the sample and 
passing through the presence of a spatial pinhole placed at the confocal 
plane of the lens. This pinhole eliminates out-of-focus light and enables 
imaging at a range of optical planes, increasing resolution and contrast. A 
detector subsequently measures light that passes through the pinhole 
(Claxton et al., 1979).	 CLSM has been extensively used in medical and 
biological sciences since the 1970s, as there is an additional benefit of 
imaging throughout the section, a process called optical sectioning (Claxton 
et al., 1979). A wide range of fluorescent and immunohistochemcial stains 
can be imaged through CLSM allowing the excitation of a range of 
fluorochromes within the electromagnetic spectrum to increase target 
specificity and the generation of multiplex images. Z-stacks of optical 
sections can be taken through the full thickness of the biofilms and maximum 
intensity-type reconstructions are then prepared using confocal software 
packages. 
 
Fluorescence in situ hybridisation (FISH) coupled with CLSM can facilitate 
the imaging of multiple species in real time using species-specific Peptide 
nucleic acid (PNA) probes in a multiplex assay. FISH is an effective and 
invaluable tool in microbiology that has been used frequently in research 
since the 1980s  (Zwirglmaier, 2005; Wagner & Haider, 2012). Initially, FISH 
typically used DNA or RNA-based probes tagged with a fluorochrome 
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(Wagner & Haider, 2012). Conventional FISH methodology using DNA 
probes experienced several limitations including reduced sensitivity of 
fluorescent signals and specificity of the probe itself (Perry-O’Keefe et al., 
2001). Peptide nucleic acid (PNA) probes are synthetic oligomers of nucleic 
acid (Figure 1.4). The uncharged sugar phosphate backbone of the PNA 
probe aids cell entry and reduces electrostatic repulsion between the probe 
and the nucleic acid target, these factors thus increase the level of 
hybridisation (Amann et al., 2001). The ability of the chosen probe to 
penetrate the cell and subsequently hybridise to the target nucleic acids 
ultimately provides cell fluorescence (Malic et al., 2009). PNA probes were 
therefore selected in this study to analyse species presence and location 
within biofilms.  
 
 
 
 
 
Figure 1.4 – The chemical structures of DNA and PNA. In PNA, the sugar 
phosphate backbone in DNA is replaced with a polyamide backbone (Perry-
O’Keefe et al., 2001). 
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1.6.7 In vitro biofilm analyses  
A variety of in vitro models can be used to develop and subsequently analyse 
biofilms. Microtitre plates can be used as substrata to develop biofilms, and 
depending on design, microbial cells may either adhere directly to the base 
of the microtitre plate wells or upon inserted PTFE pegs (Calgary biofilm 
device) which readily facilitates application of downstream analysis (Fricks-
Lima et al., 2011; Hooper et al., 2011; Malic et al., 2013). Biofilms can also 
be formed within specifically designed models such as glass bottom chamber 
slides or the constant depth film fermenter (CDFF) (Wimpenny 1997; Fricks-
Lima et al., 2011). Clinically relevant biofilm models can also be developed 
using actual medical devices such as ETTs and catheters.  Furthermore, 
complex co-culture modeling systems can be used to allow simultaneous 
analyses of infection and immune response cascades (Wimpenny, 1997; 
Guggenheim et al., 2001; Coenye & Nelis, 2010;).  
The CDFF (Figure 1.6) is a steady-state biofilm model that was initially 
developed in the 1970s, with further developments in 1988 by Peters and 
Wimpenny (Costerton et al., 1978; Kinniment et al., 1996; Wimpenny, 1997; 
Hill et al. 2010). The CDFF is equipped with a rotating stainless steel 
turntable holding polytetrafluoroethylene (PTFE) pegs in place, whereby 
microbial biofilms are continuously supplied with microbiological media and 
has proved particularly valuable in the study of dental plaque (Hope et al., 
2012). The turntable is motorised during operation, and two scraper blades 
coated with PTFE spread media evenly across the recessed pegs, with a 
sample port allowing access to individual pans during operation (Wilson, 
1996; Dalwai et al., 2007; Malic et al., 2009). 
A major advantage of the CDFF is the generation of multiple, reproducible 
and representative biofilms with the ability to vary parameters such as 
oxygen flow, nutrient feed and temperature (Kinniment et al., 1996; Vroom et 
al., 1999; Hope et al., 2012). 
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Figure 1.6 – Photograph of the Constant Depth Film Fermenter (CDFF). 
 
1.7 The microbiological analysis of complex communities  
1.7.1 Analysing the oral microbiome  
The oral microbiome has previously been analysed by conventional culture 
and molecular techniques (Keijser et al., 2008). With advances in molecular 
techniques, such as microbial gene sequencing, certain uncultivable 
organisms have been identified by detection of their DNA (Lazarevic et al., 
2009; Yamashita & Takeshita 2011). Microbial culture often underestimates 
the number and types of microbes within a microbial community. 
Conventional culture methods are unable to meet the growth requirements of 
all species, either through our lack of knowledge of nutrient requirements or 
inability to generate the correct gaseous environment in vitro. Despite this, 
microbial culture is still regarded by many as the gold standard in diagnostic 
medical microbiology, with the capability to culture and identify 280 microbial 
species from the oral microbiome (Dewhirst et al., 2010).  
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1.7.2 Microbial community profiling 
Next-generation sequencing (NGS), an umbrella term extending beyond 
Sanger sequencing which was first described in the 1970s, is used to 
describe DNA/RNA sequencing at a high-throughput capacity (Schuster, 
2008). One important application of NGS is the characterisation of mixed 
microbial communities. Previously, genome sequencing was both expensive 
and laborious. Coupled with the development of multiple platforms that can 
be employed to sequences of DNA, both the turnaround time and cost of 
producing sequence reads from unknown DNA has reduced significantly. 
Multiple platforms exist to perform high throughput sequencing and the 
choice depends to some extent on the nature of the research question. The 
454 (pyrosequencing) platform first described in the 1990s paved the way for 
high-throughput DNA sequencing based on nucleotide detection using light 
emission (Amend et al., 2010). Other technologies such as the Illumina 
Miseq platforms, employ sequencing by synthesis and a reversible terminator 
chemistry process (Lazarevic et al., 2009; Caporaso et al., 2012). Further 
advances in these technologies have allowed the simultaneous analysis of 
multiple mixed DNA sequences. 
 
1.7.3 High-through put data analysis: Bioinformatics 
High-throughput DNA sequencing undoubtedly generates large quantities of 
data. Such data require preliminary analysis before any disease association 
studies for individual bacterial phylotypes can be performed. Data analysis 
for complex microbial sequence-based data sets can be enhanced with 
appropriate software programs such as R programming, allowing the 
generation of scripts for mass analysis and data sorting. With the number of 
species ranging up to several hundred for dental plaque, and perhaps 
considerably less within the microbiota of the lower airways, data analysis 
needs specific focus. For example, Bray and Jaccard are two similarity-
distance diversity indices, based on identified Operational Taxonomic Units 
(OTU) (Lozupone & Knight, 2005; Wang et al., 2013). Both measures are 
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widely used in diversity analyses. The choice between these two indices is 
dependent upon the data to be analysed. The Jaccard approach, also known 
as the coefficient of community, first developed by Paul Jaccard in 1901, is 
one of the oldest occurrence measures. The Jaccard approach compares the 
occurrence of specific organisms according to DNA sequences (Lozupone et 
al., 2007). However, the Bray approach is based upon quantitative 
(abundance) data, and when used as a similarity measure of data, can be 
equivalent to occurrence (Wang et al., 2013). These two approaches are 
examples of community distance/similarity indices that can be adopted to 
analyse DNA profiles of the entire community. 	
Performing community analysis was enhanced in 2005 with the introduction 
of a new phylogenetic based method called UniFrac. This method is a β-
diversity measure devised by Lozupone and Knight used to distinguish 
relationships between microbial communities (Lozupone & Knight, 2005; 
Lozupone et al., 2011). In addition, there are two variations of UniFrac 
community analysis: unweighted or weighted UniFrac, with the weighted 
UniFrac approach incorporating OTU measures. This is a quantitative 
approach commonly used in the analysis of microbiome related data 
(Lozupone et al., 2007). 	
1.8 Diagnosis and treatment of VAP 
1.8.1 VAP diagnosis 
Diagnosing VAP is difficult for critical care physicians as there is no effective 
gold standard diagnostic test (Aucar et al., 2003; Bonten, 2014; Kalanuria et 
al., 2014). As with many infections or diseases, a gold standard for correct, 
efficient and quick diagnosis is of fundamental importance. The challenges 
faced in diagnosing VAP may partly originate from a lack of understanding of 
the pathogenesis. There is often confusion between signs from underlying 
conditions that overlap with those of the clinical presentation of VAP. There 
have been multiple and conflicting reports within the last decade with regards 
to accurate and efficient VAP diagnosis. Chest X-rays are indicative of 
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hospital-acquired respiratory infection, although in the case of mechanically 
ventilated patients they can be taken out of context especially when 
considering the reasons behind the patient’s initial admission to the ICU 
(Medford et al., 2009). Other studies have advocated the need for a clear 
diagnosis of VAP using lavage based testing, whereby the lung parenchyma 
is washed with saline and subjected to microbial analysis.  
 
Flanagan et al, 2000 performed a prospective comparison of non-directed 
bronchoalveolar lavages (NBLs), bronchoalveolar lavages (BALs) and a 
protected specimen brush. They reported an 83% concordance of the 
predominant pathogen between the sampling methods, and concluded that 
NBLs are a simple, safe, cheap and readily available method of diagnosing 
VAP. The use of NBLs and BALs in the diagnosis of VAP have potential 
advantages over other clinical approaches, as these allow the clinician to 
target the microorganisms in the airways and lungs to ascertain the most 
effective choice of antimicrobial therapy (Jackson et al., 2008). In practice, 
NBLs are preferred, in comparison to BALs as a reliable and cost effective 
method (Flanagan et al, 2000). In certain cases, where NBLs produce 
negative results and the clinician suspects VAP, a BAL is often performed. 
Although the collection of BALs is an invasive and costly procedure, BAL 
sampling is thought to improve microbiological diagnostic accuracy. Zaccard 
et al, 2009 reported that, statistically, unilateral right lung sampling may be 
preferable over taking bilateral sampling in cases where there are multiple 
areas on CT imaging requiring investigation, and will therefore reduce patient 
stress with the same diagnostic accuracy. Although microbiological sampling 
of the lower respiratory tract (NBLs and BALs) often provides accurate and 
informative culture based results, the sampling is invasive for the patient and 
the results turn around time is at least a few days.  
 
To improve VAP diagnosis, the Clinical Pulmonary Infection Score (CPIS) 
was introduced (Pugin et al., 1991; Kalanuria et al., 2014) which focuses on 
clinical presentations, radiographic and microbiological data to provide a 
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likelihood of VAP being present (Fartoukh et al., 2003). However Lauzier et 
al., 2008 described the lack of specificity and sensitivity in many cases using 
variables in the CPIS, leaving debate concerning the use of CPIS scoring. 
Patients presenting with a high CPIS would require a NBL/BAL, and be 
empirically treated with antibiotics whilst awaiting microbial culture results. An 
additional disadvantage of the CPIS is the lack of culture information, which 
is of increasing importance given the increase of VAP infection caused by 
multi-drug resistant (MDR) pathogens. Recently, the Center for Disease 
Control and Prevention (CDC) published updated criteria for ‘possible and 
probable’ cases of VAP, aiming to improve the classification and consistency 
between critical care units (NHSN, 2015). Patients with signs of infection and 
inflammation are classified as “infection-related ventilator-associated 
complication” (IVAC). Further evidence of purulent and pathogenic secretions 
from the lower airways will label the patient as possible and probable VAP 
(Kalanuria et al., 2014; Munro & Ruggiero, 2014). 
 
Consideration has been given to the use of systemic biomarkers in fluids 
from mechanically ventilated patients to improve diagnosis of VAP. 
Biomarkers including procalcitonin (PCT) and C-reactive protein (CRP) have 
been suggested as an alternative to predict onset of VAP (Christ-Crain & 
Müller, 2007; Palazzo et al., 2011; Zielińska-Borkowska et al., 2012). 
Although there have been reported specificity issues when considering the 
use of biomarkers such as PCT or CRP, biomarkers identified from lower 
airways fluid such as neutrophil proteases could elucidate lower airways 
infection. A study by Wilkinson et al., 2012 found significantly increased 
neutrophil-derived protease levels in the alveolar spaces within patients 
clinically diagnosed with VAP. Recent research by Hellyer et al., 2015 has 
revealed the potential for biomarkers including low concentrations of the 
cytokines IL-1β and IL-8 to specifically exclude VAP. Improving early 
diagnosis of true VAP cases may in turn improve antibiotic stewardship and 
the timely administration of antibiotics within critical care. Reducing 
inappropriate antibiotic prescriptions will reduce the generation of antibiotic 
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resistance. Biomarker development to facilitate the diagnosis of VAP is still 
very much an evolving area of research.  
 
1.8.3 VAP pathogenesis: The role of the oral microbiome 
A number of investigations suggest that bacteria colonising the oral cavity 
may be important in the aetiology of VAP (Bahrani-Mougeot et al., 2007; 
Scannapieco & Binkley, 2012). Firstly, there have been recorded cases 
where oral microorganisms may actually directly cause VAP, especially 
considering the immunocompromised status of critically ill patients. The 
Streptococcus anginosus group (previously known as the milleri group) 
compromising of three species (Streptococcus anginosus, Streptococcus 
constellatus and Streptococcus intermedius) have been the predominant 
isolated species in the lower respiratory tract in patients with VAP (Shinzato 
& Saito, 1995).  
A change in the microbial composition within the dental plaque of 
mechanically ventilated patients has been reported, with dental plaque 
becoming heavily colonised with potential respiratory pathogens able to 
cause VAP such as Pseudomonas, Klebsiella, Meticilin resistant 
Staphylococcus aureus (MRSA) and Acinetobacter  (Scannapieco et al., 
1992; Sachdev et al., 2013). Changes in the oral cavity of mechanically 
ventilated patients may be influenced by exogenous factors such as the 
hospital environment or contamination from equipment/people, but evidence 
suggesting this is the case is scarce. Previous studies indicate that VAP is 
primarily caused by endogenous factors from the patient’s microbiome, and 
microenvironment (Safdar et al., 2005).  
One study enrolled 228 mechanically ventilated patients to evaluate the 
effectiveness of respiratory pathogen decontamination in the oral cavity using 
a 0.2% CHX gel (Somal & Darby, 2006). Within their study they isolated 
highly resistant Enterobacter in dental plaque and the lower airways in 
patients with VAP. Furthermore, poor dental hygiene was apparent in 90% of 
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enrolled patients highlighting the apparent associations between the oral 
microbiome, oral health and the development of VAP. During intubation, one 
third of dental plaque cultures collected within their study were positive for 
Gram-negative rods, not commonly isolated from healthy dental plaque. 
One of the earliest studies categorically demonstrating that bacteria in the 
oral cavity were responsible for the development of VAP used pulsed field 
electrophoresis of genomic DNA to study colonisation and infection in 86 
mechanically ventilated patients (Garrouste-Orgeas et al., 1997). In patients 
that developed VAP, identical strains of bacteria were found in the oral cavity 
and lung.  
 
1.8.4 VAP pathogenesis: The role of the endotracheal tube (ETT) 
Although the ETT provides an essential conduit between the ventilator and 
patient in critical illness, the ETT is a key factor in aetiology of VAP. The 
placement of an ETT will impair normal host defence mechanisms such as 
the mucociliary clearance of microorganisms, impede cough, hold open the 
vocal cords and provide additional surfaces for microbial biofilm development 
(Perkins et al., 2010; Cairns et al., 2011). Microorganisms from the oral 
cavity can translocate, exteriorly to the ETT and down the trachea to pool 
above the inflated ETT cuff (Figure 1.7). Critically ill patients receiving MV 
are normally nursed in a semi-recumbent position, as this is thought to 
reduce gastro-acid reflux, and underlines the important of an effective ETT 
cuff seal of the airway. The inflated ETT cuff is designed to help retain the 
ETT within the trachea and will theoretically also prevent movement of 
subglottic fluids that accumulate above the cuff down into the lower airways. 
These subglottic fluids contain microorganisms including pathogens, salivary 
components and gastric fluids. However, in practice, microchannels 
frequently develop in the ETT cuff material because the fully inflated cuff is 
larger than the tracheal diameter (Hamilton & Grap, 2012). As subglottic 
fluids pool above the cuff, leakage of these fluids down the microchannels 
and into the lower airways will occur (Fisher, 2011; Miller et al., 2011; 
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Hamilton & Grap, 2012). This ultimately allows microbial access and 
translocation of microorganisms from the oral cavity to the lower airways 
(Figure 1.8). Once below the inflated ETT cuff, microorganisms can also be 
drawn into the ETT and then colonise the inner lumen in the form of a biofilm 
(Perkins et al., 2010; Vandecandelaere et al., 2012). Inside the ETT, 
adherent microorganisms can develop into complex multispecies biofilms 
which are inaccessible to administered antimicrobial agents and host 
defenses (Tarquinio et al., 2014). Biofilms have been identified along both 
the inner and outer surfaces of discarded patient endotracheal tubes and 
shown to form within 24 h of intubation (Perkins et al., 2010). The formation 
of microbial biofilms within a 24 h period highlights a rapid generation and 
source of VAP causing organisms. Fragments of biofilm can become 
detached and move directly towards the lower airways with the airflow. 
 
 
 
 
 
Figure 1.7 – An extubated endotracheal tube (ETT) showing a semi-inflated 
cuff, as indicated by the arrow.  
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Figure 1.8 – The translocation of oral microorganisms to the lower airways 
adapted from E. Diaz et al., 2005.  
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The lungs, although once often described as a sterile environment, share 
microbial commonality with the oropharynx microbiota. Recent research has 
focused on characterising the lung microbiome in both health and disease 
(Dickson & Huffnagle, 2015). Once however, the lower airways become 
compromised via pathogenic microbial invasion, an inflammatory response is 
initiated (Mojon, 2002; Joseph et al., 2010). Host defense mechanisms to 
control microbial presence in the lung parenchyma include mucociliary 
clearance, a physical epithelial cell barrier, cytokine production stimulating 
neutrophil recruitment and phagocytic activity (Wilkinson et al., 2012). 
Furthermore, in intubated patients, the movement of the tongue to dislodge 
and clear residual microorganisms, and the swallowing mechanism are both 
compromised, ultimately leading to an altered environment for 
microorganisms to accumulate. It is likely that a combination of factors 
results in disruption of oral equilibrium and facilitation of microbial 
colonisation in the lower airways. Patient illness, and ETT intubation, along 
with the introduction of respiratory pathogens originating from the oral cavity 
can all influence the development of VAP (Marra et al., 2009). 
 
1.8.5 Preventative measures for VAP	
1.8.5.1 Host defence mechanisms for respiratory infection 
The respiratory system comprises of the upper airways (nasopharynx 
including sinuses) and lower airways (trachea and lungs), and is responsible 
for gas exchange (Sato & Kiyono, 2012). The mucosal membrane lining the 
respiratory system acts as a physical barrier against pathogens in a similar 
manner to that of oral mucosal membranes (Eddens & Kolls, 2012). Epithelial 
cells in the lining of the trachea contain cilia on their surfaces which move 
foreign particles away from the lower airways, allowing expulsion via 
mucociliary clearance (Safdar et al., 2005). The physical actions of coughing 
and sneezing further expel foreign bodies and prevent them from entering 
the respiratory tract. In addition, epithelial cells are lined with mucins which 
slows pathogen translocation to the lower airways (Boyton & Openshaw, 
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2002; Wilkinson et al., 2012). Airway surface fluid (ASF) is produced by the 
lower airways, acting in a similar antimicrobial manner to that of saliva, 
recognising invading foreign bodies. ASF contains several antimicrobial 
peptides, including those produced by innate immune cells such as 
lactoferrin, defensins and lysozymes (specifically secreted by macrophages) 
(Boyton & Openshaw, 2002; Devine, 2003; Wilkinson et al., 2012).  
The immune system serves to protect the host in response to a foreign 
substance or antigen (Alamos et al., 1986). Immune responses are tightly 
regulated to maintain homeostasis in the host. If too little a response is 
initiated, pathogen clearance is insufficient, and an overly active immune 
response can lead to damaging inflammatory responses (Medzhitov, 2007; 
Sitkovsky & Ohta, 2005). Although pathogens from the upper airways can 
freely escape interactions with the epithelial lining in the trachea and can 
invade the lower airways directly through inhalation to the alveoli, there is a 
cascade of cell infiltration, cytokine and mediator production, and ultimately 
an inflammatory response to combat them (Sato & Kiyono, 2012). An 
increase in cytokine production in the lower airways can be indicative of 
microbial invasion, or alterations in respiratory homeostasis. Critical illness 
may lead to immunosuppression, with the ETT altering the microenvironment 
leading to dental plaque overgrowth and potentially increase colonisation 
within the lower airways.  
 	
1.8.5.2 VAP Care bundles 
Prevention of VAP is important given the impact on duration of mechanical 
ventilation, length of stay, attributable mortality and health care costs. The 
cost of VAP treatment frequently exceeds £10,000 per case (equivalent to 7 
extra days in ICU), emphasising the need to focus on preventative medicine 
(Al-Tawfiq & Abed, 2010; Díaz et al., 2010; Wyncoll & Camporota, 2012). 
One of the most appropriate strategies for VAP management is to implement 
and adhere to certain therapeutic guidelines and VAP specific care bundles 
have been outlined (Rello et al., 2011). A care bundle is a small set of 
	 35 
evidence-based guidelines designed to improve patient outcome (Venkatram 
et al., 2010). Care bundles provide a prioritised and consistent list of 
universal based guidelines of hospital-acquired pneumonia (HAP) and VAP, 
such as those published by the British Society for Antimicrobial 
Chemotherapy (BSAC) (Masterton et al., 2008). Previous studies suggest the 
need for further research and training for all critical care professionals (Díaz 
et al., 2010), with greater education of pathogenesis, management and 
prevention to help maintain and reduce cases of VAP (Gallagher, 2012).  
Although care bundles aimed at reducing VAP rates in critical care have 
been introduced, and shown benefit (Al-Tawfiq & Abed, 2010; Heck., 2012; 
Eom et al., 2014), the impact that care bundles have on VAP reduction rates 
nationwide still needs to be determined (Beattie et al.,  2012). VAP based 
care bundles include the use of antiseptic mouthwashes educational 
programs, and parameters for both diagnosis and treatment choices as 
outlined in table 1.6  
 
Table 1.6 – An overview of care bundles used in the prevention and 
standardisation of care in critical care units (Hutchins et al., 2009; Rello et al., 
2011; Beattie et al., 2012; Gallagher, 2012; Heck, 2012; Eom et al., 2014; 
Munro & Ruggiero, 2014). 
 	 	VAP care bundle preventative measures 
 
Semi-recumbent position 
	Oral antisepsis - chlorhexidine 
Daily sedation breaks/Minimal targeted sedation	
Daily assessment - focus to wean off ventilator 
Subglottic suctioning 
	Appropriate antibiotic use 
Glucose control 
Stress ulcer prophylaxis  
	Endotracheal cuff pressures 
VAP diagnosis parameters 
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Other VAP preventative measures have been assessed in clinical trials, for 
example the design of ETTs and their efficacy in reducing VAP rates. 
Adjustments made to the composition of the ETT biomaterial has also been 
analysed. Such studies have involved changing the design of the ETT cuff, 
with polyurethrane cuffs being used over conventional polyvinylchloride in an 
attempt to avoid microchannels forming, and therefore leakage of fluidic 
materials (Deem & Treggiari, 2010). An observational study of 284 
mechanically ventilated patients by Lorente et al., 2014 compared the effects 
of intermittent ETT cuff pressure control versus continuous cuff pressure 
control. Lorente et al showed a significantly lower (p=0.02) incidence of VAP 
with patients receiving continuous ETT cuff pressure control (11.2%) 
compared to intermittent ETT cuff pressure control (22%).  
Secondly, adjusting the composition of the inner lumen of ETTs has been a 
subject of research to minimise biofilm formation. Coating the inner lumen of 
ETTs with antimicrobial agents such as silver or antibiotics has been 
assessed to prevent biofilm colonisation. Kollef et al., 2008 enrolled 2003 
patients in a randomised clinical trial to receive either a silver coated ETT or 
an uncoated ETT (control group) during intubation. Although they reported a 
statistically significant reduction in the incidence of VAP in the patient cohort 
receiving a silver coated ETT, there were no significant differences observed 
in attributable mortality or duration of critical care stay. In 2011, Raad et al, 
specifically reported that gardine (chlorhexidine based antiseptic) 
successfully inhibited MRSA and multi-drug resistant (MDR) Gram-negative 
adherence to ETTs in in vitro analyses. Both the efficacy for reducing VAP 
incidence and the cost-effectiveness of ETT impregnated with antimicrobial 
agents remains unclear.  Further clinical studies need to examine the extent 
of biofilm formation and VAP incidence when using preconditioned ETTs.  
 
1.8.5.3 Oral and Dental scoring   
Oral care assessment plans are completed within critical care units so as to 
provide the appropriate level of oral care needed, and these can be tailored 
to individual patients. For example, at the University Hospital Wales, within 4-
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6 h of patient admission to critical care, medical staff complete a critical care 
mouth risk assessment form. This risk assessment (Appendix I) defines a 
series of categories upon which a score is assigned based on the clinical 
presentation of the patient. Categories to assess and tailor care plans include 
patient dependency, inflammation within the oral cavity i.e. mucosa and the 
tongue, number of natural teeth, state of ventilation and pharyngeal 
secretions. Once a total score is obtained it is used to place the patient into 
one of three groups for provision of oral care. This scoring system is to 
ensure the times for delivery of oral care: 12 hourly, 4-6 hourly, and 2-4 
hourly. A series of oral hygiene and management strategies such as: 
ensuring fluid intake, provision of artificial saliva, administration of 
chlorhexidine gluconate as a 0.12% rinse, and antifungal medication are 
given to the patient.  
Patients may be admitted to critical care following long-term illness 
deterioration or acute trauma. This ultimately leads to a degree of variation in 
oral hygiene status. The oral care assessment plan aims to target this 
variation, in an attempt to provide the highest quality of care. Maintaining oral 
care in critically ill patients is often, however, seen as a comfort measure by 
nursing staff rather than an intervention to maintain health (Dale et al., 2013). 
Increases in gingival inflammation and dental plaque during MV can also 
reflect the changing of oral hygiene levels (Carrilho Neto et al., 2011). 
Measuring the gingival index, a score based on severity of gum inflammation 
with a score of 0 indicating gum health and a maximum of 3 indicating severe 
gum inflammation (Pearson & Hutton, 2002; Carrilho Neto et al., 2011), and 
the scoring of dental plaque by a dental professional, based on visibility of 
dental plaque could build upon existing information available to health care 
professionals and reflect potential risk of secondary infection. Measuring 
dental plaque scores at set intervals during critical care could further be used 
as an indicator of changing oral hygiene. There is a need to emphasise the 
importance of dental scoring such as plaque scoring and gingival index to 
facilitate patient specific oral interventions (Wise & Williams, 2013). Further 
analysis examining an association between previous oral hygiene and risk of 
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VAP could further highlight the importance of oral scoring in assessing a 
patient’s risk for VAP. 
 
A dental score that is used to assess previous oral hygiene status and a risk 
indictor of oral health status is the Decayed Missing and Filled Teeth (DMFT) 
score. A DMFT score is used to assess dental caries status and is therefore 
an indicator of previous oral hygiene, and can reflect current oral health 
status within the patient (Becker et al., 2007). DMFT scores are however not 
usually performed in critical care units. To obtain a DMFT score, an oral 
healthcare professional scores each tooth as either D, M or F, to generate a 
score of between 0-28 (28 being the highest score and indicative of 
advanced dental caries). Each incidence of a tooth resembling D, M or F 
results in a score of 1. DMFT scores may reflect the level of risk of dental 
plaque changes. It is important to complete oral profiles for patients who 
undergo MV as risk of VAP increases 1% with every day patient is connected 
to the ventilator, and can increase up to 80% chance if the patient is 
mechanically ventilated >10 days (Bern et al., 2013). DMFT is one example 
whereby an external non-invasive examination can be used to assess the 
patients’ teeth upon admission to the ICU. 
 
1.8.5.4 Antiseptic mouthwashes and lubricants 
Antimicrobial mouthwashes and oral lubricants are also used to aid oral care 
in critically ill patients and have been the subject of multiple systematic 
reviews (Yoneyama et al., 2002; Labeau et al., 2011; Lam et al., 2012). 
Several oral antiseptic mouthwashes are currently available for use in oral 
decontamination in mechanically ventilated patients.  
A 10% povidone-iodine solution was used in a study by Seguin et al., 2014, 
with the primarily outcome measure of VAP reduction. Povidone-iodine 
penetrates the cell wall of bacteria and affects the functions of bacterial 
proteins (Donnell, 1999), and is highly effective against Gram-negative 
species such as P. aeruginosa. Seguin et al., 2014 however concluded that 
	 39 
the use of povidone-iodine in high-risk patients did not reduce VAP 
incidence, and recommended avoiding its use due to an associated increase 
in acute respiratory distress syndrome (ARDS). 
 
Essential oils menthol, thymol, methyl salicylate and eucalyptol (Listerine ™) 
and sodium bicarbonate combinations have also been used in oral hygiene 
intervention in critical care. However, there is little evidence of these 
combinations in reducing VAP (Berry, 2013). Eucalyptol and menthol 
(constituents of Listerine formulations), have previously been effective at oral 
biofilm penetration in in vitro studies (Chen et al., 2011). The overall 
conclusion for the use of antiseptic mouthwashes as a reduction strategy for 
VAP remains unclear, with studies reporting conflicting efficacy over the use 
of various antimicrobial mouthwashes. The most widely used and researched 
antiseptic mouthwash used in selective oral decontamination in mechanically 
ventilated patients are chlorhexidine based mouthwashes and rinses. 
 
1.8.5.5 Chlorhexidine 
A 0.12% (v/v) chlorhexidine gluconate water soluble oral rinse or gel is often 
applied in critical care units as an oral mouthwash (Jones, 1997; Kusahara et 
al., 2012). Chlorhexidine damages cell membranes of Gram-positive and 
Gram-negative bacteria, as well as being effective against yeasts such as C. 
albicans. The effectiveness of chlorhexidine is partly based on its ability to 
adsorb via its positive charge to negatively charged surfaces of the oral 
cavity (O’Reilly, 2003; Kusahara et al., 2012). After adsorption, chlorhexidine 
is released over several hours, a phenomenon called substantivity post 
adsorption, which serves to increase its duration of antimicrobial activity 
(Smith et al., 2013; Sands et al., 2014). Importantly, for chlorhexidine to be 
most effective there is a need to have a relatively clean surface prior to its 
administration (to adsorb to oral surfaces i.e. the teeth). 
Early treatment with chlorhexidine, especially in the form of oral swab 
delivery, has been reported to reduce rates of VAP (Grap et al., 2011). 
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Chlorhexidine is, however, inactivated by sodium lauryl phosphate, 
commonly found in toothpaste, and other ingredients are known to interact 
with its activity (Munro et al., 2009). Care and appropriate consideration must 
therefore be taken when using chlorhexidine in conjunction with mechanical 
brushing using fluoride based toothpastes (O’Reilly, 2003).  
Over the last 15 years, clinical studies, meta analyses and systematic 
reviews have investigated the benefits of chlorhexidine in critical care. A 
recent meta analysis and systematic review by Klompas et al., 2014 explored 
effectiveness of chlorhexidine in a critical care setting. Klompas et al 
suggested the limitations of chlorhexidine application might arise from patient 
variation, and specifically whether the patient was admitted due to declining 
health or for elective surgery. Nevertheless, the efficacy of chlorhexidine 
applications remains a matter of debate (Jones, 1997; Pineda et al., 2006; 
Zanatta et al., 2007; Bellissimo-Rodrigues et al., 2009; Scannapieco et al., 
2009; Grap et al., 2011; Kumari, 2012; Scannapieco & Binkley, 2012; 
Bonten, 2014; Klompas et al., 2014). Such contrasting evidence over relative 
benefits has led to a great variation in oral care protocols worldwide. 
Considering the cost of VAP treatments and aftercare, preventative 
measures will perhaps be more cost effective for the healthcare provider, and 
undoubtedly reduce both patient and resource stress (Joseph et al., 2010).  
 
1.8.5.6 Tooth brushing in mechanically ventilated patients 
The accumulation of dental plaque may increase a patient’s chance of 
developing VAP during MV (Munro et al., 2006). One of the most effective 
methods to prevent plaque overgrowth is the non-pharmacological approach 
of mechanical brushing (Johnson et al., 2012). The choice of toothbrush 
used can alter effectiveness of plaque removal. Research into different types 
of toothbrush has suggested the advantage of electric toothbrushes over 
manual toothbrushes in removing a greater abundance of the biofilm. A 
randomised study by Needleman et al., 2011 found a significant reduction in 
dental plaque when using a powered toothbrush. In addition, smaller 
toothbrushes, such as paediatric brushes have also been considered in 
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many ICU units as opting for a smaller brush allows access to difficult areas, 
especially around the mouth connector for ETTs (O’Reilly, 2003; Johnson et 
al., 2012; Prendergast et al., 2013). Toothbrushes with suctions and 
aspiration applicators are also used in critical care to simultaneously brush 
patients’ teeth and remove any dislodged debris before application of 
chlorhexidine (Hutchins et al., 2009). However a major challenge of tooth 
brushing is the physical ability to reach tooth surfaces around the ETT 
apparatus (Needleman et al., 2011). 
 
1.8.5.7 Oral care compliance  
Although there is great variation in the administration of oral care in critical 
care units, maintaining adequate oral hygiene is essential. Performing oral 
care does not only limit microbial colonisation and dental plaque 
accumulation, but increases patient comfort and provides lubrication in the 
oral cavity (Jones et al., 2004).  
Oral intervention for mechanically ventilated patients, although considered a 
vital component of the ICU oral hygiene care plan, is sometimes overlooked. 
In many cases the duration of oral care delivery is shorter than necessary, 
and many nurses are perhaps reluctant to clean the teeth mechanically, for 
fear of dislodging the ETT (Berry & Davidson, 2006; Lloyd et al., 2011; Munro 
& Grap, 2004). Maintaining adequate oral care is therefore challenging.   
In order to improve oral care compliance and facilitate chlorhexidine 
application in critically ill patients, manufacturers (e.g. Sage Products; Illinois, 
USA) have produced single dispensing foam swabs incorporating 
chlorhexidine, referred to as a Toothette™ for use in critical care units A 
study by Munro et al., 2009 used the Toothette™ to apply chlorhexidine to 
the oral cavity within a randomised trial. Munro et al., 2009 concluded that 
chlorhexidine applications did reduce the incidence of pneumonia in 
comparison to patients receiving tooth brushing alone. The structure and 
composition of the swab enables both lubrication of the oral cavity with 
chlorhexidine or other oral care products whilst the ridged brush gently 
removes any anchored dental plaque.  
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Tooth brushing is one of the most effective management strategies for 
maintaining dental plaque accumulation, usually performed in conjunction 
with chlorhexidine application. In critical care medicine the immediate priority 
for nurses and physicians is patient survival and oral care is often considered 
a secondary intervention.  
Overall, research into the benefits of mouthwash administration in 
mechanically ventilated patients is extensive. Oral care may reduce VAP 
incidence, however currently there is little evidence to suggest that there are 
benefits in clinical outcomes for length of ICU stay or duration of MV (Li et al., 
2015). 
 
1.8.5.8 Selective Oropharyngeal Decontamination (SOD) 
Selective oropharyngeal decontamination of the oropharyngeal tract is a 
regime to prophylactically treat the oropharynx area with topical antibiotics 
and prevent pathogenic colonisation of Gram-negative bacteria and S. 
aureus (Oostdijk et al., 2013). Unlike the application of care bundles and oral 
antiseptics, SOD programs administer antibiotics to the entire oropharyngeal 
tract. For such topical applications, tobramycin and amphotericin B (for 
overgrowth of Yeasts) are frequently used (Bonten, 2006; de Smet et al., 
2009).  
 
1.8.5.9 Selective Digestive Decontamination (SDD) 
Selective decontamination of the digestive tract (SDD) is performed to 
eradicate potentially pathogenic microorganisms in the oropharyngeal and 
digestive tract of critically ill patients (Silvestri & Saene, 2012; Oostdijk et al., 
2013). SDD is the application of the combination of both topical and 
intravenous antibiotics to reduce incidence of exogenous and endogenous 
HAIs and reduce mortality rates in critical care (Silvestri & Saene, 2012).  
Antibiotics used for SDD include a second-generation cephalosporin such as 
ceftazidime or a third-generation cephalosporin, cefotaxime, for intravenous 
application. If the patient was previously healthy (no underlying illness) a 
beta-lactam IV antibiotic is also widely used. Although there are suggested 
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antibiotics for SDD that are anti-Pseudomonas or specific antifungals, clinical 
choice is dependent on medical history, microbial culture results, and rates of 
antimicrobial resistance.  
The efficacy and advantages of SDD are still debated (Bonten et al., 2000; 
Chaari et al., 2013), however de Smet et al., 2009 regards SDD to be as 
effective as SOD. With an increase in antimicrobial resistance, SOD seems 
preferable because it can avoid widespread systemic cephalosporin usage. 
Deciding whether to prophylactically administer antibiotics further 
complicates matters for clinicians (Laxminarayan et al., 2013).  
 
1.8.5.10 SOD versus SDD 
In a landmark study, de Smet et al., 2009 performed a crossover randomised 
trial of standard care, comparing SDD and SOD in 13 intensive care units in 
the Netherlands with 5939 patients. Rather than focusing on VAP, mortality 
was chosen as the outcome measure and there was an absolute reduction of 
3.5% and 2.9% with both SDD and SOD respectively. There was no 
difference between SDD (four days intravenous antibiotics plus tobramycin, 
colistin, and amphotericin B to mouth and stomach) and SOD, (which used 
tobramycin, colistin, and amphotericin B paste four times a day). Findings of 
this study suggest similar survival rates with SOD and SDD programs.  
Furthermore, a recent meta analysis by Zhao et al., 2015 analysed the 
effects of SOD and SDD in mortalitly, length of critical care stay, and carriage 
of Gram-negatvie bacteria in 23,822 patients. There were similar clinical 
outcomes in mortality and length of stay between SOD and SDD regimes, 
however SOD resulted in a higher carriage of Gram-negative bacteria. Due 
to both cost and antibiotic resistance concerns of SDD, the suggested 
outcome for this meta analysis was the prophyaltic SOD regime. Both these 
studies demonstrate and promote a reduction in mortality with a measure 
that aims to improve oral hygiene regimes. Ultimately, the prevention of VAP 
includes assessing several parameters including patient care, critical care 
apparatus used, oral hygiene and the training of critical care professionals.  
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1.8.6 Antimicrobial treatment for VAP  
Pneumonia associated with mechanically ventilated patients, may be more 
difficult to treat, largely due to increasing incidence of antimicrobial 
resistance in the microorganisms involved. Once VAP has been diagnosed, 
or strongly suspected, antibiotic therapy is implemented. Problems can occur 
however, when deciding not only the choice of pharmacological agent, but 
also when to begin treatment. Clinicians have the choice of using empiric 
treatment using broad-spectrum antibiotics once symptoms of VAP appear, 
or wait until microbial culture results are available (Muscedere et al., 2008). 
Ideally, waiting for culture results would provide better evidence over which 
agent to use, and perhaps give an indication of the duration periods for 
antimicrobial chemotherapy (Magnotti et al., 2011).  
Optimum antibiotic treatments for VAP often differ between critical care units 
and between individual patients, with multiple classes of antibiotics becoming 
less effective. MDR pathogens are commonly associated with causing VAP 
(Magnotti et al., 2011; Tseng et al., 2012; Tedja et al., 2014). Single antibiotic 
treatments are, in many cases of limited use, however certain antibiotics 
such as meropenem and tobramycin when used in conjunction with others 
provide a greater probability of successful treatment (Kollef, 2005; 
Muscedere et al., 2008; Luyt et al., 2014). The difficulty in treating VAP 
highlights the need of effective preventative measures for VAP in critical 
care.  
Inappropriate and excessive exposure of microorganisms to antibiotics has 
occurred in recent decades. Over prescription has contributed to the 
generation of MDR strains for many bacterial genera. MDR organisms have 
disseminated globally and bacterial resistance to antibiotics is now a major 
health problem (Magiorakos et al., 2011; Aliberti et al., 2013). Briefly, there 
are 3 basic mechanisms of antimicrobial resistance (Table 1.7; figure 1.9). 
Firstly, cell wall, membrane and efflux pumps stop the antibiotic reaching 
intracellular targets. Secondly, biofilm cells can stop the antibiotic penetrating 
the cell, and finally changes in target site or excessive production of target, 
can result in the degradation of antibiotic.   
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Figure 1.9 – A schematic diagram of a bacterial cell showing mechanisms of 
bacterial antibiotic resistance adapted from Wright, 2011. 
 
 
The ability of microorganisms to acquire resistance has developed through 
multiple mechanisms with MDR species often having more than one 
mechanism (Alekshun & Levy, 2007; Wright, 2011). Antimicrobial resistance 
in biofilms adds a further dimension when considering antibiotic therapy. 
Biofilms can be up to 1,000 times more tolerant to antimicrobials compared 
to planktonic cells (Fricks-Lima et al., 2011), as summarised in figure 1.10. 
The EPS protecting the microbial species within the biofilm acts as a shield 
against external pressures such as antibiotics. A clinically relevant and 
frequently MDR resistant organism is P. aeruginosa. Pseudomonas 
aeruginosa can develop resistance through several mechanisms, resulting in 
resistance to carbapenems (such as meropenem) a group of broad-spectrum 
β-lactams. The two main mechanisms of resistance to carbapenems are use 
of efflux-pumps (Pai et al., 2001) and production of β-lactamases (Pitout et 
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al., 2005). Resistant strains of P. aeruginosa actively exclude antibiotics via 
efflux pumps, whilst altered membrane permeability can further limit delivery 
of antibiotic into the bacterial cell. MDR pathogens are now the cause of 
several antibiotic resistant bacterial outbreaks both within the hospital and 
the wider community (Consales et al., 2011; Tseng et al., 2012). It is 
essential to develop alternative treatments to reduce mortality rates of HAIs.  
 
 
Figure 1.10 – Mechanisms of resistance in biofilms, adapted from Thien-Fah 
and O’Toole 2001. The bacteria within the extracellular matrix (represented 
in yellow) undergo changes to enhance resistance mechanisms within the 
biofilm community. 
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1.9 Summary  
VAP is the most prevalent HAI in intensive care (Joseph et al., 2010). The 
ETT is an essential interface between patient and ventilator but its placement 
promotes VAP, by impeding host defence mechanisms, and supporting 
potentially pathogenic biofilms within its inner lumen that can subsequently 
disseminate into the lower airways. Timely diagnosis of VAP in mechanically 
ventilated patients in critical care units is often difficult. Treatment of clinically 
diagnosed VAP is challenging, as it is a biofilm-mediated infection that is 
increasingly caused by multidrug resistant organisms.  
 
The composition of dental plaque is thought to change during MV, with 
respiratory pathogens dominating the polymicrobial biofilm, however the 
reasons for this suggested microbial shift remain poorly understood. A 
greater understanding of how to achieve good oral hygiene in patients and 
control dental plaque is essential for improving health. Microorganisms within 
the oral cavity have access to the lower airways, via the ETT.  Examining the 
occurrence and extent of dental plaque community changes during MV is the 
overarching aim of this PhD project. 
 
	 49 
1.10 Project Aims and objectives  
Reducing the prevalence of VAP requires a greater understanding of the 
exact pathogenesis and aetiology. Given the importance of the oral 
microbiome in the development of VAP and the lack of understanding of the 
changes of the oral microbiome during MV, within this project, there are four 
main aims: 
 
CHAPTER 2: To longitudinally assess dental plaque and the 
microenvironment of the oral cavity throughout the course MV, and, where 
possible, into the post ETT-extubation recovery period of critical illness. The 
aim of this work is to evaluate changes to dental plaque during MV. 
 
CHAPTER 3: Molecular characterisation of dental plaque and lower airways 
microbial communities will further fulfill project aims by profiling communities 
during MV using a new technique, without the bias of microbial culture.  
 
CHAPTER 4: Saliva and blood (plasma extractions) will be subject to 
proteomic analysis to ultimately assess host immunity. The aim of this work 
is to ascertain whether salivary parameters are associated with dental plaque 
colonisation by respiratory pathogens. 
 
CHAPTER 5: Based on clinical findings, biofilm models will be developed to 
mirror any dental plaque compositional changes under controlled conditions. 
The aim of this work is to assess the possible aetiology of compositional 
changes and to evaluate any associations with saliva. 
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Chapter 2 
Characterisation of biofilms from 
mechanically ventilated patients 
by culture and imaging 
	 51 
2. 1 Introduction  
 
Critical illness requiring mechanical ventilation (MV) occurs as a result of 
many disease processes, critical care populations are therefore 
heterogeneous. Up to 50% of patients admitted to critical care require MV, 
usually as a consequence of respiratory failure or impaired consciousness 
(Estern et al., 2000; Anzueto et al., 2002). Often in these patients, priorities 
are understandably given to addressing the immediate clinical problem and 
in such circumstances, provision and compliance of oral care may not be 
adequately delivered (Ames, 2011).  
 
Colonisation of dental plaque by respiratory pathogens during MV has been 
reported previously, primarily using microbial culture techniques (Heo et al., 
2008; Scannapieco et al., 2009; Needleman et al., 2011; Sachdev et al., 
2013; Shi et al., 2013). Heo et al., 2008 performed pulsed-field gel 
electrophoresis upon DNA collected from dental plaque and the lower 
airways of 100 patients during ventilation, identifying several 
indistinguishable strains of Staphylococcus aureus, Pseudomonas 
aeruginosa, Escherichia coli, Klebsiella pneumonia, Acinetobacter species 
and Enterobacter species. Other studies including Needleman et al., 2011 
and Sachdev et al., 2013, performed microbial culture analysis of dental 
plaque during mechanical ventilation, though with a smaller sample size (45-
50 patients). Both Needleman et al., 2011 and Sachdev et al., 2013 revealed 
similar respiratory pathogen colonisation of dental plaque to that ascertained 
by Heo et al., 2008, and additional pathogens Haemophilus influenzae, 
Proteus mirabilis and Serratia species were also isolated from dental plaque 
during MV in these studies. The extent of respiratory pathogen colonisation 
of dental plaque and the role in the aetiology of VAP however, remains 
poorly understood.  
In mechanically ventilated patients, the ETT provides the essential interface 
between the lung and the ventilator. Unfortunately, the presence of an ETT 
will also impair pulmonary host defences and can promote ventilator-
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associated pneumonia (VAP) through supporting biofilms within its inner 
lumen (Raad et al., 2011; Gil-Perotin et al., 2012; Vandecandelaere et al., 
2012). The physical placement of the ETT and associated equipment to 
secure it may also impede the ability to deliver oral care. ETT biofilms can 
form within a period of 24 h (Perkins et al., 2010) and may serve as a 
reservoir of respiratory pathogens that are largely protected from host 
defence mechanisms. Cairns et al., 2011 analysed the microbial 
communities of 24 ETT biofilms using molecular techniques including 
denaturing gradient gel electrophoresis (DGGE), revealing ETT colonisation 
by P. aeruginosa and S. aureus. In addition Cairns et al., 2011 found 
representative species of the oral microbiota including Streptococcus 
mutans, Porphyromonas gingivalis and C. albicans colonising within ETTs. 
Once formed, aggregates of respiratory pathogens can dislodge from the 
biofilm to the lower airway. It could be postulated that this facilitates the 
delivery of pathogenic agents already within a biofilm phenotype which, it 
could be argued are already more resistant to host defence mechanisms and 
administered antimicrobials.  
 
In recent years, studies into the origin of VAP-causing microorganisms have 
primarily focused on oropharyngeal sites rather than the gastro-intestinal 
tract (Bonten et al., 1994; Garrouste-Orgeas et al., 1997; Bahrani-Mougeot et 
al., 2007; Heo et al., 2008). As a consequence, a number of current 
strategies aimed at preventing VAP now involve targeting oral 
microorganisms (Shi et al., 2013; Silvestri et al., 2014). The most obvious 
means of reducing the numbers of infectious microorganisms within the oral 
cavity is the provision of effective oral care regimes. This could be 
considered to work in two ways, either reducing the colonisation of plaque by 
potential respiratory pathogens and/or reducing the microbial load in plaque 
already colonised in an attempt to reduce colonisation of the lower airways. 
 
To highlight the importance of effective oral care in mechanically ventilated 
patients to healthcare providers, demonstrating the complex dynamics within 
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oral microbial communities that culminate in respiratory pathogen 
colonisation is important. In addition, showing the translocation of such 
pathogens from the mouth to the ETT lumen and the lower airways will 
further strengthen the argument for effective oral care in mechanically 
ventilated patients. This in turn will help to facilitate the development of 
interventions that could reduce the colonisation of dental plaque by potential 
respiratory pathogens and or the translocation of respiratory pathogens from 
the mouth to the lower airways. 
 
The primary aim of the work reported in this chapter was to reveal the extent 
of respiratory pathogen colonisation of dental plaque and lower airways of 
mechanically ventilated patients on a longitudinal basis, both during MV and 
into the post ETT-extubation (recovery from critical illness) period. 
Specifically, the objectives were three-fold: 
(1) To ascertain the extent of respiratory pathogen colonisation within 
dental plaque and the lower airways during MV by culture and 
species-specific PCR. 
(2) To ascertain whether respiratory pathogens were present in the 
dental plaque during the post-ETT extubation period corresponding to 
recovery from critical illness.  
(3) To perform image analysis on ETT biofilms via SEM and CLSM 
coupled with FISH and species-specific PNA probes to identify and 
locate target respiratory pathogens within the ETT biofilm. 
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2.2 Materials and Methods 
 
2.2.1 Cohort observational study: ethical approval 
Ethical portfolio adoption for the observational cohort study was submitted on 
the 11th April 2013 to the NISCHR CRC Central Office. Ethical approval was 
obtained from National Research Ethics Service (NRES) within the Research 
Ethics Committee (REC), Wales (Ref: 13/WA/0039) for a single NHS 
organisation study on 20th June 2013 to evaluate dental plaque biofilms 
during the course of MV. To ensure sufficient statistical power (>80%) to 
observe a 20% change in at least one phylum in microbial profiles and 
associated downstream high-throughput techniques (Chapter 3), the 
minimum number of participants required for the study was 101.  
2.2.2 Patient recruitment    
Mechanically ventilated patients at a single University Hospital Critical Care 
Unit were eligible for inclusion in the study if they were aged >18 years, had 
>8 original teeth, anticipated period of MV >24 h, and an expected survival of 
>24 h. Informed consent for participation in the study was obtained from the 
next of kin by the responsible clinician. I gratefully acknowledge the research 
nurses within Critical Care Unit at The University Hospital of Wales, Cardiff 
for taking patient consent, collecting demographic data and sampling of 
mechanically ventilated patients recruited to the study. The following 
participant information was collected during the course of the study: gender, 
age, and diagnosis/critical care admission details.  The number of decayed, 
missing, and filled teeth (DMFT score) was determined by a dental 
practitioner and used as an indirect indicator of previous general dental 
health status and oral hygiene (Becker et al., 2007). Standard oral care was 
routinely performed (every 4-12 h) following a critical care mouth assessment 
to determine level and frequency of oral care required.  
 
VAP was diagnosed using the existing Clinical Pulmonary Infection Score 
(CPIS) score (with a score >6), with aetiology confirmed by blood culture and 
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quantitative microbiological culture (>103 colony forming units (CFU)/ml) of 
the lower airways samples (bronchoalveolar lavage (BAL)/non-directed 
bronchoalveolar lavage (NBL) (Pugin et al., 1991; Zilberberg & Shorr, 2010; 
Estella & Álvarez-Lerma, 2011; Kalanuria et al., 2014; Hellyer et al., 2015). 
Antibiotics were prescribed at the clinicians’ discretion and a thrice-weekly 
ward round provided further stewardship with clinical microbiologists. 
 
2.2.3 Microbial culture of dental plaque, subglottic aspirations and non-
directed bronchoalveolar lavage (NBLs)  
2.2.3.1 Dental plaque, subglottic aspiration and NBL collection  
Subgingival and supragingival dental plaque was collected by a healthcare 
professional using paper points (specifically rolled absorbent and narrow 
strips of paper) (size 40, QED, Peterborough, UK) and dental examination 
kits (Minerva Dental) (Bollen & Quirynen, 1994). Paper points are also 
effective in collecting subgingival and supragingival dental plaque by direct 
mechanically scraping of target sites, minimising the risk of contamination 
from other colonised sites of the oral cavity (Smola, 2003). Dental plaque 
collection was performed on 3 occasions during the first week of admission 
to critical care, and then weekly until hospital discharge, for up to a maximum 
of 3 months post admission to the intensive care unit (ICU). To standardise 
collection, dental plaque was collected on the morning of the due date. A 
total of 9 paper points, sampling 3 teeth per area (front, middle and back) 
were used per collection. In cases where the patient did not have sufficient 
teeth for the above protocol, samples were taken from the areas closest. 
Dental plaque was suspended in 1 ml of filter sterilised (0.22 µm, Fisher) 
transport medium (TM) at a pH of 7.0 (75 ml of stock solution 1 (0.6% 
dipotassium phosphate – K2PO4), 75 ml of stock solution 2 (1.2% sodium 
chloride – NaCl, 1.2 ammonium sulphate, 0.6% potassium dihydrogen 
phosphate and 0.25% magnesium sulphate), 10 ml of 0.1 M EDTA, 5 ml of 
8% sodium carbonate, 20 ml of 1% dithiothreitol (DTT) and 815 ml of distilled 
water (Syed & Loesche, 1972)). TM bottles were then placed in an aerobic 
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incubator at 37°C overnight to confirm sterility. Before use, 1 ml of TM was 
aliquoted into microcentrifuge tubes in the class II safety cabinet and stored 
at 4-8°C. 
 
Subglottic aspirations were collected through a port in the ETT using a 
syringe and transferred into sterile universals. NBLs were collected using a 
suction catheter through the ETT, when clinically necessary as determined 
by the responsible Critical Care Consultant. Subglottic aspirations and NBLs 
were aseptically transferred into universal containers for transport to the 
microbiology laboratory.  
 
2.2.3.2 Microbial culture of dental plaque and fluid collected from the 
lower airways  
Processing and subsequent analyses of clinical specimens was undertaken 
in the class II safety cabinet using additional personal protective equipment 
(PPE) including Sheildskin nitrile PPE Category III gloves (AQL score of 
0.65) when appropriate. Dental plaque was vortex mixed for 30 s and paper 
points removed using sterile tweezers. Aspirations and BALs/NBLs were 
centrifuged for 5 min at 10,000 × g and resuspended in 1 ml of PBS. A 500-µl 
volume of resuspended sample was used to inoculate Microbank™ Beads 
(Fisher) for subsequent storage and analysis. For microbial culture, 25µl of 
dental plaque, NBL and subglottic aspirate was added to selective agars for 
detection of S. aureus (Mannitol Salt Agar; MSA, LAB 007), P. aeruginosa 
(Pseudomonas agar base; Pseudo, LAB 108), C. albicans (Sabouraud 
Dextrose agar; SAB, LAB 009) and S. mutans (Mitis Salivarius-Bacitracin 
agar; MSB, Oxoid 229810). Agar media were incubated at 37°C in the 
presence of O2 (aerobically) for a period of 5 days. All microbial growth was 
recorded for data analysis using Microsoft Excel. Suspected Candida species 
on SAB agar were subcultured on CHROMagar® Candida media (Oxoid) 
and incubated for 24 h at 37°C, for the selective identification of yeast 
species. Any culture media positive isolates of P. aeruginosa and S. aureus 
were subject to further biochemical identification tests. Presumptive P. 
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aeruginosa isolates were subjected to an oxidase test (Oxoid) using a non-
metallic loop. For presumptive staphylococci isolates, 3 individual colonies 
were subjected to a catalase test (hydrogen peroxide; Sigma) to distinguish 
and these were subsequently tested for coagulase (with positive coagulation 
largely indicative of S. aureus; Oxoid). All confirmed species of S. aureus and 
P. aeruginosa were stored on Microbank™ Beads (Fisher) for subsequent 
species-specific PCR analysis.  
 
2.2.3.3 Microbial analysis of ETT biofilms  
ETTs were collected post extubation, wrapped in sterile moist tissue paper, 
and placed into an autoclaved bag for transport across to the School of 
Dentistry Microbiology Laboratories for processing. All analyses were 
performed in a Class II Safety Cabinet. The exterior of the tube was wiped 
with 70% ethanol and the tube was transferred onto a corkboard wrapped in 
sterile paper. 
A sterile scalpel was used to cut 4×0.5 cm sections of the ETT from its 
midpoint or region where a biofilm was most evident. One section was 
processed for imaging (section 2.2.5 - 2.2.7), and the remaining three 
sections were processed for microbial culture. Biofilms were scraped from 
the 3 sections of the extubated ETTs using a cotton swab. The swab was re-
suspended in 5 ml PBS, vortex-mixed for 30s and serial-decimally diluted. All 
dilutions were plated onto selective agar and incubated as described in 
section 2.2.3.2. The remaining ETT was discarded for incineration. 
2.2.3.4 Identification of isolated respiratory pathogens using species-
specific PCR  
Definitive identification of S. aureus and P. aeruginosa isolates was achieved 
by species-specific PCR. Total DNA extraction was performed using a DNA 
extraction kit (Qiagen). The Gram-positive extraction protocol was followed 
as described by the manufacturer with minor modification.  In the case of S. 
aureus, a 1 ml volume of overnight culture, in Brain-Heart Infusion (BHI) 
broth (Oxoid) was placed in a sterile 1.5 ml microcentrifuge tube and 
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centrifuged for 1 min at 16,000 × g. The pellet was resuspended in 300 µl of 
cell suspension buffer containing 1.5 µl of lytic enzyme solution (Qiagen). 
The tube was inverted 25 times, and incubated at 37°C for 30 min. An 
additional step was required for P. aeruginosa, an additional incubation step 
of 5 min at 80°C was necessary after the initial cell suspension was added to 
aid bacterial cell lysis. After centrifugation for 1 min at 16,000×g, the sample 
was then re-suspended in 300 µl of cell lysis solution (Qiagen). A 100-µl 
volume of was added and the tubes were vortex mixed for 20 s. After a 3 min 
centrifugation step at 16,000 × g the supernatant was transferred to a clean 
1.5 ml microcentrifuge tube containing 300 µl of isopropanol, and gently 
inverted 50 times. Samples were centrifuged for a further 1 min period at 
16,000 × g, with the supernatant being discarded and the microcentrifuge 
tubes drained on to a clean absorbent tissue. A 300-µl volume of 70% 
ethanol (v/v in water) was added to the remaining pellet and centrifuged for 1 
min at 16,000 × g. A 100-µl volume of DNA hydration solution and 1.5 µl of 
RNase A solution (Qiagen) was then added, and the tubes were vortex 
mixed for 5 s. The tubes were incubated at 37°C for 30 min and then at 65°C 
for 1 h to dissolve the DNA.  
PCR was performed with a total volume of 50 µl (2 µl of DNA, 22 µl of 
nuclease free water, 25 µl Mastermix PCR reagents (Promega) and 0.5 µl of 
forward primer, and 0.5 µl of reverse primer (Table 2.1)). Thermal cycling 
parameters for S. aureus PCR included an initial 5 min at 94ºC, followed by 
35 cycles of 94ºC for 40s, 50ºC for 40 s and 72ºC for 1 min with a final 
elongation step of 72ºC for 10 min. For P. aeruginosa PCR, cycling 
parameters included an initial denaturation step of 95ºC followed by 35 
cycles of 94ºC for 45 s, 58.4ºC for 45 s and 72ºC for 1 min ending with 5 min 
at 72ºC. Where multiple bands were encountered, repeat culture onto 
selective agar for re-biochemical testing and PCR amplification was 
undertaken to ensure single species.  
 
 
	 59 
Table 2.1 - PCR primers used for identification of S. aureus and P. 
aeruginosa  
 
Species Target 
Gene 
 
Primers Amplicon 
size 
Reference 
 
S. aureus 
 
Vick 
 
vicK1: 5’-CTA ATA CTG 
AAA GTG AGA AAC GTA-3’ 
vicK2: 5’-TCC TGC ACA 
ATC GTA CTA AA-3’ 
 
 
289 bp 
 
(Liu et al.,     
2007) 
P. aeruginosa ecfX Ps.aeru_ECF1: 5’-ATG GAT 
GAG CGC TTC CGT G -3’ 
Ps.aeru_ECF2: 5’-TCA TCC 
TTC GCC TCC CTG -3’ 
 
528 bp (Lavenir et al., 
2007) 
 
2.2.4 Dental plaque imaging  
The viability and distribution of bacteria in dental plaque biofilms was 
assessed using fluorescent microscopy using a live/dead stain (LIVE/DEAD® 
BacLight™; LifeTechnologies). A microbial loop was used to transfer dental 
plaque vortex mixed in TM on to a microscope slide (SuperFrost, Fisher) 
which was air dried for 5 min. Equal volumes (50-µl) of SYTO® 9 dye (live 
cell stain) and propidium iodide (dead cell stain) were combined in PBS and 
transferred into a microcentrifuge tube and vortex-mixed for 20 s. A 25-µl 
volume of the dye preparation was added to each slide to cover the dental 
plaque smear and overlaid with a coverslip. The slides were covered with tin 
foil and incubated at 37°C for 15 min before imaging by confocal 
fluorescence microscopy (Emission green – live, red – dead) (2.2.7.3).   
 
2.2.5 Preparation of ETTs for microscopic imaging  
ETT sections (0.5 cm length) were washed in 2 ml of PBS and immersed in 2 
ml of 10% (v/v) formalin for a minimum period of 24 h. The ETTs were 
paraffin wax embedded using routine methodology, sectioned at 20 µm and 
placed on to glass histology slides (SuperFrost, Fisher).  
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2.2.6 SEM analysis of endotracheal tube biofilms 
To de-wax the sections for imaging, 3 incubation periods of 10 min each in 
xylene was undertaken, followed by a wash with 100% ethanol. The slides 
were air-dried and sputter coated with gold for 8 min in readiness for 
scanning electron microscopy (SEM). Biofilms were viewed in a JEOL 840A 
SEM at 5kV and digital images captured using SIS software (School of 
Medicine, Cardiff University).  
 
2.2.7 Peptide nucleic acid fluorescent in situ hybridisation (PNA-FISH) 
confocal microscopy of endotracheal tube (ETT) biofilms  
2.2.7.1 PNA FISH on extubated ETTs 
The ETT 20 µm sections were prepared and de-waxed (2.2.6). A 100-µl 
volume of Sputasol (Sputum liquefying agent, Oxoid) was added to the ETT 
section and incubated at 37°C for 30 min. A 100-µl volume of PBS was 
added to wash the sections, followed by 100 µl of each of the following 
enzymes; proteinase K, lysostaphin or chitosan (in the volume and 
incubation temperature/length) as described below. Proteinase K (Sigma) 
was diluted from a stock solution (10 mg/ml) to 0.1 mg/ml and 100 µl added 
to each slide and incubated at 37°C for 30 min. Lysostaphin (Sigma) was 
diluted from stock solution of 1 mg/ml to 0.2 mg/ml and 100 µl added to each 
slide and incubated at 37°C for 1 h. Chitosan (Sigma; 1 g) was added to 50 
ml of 1% acetic acid and carefully mixed to a gel. A further 50 ml of 1% acetic 
acid was added to create a final solution of 1% chitosan in 1% acetic acid. A 
100-µl portion of this mixture was added to each slide and incubated at 20°C 
for 30 min. A 100-µl volume of lysozyme (10 mg/ml) was then added and 
incubated at 37°C for 45 min.  
 
2.2.7.2 PNA probe hybridisation buffer and washing solution 
preparation 
The PNA probes (Panagene) (Table 2.2) were prepared at a stock 
concentration of 100 µmol in sterile H20 for storage at -20°C. Stock 
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concentration of probes were diluted with hybridisation solution (10% (w/v) 
dextran sulphate, 10 mM NaCl, 30% (w/v) formamide, 0.1% (w/v) sodium 
pyrophosphate, 0.2% (w/v) polyvinylpyrolidone, 0.2% (w/v) ficol, 5 mM 
disodium EDTA, 50 mM Tris HCl and 0.2% Triton-X at pH 7.5) to either 300 
nM or 450 nM. A 1 L wash solution (5 mM Tris 15 mM NaCl and 0.1% (v/v) 
Triton-X-100 at pH 10) (Lefmann et al., 2006), was prepared in sterile H20 
and stored at 4°C. 
 
Table 2.2 - Species-specific PNA probes and associated fluorescent markers 
 
Probe 
 
Probe sequence 
Working 
concentration 
(nM) 
Fluorescent 
marker (N- 
terminal) 
    
Bacterial 
Universal 
CTGCCTCCCGTAGGA 300 Cy3-00- 
Pseudomonas 
aeruginosa 
 
AACTTGCTGAACCAC 300 FITC-00- 
Staphylococcus 
aureus 
 
GCTTCTCGTCCGTTC 450 Cy5-00- 
Streptococcus 
mutans 
 
ACTCCAGACTTTCCTGAC 450 Alexa405-00- 
Candida 
albicans 
 
ACAGCAGAAGCCGTG 300 FITC-00- 
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A 100-µl volume of each PNA probe (Table 2.2) was added to a 
microcentrifuge tube and gently pipette mixed for hybridisation. A 100-µl of 
mixed PNA probes were added to 20µm sections of ETT and was covered 
loosely with tin foil and incubated at 55°C for 90 min for probe hybridisation. 
A 100-µl volume of wash solution was added to the slide and incubated at 
55°C for 15 min. This process was repeated three times and the slides were 
removed until completely dry. A drop of Vectashield™ was added to the 
coverslip to mount the slide, and the slide was sealed using varnish 
(commercially available nail varnish) for CLSM. 
2.2.7.3 Confocal Laser Scanning Microscopy (CLSM) 
Confocal laser scanning microscopy (CLSM) was used to image the biofilms 
following PNA probe hybridisation. Biofilms were imaged using a Leica TCS 
SP2 AOBS spectral confocal microscope (Leica, Heidelberg, Germany) at 
appropriate excitation and emission settings for Fluorescein isothiocyanate 
(FITC) (ex max 494nm; em max 518nm); Cy 3 (ex max 550nm; em max 
570nm) and Cy 5 (ex max 650nm; em max 670nm). Z-stacks of optical 
sections were taken through the full thickness of the biofilms and maximum 
intensity-type reconstructions were prepared using confocal Leica software 
packages. Micrographs were presented as image overlays of confocal 
fluorescence (colour) superimposed upon Nomarski differential interference 
contrast (greyscale). 
  
2.2.8 Antimicrobial susceptibility of S. aureus and P. aeruginosa 
isolates 
Isolated colonies of S. aureus and P. aeruginosa were cultured on Mueller 
Hinton (MH) agar at 37°C for 18-24 h. A 0.5 McFarland standard (108 CFU/ 
ml) was created direct from these colonies to create an inoculum for 
antimicrobial sensitivity testing. A sterile swab was used to spread a lawn of 
the 0.5 McFarland standard across the MH agar plate. Cefoxitin discs were 
used to identify MRSA. The agar media were incubated for 18-24 h at 37°C 
and subsequent zones of inhibition measured (in mm) according to The 
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British Society for Antimicrobial Chemotherapy (BSAC) guidelines to 
determine isolate sensitivity to antibiotics. A total of 15 antibiotics were 
chosen, based on the antibiotics the patients received during MV, standards 
from BSAC, and standard procedures for antimicrobial testing isolates of S. 
aureus and P. aeruginosa (Standard microbiological investigations (SMIs)). 
Predefined criteria for sensitive, resistant and intermediate activities of tested 
antibiotics were outlined in the BSAC zone of inhibition (ZOI) measurements 
(BSAC, The European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) disc diffusion method, V5). An isolate with a ZOI falling between 
the ranges defined as susceptible or resistant was subsequently designated 
as being of intermediate resistance. In the context of this study, an MDR 
pathogen was defined as exhibiting a resistant profile (according to BSAC 
guidelines) to at least three antibiotics.  
 
 
2.2.9 Statistical analysis 
Analysis of microbial growth was recorded and performed using Microsoft 
Excel. Analysis of the DMFT scoring and age group was performed using a 
Box and Whisker plot in IBM SPSS V20. 	
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2.3 Results 
2.3.1 Patient demographics  
A total of 1016 patients’ were screened over a 14-month period. Of these, 5 
patients were <18 years, 20 patients had <8 teeth, 210 patients were 
anticipated to be mechanically ventilated for <24h, 439 patients were not 
mechanically ventilated, and no final consent was obtained for 232 patients. 
Of the 110 patients recruited to the study, 3 withdrew their consent from the 
study post-recovery and their details and samples were deleted and 
destroyed.  
2.3.2 Age and gender 
Informed consent was obtained from 107 patients (65 male and 42 females, 
mean age 54). These patients were divided into 4 age group categories for 
comparative analysis (Table 2.3). 
 
Table 2.3 – Age groups categories of recruited patients. All patients were 
grouped into four groups for comparative analysis.  		
Age group (years) No’ of patients 
18-29 12 
30-49 30 
50-69 42 
70+ 23 
Mean age 54 
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2.3.3 Critical care admission analysis  
The study was performed in a single adult critical care unit (Adult Critical 
Care, University Hospital of Wales). Patients were recruited to the study 
following ICU admission encompassing a range of illnesses and conditions 
(Table 2.4).  
 
Table 2.4 – Underlying illnesses and conditions for the admission of 107 
recruited patients to primary critical care1. 
Primary reason for admission Number of patients 
  
 Respiratory failure 31 
Overdose/suicide attempt 3 
Stroke/brain injury/seizures 35 
OOHCA 11 
Poly-trauma  9 
General surgery - Stomach 5 
Dental/Oral cavity 1 
Other 12 
*OOHCA – Out of hospital cardiac arrest. 
 
2.3.4 Antibiotic administration during critical care and MV 
Seventy-seven (71%) mechanically ventilated patients received at least one 
antibiotic and 53 of these received more than two different antibiotics over 
the course of MV. Over 30 antibiotics were administered to the patients as 
indicated in table 2.5. Antifungals (including nystatin and fluconazole) were 
also administered to mechanically ventilated patients (n=12).  
 
 
 
 
 
 																																																								1 Admission details for all patients in Appendix I 2 +VE – positive control –VE – negative control and M represents the molecular marker. 
	 66 
Table 2.5 - The 10 most frequently prescribed antibiotics  
Antibiotic Number of patients 
Tazocin 24 
Meropenem 23 
Cefuroxime 10 
Co-amoxiclav 9 
Augmentin 7 
Clindamycin 6 
Gentamicin 6 
Vancomycin 6 
Ciprofloxacin 4 
Colomycin 2 		
2.3.5 Decayed, missing and filled teeth (DMFT) scoring and analysis 
DMFT indices were obtained for 97 of the 107 recruited patients. DMFT 
scoring is shown in Appendix I. For 10 patients a DMFT was not obtained 
due to death of the patient. Table 2.6 summarises DMFT scores for all age 
groups. Results indicated that the lowest median DMFT score of 4 occurred 
for the 18-29 years age group, with one outlier (patient of 18 years scoring 
25/28 DMFT). There was no statistical difference between gender (n=60 M, 
n=36 F) and DMFT score (p=0.101). Furthermore, DMFT scores increased 
with older age. The DMFT score was three times higher for the 70-89 year 
patient group compared to the youngest age group (18-29 years). Although 
DMFT analysis was representative for each age group, it should be noted 
that the sample size of patients differed for each age group recruited to the 
study (Figure 2.1; table 2.6).  
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Table 2.6 - DMFT (D – decayed, M – missing and F – filled) score for each 
age group category (years). 
   
  Mean   
 Age  
group 
No of 
patients 
No of DMFTs 
performed D M F 
DMFT 
Score 
18-29 12 11 1.36 2.00 1.91 5.27 
30-49 30 27 1.92 3.12 5.19 10.23 
50-69 42 38 1.08 7.86 5.89 14.84 
70-89 23 21 1.67 7.29 6.52 15.48 
Total 107 97 1.46 5.70 5.39 12.54 
*Individual DMFT scores in appendix I 
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Figure 2.1 - Box and whisker plot summarising DMFT score per age group of 
recruited patients. The whisker bars indicate the minimum and maximum 
DMFT score for each age group. Data outliers are classed into two 
categories: ‘far out’ (o) and extreme values (*), 2 and 3 times outside the 
standard deviation around the mean respectively.  			
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2.3.6 Molecular identification of isolates of S. aureus and P. aeruginosa 
from mechanically ventilated patients 
In total, 177 isolates of S. aureus and P. aeruginosa were cultured from 
dental plaque, NBL, subglottic aspirations and ETTs. All isolates 
presumptively phenotypically identified as respiratory pathogens were 
subject to molecular confirmation by species-specific PCR. Using this 
approach the presumptive identity of >85% of isolates was confirmed using 
PCR (Table 2.7). PCR amplicons (Figure 2.2) showed that some isolates 
were of mixed species (multiple band presence).  
 
Table 2.7 - Species-specific PCR for S. aureus and P. aeruginosa 
Species 
Total 
isolates 
Total 
confirmed 
% PCR 
Confirmed 
S. aureus 114 97 85 
P. aeruginosa 57 54 95 
 
 
 
Figure 2.2 – Examples of species-specific PCR for the detection of S. aureus 
from dental plaque, non-directed bronchoalveolar lavage, subglottic 
aspirations, and endotracheal tubes. Individual PCR amplicons for S. aureus 
and P. aeruginosa are in appendix I2. 																																																								2 +VE – positive control –VE – negative control and M represents the molecular marker. 
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2.3.7 Summary of microbial culture of dental plaque:  
Longitudinal microbial culture analysis results for the presence of selected 
microorganisms (S. mutans and C. albicans, S. aureus and P. aeruginosa) 
provided insight into the microbial content of dental plaque during MV. Figure 
2.3 illustrates recovery of four target microorganisms from dental plaque over 
the course of MV (Target microbial culture for patients in Appendix I). 
Co-culture of C. albicans and S. mutans from dental plaque occurred for 20 
patients, whilst 14 patients harboured both C. albicans and S. aureus (Figure 
2.4). For 17 patients, P. aeruginosa was isolated with C. albicans (Figure 
2.4). Figure 2.5 is a typical micrograph of recovered dental plaque, 
highlighting microbial diversity (Image B) and live/dead proportions of cells 
(Figure 2.5).  
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Figure 2.3 – Recovery of target microbial species at commencement and 
during MV. Shaded boxes represent the numbers of patients who became 
colonised with potential respiratory pathogens during the course of MV.  
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Figure 2.4 – A Venn diagram illustrating the co-isolation results of selected 
organisms within dental plaque during the entirety of the clinical study by 
microbial culture. There was a high incidence of co-colonisation between C. 
albicans, S. mutans and S. aureus.  
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Figure 2.5 - Live/dead viability assay of dental plaque with the SYTO® 9 dye 
(live) and propidium iodide (red). A and B show an overlay of fluorescence 
(A) and light microscopy (B); C indicates that a large portion of the cells were 
dead (stained as red); D shows a magnified portion of dental plaque with 
intact live cells intact (stained green; arrowed). 
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2.3.8 Microbial culture of dental plaque during mechanical ventilation 
A total of 848 dental plaque samples were collected from recruited patients 
during MV (n=592) and after ETT extubation (n=256). Dental plaque from 53 
patients was culture positive for target respiratory pathogens (S. aureus 
and/or P. aeruginosa). Of those patients, 35 were culture negative for target 
respiratory pathogens at the time of ETT intubation.  
Of 43 patients whose dental plaque was culture positive for S. aureus during 
MV, 22 were culture negative at time of intubation (Figure 2.3). Similarly, the 
dental plaque of 23 patients was culture positive for P. aeruginosa during 
MV, 18 patients (78%) culture negative at time of ETT insertion. These 
findings would be indicative of a microbial change in the dental plaque 
community to incorporate these targeted respiratory pathogens.  
The dental plaque of 10 patients was culture positive for both S. aureus and 
P. aeruginosa during MV. Candida albicans and S. mutans were detected by 
culture in 86 and 48 patients, respectively during MV.  
 
2.3.9 Prevalence of VAP and respiratory colonisation of dental plaque 
Forty-one of the recruited patients were clinically diagnosed and treated for 
VAP during this study. The apparent high VAP rate could be related to this 
cohort of patients representing patients with prolonged ventilation (11 
ventilated >5 d and 57 ventilated >7 d). Eighteen of these VAP patients 
demonstrated colonisation by either S. aureus and/or P. aeruginosa in their 
dental plaque during mechanical ventilation. An additional 9 VAP patients 
had been shown to harbour respiratory pathogens in their dental plaque from 
the beginning of intubation and during MV.  
2.3.10 Association of dental plaque and lower airway microbiology 
Figures 2.6 and 2.7 illustrate the detection of target respiratory pathogens in 
dental plaque, NBLs, subglottic aspirations and extubated-ETTs.   
For S. aureus (Figure 2.6), 11 patients were culture positive for S. aureus 
only in their dental plaque during MV. Of 50 patients where S. aureus was 
cultured from any sample site, 7 patients did not have S. aureus in their 
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dental plaque. Analysis of dental plaque alongside NBL fluid showed that 
43/52 patients had S. aureus in their dental plaque and/or the lower airways. 
A further 2 patients were colonised with S. aureus in the ETT biofilm only. 
However 17 patients were colonised with S. aureus in the ETT concurrently 
with the dental plaque.  
Figure 2.7 shows the microbial isolation of P. aeruginosa at multiple sampling 
sites. Pseudomonas aeruginosa was detected in lower airways and 
subglottic secretions, however the majority of P. aeruginosa detection 
occurred only in the dental plaque (n=15). Ten patients were culture positive 
for P. aeruginosa within the ETT and the lower airways only (ETT n=5; NBL 
n=4; SUB n=1).  
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Figure 2.6 – Venn diagram representing the number of patients culture 
positive for S. aureus during MV from the 107 patients at different locations; 
within the dental plaque (DP – purple oval), non-directed bronchoalveolar 
lavage (NBL – blue oval), subglottic aspiration (SUB – red oval) and 
endotracheal tube (ETT – orange oval).  
  
Clinical site Number of patients 
Dental plaque 43 
Non-directed bronchoalveolar lavage 36 
Subglottic aspiration 15 
Endotracheal tube 21 
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Figure 2.7 - Venn diagram representing the number of patients culture 
positive for P. aeruginosa during MV, from the 107 patients at different sites; 
within the dental plaque (DP – purple oval), non-directed bronchoalveolar 
lavage (NBL – blue oval), subglottic aspiration (SUB – red oval) and 
endotracheal tube (ETT – orange oval).  
 
Sample type Number of patients 
Dental plaque 23 
Non-directed bronchoalveolar lavage 12 
Subglottic aspiration 4 
Endotracheal tube 5 
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2.3.11 Quantitation of polymicrobial biofilm development on 
endotracheal tube biofilms 
ETTs (n=110) were obtained from 97 mechanically ventilated patients. ETTs 
were not available for microbiology analysis for all patients, and some 
patients required >1 ETT insertion during MV. Table 2.8 summarises the 
findings of microbial culture and ETT biofilm communities. Respiratory 
pathogens were isolated from the ETTs of 21 patients, and microorganisms 
representing frequent colonisers of the dental plaque i.e. S. mutans and C. 
albicans) were recovered from 7 and 40 patients, respectively (Figure 2.8). 
For 7 patients, both oral microorganisms and respiratory pathogens were 
isolated from ETT biofilms. The ETTs from 44 patients were colonised by oral 
microorganisms. Staphylococcus aureus and P. aeruginosa were isolated 
from ETTs of 21 and 5 patients, respectively.  
The number of microorganisms in ETT biofilms was quantified by culture 
(CFU/cm2; Figure 2.9). Colonisation by C. albicans (Figure 2.9) was variable, 
with a minimum count of 3.08x103 CFU/cm2 and maximum of 2.45x107 
CFU/cm2. Mean counts were similar for S. aureus (1.04 x106 CFU/cm2), C. 
albicans (1.05 x106 CFU/cm2) and P. aeruginosa (9.33x105 CFU/cm2), with 
the lowest counts recorded for S. mutans (1.61x105 CFU/cm2).  
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Table 2.8 – Microbial analysis of ETT biofilms (107 patients)  
ETT culture  
Number of 
patients 
 
No ETTs collected 
 
10 
No microbial growth 29 
Respiratory pathogens  21 
Oral microorganisms  40 
Oral & respiratory co-culture 7 
 
 
 
 
 
Figure 2.8 – Number of patients whose endotracheal tube (ETT) was 
colonised by targeted microbial species in mechanically ventilated patients. 
Oral species (S. mutans and C. albicans) and respiratory pathogens (S. 
aureus and P. aeruginosa) were found to colonise ETT biofilms.  
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Figure 2.9 - A box and whisker plot for numbers of selected species per unit 
area (cm2) of ETT colonisation. The box plot shows average ETT colonisation 
was greater for P. aeruginosa and S. aureus, with more variability in 
colonisation levels for these two respiratory pathogens.  
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2.3.12 Microscopy of ETT biofilms 
2.3.12.1 Scanning electron microscopy  
Extubated ETTs were subjected to microscopic analysis (Figure 2.10). ETTs 
were selected for biofilm analysis by microscopic imaging based on microbial 
culture results, whether oral-indicator organisms and/or respiratory 
pathogens were initially cultured (2.2.3). SEM imaging (Figures 2.10, 2.11 
and 2.12) revealed mature microbial biofilms, greater than 200µm, present 
on ETTs from mechanically ventilated patients. In addition, EPS production 
and different cellular morphology was evident (Figure 2.11 and 2.12), 
emphasising polymicrobial biofilm formation. Biofilms were developed within 
ETTs after as little as 24 h through to ETTs being in situ for up to a period of 
5-7 days (Figures 2.11 and 2.12).  
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Figure 2.10 – A, B; macroscopic biofilms inside extubated endotracheal 
tube, C; scanning electron micrograph with distinct cellular morphology and 
the production of extracellular polymeric substances as indicated by the 
arrows. 
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Figure 2.11 - Scanning electron micrographs of biofilms (indicated by 
arrows) formed on the inner lumen on endotracheal tubes from mechanically 
ventilated patients. 
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Figure 2.12 - SEM micrograph of a multi-layered and stratified biofilm 
(indicated by arrows) on the inner lumen of an endotracheal tube. 
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2.3.12.2 Peptide nucleic acid (PNA) probe fluorescent in situ 
hybridisation and confocal laser scanning microscopy (CLSM) of ETT 
biofilms 
CLSM of ETT biofilms from 10 patients revealed aggregates of bacterial cells 
embedded within a complex EPS. The use of species-specific PNA probes 
allowed culture-independent detection of targeted microbial species in the 
ETT biofilm. Oral microorganisms and putative respiratory pathogens were 
detected in the ETT biofilm and different cellular morphologies and EPS were 
evident (Figure 2.13, A-D). Furthermore, various degrees of total bacterial 
(Universal, Cy-3) biofilm formation and aggregates of bacterial cells adjacent 
to the ETT lumen (Figure 2.14, image B) were apparent. PNA-FISH analysis 
of extubated ETTs indicated that these biofilms contained a diversity of 
bacterial morphologies and were therefore polymicrobial, further supporting 
the microbial culture results and building upon the SEM analysis initially 
undertaken.  
  
	 86 
 
 
Figure 2.13 - Micrographs of endotracheal tube (ETT) biofilms obtained by 
confocal laser scanning microscopy (CLSM). Micrographs are overlays of the 
superimposed fluorescence on Nomarski differential interference (greyscale) 
images. A) Aggregates of bacteria hybridised with the universal bacterial 
Peptide Nucleic Acid (PNA) probe labelled with Cy-3 (red); B) Aggregates of 
Candida albicans hybridised with FITC conjugated PNA probe (green) and 
bacteria hybridised with the universal bacterial PNA probe labelled with Cy-3 
(red); C) Pseudomonas aeruginosa hybridised with species-specific FITC 
labelled PNA probe (green); D) Staphylococcus aureus hybridised with 
species-specific PNA probe conjugated with Cy-5 (blue). Edge of the ETT 
section is arrowed.  
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Figure 2.14 - Micrographs of endotracheal tube (ETT) biofilms obtained by 
confocal laser scanning microscopy (CLSM). A) Aggregates of bacteria 
within the microbial biofilm; B) aggregates of bacteria within a polymicrobial 
biofilm and; C) Clusters of cocci-shaped bacteria. Bacteria were hybridised 
with a universal bacterial Peptide Nucleic Acid (PNA) probe labelled with Cy-
3. The edge of the ETT section is arrowed. 
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2.3.13 Antimicrobial susceptibility of S. aureus and P. aeruginosa 
detected from mechanically ventilated patients 
All S. aureus and P. aeruginosa isolates confirmed by molecular techniques 
were subject to antimicrobial profiling. The majority (>70%) of isolates from 
all sites were susceptible to the antibiotics tested. Antimicrobial sensitivity 
patterns for recovered isolates of P. aeruginosa between dental plaque, the 
lower airways and endotracheal tube biofilms were largely similar for 7 out of 
10 patients (isolates recovered at dental plaque, from NBL and ETT biofilms). 
Similarly, for recovered isolates of S. aureus between dental plaque, the 
lower airways and endotracheal tube biofilms, antimicrobial sensitivity 
patterns were related for 21 out of 30 patients (isolates recovered at dental 
plaque, from NBL and ETT biofilms).  
 
Where differences occurred, S. aureus isolates with antibiotic resistance 
profiles were most frequently isolated from subglottic secretions and most 
frequently exhibited resistance to erythromycin, penicillin and cefepime. Of 
the 56 P. aeruginosa isolates, 35 were from dental plaque. Antimicrobial 
resistance patterns for all tested antibiotics ranged between 2% 
(ciprofloxacin) to 23% of isolates (meropenem). Whilst only 5 P. aeruginosa 
isolates were recovered from endotracheal tube sections, one of these had 
the most resistant profile across all antibiotics tested. Pseudomonas 
aeruginosa isolates were most sensitive to tobramycin, with 80% of ETT 
isolates and 97.1% of dental plaque isolates sensitive to all antimicrobials. A 
total of 3 patients were colonised by MDR P. aeruginosa and 21 with an 
MDR S. aureus (8 patients colonised with MRSA as determined by 
resistance to cefoxitin with a ZOI <20mm). 
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Table 2.9 - Antimicrobial susceptibility of 12 antibiotics for 114 S. aureus 
isolates3.  
	 	 	 	 	 	 	
	
114 Isolates of S. aureus  
  Cefepime  Cefoxitin Ceftazidime  
Fusidic 
Acid Gentamicin  Meropenem  
Sensitive % 65 88 88 89 82 86 
Intermediate % 20 0 2 4 13 6 
Resistant % 15 12 11 7 4 8 
	 	 	 	 	 	 	
 
Ciprofloxacin  Clindamycin Erythromycin  Penicillin Tobramycin  Vancomycin  
Sensitive % 86 61 62 55 79 88 
Intermediate % 4 27 16 31 15 1 
Resistant % 11 12 22 14 6 11 
 		
Table 2.10 - Antimicrobial susceptibility of 56 isolates of P. aeruginosa 
indicates high levels of sensitive isolates4.  		
  56 Isolates of P. aeruginosa   
  Ceftazidime Ciprofloxacin Gentamicin Tobramycin 
Resistant % 8.8 1.8 1.8 1.8 
Sensitive % 82.5 87.7 66.7 96.5 
Intermediate % 8.8 10.5 31.6 1.8 
	
Meropenem Piperacillin Piperacillin-Tazobactam 
	Resistant % 22.8 15.8 10.5 
	Sensitive % 64.9 40.4 63.2 
	Intermediate % 12.3 43.9 26.3 
	
																																																								3	Individual isolate sensitivities in appendix I		4 Individual isolate sensitivities in appendix I	
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2.3.14. Microbial culture of dental plaque after ETT extubation  
Out of 848 dental plaque samples, 256 were obtained post-ETT extubation. 
Eighty-eight samples were collected within 1 week of ETT extubation, 66 
were 2 weeks post-ETT extubation, 43 were 3 weeks post- ETT extubation 
and a further 59 were collected >1 month post ETT extubation. For 31 
patients, it was not possible to follow up dental plaque collection and 
microbial analysis.  
These analyses enabled assessment of persistence of respiratory pathogens 
in dental plaque after extubation. Of the 21 patients whose dental plaque 
became colonised by S. aureus during MV, S. aureus was not detectable by 
microbial culture in the post-ETT period for 15. For 18 patients who had P. 
aeruginosa colonisation of their dental plaque, 10 became culture negative 
for P. aeruginosa after extubation. Eight of the 35 mechanically ventilated 
patients exhibiting such microbial changes in total remained culture positive 
for respiratory pathogens post-ETT extubation.   
Figure 2.15 compares the number of patients (pooled data) colonised with 
either S. aureus and/or P. aeruginosa at different times during MV and post-
ETT extubation. As previously described, a microbial change occurred to 
colonisation by S. aureus and P. aeruginosa in 21 and 18 patients, 
respectively (as shown in the graph by the shaded section). This figure also 
shows the proportion of the patients in whom the change was reversed 
following removal of the ETT. Of the 21 patients that exhibited a microbial 
change to S. aureus dental plaque colonisation, 15 were no longer culture 
positive post ETT extubation.  
In the case of P. aeruginosa dental plaque colonisation, this species 
appeared to be absent from dental plaque in 10 out of 18 patients post 
extubation. However, P. aeruginosa continued to be detected in 8 patients 
into the post ETT-extubation period. A higher proportion of patients whose 
dental plaque was colonised with P. aeruginosa retained colonisation in post-
ETT extubation compared to those colonised by S. aureus. For the remaining 
8 patients for whom an initial change in plaque microbiota during MV was 
documented, it was not possible to analyse dental plaque from the post-ETT 
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extubation period (due to patient death, removal from participation of the 
study, or because of a discharge to a different hospital).  
 
 	
		
Figure 2.15 – Microbial colonisation of respiratory pathogens during 
endotracheal intubation and analysis up to 8 weeks post ETT- extubation.  
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2.4 Discussion 
  
The microbiome of the oral cavity is both highly diverse and dynamic, 
primarily because of the wide range of microbial habitats that exist in the 
mouth and the fluctuations that can arise in these environments due to 
changes in diet, salivary flow and oral hygiene interventions (Dennesen et 
al., 2003; Wise et al., 2008; Marsh, 2010; Tada & Hanada, 2010; Wade; 
2013b). Established dental plaque in healthy and stable oral environments 
will exhibit colonisation resistance. This is the inhibition of colonisation by 
new bacterial species (Wade, 2012). Synergistic and inter-relationships are 
formed in dental plaque communities serving to minimise the introduction of 
foreign microorganisms. It is however known that dental plaque community 
dynamics can be influenced by prolonged changes to the local environment 
that introduce new selective pressures that favour the presence of other 
species better suited to grow and persist under the new environment. Oral 
disease resulting from changes to the dental plaque composition is referred 
to as the ecological plaque hypothesis (Marsh, 1994; Marsh, 2003; 
Kolenbrander et al., 2010). An example of this is seen in plaque-mediated 
disease such as dental caries where a change in diet to one consisting of a 
high frequency intake of sucrose elevates the numbers of aciduric bacteria to 
the detriment of those species that are less tolerant of lower pH 
environments (Marsh, 1994). Potential pathogens, which may be present in 
low numbers in a healthy plaque composition, will only be able to outcompete 
other members of the oral microbiota following certain ecological pressures, 
for example a low pH or low saliva flow resulting in shifts in the microbial 
community (Marsh, 2006; Kolenbrander et al., 2010).  
 
In the case of critically ill patients, there will be changes to the normal oral 
environment arising from several mechanisms. Firstly, mechanical ventilation 
(MV) via an endotracheal tube results in the mouth being partially held open, 
leading to dehydration of the oral environment. Secondly the presence of the 
endotracheal tube (ETT) physically impedes delivery of normal oral care, and 
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finally, local and systemic effects of any underlying illness or administered 
therapy may result in local and systemic changes affecting the oral cavity. 
The reason(s) dental plaque becomes colonised with respiratory pathogens 
is as yet unclear, but are likely linked to local environmental changes in the 
mouth. These may include plaque accumulation and gingival inflammation 
from inadequate delivery of oral care during MV, a reduced salivary flow as a 
consequence of drugs and reduced circulating saliva due to incomplete 
mouth closure (Wood et al., 2002; Jones et al., 2011). Furthermore, there 
may be patient-specific factors related to co-morbidities contributing to 
plaque changes, the cause of critical illness or treatment thereof.  
 
The present study was undertaken to examine the colonisation of dental 
plaque by target species during and after MV. A total of 107 mechanically 
ventilated patients were examined over a 14-month period, generating a 
large quantity of data. Through targeting specific species (S. mutans and C. 
albicans) normally present in dental plaque, as well as species (S. aureus 
and P. aeruginosa) implicated in causing VAP, the study sought to confirm 
and expand upon previous research indicating compositional dental plaque 
changes during MV. Establishing the extent of respiratory pathogen 
colonisation of dental plaque could result in increased focus to maintain the 
oral biofilm during MV to directly limit the accumulation of dental plaque in 
critically ill patients and lower the numbers of respiratory pathogens within 
dental plaque, a risk factor for VAP. Ultimately, the purpose of targeted 
microbial culture analysis within mechanically ventilated patients was to 
assess the dynamics of the dental plaque community and by extension, the 
lower airways via the ETT, in the context of VAP pathogenesis. Targeted 
microbial culture also provided a collection of clinical isolates including 
respiratory pathogens, and organisms typically associated with the oral 
microbiota for in vitro biofilm dynamic studies (Chapter 5). 
 
Previous studies have examined plaque community dynamics during critical 
illness, but often these studies have only been for comparatively short 
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periods of time during MV. A study by Sachdev et al., 2013, recruited 50 
patients in a critical care unit for microbial enumeration and plaque analysis. 
Within their study, dental plaque was sampled at baseline, day 7 (±2 days) 
and day 14 (±2 days), revealing an increase in total viable dental plaque. In 
addition, 26% of patients exhibited colonisation by pneumonia-related 
pathogens including P. aeruginosa, Klebsiella pneumoniae and 
Staphylococcus aureus. The interaction between potential respiratory 
pathogens and the commensal dental plaque microbiota over a prolonged 
period of hospitalisation and recovery however has not previously been 
studied.  
Patients were diagnosed and treated for VAP based on clinical presentation, 
X-ray changes and previously explained diagnostic criteria. In the treatment 
of these patients, antibiotics were frequently administered with changing 
clinical presentation. The VAP incidence rate for the studied patients was 
~35% (n= 41) and this falls within previously reported ranges of 5-67% (Mori 
et al., 2006; Joseph et al., 2010; Sundar et al., 2012). Some recent studies 
have reported a lower average global incidence of VAP of 15% (Branch-
Elliman et al., 2015; Kollef, 2015). Regardless of the true incidence, a 
diagnosis of VAP is significant for individual patients and the number of 
patients affected places considerable economic costs in healthcare systems. 
The most effective intervention would be the development of appropriate 
preventative strategies (Safdar et al., 2005; Al-Tawfiq & Abed, 2010; Heck, 
2012). 
During this study, mechanically ventilated patients presented with an age 
range between 18 and 86, and variable illness/requirement of critical care 
admission  (Table 2.4), antibiotic administration (Table 2.5) and oral status as 
deemed by DMFT scores. DMFT scoring is usually performed as an indicator 
of dental caries (Becker et al., 2007), and dental scoring parameters such as 
DMFT scores, are not currently performed in ICU. A future management 
strategy administering tailored and specialised oral hygiene procedures by 
identifying ‘high risk’ patients (as indicated with large DMFT scores) could 
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minimise dental plaque accumulation and overgrowth of opportunistic oral 
organisms alongside potential respiratory pathogens. A total of 97 DMFT 
scores were performed within this clinical investigation. A Mean DMFT score 
of 12.54 for this patient cohort (Table 2.6) indicated that the oral hygiene 
status of these patients, was, in many causes previously poor, correlating 
with previous studies (Tanaka et al., 2009; Rai et al., 2015). A study by Rai et 
al., 2015 determined the DMFT scores of 300 hospitalised patients. A mean 
DMFT score of 6.18 was calculated, considerably lower than the present 
study. Within the study by Rai et al., 2015 however, 243 of the 300 (81%) 
patients were < 60 years old. Within the present study, a lower proportion of 
patients were < 60 years (63 out of 107 (59%)). Furthermore, a box and 
whisker plot evaluation (Figure 2.1) suggested that, in general, the higher the 
age of the patient, the higher the DMFT score. To assess localised changes 
in the oral cavity during MV, in particular the abundance of dental plaque and 
associated gingival inflammation, dental plaque scoring and gingival indexes 
could have been performed to further the information provided by the initial 
DMFT scores. Such additional information would have allowed correlation 
analysis between dental plaque abundance, gingival inflammation and the 
occurrence of respiratory pathogens in the dental plaque during MV. 
 
A notable finding of this study was that the composition of dental plaque in a 
significant proportion (n=35) of mechanically ventilated patients altered with 
inclusion of the respiratory pathogens S. aureus and/or P. aeruginosa (Figure 
2.3). Of those patients harbouring S. aureus and/or P. aeruginosa within their 
dental plaque during MV, 27 were clinically diagnosed with VAP and treated 
accordingly.  
Staphylococcus aureus and P. aeruginosa are frequent causative pathogens 
of VAP often exhibiting resistance to antibiotics, e.g. MRSA and mucoidal P. 
aeruginosa, (Hunter, 2006; Parker et al., 2008; Bouza et al., 2012). A study 
by Parker et al., 2008 investigated the prevalence of P. aeruginosa amongst 
other multi-drug resistant bacterial pathogens using microbial culture 
techniques in 739 patients with suspected VAP. The prevalence of 
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Pseudomonas species was 13.4% (99/739), with 9.2% of patients (68/739) 
colonised with other MDR pathogens. A further study by Bouza et al., 2012 
evaluated the bacterial causes of 474 cases of VAP, with 148 (31.2%) of 
cases caused by P. aeruginosa and a further 111 (23.4%) caused by MRSA 
(with an additional 75 cases (15.8%) caused by MSSA).  
 
Within the present study, although only a small proportion of S. aureus 
isolates were identified as MRSA (n=8), ~25% isolates recovered from dental 
plaque were resistant to at least one antibiotic tested in vitro (Tables 2.9 and 
2.10). Where differences occurred within isolate sensitivities between the 
dental plaque and lower airways, resistance rates were highest for P. 
aeruginosa derived from the ETT biofilm and for S. aureus within subglottic 
secretions (Table 2.10). This could imply higher rates of resistance within the 
airways, and if VAP were to develop in these patients then this could 
diminish the success of antimicrobial therapy. 
Importantly, for the majority of patients where microbial changes occurred in 
the dental plaque, a reversal occurred once the patient was extubated and 
recovering from critical illness, and this was most readily evident for S. 
aureus colonisation (Figure 2.15). A higher proportion of patients colonised 
with P. aeruginosa retained the respiratory pathogen colonisation post 
extubation. Further investigation of bacterial strain typing and further 
genomic analysis of biofilm-related genes would elaborate on whether 
patients’ who remain colonised in the post-ETT extubation period harbor the 
same strain. Although most dental plaque communities reverted back to a 
phenotype without respiratory pathogens within one week of extubation, the 
fact that some patients remained colonised with respiratory pathogens over a 
prolonged duration could represent a patient group at risk of subsequent 
hospital-acquired pneumonia. Dental plaque colonisation is dynamic, and 
during this study a reduction in respiratory colonisation occurred post-ETT 
extubation. With the extubation of the ETT, normal host defence mechanisms 
(within saliva, swallowing reflex) are re-introduced, and such defenses may 
facilitate further changes to the dental plaque composition.   
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Staphylococcus aureus colonises the nose and skin of up to 30% and 20% of 
healthy individuals respectively. Given the anatomical proximity of the nasal 
area and the oropharangeal, it is not surprising that S. aureus colonises the 
oral cavity. Although not regarded as a normal inhabitant of the oral cavity, S. 
aureus has been detected within the dental plaque of debilitated or elderly 
individuals (Smith et al., 2001). Furthermore, S. aureus has been isolated in 
the dental plaque community of healthy people in up to 24-36% of individuals 
(Heo et al., 2013). In the current study, the high incidence (43 of 107 
patients) of S. aureus in dental plaque was nevertheless surprising, 
particularly as half of these patients did not have S. aureus in their dental 
plaque at the time of intubation. Similarly, dental plaque also became 
colonised with P. aeruginosa during ventilation, albeit at a lower incidence. 
The current study also targeted two microbial species frequently associated 
with the normal oral microbiota, namely Streptococcus mutans and Candida 
albicans. These oral indicator species allowed tracking of oral microbial 
dissemination following intubation. During this study, polymicrobial 
colonisation of the ETT involving both oral indicator species and respiratory 
pathogens highlighted a link between the oral cavity and the ETT, and also 
the role of the ETT as source of infectious agents. Importantly, oral-indicator 
species were isolated from the dental plaque of 90% patients and were 
further detected in ETT biofilms (n=40 for C. albicans and n=7 for S. mutans). 
In accordance with the present study, ETT colonisation by both respiratory 
pathogens and frequent members of the oral microbiota has been previously 
reported. Cairns et al., 2011 revealed the detection of S. mutans in 5 out of 
20 patients’ ETT biofilms, with 8 out of 20 patients’ ETT biofilms being 
colonised with S. aureus and/or P. aeruginosa.  
 
Subglottic secretions pool around the ETT, and these may leak below the 
cuff through folds and micro-channels that form in the cuff material (Hamilton 
& Grap, 2012). Continuity between the lower airways and the oral cavity is 
emphasised by the colonisation of oral microorganisms such as S. mutans 
and C. albicans within ETT biofilms, (and NBL fluid), shown through both 
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SEM (Figures 2.0 - 2.12) and CLSM imaging coupled with species-specific 
PNA probe hybridisation (Figures 2.13 and 2.14). Aggregates of respiratory 
pathogens were clearly evident in the ETT biofilm using CLSM and 
dissemination of these to the lower airway would deliver infectious agents 
already existing within a biofilm phenotype and therefore potentially more 
resistant to host defence mechanisms and administered antimicrobials.  
 
To further analyse the microbial relationships between the dental plaque and 
lower airways (including ETT biofilms) recovered isolates of target respiratory 
pathogens (S. aureus and P. aeruginosa), and oral-indicator species (C. 
albicans and S. mutans) could be genotyped to reveal the extent of isolate 
matching between the dental plaque and the lower airways, and the amount 
of translocation occurring between these clinical sites. Such strain typing 
would build upon previous studies, namely an investigation by Heo et al., 
2008 (as outlined in 2.1.2).  
It is important to recognise that other possible respiratory pathogens were 
not tested for in this study (due to time, cost and the ability to assess all 
microbial species using tailored culture techniques), others have found that 
Escherichia coli, Klebsiella species and Acinetobacter species may also 
colonise dental plaque and ETT biofilms during MV (Gil-Perotin et al., 2012). 
A review by Kalanuria et al., 2014, lists the ten most frequent VAP 
pathogens. Within the review, P. aeruginosa and S. aureus were responsible 
for ~45% of VAP cases. Other VAP causative pathogens include 
Enterobacteriaceae (E. coli, Klebsiella and Proteus species), Streptococcus 
species, and Acinetobacter species. In acknowledgment of the limitations of 
microbial culture, community profiling of dental plaque (Chapter 3) was 
performed to characterise the microbiome during the course of MV.  
 
Conclusion 
In accordance with the aims of this chapter, the occurrence of respiratory 
pathogens within both the dental plaque and the lower airways were revealed 
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during this longitudinal study. Irrespective of patient demographics including 
age and current oral health (as indicated by the DMFT scores), microbial 
changes within the dental plaque composition were observed. Interestingly, 
respiratory pathogens were also isolated from mechanically ventilated 
patients in the recovery phase of critical illness following removal of the ETT. 
In relation to the third aim, microscopic imaging of ETT biofilms further 
revealed the colonisation of respiratory pathogens and oral-indicator species 
including S mutans and C. albicans. Furthermore, such longitudinal and 
target microbial culture not only revealed that extensive changes occurred 
within the dental plaque composition during MV, there are also polymicrobial 
and pathogenic biofilms within the ETTs. 	
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Chapter 3 
 
Molecular community profiling of 
oral biofilms within mechanically 
ventilated patients; a 
longitudinal study  
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3.1 Introduction 	
Mapping the oral microbiota has been the subject of numerous molecular 
studies over the past decade (Wade, 2013a). Since the introduction of 
Sanger sequencing, technological advances has allowed in-depth analysis of 
both whole microbial communities and of individual species genomes 
(Lazarevic et al., 2009; Perkins et al., 2010). The oral cavity is colonised by 
an array of microorganisms including bacteria, fungi and viruses and 
currently over 1000 bacterial species have been detected using culture-
independent approaches (1.1) (Avila et al., 2009; Lazarevic et al., 2009; 
Dewhirst et al., 2010; Zaura, 2012; Wade, 2013a; Wang et al., 2013; Palmer, 
2014). The use of contemporary DNA based technologies facilitates 
identification of uncultured, dormant and dying cells that are unable to 
replicate even on the most tailored media and as yet uncultured 
microorganisms whose culture requirements have yet to be determined and 
reproduced.  
 
Furthermore, the diversity of microbial species within the oral cavity of 
healthy individuals is increasingly well characterised. The microbiome of a 
range of oral niches has been analysed, including the mucosal membranes, 
the cheeks and tongue and scrapings of dental plaque (Dewhirst et al., 2010; 
Liu et al., 2012). Although there are many shared species, different sites 
within the oral cavity have a characteristic and often unique microbial 
composition, relating to the different biological and physical properties of 
each site (Dewhirst et al., 2010; Xu et al., 2015).  
 
There is a large surface area provided by teeth for colonisation and 
maturation of plaque.  Areas with lowered oxygen potentials such as the 
interproximal spaces of teeth and in deep periodontal pockets are frequently 
colonised by large numbers of predominantly anaerobic species (Jefferson, 
2004; Faran & Tanwir, 2012). The difference in the microbial composition at 
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different sites emphasises the adaptability of the microbiome to specific 
surroundings.  
 
There is a natural progression in dental plaque development to maturation, 
with initial colonisation by ‘pioneer’ bacteria including Streptococcus and 
Lactobacillus species, and subsequently combinations of anaerobic species 
such as Prevotella, Veillonella and Porphyromonas are detected (Peyyala & 
Ebersole, 2013; Kolenbrander et al., 2005; Xie et al., 2010). Several species, 
including those of Streptococcus and Prevotella have been identified within 
the polymicrobial biofilm of dental plaque using next-generation sequencing 
techniques and are associated with oral diseases including dental caries and 
periodontitis, and are increasingly linked with systemic infections, including 
respiratory infections (Paju & Scannapieco, 2007; Preshaw et al., 2012).  
 
The majority of critically ill patients require mechanical ventilation (MV) to 
treatment survival. An endotracheal tube provides the interface between the 
patient and the ventilator and following insertion of the ETT (intubation) 
alterations can occur in the oral microenvironment and oral microbiome. 
These alterations have been hypothesised to facilitate the colonisation and 
proliferation of both respiratory and other potentially exploitative pathogens in 
oral and pulmonary niches (Scannapieco et al., 1992; Perkins et al., 2010; 
Zuanazzi et al., 2010; Berry et al., 2011). The mechanisms underlying this 
‘microbial shift’ are not clear, but may, in part, be due to the physical 
presence of the ETT, which indirectly affects plaque clearance (difficulties in 
oral hygiene interventions, saliva flow and mucosal drying), in addition to the 
interventions and medications related to the management of the underlying 
condition during critical illness.   
 
Given the limitations of traditional microbiological culture, the aim of this 
current study was to use molecular community profiling to comprehensively 
analyse, on a longitudinal basis, the microbiome of dental plaque and the 
lower airways during MV. The use of high-throughput sequencing platforms 
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in this way allows the investigation of a microbiome without placing specific 
focus or bias towards certain genera or pathogen. It also provides a more 
representative profile of the community. Specifically the aims were on a 
longitudinal basis to: 
 
(1). Analysis of dental plaque derived sequences was performed to assess 
three principle criteria: 
1. Occurrence of potential respiratory pathogens during MV 
2. Assessment of the most dominant species during MV  
3. Microbiome analysis at four time points (covering dental plaque 
collection at baseline, during MV and the post-ETT extubation 
recovery period). 
 
(2). The second aim of this chapter was to compare dental plaque derived 
sequences during MV to those of microbial sequences extracted from the 
lower airway fluids and ETT biofilms.  
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3.2 Materials and Methods 
3.2.1 Samples for bacterial community profiling 
DNA extraction was performed on a total of 48 samples from 13 
mechanically ventilated patients for community profiling at Research and 
Testing Laboratory, LLC (Lubbock, Texas, USA). Dental plaque, ETTs and 
lower airways fluids were selected based on initial microbial culture results 
from Chapter 2, and available patient information including critical condition, 
antibiotic administration and patient demographics such as age and gender. 
3.2.2 Total bacterial DNA extraction for MiSeq Illumina Sequencing  
3.2.2.1 DNA extraction from dental plaque  
Total bacterial DNA extraction was performed as described in 2.2.3.4. All 
incubation steps were extended to 1 h to maximise DNA elution. A 150-µl 
volume of re-suspended dental plaque was transferred into a sterile 
microcentrifuge tube for total microbial DNA extraction using an adapted 
Gram-positive protocol as described in 2.2.3.4. Once the lysis suspension 
was added and the pellet re-suspended, the sample was transferred to a 
lysis tube (Qiagen) for a 1 min bead-beating step. After centrifugation for 1 
min at 16,000 × g, the supernatant was transferred to a 1.5 ml centrifuge 
tube and the protocol continued from the RNase A solution step, as 
previously described in 2.2.3.4.  
3.2.2.2 DNA extraction from NBLs and subglottic aspiration  
A 150-µl volume of NBL/subglottic aspiration fluid was transferred into a 
sterile microcentrifuge tube. An equal volume of Sputasol™ was added to the 
tube, gently inverted and vortex mixed for 5 s. The DNA extraction procedure 
was then followed (2.2.3.4, 3.2.2.1).  
3.2.2.3 DNA extraction from endotracheal tube biofilms  
The microbial biofilm was scraped from the lumen of the ETT using a cotton 
swab and suspended into 1 ml of Sputasol™ (Fisher). The tubes were vortex 
mixed for 20 s to disrupt the biofilm. DNA extraction procedure was followed 
as described above (3.2.2.2).  
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3.2.2.4 Bacterial 16S rRNA PCR and gel electrophoresis 
To confirm the presence of DNA and to detect the amplicons before 
preparation for Miseq Illumina sequencing, 16S rRNA was amplified using 
universal primers. The primers used were: 1492r 
(CACGGATCCTACGGGTACCTTGTTACGACTT) and 27f 
(GTGCTGCAGAGAGTTTGATCCTGGCTCAG) (Eurofins MWG Operon) 
(Zuanazzi et al., 2010; Dalwai et al., 2007). The total volume of PCR 
reagents was 50 µl (25 µl PCR master mix, 2 µl DNA template, 0.5 µl reverse 
primer, 0.5 µl forward primer, and 22 µl of nuclease water). PCR thermal 
cycling parameters consisted of an initial denaturation step of 95°C for 1 min, 
followed by 26 cycles of 94°C for 45 s, 50°C for 45 s and 72°C for 90 s 
(Thermocycler G-Storm). A final single cycle extension step of 72°C for 15 
min was also included. Gel electrophoresis (1.0% agarose gel) was 
performed at 70/Vcm2 for 50 min, in a 0.5 × Tris Borate EDTA (TBE) buffer 
with 10% SafeView™ for detection of nucleic acids (NBS Biologicals NBS-
SV1) alongside a 1 Kbp molecular weight ladder (Promega). A gel doc 
system was used to determine DNA presence pre-sequencing (Gel-
DocIT_UVP; Biorad). 
 
3.2.3 Preparation and transportation of DNA extracts for MiSeq Illumina 
sequencing 
Amplicons were stabilised via the addition of a DNA elution reagent (Qiagen), 
and tubes were individually wrapped in Parafilm M™ Wrapping film (Fisher) 
to minimise evaporation and pressure changes.  
 
3.2.4 MiSeq Sequencing: Illumina platform 
MiSeq sequencing was performed at Research and Testing Laboratory, LLC 
(Lubbock, Texas, USA). Bacterial universal primers (28F; 
GAGTTTGATCNTGGCTCAG and 388R; TGCTGCCTCCCGTAGGAGT) 
were used to generate multiple sequences of 250 bp overlapping at the V4 
region of the 16S rRNA gene. DNA extracts were randomly fragmented and 
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DNA adaptors (ligates) were added to both fragment ends. The DNA mixture 
was injected into the glass flow-cell channel containing multiple attached 
primers. The single stranded fragments were bound randomly to the surface 
and nucleotides and polymerases were passed through the flow cell creating 
double stranded bridge amplifications. The dsDNA were denatured leaving 
anchored single strands and several million clusters of DNA in each flow cell 
cycle. Four fluorescently labeled dNTPs, primers and DNA polymerase were 
added to determine accurate pair base using the principle of laser excitation. 
This cycle was repeated until 250 bp sequences were generated. The 
sequencing by synthesis process is summarised in figure 3.1. 
 
Figure 3.1 - Overview of the MiSeq Illumina DNA sequencing platform. 		
3.2.5 Phylogenetic identification 
Data analysis from the raw sequences generated from the MiSeq Illumina 
platform was performed within Mothur (Schloss et al., 2009) to check the 
quality, pre-process, align and join the sequences to obtain a total number of 
sequences in each sample. Sequences were scanned for errors by a series 
of error command checks. Mothur was further utilised to cluster the data 
according to operational taxonomic units (OTUs), to a species level of 97% 
similarity (sequence data <97% confirmation were not identified in this study). 
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sample were collated into OTU_singletons and OTU_rare phylotypes 
respectively to maintain normalisation and to minimise artifacts. 
3.2.6 Data analysis 
Phylogenetic data from Mothur was analysed using a combination of 
statistical programs R-script (R Development Core Team, 2008), STAMP 
(Parks & Beiko, 2010), SPSS V20 and Microsoft Excel (1.1.3). The two 
methods used in this study to compare the similarity between each sample 
were Jaccard’s index of similarity and the Bray-Curtis distance measure 
(measure of dissimilarity) (Lozupone & Knight, 2005; Wang et al., 2013). 
Weighted Unifrac distance matrices were analysed in R using non-metric 
multidimensional scaling ordination and the shared OTU file was used to 
determine the number of times that an OTU was observed in multiple 
samples and for multivariate analysis in R. OTU taxonomies (from Phylum to 
Genus) were determined using the RDP Multi Classifier script to generate the 
RDP taxonomy (Wang, et al., 2007), while species level taxonomies of the 
OTUs were determined using the USEARCH algorithm combined with the 
cultured representatives from the RDP database (Edgar, 2010). Using the 
Vegan package alpha and beta indices were calculated from these datasets 
with Mothur and R.  
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3.3 Results 
3.3.1 Sequencing data details  
Before the extracted DNA was stabilised for transport to the sequencing 
facility, a 2-µl aliquot was used as template for a 16S ribosomal RNA 
(16SrRNA) PCR reaction to confirm the presence of amplifiable DNA, and 
typical amplicons are shown in figure 3.2. A total of 48 samples were 
successfully sequenced using the MiSeq Illumina platform (one DNA sample 
was removed from data analysis post-sequencing due to low sequence reads 
producing low quality data, a total of 30 reads, compared to a mean average 
of >1000).  
 
A total of 38 samples of dental plaque (DP), 4 non-directed bronchoalveolar 
lavage (NBL), 3 subglottic aspiration (SUB) and 3 endotracheal tubes (ETTs) 
were analysed by community profiling, from a total of 13 mechanically 
ventilated patients. A 97% or higher similarity was used as the criterion for 
identification of microorganisms (Mothur output in Appendix II).  
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Figure 3.2 – 16S rRNA amplicons of total extracted bacterial DNA 1-52. The 
following amplicons were negative following 16S PCR: 5, 39 48 and 50 
respectively, and were discarded from the analysis (expected band size 
1,000-1,500 bp).  
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3.3.2 Patient demographics  
The age of patients included in this analysis ranged from 18-75 years, with 5 
female and 8 male subjects. The DMFT scores for 10/13 patients was >10. A 
total of 6/13 patients were diagnosed with VAP. An additional two patients 
were admitted with pre-existing respiratory disorders. Out of a total of 9 
patients exhibiting respiratory pathogens within their dental plaque 
community during ETT intubation, 5 were treated with antibiotics >48 h after 
ETT intubation, and 3 patients were treated with antibiotics from the 
beginning of ETT intubation.  
 
3.3.3 Community profiling of dental plaque during mechanical 
ventilation 
3.3.3.1 Cluster analysing dental plaque bacterial sequences 
All 38 samples of dental plaque were subject to initial analysis to determine 
distance similarity between each sample. In total 1,911,760 sequence reads 
(before quality control) were determined from pooled subgingival and 
supragingival dental plaque, obtained from 13 mechanically ventilated 
patients. OTUs were sub-sampled to the lowest read count of 1016, which 
retained 97% of all OTU counts for clustering analysis. Furthermore, 
clustering analysis was performed to provide an overview of the level of 
bacterial similarity within dental plaque. Figure 3.3 shows the clustering 
results using Jaccard’s index of similarity and the Bray-Curtis distance 
methods of analysis. Figure 3.3 shows that the majority of dental plaque 
sequences form a tight cluster with a minority of dental plaque (7/38) 
sequences falling outside the tightly clustered main group. 
A total of 5 bacterial phyla were detected during the analysis of dental plaque 
of 13 mechanically ventilated patients (Figure 3.4). Furthermore, a total of 40 
different genera, and over 100 microbial species were detected (Raw 
sequencing data in Appendix II). Species identification was performed 
according to two sequence confident parameters, at 80% and 97% 
respectively. As previously stated, organisms identified at the 97% similarity 
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level were accepted as positive organism identification, and this similarity 
level was therefore used throughout data analysis and interpretation of the 
results.  
 
  
Figure 3.3A – Bray-Curtis analyses of dental plaque (n=38). A red spot 
represents each sample. These clustering analyses illustrate the similarity of 
dental plaque derived sequences based on comparisons of final species 
composition. By both methods, 31 communities of dental plaque were seen 
to cluster tightly, with seven outliers identifiable. 
 
A 
Bray-Curtis 
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Figure 3.3B – Jaccard analyses of dental plaque (n=38). A red spot 
represents each sample. These clustering analyses illustrate the similarity of 
dental plaque derived sequences based on comparisons of final species 
composition. By both methods, 31 communities of dental plaque were seen 
to cluster tightly, with seven outliers identifiable. 
 
B 
Jaccard  
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Figure 3.4 - The proportion of each of the 5 major bacterial phyla identified 
from dental plaque specimens. Over 50% of all organisms identified 
belonged to the Firmicutes phylum.  
 
 
3.3.3.2 Potential respiratory pathogens detected within dental plaque  
Of the 40 bacterial genera identified within this group of patients, 6 
represented species not generally considered to be permanent members of 
the dental plaque community, including Enterococcus and Staphylococcus 
species.  
In total, 8 potential respiratory pathogens were identified at the species level 
from the dental plaque. Figure 3.5 shows the prevalence of potential 
respiratory pathogens within dental plaque communities analysed. The four 
most frequently occuring species and the percentage of plaque samples from 
which they were isolated are as follows;  Staphylococcus aureus (68%);  
Streptococcus pseudopneumoniae (66%); Enterococcus faecalis (37%); and 
Escherichia coli/Shigella flexneri (32%).  
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Interestingly, although Pseudomonas aeruginosa was identified by culture 
analysis of the dental plaque of mechanically ventilated patients (Chapter 2), 
this species was not identified using the culture-independent approaches 
performed within this study. Dental plaque from patients, including those 
patients where P. aeruginosa was isolated (as documented in chapter 2) 
were analysed via high-throughput sequencing. A total of 6/38 dental plaque 
communities analysed using molecular techniques were microbial culture 
positive for P. aeruginosa. Although Pseudomonas was detected at the 
genera level, albeit in low abundance, P. aeruginosa was not identified at 
species level for any of those samples. Following in house species-specific 
PCR, 5 out of 6 dental plaque communities were positive for P. aeruginosa 
(Figure 3.6).  
 
Figure 3.5 – Putative respiratory pathogen colonisation within dental plaque 
of mechanically ventilated patients. 
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Figure 3.6 – Species-specific PCR for the detection of Pseudomonas 
aeruginosa in dental plaque.  Dental plaque samples had been found to 
contain P. aeruginosa by microbial culture (but were negative by high-
throughput sequencing). A total of five dental plaque samples (from the same 
patients represented in high-throughput sequencing) were positive for P. 
aeruginosa5.  
 
3.3.3.3 Profiling dental plaque communities during early stages of 
mechanical ventilation (d1-2) 
Baseline dental plaque collected from recruited mechanically ventilated 
patients was taken as close to ETT intubation as possible. The time period 
from obtaining consent for patient recruitment to the study and the 
introduction of MV to the time of dental plaque collection varied between 4 h 
and 48 h. In order to analyse differences in microbial relationships and 
species for mechanically ventilated patients, a stacked bar graph depicting 
the 5 most abundant genera was produced. Figure 3.7 shows the 5 most 
abundant bacterial genera (accumulated based on the numbers of identified 
sequence reads) identified in dental plaque within 48 h of ETT intubation. 
From this analysis, we can see that abundant genera from early stages of 
MV included those that are recognised as common oral bacteria as well as 
those not frequently found in the oral cavity. The top 10 species detected in 
dental plaque during MV (midpoint of MV, typically 3-6 days) are listed in 
table 3.1, and the most abundant species belonged to the genus Veillonella. 
Within this list, 50% (5 out of 10) of the most abundant organisms during 
early stage MV were considered putative respiratory pathogens.  																																																								5 M = Molecular marker, -VE = negative control, +VE = positive control 
  M    -VE   +VE    1       2       3       4      5       6       
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Figure 3.7 – The five most abundant organisms (genera level) present in the 
dental plaque community at the start of mechanical ventilation for each of the 
13 patients. Each patient is represented by a different colour. 
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Table 3.1 – Ten most abundant bacterial species at the midpoint of MV. 
Abundance Ten most abundant species at midpoint of MV 
1 Veillonella parvula 
2 Escherichia/Shigella flexneri* 
3 Streptococcus pseudopneumoniae* 
4 Enterococcus faecalis* 
5 Staphylococcus aureus* 
6 Granulicatella adiacens 
7 Enterococcus villorum* 
8 Lactobacillus gasseri 
9 Prevotella melaninogenica 
10 Lactobacillus salivarius 
*Respiratory pathogen 
 
3.3.3.4 Community analysis of the respiratory pathogen colonisation 
during mechanical ventilation 
During MV, there was a degree of inter-patient microbial variability within the 
dental plaque community of mechanically ventilated patients. Non-Metric 
Multidimensional Scaling (NMDS) coupled with t-tests were performed to 
analyse the level of similarity between communities isolated from dental 
plaque during the course of MV, and into the post-ETT extubation period. 
Each dental plaque community was assigned coordinates based on Unifrac 
(phylogenetic community distance measure) analysis to generate a scatter 
plot to assess similarity in the microbial community of dental plaque between 
periods of MV and post extubation (Figure 3.8A). Dental plaque was divided 
into four groups for subsequent analysis focusing on the change in microbial 
composition or ‘microbial shift’ previously observed by culture analysis and 
reported in Chapter 2 (Group 1 – commencement of MV, group 2 – midpoint 
of MV typically 3-6 days, group 3 – end of MV and group 4 – post-ETT 
extubation recovery period). Results revealed that changes in the 
microbiome of dental plaque during MV occurred, and such changes were 
statistically significant. Despite overlapping of microbial communities (Figure 
3.8 B and C), statistically significant changes in the microbial composition of 
dental plaque were evident during MV. Pairwise comparisons using t tests 
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with pooled Standard Deviation (SD) were performed to compare data for 
each of the time points groups. P-value adjustment was performed using the 
Benjamini–Hochberg (BH) method, to control the false discovery rate (FDR) 
when performing multiple comparisons. (FDR is a measure of true 
significance, controlling any false discoveries in multiple comparison data 
sets). 
 
Furthermore, to analyse the microbiome of dental plaque at different time 
points of MV, NMDS was performed. The parameters used were Unifrac 
against time, to determine the level of organism diversity. The change in 
microbial composition of dental plaque between the start and midpoint of MV 
was shown to be statistically significant, p=0.0033. In addition, the 
community profiles between the start and end, and between the midpoint and 
end, were also shown to be significantly different (p=0.0403 and p=6.3e-05 
respectively). Descriptive statistics are presented in the box and whisker plot, 
and are visual representations of the data revealing changes in microbial 
composition during MV (Figure 3.9).  
A stacked bar graph was generated to compare the 10 most abundant 
species at the four defined stages of MV and post-ETT extubation recovery 
period. The stacked bar graph (Figure 3.10) reveals a sweeping pattern, 
indicating a trend of microbial differences during the course of MV. 
Furthermore, the most abundant organisms detected at the start of MV 
differed from that at the end of MV. Bacteria detected at the start and 
midpoint of MV both showed a high prevalence of respiratory and non-oral 
pathogens. 
Microbial changes and the occurrence of respiratory pathogens in the dental 
plaque during MV are presented in table 3.2, where the OTU abundance of 
respiratory pathogens is compared. Furthermore, heat maps were 
constructed to compare and quantify community-profiling data over time. 
Figure 3.11 illustrates the phyla variation in dental plaque collected from 
mechanically ventilated patient (PN021), and figure 3.12 extends upon this, 
comparing species variation between the microbiome of dental plaque and 
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the lower airways. Species level heat maps for all 13 mechanically ventilated 
patients analysed via microbial community profiling are depicted in Appendix 
II. 
 
 
 
Figure 3.8A – Non-Metric Multidimensional Scaling (NMDS) analysis of 
dental plaque - scatter representations of dental plaque communities.  
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Figure 3.8B - Non-Metric Multidimensional Scaling (NMDS) analysis of 
dental plaque groupings and relationship between dental plaque 
communities from the start and end of intubation. 
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Figure 3.8C - Non-Metric Multidimensional Scaling (NMDS) overlapping 
analysis of dental plaque communities during MV. 6 
 
 
																																																								6 Ward – represents dental plaque collected in the post-ETT extubation period  
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Figure 3.9 – A box and Whisker plot displaying the unifrac-weighted 
distances (measure to compare organism differences in communities) for the 
four dental plaque community time points during MV. The interquartile range 
(IQR), the box elements shows data dispersion for each group of dental 
plaque samples.  
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Figure 3.10 – The ten most abundant microbial species in dental plaque for 
each time point group. This bar graph allows the comparison between oral 
organisms and potential respiratory pathogens.  
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Table 3.2 – Abundance measurements (operational taxonomic units (OTUs)) 
of potential pathogens during MV.7  
Respiratory pathogen Total OTUs detected  
PN002 d1 d4 d5     
Enterococcus villorum 623 983 135 
 
  
Staphylococcus aureus 11 2 35 
 
  
Enterococcus faecalis 0 1 20 
 
  
Serratia nematophilia 214 0 30 
 
  
PN004 d1 d30 post-ETT post-ETT   
Streptococcus pseudopneumoniae 101 12 1 0   
PN007 d1 d11 post-ETT     
Serratia nematophilia 1 0 0 
 
  
Streptococcus pseudopneumoniae 155 766 796 
 
  
Staphylococcus aureus 1 241 217 
 
  
PN018 d1        
Streptococcus pseudopneumoniae 96 
  
    
PN019 d1 post-ETT      
Streptococcus pseudopneumoniae 11 1 
  
  
Staphylococcus aureus 0 3 
  
  
Enterococcus faecalis 4 0 
  
  
PN022 d1 d6 post-ETT    
Streptococcus pseudopneumoniae 159 126 7 
 
  
Staphylococcus aureus 2 1 0 
 
  
Enterococcus faecalis 0 4 0 
 
  
PN012 d1 d6 post-ETT    
Streptococcus pseudopneumoniae 99 1 0 
 
  
Enterococcus faecalis 0 568 0 
 
  
PN021 d1 d3 post-ETT    
Streptococcus pseudopneumoniae 130 145 325 
 
  
Staphylococcus aureus 61 34 3 
 
  
PN030 d1 d5 post-ETT    
Escherichia coli 349 385 1001 
 
  
Enterococcus villorum 451 296 5 
 
  
																																																								7PN – patient number, d - day of mechanical ventilation, post-ETT - collection of dental 
plaque into the post-ETT extubation recovery period.7	
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Staphylococcus aureus 0 17 1 
 
  
Enterococcus faecalis 0 136 4 
 
  
PN032 d1 d3 d6    
Escherichia coli 949 863 13 
 
  
Enterococcus villorum 0 3 0 
 
  
Staphylococcus aureus 2 1 5 
 
  
Enterococcus faecalis 0 1 0 
 
  
PN046 d3 d13 d26 d34 d48 
Escherichia coli 0 3 1 18 0 
Streptococcus pseudopneumoniae 12 0 0 18 102 
Enterococcus villorum 0 0 0 22 0 
Staphylococcus aureus 0 27 9 23 4 
Enterococcus faecalis 0 22 916 549 2 
Stenotrophomonas pavanii 0 0 1 0 0 
PN049 d1 d8       
Escherichia coli 422 0 
  
  
Streptococcus pseudopneumoniae 0 225 
  
  
Staphylococcus aureus 3 11 
  
  
Enterococcus faecalis 29 20 
  
  
Clostridium bolteae 20 0 
  
  
PN050 d1 d27 post-ETT    
Streptococcus pseudopneumoniae 91 0 0 
 
  
Staphylococcus aureus 0 2 104 
 
  
Enterococcus faecalis 578 0 54 
 
  
Stenotrophomonas pavanii 0 0 2    
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Figure 3.11 - Heat map indicating phylum variation within dental plaque and 
lower airways during mechanical ventilation (a total of 7 samples were 
pooled).  
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Figure 3.12 – Heat map indicating the level of phyla, species variation and 
species abundance during MV. In the X1 key – a=subglottic aspiration, l= 
NBL, and p=dental plaque. If none stated, the samples for analysis were 
dental plaque. 
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3.3.3.5 Presence of respiratory pathogens in dental plaque post-ETT 
extubation  
The final aspect of analysis of microbial communities of dental plaque was to 
determine whether the bacterial communities at the start of MV (d1) were 
similar to that of dental plaque communities post-ETT extubation (Figure 
3.13). The 10 most abundant species were compared, revealing both oral 
and potential respiratory pathogens were detected at the beginning of MV 
and post-extubation. A pairwise t-test measuring the weighted Unifrac 
against the data sets indicated a lack of significance (p=0.1945). Although 
there was no significant difference between these two-pooled microbial 
communities, there was a decrease in abundance of many respiratory 
pathogens in the post-ETT extubation recovery period. There were however 
similar or higher numbers of S. pseudopneumoniae and S. aureus 
respectively, in the post-ETT extubation period (Figure 3.13). Veillonella and 
Lactobacillus were the two most abundant genera in the post-ETT extubation 
period, whilst Veillonella and E. coli were the two most abundant bacterial 
types at the start of MV. In the post-extubation period, potential respiratory 
pathogens including E. coli and S. aureus were detected, however their 
abundance was lower compared to the start of MV. This can be seen by the 
smaller bar on the stacked bar graph suggesting a decrease in total 
abundance of pathogens (Figure 3.13). In contrast, Enterococcus species 
were not identified in the post ETT-extubation period.  A total of 50% of the 
most abundant species in dental plaque collected during the recovery period 
were recognised as frequent members of the oral microbiota.  
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Figure 3.13 - The ten most abundant microbial species in patients' dental 
plaque communities at the commencement of MV (start) and into the post-
ETT extubation recovery period (ward).  	  
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3.3.3.6 DMFT scoring and the abundance of dental plaque: correlation 
analysis 
DMFT scores were recorded for 97 patients and have been reported in 
Chapter 2 (Section 2.3.1.6). DMFT scores for the 13 mechanically ventilated 
patients during microbial profiling analysis ranged from 0 to 22, with 9 out of 
13 patients having a DMFT score >10. Pearson's product-moment correlation 
coefficient is a statistical analysis used to determine whether there is any 
correlation between two measured variables. Correlation analysis was 
performed to determine if there was a relationship between the patients’ total 
dental plaque abundance (indicator of plaque abundance) and DMFT score 
(Figure 3.14). The correlation coefficient was -0.432, indicating a negative 
correlation between species abundance and DMFT scores within 
mechanically ventilated patients. The 95% confidence interval ranged from -
0.637 to -0.168, and the extent of this range (~0.5) suggests a degree of 
patient variability. The p-value derived from the statistical analysis 
(p=0.002159) implies a very strong negative relationship between DMFT 
scores and bacterial abundance, suggesting with increases in DMFT scores, 
there are decreases in recovered bacterial abundance.  
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Figure 3.14 - Correlation analysis between total dental plaque species 
abundance and the DMFT score. This scatter plot shows the relationship 
between species abundance (recovered DNA sequence reads from dental 
plaque) with the previously recorded DMFT score.  
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3.3.4 Similarity analysis of dental plaque, NBL, subglottic aspirations 
and ETTs 
Microbial community profiling was also performed to compare communities of 
dental plaque, NBL, subglottic aspirations and ETT biofilms. The analyses 
aimed to assess the degree of microbial similarity or otherwise between the 
oral cavity and lower airways. ANOVA Bonferroni correlation analysis 
(performed in STAMP) provided statistical comparison for two potential 
respiratory pathogens identified in mechanically ventilated patients during 
MV. Streptococcus pseudopneumoniae was identified in 11/13 patients, as 
represented in figure 3.15, and E. coli was detected in 4/13 patients (Figure 
3.16). For S. pseudopneumoniae, the abundance from all pooled samples 
per patient was <25% with the exception of PN007 for whom S. 
pseudopneumoniae represented >50% of all identified sequences. The 
abundance of E. coli/Shigella flexneri when analysing total pooled samples 
collected per patient, ranged from <10% to >90% of total OTU reads 
sequenced.  
To compare the microbiome at different clinical sites, a stacked bar graph 
representing the ten most abundant species from each sampling site was 
generated (Figure 3.17). The most abundant bacterium detected within 
pooled dental plaque was Veillonella parvula. For NBL and subglottic 
aspiration samples the most abundant organisms were Haemophilus 
influenzae and Lactobacillus salivarius, respectively. In the case of ETT 
biofilms, the most abundant organism was the potential respiratory pathogen 
S. aureus. Oral bacteria such as Veillonella species were detected from non-
oral sites, and potential respiratory pathogens such as S. aureus were also 
identified in multiple sites.  
The abundance of both the genera Staphylococcus and for S. aureus 
between dental plaque, NBL, SUB and ETTs was analysed via one-way 
ANOVA (Figure 3.18). The proportion of Staphylococcus species sequences 
was significantly higher for ETT biofilms compared with dental plaque (p= 
0.00019). Staphylococcus aureus was detected at all patient sample sites, 
with a significantly increased proportion of S. aureus sequences detected 
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within ETT biofilms, compared with dental plaque and the lower airways 
(NBL and SUB).  
Furthermore, ANOVA was performed for an oral-indicator species. 
Interestingly, ANOVA comparing the sequence proportion of Prevotella 
nanceiensis between dental plaque and ETTs revealed a statistically 
(p=0.023) greater detection of this oral species from the ETT biofilm 
compared to dental plaque. Figure 3.19 represents this graphically, showing 
a proportion of sequences for ETTs >25% for Prevotella nanceiensis, and 
<5% from all other sampled sites.  
NMDS analysis was performed to compare the microbiome of dental plaque 
the lower airways, and ETT biofilms. Figure 3.20 (A) shows the NMDS 
analysis assigned scatter plot per each sample analysed via community 
profiling. Figure 3.20 (B) demonstrates the microbial relationship between the 
dental plaque microbiota and ETT biofilms. In addition, to compare similarity 
between microbial species in dental plaque and ETTs, a series of t-tests 
were performed on 5 of the most abundant species detected in both sample 
types. Figure 3.21 compares the sequence coverage (abundance) between 6 
microbial species isolated within both dental plaque and ETT biofilms. T-tests 
explored the level of significance between the relative abundance of species 
between the dental plaque and ETT biofilms, with q-values for all t-tests 
revealing all were statistically significant (<0.05). A q-value is the analogue of 
the false discovery rate (to correct for multiple testing and comparisons), and 
represents the p-values. Analysis indicates significant differences between 
the species level at different sample sites. All species examined, including S. 
aureus, Streptococcus agalactiae, Prevotella nigrescens and Aggregatibacter 
segnis were isolated in a significantly higher abundance in ETT biofilms 
except Veillonella parvula, which was significantly more abundant within the 
dental plaque.  
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Figure 3.15 - Box and whisker plots comparing the proportion of total 
sequences identified as Streptococcus pseudopneumoniae. ANOVA 
Bonferroni correlation analysis compared the abundance of S. 
pseudopneumoniae against all other microbial species identified. A corrected 
p-value of 2.893-3 indicated the abundance of S. pseudopneumoniae in total 
sequences identified was statistically higher than other microbial species.   
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Figure 3.16 - Box and whisker plots comparing the detection of E. coli from 
total sequences collected from clinical samples from patients during 
mechanical ventilation. ANOVA Bonferroni correlation analysis compared the 
abundance of E.coli/Shigella flexneri against all other microbial species 
identified. A corrected p-value of 0.014 indicated the abundance of E. coli/ S. 
flexneri in total sequences identified was statistically higher than other 
microbial species.   
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Figure 3.17 - The ten most abundant microbial species within dental plaque, 
NBL, subglottic aspirations and ETT biofilms. 
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Figure 3.18A – Box and whisker plot comparing the percentage of dental 
plaque sequences for Staphylococcus between dental plaque, the lower 
airways and ETT biofilms. The addition of multiple testing corrections allows 
the testing of multiple hypotheses.  
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Figure 3.18B – Box and whisker plot comparing the percentage of dental 
plaque sequences for Staphylococcus aureus between dental plaque, the 
lower airways and ETT biofilms.  
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Figure 3.19 – Box and whisker plot at the species level for the oral organism 
Prevotella nanceiensis. Prevotella nanceiensis was detected in the subglottic 
aspirations, the dental plaque, and the ETT. ANOVA (with Benjamini-
Hochber multiple correction testing) was performed and a p-value of 0.023 
emphasised a statistically significant difference between P. nanceiensis 
detection amid clinical sites.  
  
	 140 
 
Figure 3.20A - NMDS analysis of microbial communities taken from all 
sample sites: dental plaque (green), NBL (red), subglottic aspiration (black) 
and ETTs (blue), based on the weighted distances. 
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Figure 3.20B - NMDS analysis of microbial communities of dental plaque 
and ETT biofilms   
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Figure 3.21 – Comparison of the isolation of six different microbial species 
from the dental plaque and the ETTs using t-tests. The first bar-row (green) 
represents dental plaque isolation, and the second bar-row (purple) 
represents the ETT. The mean proportion of sequence is situated on the left 
of the image, followed by the difference in mean proportions between the 
dental plaque and the ETTs. On the far right of figure 2 are the 
corresponding q-values for the t-tests. 
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3.4 Discussion  
This is the first time that molecular community profiling has been used to 
characterise changes that occur within the microbial communities of dental 
plaque and the lower airways both during MV and post ETT-extubation. In 
addition, the microbiome of the lower airways and biofilms from extubated 
ETTs were analysed. Next-generation sequencing based technologies to 
enable microbial community profiling provide simultaneous identification of 
microorganisms as well as species quantitative data (Zaura, 2012).  
During this study, MiSeq Illumina sequencing provided comprehensive 
microbial profiles for different clinical sites within mechanically ventilated 
patients, and highlighted significant increases in the detection of respiratory-
relevant pathogens within dental plaque of mechanically ventilated patients. 
These findings confirmed and considerably extended those obtained from 
culture-based studies, that have previously demonstrated changes in 
microbial plaque composition which may facilitate the development of 
secondary respiratory infections such as VAP (Mori et al., 2006; Zuanazzi et 
al., 2010). In this context, it has been proposed that the placement of the 
ETT may be one of the drivers that changes oral environmental factors 
(Cairns et al., 2011; Lloyd et al., 2011). The results demonstrated that 
several ‘non-oral’ genera co-existed with oral microorganisms in the dynamic 
biofilm that is dental plaque. Physical alterations (such as the insertion of 
ETTs) may influence microbial displacement and translocation within the 
upper and lower respiratory system.  The dynamics and influence of dental 
plaque may in fact be underestimated and the amount of dental plaque can 
be a significant contributing factor to several oral and systemic infections, 
such as VAP.  
Respiratory pathogens were identified within the dental plaque during the 
early stages of MV, however a significant increase in pathogen abundance 
was demonstrated during MV (Table 3.1; figure 3.7). The result emphasises 
the potential of the mouth to act as a reservoir for pneumonia causing 
bacteria. Zuanazzi et al., 2010 performed similar community profiling 
analyses, in which the dental plaque and saliva of hospitalised patients was 
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analysed by microbial culture and culture-independent analysis. Zuanazzi et 
al., 2010, did not isolate staphylococcus aureus, however, coagulase 
negative staphylococci were present. In contrast, during the present 
microbiome study, S. aureus was the most abundant respiratory pathogen 
identified in ETT biofilms (Figure 3.18A, B) and was amongst the most 
abundant species of the dental plaque microbiome during MV (Figures 3.12 
and 3.18). Performing high-throughput analysis alongside conventional 
cultivable studies is useful for revealing any differences in the methodologies 
and highlighting cases where respiratory pathogen detection was different 
between microbial culture and culture-independent analysis. Although such 
variation exists, the detection of respiratory pathogens in dental plaque and 
the lower airways reinforces results from previous studies using microbial 
culture analysis of dental plaque during MV.  
Pseudomonas aeruginosa is considered a virulent and prominent species in 
the aetiology of VAP and other associated lower airways infections (Parker et 
al., 2008; Luyt et al., 2014). Interestingly, Pseudomonas species were rarely 
detected in the high-throughput analyses of the 13 mechanically ventilated 
patients. However, P. aeruginosa had previously been isolated in ~25% of 
dental plaque via microbial culture (Chapter 2 - 2.3.2). Previous studies have 
suggested that P. aeruginosa is a predominant coloniser of dental plaque 
during MV and a causative pathogen of VAP (Parker et al., 2008; Raad et al., 
2011; Tarquinio et al., 2014). Pseduomonas aeruginosa is a frequent 
coloniser of both water and soil (Perkins et al., 2010). Evaluating the 
presence of P. aeruginosa in the water supply within the hospital could help 
detect one of the sources for this pathogen.  
Current microbiological analysis relies on cost effective, readily available and 
reproducible microbial culture. Pseudomonas aeruginosa is a rapid coloniser 
on nutritional media and can effectively outcompete the growth of other 
microbial species and may therefore be misrepresented as a dominant 
species by culture. The composition of dental plaque is extremely diverse 
with many species not yet capable of being cultivated, reinforcing the 
potential for P. aeruginosa, to ‘out-compete’ and be over-represented on 
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microbiological media. Although, P. aeruginosa is considered an 
opportunistic pathogen of the oral cavity within mechanically ventilated 
patients, further high-throughput studies could elucidate the true extent of P. 
aeruginosa within dental plaque during MV. Future studies could investigate 
and compare commercially available total bacterial DNA extraction methods, 
as certain elution techniques could result in a low detection of Pseudomonas 
species. Further analysis concerning the detection of P. aeruginosa is 
warranted to determine whether P. aeruginosa should still be considered the 
predominant bacterium in this context, compared to S. pseudopneumoniae, 
S. aureus and Gram-negative species such as E. coli.  
 
Dental plaque is known to be diverse and dynamic with its microbial 
constituents responding and adapting to their immediate microenvironment 
(Hojo et al., 2009; Robinson et al., 2006). Within this study, 5 major phyla 
and 40 genera were identified (Figure 3.4). These organisms ranged from 
frequently identified and studied genera such as streptococci, Tannerella 
species and Oscillibacter species; some of which lesser known genera have 
been revealed in similar community profiling studies (Galimanas et al., 2014).  
 
Haemophilus influenzae, an organism associated with respiratory infection, 
was also detected within the dental plaque of mechanically ventilated 
patients. Haemophilus influenzae, can often colonise the upper and lower 
respiratory tract of healthy individuals and is considered a significant 
pathogen in respiratory infection (King, 2012).  
Microbial changes occurred in a high proportion of mechanically ventilated 
patients, and at least one putative respiratory pathogen was detected in the 
dental plaque of all 13 patients analysed in this study. Streptococcus 
pseudopneumoniae has been suggested to be an early onset causative 
pathogen of VAP, alongside S. aureus and Gram-negative bacilli (Kalanuria 
et al., 2014). Streptococcus pseudopneumoniae was detected in 11 of the 13 
mechanically ventilated patients (representing the larger cohort) during this 
study (Figure 3.16 and table 3.2). Enterococcus faecalis, an opportunistic 
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pathogen identified as being amongst the four most frequently occurring 
species in dental plaque during MV, has the ability to integrate into the 
polymicrobial dental oral biofilm in situ (Al-Ahmad et al., 2010). Enterococcus 
faecalis, although not commonly regarded as a member of the oral 
microbiota in health, may be isolated from the oral cavity in some individuals 
and is interestingly frequently isolated from secondary endodontic infections 
(Al-Ahmad et al., 2009). Vancomycin-resistant enterococci are increasingly 
associated with hospital-acquired infections (HAIs), especially after the 
patient has been in receipt of antibiotics (Austin et al., 1999; Rengaraj et al., 
2016). It may therefore not be surprising that Enterococcus colonisation 
persisted during MV, emphasising the vast changes that are occurring in the 
homeostasis mechanisms in dental plaque and host immunity. 
 
Sachdev et al., 2013 reported that the amount of dental plaque in 
hospitalised and ventilated patients increases. Associating increases in 
gingival inflammation is one marker of host immune activity in response to 
such elevated plaque levels thus highlighting the importance of oral 
measures such as plaque scoring in critical care medicine (Wise & Williams, 
2013). DMFT scores were recorded for all patients recruited to the 
observational cohort study (2.3.1.5). Correlation analysis between DMFT 
scores and total dental plaque abundance (OTU abundance average per 
patient) was performed to analyse microbial communities in relation to DMFT 
scores (Figure 3.15). Although not a measure of current health, DMFT scores 
can provide an indication of previous oral health status (Becker et al., 2007). 
Analysis (Figure 3.15) revealed there was no positive correlation between 
increased DMFT scores and mean dental plaque abundance, in fact a slight 
negative correlation was found. This may suggest that patients with previous 
good oral hygiene may be at risk of increasing dental plaque and 
furthermore, the introduction of respiratory pathogens during MV. Along with 
the DMFT score, future work could investigate if correlations exist between 
DMFTs, dental plaque and gingival index scores, and respiratory pathogen 
colonisation of dental plaque. Such correlation analyses on larger cohorts 
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could reveal whether patients admitted with poor pre-existing oral hygiene 
were at greater risk of respiratory pathogen colonisation of dental plaque in 
comparison to patients with previously good oral hygiene. 
In addition to microbial profiling of dental plaque during MV, NBL, subglottic 
aspirations and ETT biofilms were characterised for microbial content during 
MV. A total of 10/48 samples processed for community profiling were non-
dental plaque samples. Within these microbial profiles, both oral-indicator 
species including Prevotella species and respiratory pathogens were 
detected (Figures 3.17 and 3.19). These findings may support the theory of 
microbial translocation from the oral cavity towards the lower airways (Li 
Bassi et al. 2015; Cairns et al. 2011). NMDS analysis comparing the 
microbiome at different clinical sites (Figure 3.20A, B) analysed 3 patients’ 
ETT biofilms and compared these to 38 dental plaque samples. Preliminary 
results indicated overlapping clusters, highlighting similarities between the 
microbiomes of dental plaque and ETT biofilms. This analysis therefore, 
although indicative of microbial similarities between sampling sites, in this 
instance did not hold true statistical power, due to incomplete and uneven 
sample size. A series of t-tests were performed on six different species, 
comparing the mean proportion of sequences detected from either dental 
plaque or ETT biofilms. S. aureus, Streptococcus algalactiae and 
interestingly Prevotella species were present in higher numbers in the ETT 
biofilm compared to dental plaque.  
 
Analysis of the patients’ dental plaque during their recovery and post 
extubation, revealed a decrease in detection of respiratory pathogens for 
many patients, and suggests that the microbial community begins to revert 
back to one that is predominantly comprised of healthy oral microbiota 
(Figure 3.13). Respiratory pathogens, although at a lower abundance, were 
detected from dental plaque of patients into their recovery period, suggesting 
that once these organisms proliferate into the biofilm, they may resist 
replacement whilst the patient is still immunocompromised. Future studies 
could analyse dental plaque with a larger sample size and over a longer time 
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 period post recovery to statistically reflect the community and recovery 
period of critically ill patients 
 
Conclusion 
Microbial community profiling was successfully applied to characterise the 
microbiome of dental plaque in mechanically ventilated patients, both during 
MV and into the recovery period when the patient was liberated from 
mechanical ventilation. A significant ‘microbial shift’ in the composition of 
dental plaque was demonstrated for patients with potential respiratory 
pathogens including S. aureus, S. pseudopneumoniae and E. coli 
increasingly detected during MV. Interestingly, and in contrast to previous 
culture studies (Chapter 2), P. aeruginosa was not detected in this molecular 
analysis.  
 
The lower airways and ETT biofilms were also subjected to characterisation 
via community profiling. The detection of oral species within the lower 
airways and strict oral anaerobic species including Prevotella within the ETT 
biofilm highlights their presence, and preventing the translocation of dental 
plaque may be important.  
 
Fulfilling the chapter’s aims, dental plaque was further characterised into the 
post-ETT extubation period whereby both the presence and abundance of 
respiratory pathogens was reduced following extubation. However, some of 
these microbial species could still be identified at reduced number within the 
community, and may therefore still represent risk factors for infection in the 
longer term.  Both oral indicator species and potential respiratory pathogens 
were detected in oral and lower airways. This is the first comprehensive 
characterisation of the microbiomes of dental plaque and lower airways in 
this patient group. A better understanding of the compositional changes 
within dental plaque, and the extent of microbial translocation may inform 
interventional strategies to reduce incidence of VAP. 
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.  
Chapter 4 
 
A longitudinal study of saliva 
properties and protein 
composition during mechanical 
ventilation 
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4.1 Introduction 
 
The oral cavity is unique, containing both hard surfaces, namely the teeth, 
and soft mucosal tissues, which are constantly subject to change both in 
health and in illness. In addition, the oral microbiota is complex with distinct 
microbial communities within different oral sites and currently over 1,000 
bacterial species have been identified (Lazarevic et al., 2009; Wade, 2013b). 
Dental plaque, an archetypal biofilm upon tooth surfaces, harbours an 
estimated 500 different bacterial species indicating that the microbial 
structure is not uniform, more so ever-changing (Rosan & Lamont, 2000).  
 
Streptococcus species are recognised as primary pioneer colonisers of teeth 
and therefore initiators of dental plaque development (Denepitiya & Kleinberg 
1982). Early microbial colonisers within dental plaque, predominantly 
members of the Streptococci genera including Streptococcus mitis and 
Streptococcus salivarius, adhere to immobilised proteins within saliva such 
as statherin that are anchored on the enamel surface of the tooth (Chaudhuri 
et al., 2007; Rudney et al., 2003).  Saliva therefore promotes positive 
bacterial selection thus contributing to the production of dental plaque and 
biofilm formation upon the tooth surface (Sekine et al., 2004). 
 
Salivary mucins can bind to bacterial cells, ultimately maintaining adequate 
levels of bacterial adhesion to the tooth’s enamel. The composition of saliva, 
in particular free calcium and phosphate form buffering systems helping to 
maintain the integrity of the tooth (Amerongen & Veerman, 2002; Lamkin & 
Oppenheim 1993). Salivary proteins extend to the inclusion of antibacterial 
peptides such as lysozyme and lacotransferrin serving to protect and defend 
against organisms and foreign debris entering the oral cavity (Gorr & 
Abdolhosseini, 2011; Silva et a., 2012).  
 
In the past 10-15 years there have been numerous studies suggesting that 
changes occur to the composition of dental plaque in critically ill and 
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mechanically ventilated patients (Scannapieco et al., 1992; Fourrier, et al., 
1998; Heo et al., 2008; Zuanazzi et al., 2010; Jones, Munro & Grap, 2011; 
Sachdev et al., 2013). The current study has documented the extent of 
dental plaque changes during MV by longitudinal microbial culture and 
microbiome community profiling (Chapters 2 and 3). Dental plaque was 
shown to become heavily colonised with respiratory pathogens including S. 
aureus, E. coli, P. aeruginosa and S. pseudopneumoniae during MV, species 
which in many cases are absent at the beginning of ventilation. These 
microbial changes will likely have been driven by alterations to the local 
and/or systemic environment. Potential variables that could drive microbial 
compositional changes within dental plaque include saliva flow, pH and 
proteomic composition.  
 
Currently, there is little evidence of large studies investigating saliva 
properties and any subsequent role that saliva may have in dental plaque 
colonisation by respiratory pathogens. Dennesen et al., 2003, have however 
measured saliva flow of 44 hospitalised patients (24 during intubation and 20 
elective surgery). They reported inadequate salivary flow in intubated 
intensive care patients, with a nearly absent stimulated salivary flow during 
intubation, and comparably, only a temporary reduced postoperative 
stimulated salivary flow for elective surgical patients (Dennesen et al., 2003). 
Most existing literature addressing salivary flow during MV, or assessing the 
benefits on the application of oral gels to intubated patients are primarily 
focused around oral decontamination, and oral moistening (O’Reilly, 2003; 
Scannapieco et al., 2009). In recent years there has been much emphasis on 
the value of saliva as a prognostic and diagnostic fluid with proteomic 
changes in saliva being used to assess and potentially predict certain 
disease progression (Schipper et al., 2007; Pfaffe et al., 2011). Use of saliva 
in this manner has the advantage of being a minimally invasive process.  
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The overall aim of the work presented in this chapter was to determine if 
there were detectable changes in the saliva of patients during and after 
mechanical ventilation and to relate any changes to the composition of dental 
plaque.  
 
 Specifically, the objectives were: 
 
(1) - To determine whether there were changes in salivary parameters during 
MV, including volume, protein concentration and pH. 
 
(2) – To analyse the proteome of saliva during MV and in the post-ETT 
extubation period. 
 
(3) - To quantify pro-inflammatory cytokines in saliva, plasma and ETT fluid 
during MV and (saliva) into the post-ETT extubation period.  
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4.2 Materials and Method  
4.2.1 Ethical approval  
Ethical approval was obtained from National Research Ethics Service 
(NRES) within the Research Ethics Committee (REC), Wales (Ref: 
13/WA/0039) for a single NHS organisation study on 20th June 2013 to 
evaluate dental plaque biofilms and salivary parameters during the course of 
MV (2.2.1). Mechanically ventilated patients at a single University Hospital 
Critical Care Unit were eligible for inclusion in the study if they were aged 
>18 years, had >8 original teeth, anticipated period of MV >24h, and an 
expected survival of >24 h. Informed consent for participation in the study 
was obtained from the next of kin by the responsible clinician (2.2.2). 
 
Ethical approval was granted on April 2014 from the School of Dentistry, 
Cardiff University, for the collection of 5 saliva samples over a period of 10 d 
from 5 healthy volunteers, forming the control group. The inclusion criteria for 
the healthy volunteers was as follows: >18 years, >8 original teeth, and not in 
receipt of prescription medications. The collected saliva was anonymised and 
stored at -80°C following HTA guidelines for fluid containing human cells.  
 
4.2.2 Saliva, plasma and ETT fluid from mechanically ventilated patients 
Saliva and blood were collected three times during the first week of MV and 
weekly thereafter until ETT extubation. All collections were undertaken at the 
same time in the morning of the due date. Saliva was also collected weekly 
during the post ETT extubation recovery period, and for up to 3 months post-
ICU discharge.   
 
Whole saliva was obtained using Salivettes® (Sarstedt™), an effective and 
non-laborious device containing a sterile cotton plug, within polypropylene 
collection tubes. The cotton plug was placed and held securely in the oral 
cavity of the individual for 45 s and placed in the polypropylene tube (Topkas 
et al., 2012). Saliva was recovered by centrifugation at 1,000 × g for 2 min. 
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The supernatant (saliva) was transferred into a 1.5 ml microcentrifuge tube 
and the saliva stored at -80°C within 5 h of collection to prevent activity of 
proteases (Thomadaki et al., 2011). Where possible, fluid was also collected 
from the inner lumen of extubated ETTs using sterile swabs.  The swab was 
then immersed in 1 ml of PBS and stored -80°C prior to analysis.  
 
Whole blood was collected in an anticoagulant (EDTA) treated vial to prevent 
clotting. The tubes were inverted gently between 8-10 times to ensure even 
distribution of EDTA before centrifugation. Blood cells were separated via 
refrigerated centrifugation for 10 min at 1,000-2,000 × g. After blood 
components were separated, plasma was collected using a pipette, 
transferred to a 1.5 ml screw cap tube and stored at -80°C.  
 
4.2.3 Measurement of salivary parameters: volume, pH and protein 
concentration 
4.2.3.1 Measuring salivary volume and pH 
The volume of collected saliva (obtained over 45 s) was measured using a 
pipette and a calibrated collection tube.  A microelectrode pH meter (Fisher) 
attached to a pH reader (Eutech Instruments) was used to measure the pH. 
4.2.3.2 Bicinchoninic acid assay (BCA) for total protein measurement 
Whole saliva samples were diluted 1:10 in double distilled water (ddH2O). For 
analysis of fluids obtained from the ETTs, a 1 cm section of the lumen was 
scraped with a cotton swab for 30 s and placed in 500 µl of SputasolTM 
(Oxoid) and vortex mixed for a further 30 s. Cells were removed by 
centrifugation at 14,000 × g at 4°C for 20 min. 
Serial dilutions of bovine serum albumin (BSA) from 1 ng/µl were prepared in 
ddH2O in the wells of 96-well microtitre plates. These dilutions were used as 
concentration standards, and were prepared in triplicate for each assay. A 
25-µl volume of the diluted sample was added to duplicate clean wells. A 
200-µl volume of BCA solution (5 ml BCA to 100 µl reducing agent (copper 
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sulphate solution)) (Sigma) was added to all test and standard wells.  The 
microtitre plate was incubated at 37°C for 30 min and the absorbance 
measured at 570nm. A standard curve was generated from the diluted BSA 
and used to quantify protein concentrations of test samples. 
4.2.4 Gel based salivary proteomics 
4.2.4.1 SDS-PAGE 1D electrophoresis  
A total of 13 µl of 30-ng/µl protein (diluted in ddH2O water, using protein 
concentration data obtained from 4.2.3.2), 2 µl of reducing agent (x10 
NuPAGE) and 5 µl of SDS buffer (x4 NuPAGE) was loaded into each well of 
a microtitre plate. The samples were placed in a heating block at 70°C for 10 
min before loading. An 800-ml volume of running buffer (NuPAGE SDS-
Invitrogen) was prepared using 40 ml of 3-(N-morpholino) propanesulfonic 
acid (MOPS) × 20 buffer (NuPAGE) and 760 ml of ddH2O. A 200ml volume 
of this solution was added to the cathode section of the tank (containing the 
gel), the remaining buffer was added to fill the tank. A 20-µl volume was 
added to each well (4-12% gel), including 20 µl of unstained molecular 
marker (Invitrogen). Electrophoretic conditions were 200 V/ cm2 (120 mA, 25 
W) for 55 min (plus 25 min for extra separation if required). 
 
4.2.4.2 Staining electrophoretic protein gels 
4.2.4.2.1 Colloidal Coomassie Blue staining  
Electrophoretic gels were transferred to weighing boats and placed in fixing 
solution (40 ml ddH2O, 50 ml methanol and 10 ml of glacial acetic acid) on a 
rocking platform at room temperature for 10 min. The fixing solution was 
discarded and replaced with 20 ml of staining solution A (55 ml of ddH2O and 
20 ml of methanol). The gel was returned to the rocking platform at room 
temperature for 10 min, and 5 ml of stainer B (Invitrogen) added to stain 
overnight. The staining solution was then removed and the gel washed and 
kept hydrated in 200 ml of ddH2O prior to scanning using ImageScannerIII 
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(GE Healthcare). For long-term storage of the gel, a 1% acetic acid solution 
was used as a preservative.  
4.2.4.2.2. Silver nitrate staining  
For silver nitrate staining, the gel was transferred to a plastic weighing boat 
and placed on a rocking platform at room temperature. The procedure was 
as described by the PlusOne Silver Nitrate Staining Kit (GE Healthcare). The 
gel was placed in 250 ml of fixing solution (10% acetic acid and 40% ethanol) 
for 30 min. The fixing solution was discarded and replenished with 250 ml of 
sensitising solution (75 ml of ethanol, 17g of Na-acetate and 10 ml of 5% Na-
thiosulphate) for 30 min. The solution was discarded and replaced with 250 
ml of ddH2O for a total of 3 separate 5 min washing steps. After the final 
ddH2O was discarded, a 25-ml volume of 2.5% silver nitrate in 250 ml of 
ddH2O was added for 20 min, followed by two 5 min washing steps in ddH2O. 
After the ddH2O was discarded, a 250-ml volume of developing solution (6.25 
g of Na-carbonate and 100 µl of 37% formaldehyde) was added to the gel. 
This solution was left for 4 min, discarded and replaced with 250 ml of 
stopping solution (containing 3.65 g of EDTA) for 10 min. Following three 
final 5 min ddH2O washes, the gel was scanned using the ImageScannerIII 
(GE Healthcare) and placed in a preservative solution of 500 ml of 1% acetic 
acid. 
 
4.2.5 2D gel electrophoresis (2DE) 
4.2.5.1 Protein precipitation for 2DE  
The starting protein concentration needed for 2D gel electrophoresis was 150 
µg/µl (with a maximum volume for the kit of 100 µl; using the ‘2D clean up kit’ 
by GE Healthcare). A 300-µl volume of protein precipitant was added, the 
sample was vortex mixed for 5 s and incubated on ice for 15 min. A 300-µl 
volume of co-precipitant was added and the sample was vortex mixed for 5 s 
and centrifuged at 12,000 × g for 5 min. The supernatant was removed and a 
further 40-µl volume of co-precipitant was added on top of the pellet, and 
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placed on ice for 5 min. The samples were centrifuged at 12,000 × g for 5 
min with the supernatant discarded, replenished with 25-µl of ddH2O, and 
vortex mixed until the sample was dispersed into the liquid. A 1-ml volume of 
chilled wash buffer and 5 µl of wash additive (GE Healthcare) was added to 
the sample and incubated at -20°C for 30 min with a 30 s vortex mix every 10 
min. The samples were centrifuged (12,000 × g for 5 min) and the pellet was 
left to dry for 5 min.  
4.2.5.2 Isoelectric focusing (IEF) 
The protein pellet (obtained from section 4.2.5.1) was resuspended in 116 µl 
of rehydration solution (7M urea, 2M thiourea and 2% (v/v) 3-[(3-
cholamidopropyl) dimethylammonio]-1 propanesulfonate (CHAPS)) and 
vortex mixed for 5 s. A 1-µl volume of bromophenol blue (10 mg/mL), 2 µl of 
IPG Buffer (GE Healthcare) and 6.25 µl of dithiothreitol (DTT, 50 mM) were 
added to the resuspended protein pellet to create the rehydration solution. 
A total volume of 125 µl was required to distribute evenly into the IPG gel 
strip (Immonbiline™ DryStrip pH 3-10 NL, 7cm) IPGphore coffin. The 
immobilised pH gradient (IPG) gel strip was inserted into the coffin gel. An 
800-µl volume of DryStrip cover fluid (mineral oil, Fisher) was placed over the 
strip and the coffin was then placed on the IEF manifold for an initial 
rehydration period of 12 h at 20°C. IEF parameters were 50 microamps 
(µA)/strip at 20°C (step and hold 500 V 1 h, gradient 1000 V 2 h, step and 
hold 1,000 V 1 h, gradient 8,000 V 2 h and step and hold 8,000 V 8 h). 
 
4.2.5.3 Equilibration of the IPG strip 
The IPG strip was removed from the gel-coffin and placed in 5 ml of reducing 
solution (0.5 ml of NuPAGE sample reducing agent and 4.5 ml of 1× 
NuPAGE LDS buffer), which was gently rocked for 15 min. The IPG strip was 
then transferred to 5 ml of alkylating solution (116 mg of iodoacetamide and 
5 ml of 1× NuPAGE LDS buffer) for 15 min on the rocking platform. The IPG 
strip was then transferred into the loading well of the Zoom™ gel (Invitrogen). 
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4.2.5.4 SDS-PAGE using Zoom™ gels  
A 200ml volume of running buffer (prepared as previously described, 4.2.4.1) 
was added to the centre chamber, and the IPG strip was transferred to the 
loading well of the gel (NuPAGE 4-12% Bis-Tris Zoom Gel). A 5-µl volume of 
a 1:20 Mark 12 unstained molecular marker (Invitrogen) was added to the 
single well. The SDS-PAGE and protein staining was performed as 
previously described (sections 4.2.4.1 and 4.2.4.2). 
4.2.5.5 Preparation of peptides from gel electrophoresis for Mass 
Spectrometry (MS) 
4.2.5.5.1 Gel spots and de-staining 
Using a manual spot cutting pipette tip, targeted spots were cut and 
transferred into an Ettan Disgestor 96 well plate (total gel volume 2.65mm3). 
For quality control, one gel plug was cut from the protein marker (Invitrogen 
Unstained Protein Standard Mark12) – β-galactosidase (116.3kDa). Any 
remaining liquid in the wells was removed to prevent protein leeching from 
the bands into solution. A 50-µl volume of acetonitrile (50% acetonitrile 
(ACN) (v/v) in 0.1% (v/v) trifluoroacetic acid (TFA)) was added to the gel 
plugs for 5 min until the plugs turned opaque. To de-stain from coomassie 
blue, each gel plug was covered with 50 µl of 50% (v/v) ACN in 25 mM 
ammonium bicarbonate (NH4HCO3) and this was gently rocked for 1 h. 
 
The supernatant was discarded and the protein plug washed ×3 times in 50 
µl of 25 mM NH4HCO3. The gel plugs were dehydrated in 50 µl of 50% (v/v) 
ACN for 15 min followed by rehydration in 50 µl 25 mM NH4HCO3 for 10 min. 
This process was repeated twice and the spots were then incubated at 65ºC 
for 20 min.  
4.2.5.5.2 Reducing and alkylation 
Disulphide bonds of the proteins were irreversibly broken to achieve optimum 
unfolding of the tertiary structure for downstream protein identification. A 25-
µl volume of 10 mM DTT in 25 mM NH4HCO3 was added to the 96-well plate, 
covered and incubated at 56ºC for 1 h. Once the plate had cooled for 15 min, 
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the supernatant was removed and replenished with 25 µl of 55mM 
iodoacetamide in 25 mM NH4HCO3, covered and incubated for 45 min at 
room temperature in the dark. The gel plugs were washed with 25 µl of 25 
mM NH4HCO3 for 10 min and two dehydration steps were performed as 
described previously (section 4.2.5.5.1). 
4.2.5.5.3 Trypsin digestion 
Trypsin (V5111 Promega UK Ltd) was prepared to a final concentration of 
12.5 ng/µl in 25 mM NH4HCO3. A 5-µl volume of trypsin was added to fully 
dehydrate the gel plug and the plate was sealed and incubated at 37ºC for 20 
min. Once fully rehydrated, the plug was covered with 10 µl of 25 mM 
NH4HCO3 (to keep the gel wet during digestion) and incubated for 4 h at 
37ºC.  
4.2.5.6 Spotting peptides onto the mass spectrometry plate for Matrix-
Assisted Laser Desorption Ionization (MALDI) analysis 
Peptides were resuspended from the gel plug in 5 µl of 50 ACN % (v/v) in 
0.1% TFA (v/v) and sealed for incubation at 60°C for 1 h.  A 0.5-µl volume of 
peptide solution was spotted onto the mass spectrometry (MS) plate and left 
to air dry. After 10 min, a 0.5-µl volume of matrix (section 4.2.6.5) was added 
to each spot. Standards using pre-defined calibrations were also added to 
the MS plate (Applied Biosystems MALDI TOF/TOF analyser 4800). Peptide 
MS loading was devised and employed by qualified employees at The Henry 
Wellcome Building (Cardiff University).  
 
4.2.6 Gel free proteomics: Liquid chromatography, MALDI MS & Mascot 
global protein identification (LC-MS/MS) 
4.2.6.1 Protein extraction from extracellular saliva  
Saliva was incubated on ice with a 500-µl volume of lysis buffer (1 ml of 
tergitol-type nonyl phenoxypolyethoxylethanol detergent (NP-40) (10% v/v), 
200 µl of triethylammonium bicarbonate (1 M), 100 µl of protease inhibitor (20 
mg/ml) and 8.7 ml of distilled water for 15 min. Saliva was centrifuged 
	 160 
(Allegra 21R, Beckman Coulter) at 14,000 × g for 5 min at 4°C and the 
protein levels were quantified using the protein assay as described in 4.2.3.2. 
 
4.2.6.2 Trypsin digestion for iTRAQTM labelling 
Trypsin digestion was completed following sample reduction, denaturing and 
cysteine blocking. A-20 µl volume of dissolution buffer, 1 µl of denaturant 
reagent (Applied Biosystems) and 2 µl of reducing reagent (Applied 
Biosystems) were added to samples containing 100 µg of protein. After 
gentle vortex mixing the tubes were incubated at 60°C for 1 h. A 1-µl volume 
of cysteine blocking reagent (Sigma) was added to each sample, vortex 
mixed and incubated at room temperature for 10 min. A 2-µl volume of 0.8 µg 
of trypsin solution was added and gently vortex mixed. The samples were 
incubated overnight (12-16 h) at 37°C. Each tube was centrifuged for 1 min 
at 6,500 ×g to move the sample digest at the bottom of the tube for iTRAQTM 
labeling.  
4.2.6.3 iTRAQTM labelling 
iTRAQTM reagent vials 114-117 (Sciex) were mixed with 70 µl of ethanol 
added and gently vortex mixed for 10 s. The contents of one iTRAQTM 
reagent vial were mixed with extracted salivary proteins representing one 
saliva sample and incubated for 1 h. 
4.2.6.4 Liquid chromatography (LC)  
iTRAQ™ labeled peptides were fractionated using LC for the downstream 
application of MS/MS analysis to provide peptide sequences. The pump 
wash was filled with 50% isopropanol, with the transport solvent at 2% ACN 
in 0.05% TFA. Buffers A (2% ACN) and B (90% ACN) (flush and washing 
buffers respectively) were prepared for each run. Buffer A was flushed 
through the system for 20 min ensuring the buffer flowed to the needle of the 
Probot. For quality control measures, Cytochrome C (1:80 water) was run as 
an internal control to validate the performance of the LC. Two runs were 
performed to retrieve the optimum data and spot sets for MALDI MS plating, 
	 161 
the 1-D long run (210 min) and the short salt plug run (6×75 min), using a 
reverse phase column aiding the sample spotting onto the MALDI plate.  
4.2.6.5 MALDI Matrix (α-cyano-4-hydrxycinnamic acid) preparation  
Matrix facilitated the ion adsorption of sample matter from the plate into the 
MALDI workflow. A 1-ml volume of 70% ACN/0.1% TFA (v/v) was added to a 
prepared α-cyano-4-hydrxycinnamic acid vial (Sigma) producing 10 mg/ml. 
The matrix was further diluted to 2 mg/ml (800 µl to 3.2 ml of water) with 2 µl 
of 50 pmol/µl Glu-Fib spike. The matrix was placed in a syringe (1 ml) and 
loaded into the Probot mechanical spotter.  
4.2.6.6 MALDI MS peptide analysis  
Samples were spotted onto the MALDI plate using a Probot fraction collector 
running in conjunction with LC. Two additional calibration spots were loaded 
onto the plate (8% calibration mix and 92% matrix solution) as controls. 
Figure 4.1 is a schematic highlighting the gel-free proteomic workflow used. 
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Figure 4.1 - Schematic illustrating the stages for global protein identification 
from whole saliva, adapted from Amado et al., 2013. 
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4.2.6.7 Bioinformatics: proteomic data analysis  
During analyses, saliva from three time points during MV were analysed from 
one patient, whilst saliva from four time points (over a period of 10 d) was 
analysed from one healthy volunteer. Each proteomic workflow (LC-MS/MS 
of pooled saliva per individual) was repeated twice. Peptides were identified 
according to peptide sequence matches at a 95% confidence, 2+ peptide 
match level using search engines MASCOT and Paragon™ (applicable with 
downstream quantitative software Protein Pilot™).  
Gel-based (SDS-PAGE and 2DE) protein identification analysis was 
performed using MS coupled with Mascot. For gel-free quantitative analysis, 
raw peptide sequences were input into Protein Pilot™ coupled with the 
Paragon algorithm to automatically optimise peptide identification. Paragon™ 
uses hybrid sequence tags and precursors to simultaneously identify and 
analyse protein modifications in large quantities. ProteinPilot™ transferred 
the proteomic data from MS (protein identification using Mascot search 
engine) to generate expression peaks. Pooled saliva samples were identified 
according to their iTRAQ label for differential protein expression (a relative 
measure of quantitation) comparing proteomic content of saliva between 
mechanically ventilated patients and healthy volunteers. Protein classification 
and biological function comparisons were performed using a protein-to-gene 
converter tool- neXtProt coupled with the Protein Analysis Through 
Evolutionary Relationships (PANTHER) classification system, using gene 
names (Vitorino et al., 2012). 
 
 
4.2.7 IL-6 detection in plasma by ELISA - pilot assay to determine 
cytokine recovery 
ELISA was used to detect IL-6 cytokine in plasma from mechanically 
ventilated patients. Fifty µl of capture antibody (1:250 anti-human IL-6 
capture antibody eBioscience) were placed in the wells of a Nunc ELISA 
plate which was incubated with shaking (100 rev/min; 30 s) overnight at 4°C. 
The wells were aspirated, washed (×3; washing buffer – PBS, 0.05% Tween-
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20) and 100 µl of blocking buffer (×5 assay diluent; eBioscience) was added 
to each well and incubated for 2 h at room temperature. After a further three 
washing steps, 50 µl of control standards were added, ranging between 200 
pg/ml to 3.125 pg/ml. A 150-µl volume of sample was added to triplicate 
wells, and the plate was incubated overnight at 4°C. The wells were washed 
(×6) and a 100-µl volume of detection antibody (IL-6 anti-human detection 
antibody 1:250, eBioscience) was added to each well, and incubated at room 
temperature for 1 h. The plate was washed (×6) and 50 µl of horseradish 
peroxidase (HRP) (eBioscience) added at room temperature for 30 min. After 
washing (×6), 50 µl of tetramethylbenzidine (TMB) ELISA substrate (×1; 
eBioscience) was added, and the plate placed in the dark for 30 min for 
colour development. The reaction was stopped with 50 µl of stopping solution 
(ELISA stopping solution; eBioscience), and the absorbance read at 450nm 
wavelength.  
 
4.2.8 Cytometric bead array (CBA) analysis of inflammatory cytokines 
in saliva, plasma and fluid from ETTs 
4.2.8.1 Preparation of standards: human inflammatory cytokines 
All reagents unless otherwise stated were from the Cytometric Bead Array 
(CBA) Human Inflammatory Cytokines Kit (BD Biosciences). Standards were 
reconstituted as described by the manufacturer.  
4.2.8.2 Preparation of cytokine beads 
Each capture bead preparation was vigorously vortex mixed and 5-µl 
transferred into single tube for each sample. For plasma analysis, beads 
were centrifuged (200 × g for 5 min), the supernatant was removed and 
replaced with an equal volume of serum enhancement buffer before vortex 
mixing. The mixed capture beads were incubated for 30 min at room 
temperature in the dark. 
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4.2.8.3 ETT preparation for cytokine analysis 
The lumen of the 1 cm ETT section was scraped with a cotton swab for 1 
min, and the swab was then placed into 1 ml of Sputasol™ (Oxoid) in a 
microcentrifuge tube. The preparation was centrifuged (16,000×g, 1 min) and 
the supernatant removed and used for cytokine analysis.  
4.2.8.4 Cytokine bead assay for saliva and ETT fluid 
Saliva samples were diluted based on total protein concentration (determined 
in 4.2.3). ETT fluids were initially added undiluted from the preparation 
described above. A 25-µl volume of the diluted samples (and all standards 
and controls) was transferred into a labeled microcentrifuge tube (StarLab), 
and a further 25 µl of the vortex mixed pooled capture beads added to all 
samples. A 25-µl volume of pro-inflammatory cytokine PE detection reagent 
was added to all assay tubes and gently mixed. All assay tubes were 
incubated in the dark at room temperature for 3 h. A 500-µl volume of wash 
buffer was added to each assay tube and centrifuged (200×g for 5 min). The 
supernatant was discarded, leaving the cytokine beads, which were re-
suspended in 150-µl of wash buffer and transferred into a flow acquisition 
tube (BD FalconTM) for flow cytometry multiplex analysis. 
 
4.2.8.5 Cytokine bead array for plasma samples  
A 25-µl volume of undiluted sample was transferred into a labeled 
microcentrifuge tube (StarLab), and a further 25 µl of the vortex mixed pooled 
capture beads added. All assay tubes were incubated in the dark at room 
temperature for 90 min. A 500-µl volume of wash buffer was added to each 
assay tube and centrifuged (200 × g for 5 min). The supernatant was 
discarded, leaving 50 µl of liquid above the pellet and a 25-µl volume of 
human inflammatory cytokine PE detection reagent was added to all assay 
tubes, and gently mixed. Tubes were incubated away from direct light 
exposure at room temperature for 90 min. The washing step before bead 
analysis was repeated as with the saliva samples (4.2.8.4). 
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4.2.8.6 Cytokine FACS analysis  
For the multiplex analysis there were 6 different cytokine parameters with 
different measured fluorescent intensities, ultimately allowing the collection of 
six different clusters. A sandwich complex (capture bead and analyte 
(cytokine) and detection reagent) was measured using the flow cytometer.  
 
The Flow Cytometric Analysis Program (FCAP) array™ software was used to 
analyse raw data collected from the cytometer, assigning each bead 
(cytokine) to one of six clusters and creating a standard curve for each 
detected cytokine bead. Fluorescence-activated cell sorting (FACS) was 
performed and the standard curves used to measure the mean fluorescence 
intensity and thus cytokine concentration in each test sample.  
 
4.2.9 Statistical analysis 
Mechanically ventilated patients were grouped in relation to respiratory 
pathogen colonisation of dental plaque based on previous microbiological 
results (Chapters 2 and 3). A series of t-tests were performed analysing 
salivary volume, pH (untransformed hydrogen ion concentration data) and 
total protein concentration during MV in relation to respiratory colonisation of 
dental plaque. All statistical analysis was performed using IBM SPSS v20. 	
Non-parametric analysis was performed upon cytokine analysis using one-
way ANOVA (Kruskal- Wallis) (Rogers, 2013). In addition, correlation 
analysis between cytokine expression and previous microbiological findings 
(respiratory pathogen colonisation of dental plaque) was also undertaken 
using R script programming and STAMP software (3.2.6).  
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4.3 Results 
4.3.1 Salivette® processing  
Saliva samples were collected from 107 mechanically ventilated patients 
during MV and where possible into the post-ETT extubation period. A total of 
488 Salivettes® were processed, yielding 136 saliva samples for analysis.  
 
Over the course of 10 d, 5 saliva samples were collected from 5 healthy 
volunteers (n=25), representing a control group. The control group age range 
was between 23-35 years, 3 males and 2 females.  
 
4.3.2 volume of saliva during mechanical ventilation 
Of 107 patients, 36 failed to produce saliva at a detectable level either during 
MV or into the post-ETT extubation period. A further third of patients (n=37) 
only produced sufficient saliva only at the commencement of MV, with no 
detectable saliva produced during MV (Table 4.1). The dataset of measured 
salivary parameters (volume, pH, protein concentration) for individual saliva 
samples and each mechanically ventilated patient is presented in Appendix 
III. For analysis of salivary volume, patients were grouped according to 
previous microbiological culture and next-generation sequencing findings 
(Chapters 2 and 3) dependent on whether respiratory pathogens were 
isolated within dental plaque during MV. 
Saliva production decreased for 52 mechanically ventilated patients during 
ETT intubation. Whilst there was an average reduction in the salivary volume 
during MV for those patients exhibiting respiratory pathogen colonisation 
within dental plaque (Figure 4.2), the reduction was not statistically significant 
for these patients in comparison to those patients not colonised with target 
respiratory pathogens (S. aureus and P. aeruginosa). 
 
4.3.3 pH of Saliva during mechanical ventilation 
The pH of saliva is shown in table 4.1 and figure 4.3. A full list of salivary pH 
measurements per patient can be found in appendix III. In comparison to the 
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mean pooled salivary pH of the healthy volunteers, (pH 6.98; table 4.2), the 
greatest decrease in pH is observed around the commencement of MV, for 
both groups (pH 6.57 for patients exhibiting normal oral microbiota and pH 
6.44 for patients exhibiting respiratory pathogens within their dental plaque).  
 
Salivary pH was slightly acidic (mean pH 6.51) for all mechanically ventilated 
patients, in comparison with the mean pH values obtained from saliva 
collected from healthy volunteers (pH 6.98). Importantly, at midpoint of MV 
(mean time of 2-4 d) there was a significant reduction (p=0.009) in pH for 
those patients exhibiting respiratory pathogens in their dental plaque (Figure 
4.3) in comparison with those patients exhibiting predominantly oral 
microbiota.  
 
Table 4.1 - A summary of saliva volume production and pH from 
mechanically ventilated patients.  
Saliva measurement 
		
Number 
of 
patients 
No detectable saliva during intubation 36 
Respiratory pathogen colonisation and no detectable saliva during intubation	 6 
>2 saliva samples  34 
Respiratory pathogen colonisation and decrease in saliva volume	 8 
Saliva volume reduced during MV 52 
Acidic pH <6.2 developed 20 
Saliva pH reduced by 1 unit  8 
Respiratory pathogen colonisation and decrease in saliva volume and pH 12 
MV, mechanical ventilation 
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Figure 4.2 – Salivary volume produced (over 45 s) for patients during MV in 
relation to respiratory pathogen presence in dental plaque. 
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Figure 4.3 – The pH of saliva during MV for patients exhibiting predominantly 
normal oral microbiota, and patients colonised with respiratory pathogens. 
 
4.3.4 Protein concentration of saliva during mechanical ventilation 
Total protein concentration was determined for saliva, primarily to inform 
downstream applications. For 128/136 samples there was sufficient volume 
to complete a protein concentration assay. The protein concentration range 
of saliva from healthy volunteers (Table 4.2) was 1.5 - 4.95 µg/µl. Protein 
concentration levels in healthy saliva were relatively stable during a 10 d 
period (collected every 2-3d), however they were significantly lower than 
those of mechanically ventilated patients (p<0.035). Furthermore, there was 
less variation in protein concentration over time for saliva from healthy 
volunteers compared to mechanically ventilated patients.  
 
On average, at the start of MV, salivary protein concentration was ~15 µg/µl, 
compared to ~10 µg/µl during the remainder of MV and post extubation 
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(Figure 4.4). Patients exhibiting respiratory pathogen colonisation of dental 
plaque had greater variations in salivary protein concentration during MV, 
with an average concentration >10 µg/µl.  
 
Table 4.2 – Salivary volume, protein concentration and pH for 5 healthy 
volunteers over a 10 d period.  
Volunteer Sample 
Protein 
(mg/µl) 
Volume 
(µl) pH 
 
1 2.55 750 7.1 
 
2 1.65 700 6.97 
A 3 1.50 800 7.15 
 
4 1.80 700 7.15 
 
5 2.40 900 6.89 
 
Average 1.98 770 7.05 
  SD 0.50 83.7 0.1 
 
1 3.3 850 7.09 
 
2 2.7 1000 7.01 
B 3 3.75 900 7.00 
 
4 3.45 1200 6.81 
 
5 3.3 1000 7.00 
 
Average 3.3 990 6.98 
  SD 0.4 134.2 0.1 
 
1 1.8 750 7.03 
 
2 2.4 700 7.04 
C 3 1.8 800 7.04 
 
4 2.4 800 7.02 
 
5 4.8 750 6.78 
 
Average 2.64 760 6.98 
  SD 1.2 41.8 0.1 
 
1 2.25 1200 6.68 
 
2 1.35 1300 6.96 
D 3 3.3 900 6.91 
 
4 1.8 1000 7.01 
 
Average 2.175 1100 6.89 
  SD 0.8 182.6 0.1 
 
1 3.75 600 7.02 
 
2 3.6 550 7.04 
E 3 4.05 650 6.99 
 
4 3.3 600 7.10 
 
5 4.95 700 6.91 
 
Average 3.93 620 7.01 
  SD 0.6 57.0 0.1 
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Figure 4.4 – Total saliva protein concentration (µg/µl) obtained during the 
course of MV and in relation to respiratory pathogen presence in dental 
plaque. 
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4.3.5 Gel based salivary proteomics 
4.3.5.1 SDS-PAGE 
Saliva from 10 patients was analysed by SDS-PAGE for salivary protein 
composition over MV. SDS-PAGE compared 5 saliva samples from 5 
different time points during MV and into the post-ETT extubation/recovery 
period (Figure 4.5, gel A). These were further compared to 5 saliva samples 
from a single healthy volunteer over 10 d (Figure 4.5, gel B).  
During MV, numerous protein compositional and abundance changes were 
evident in saliva (Figure 4.5 gel A). In contrast, very similar protein profiles 
were evident from the healthy volunteer over a period of 10 d (Figure 4.5, gel 
B). 
 
SDS-PAGE analysis of saliva from 3 mechanically ventilated patients was 
compared to the proteomic profile of fluid collected from extubated-ETTs 
(Figure 4.6). Peptides of low and high molecular weight were isolated from 
saliva and ETTs. There were multiple differences in protein profiles between 
saliva samples and fluids from ETTs over the course of MV (Figure 4.6).  
 
Peptides were stained with colloidal coomassie blue (Figures 4.5 and 4.6). 
Figure 4.7 illustrates peptide staining using two techniques, colloidal 
coomassie blue and silver nitrate. The silver staining was deemed more 
sensitive, revealing numerous additional protein bands, not detected using 
colloidal coomassie blue (Figure 4.7 gel B). Proteins of higher abundance 
within the separation were found to cross over on occasion leading to 
blurring (Figure 4.7), and this was particularly evident for proteins within the 
range of 116.3 kDa to 36.5 kDa. There were likely to be multiple proteins 
within these overlapped bands.  
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Figure 4.5 – SDS-PAGE analysis A; Mechanically ventilated patient 
colonised with respiratory pathogens during the course of MV (peptide 
differences shown by the arrows); B, 5 saliva samples within a 10 d period 
from a healthy volunteer. M protein marker.  
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Figure 4.6 - SDS-PAGE of saliva from 3 patients during MV whose dental 
plaque was colonised with respiratory pathogens. A total of 2 saliva samples 
(S) and the fluid from 1 ETT (E) was analysed for each patient. Peptides 
were detected from both saliva and ETT fluid, as shown by the arrows. M, 
protein marker. 
  
      S     S     E     S  S E S S E 
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Figure 4.7 - SDS-PAGE of saliva from 3 mechanically ventilated patients (2 
saliva samples per patient). A; stained with coomassie blue; B stained with 
silver nitrate, with additional peptide bands detected (arrowed). M, protein 
marker.  
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4.3.5.2 2DE analysis of saliva 
Based on results from the SDS-PAGE, saliva was further analysed by 2DE. 
During 2DE, one saliva sample can be processed per gel, yielding higher 
quantities of data (Figures 4.8, 4.9 and 4.10).  
 
Saliva from two time points during MV of a patient was analysed via 2DE 
(Figure 4.8). A series of defined protein spots (Figure 4.8) were subject to 
protein identification using MALDI-MS. Protein identifications from peptide 
gel plugs (Figure 4.8) are present in Table 4.3. Extremely low e-values were 
evident highlighting high quality and confidence of identification (Table 4.3). 
Proteins frequently isolated from healthy saliva were identified using MALDI-
MS including α-amylase, serotransferrin and cystatins. At 3 different locations 
within the gel (Figure 4.8), α-amylase was identified indicating potential 
complex formation.  
 
Silver nitrate staining (Figure 4.9) of the same salivary samples was 
performed. As highlighted by arrows in gel B, there were numerous proteins 
absent in Figure 4.9 gel A, and by coomassie blue staining (Figure 4.8).  
 
2DE was also performed on two separate saliva samples from a healthy 
volunteer. There were areas within the gel that highlighted compositional 
differences over time (Figure 4.10). Fewer peptides and compositional 
changes were detected over time for the healthy saliva, compared with saliva 
from a mechanically ventilated patient.  
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Figure 4.8 - 2DE analysis of two saliva samples during MV. A; 
commencement of MV and B; midpoint (day 3) MV. 
 
Table 4.3 – Protein Identification (with 2 peptides8) for gel-plugs A3-A7, B4-
B5 (gel, figure 4.9). 
 
 																																																								8 Identification at a 95% confidence level 
Sample spot Protein Name Peptide(s) e value 
A3 Ig kappa chain C  SGTASVVCLLNNFYPR 1.20E-12 
A4 Alpha-amylase 2B   EVTINPDTTCGNDWVCEHR 2.20E-14 
  TGSGDIENYNDATQVR 8.70E-12 
A5 Serum albumin   FQNALLVR 7.80E-05 
  KVPQVSTPTLVEVSR 2.60E-04 
A6 Alpha-amylase 1  NVVDGQPFTNWYDNGSNQVAFGR 6.20E-18 
  EVTINPDTTCGNDWVCEHR 6.60E-16 
A7 Serotransferrin   FDEFFSEGCAPGSK 1.00E-07 
  EGYYGYTGAFR 6.00E-05 
B4 Alpha-amylase 1  EVTINPDTTCGNDWVCEHR 1.10E-14 
  TGSGDIENYNDATQVR 1.00E-13 
B5 Cystatin-S   SQPNLDTCAFHEQPELQK 4.70E-07 
    IIPGGIYDADLNDEWVQR 1.80E-06 
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Figure 4.9 - 2DE of 2 saliva samples from a patient during MV stained with 
silver nitrate (repeat saliva samples as analysed in figure 4.7) A; start of MV, 
B; day 3, midpoint MV. Arrows (B) highlight additional differences in protein 
spots/clusters identified during MV.  
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Figure 4.10 – 2DE analysis performed on two saliva samples from a healthy 
volunteer. A; collected on day 1 and B; collected on d 5. Arrows highlight 
areas of potential peptide compositional differences over time. 
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4.3.6 Gel-free proteomics 
4.3.6.1 Global-scale protein identification 
To complete gel-free proteomic analysis, based on results from gel-based 
proteomics, whole saliva was initially separated according to peptides using 
liquid chromatography (LC). The complex peptide mixture was further 
analysed using MS/MS coupled with databases (MASCOT and Uniprot) for 
global peptide identification/ quantification. Proteins were identified according 
to peptide sequences and were grouped according to their protein class and 
biological function (4.3.6.2). Relative protein expression was quantified 
during MV (and within a 10 d period for ‘healthy saliva’) using iTRAQ labeling 
(4.3.7). 
 
Total number of proteins identified from pooled salivary samples collected 
from a healthy individual and a mechanically ventilated patient are presented 
in table 4.4. For fresh saliva a total of 178 and 141 proteins were identified 
(at a 95% CI level) for the healthy volunteer and the mechanically ventilated 
patient, respectively. At the 2+peptide parameter (proteins identified with >2 
matching peptides and the >95% CI), 116 and 98 proteins were identified for 
saliva from the healthy volunteer and the mechanically ventilated patient, 
respectively. The number of peptides identified during the frozen repeat was 
141 and 146 proteins (at a 95% CI level), and using the 2+matching peptide 
for identification parameter >90 proteins were identified for both healthy 
saliva and saliva collected during MV (Table 4.4).  
 
Haemoglobin, complement factors B and C4-B, and neutrophil elastase and 
neutrophil defensin were identified in saliva from a mechanically ventilated 
patient (Table 4.5). These proteins were absent from saliva obtained from the 
healthy individual. Identified peptides were grouped according to protein 
class and biological function.   
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Table 4.4 - Peptides identified with high confidence during the LC- MS/MS 
workflow9. 
 
LC-MS/MS 
work flow  
Identification 
criteria 
Healthy 
volunteer 
Mechanically 
ventilated patient 
FRESH RUN 2+ peptides 116 98 
 
>95% CI 178 141 
FROZEN RUN 2+ peptides 92 90 
 
>95% CI 141 146 
Two parameters for identification criteria were used: 2+ peptides –proteins identified 
according to 2+ matching peptides, and a protein identification scoring at >95% confidence 
interval (CI), relating to high confidence in the protein ion score. 
 
 
 
Table 4.5 - Proteins identified in saliva from a mechanically ventilated 
patient, but absent in healthy saliva. 
 
Protein Name 
Accession 
number 
Protein 
MW 
Protein 
PI 
Peptide 
Count 
Haptoglobin HPT_HUMAN 45728 6.13 13 
Complement factor B CFAB_HUMAN 86582 6.67 8 
Protein S100-A8 S10A8_HUMAN 10874 6.51 8 
Haemoglobin subunit alpha HBA_HUMAN 15294 8.72 4 
Lysozyme C LYSC_HUMAN 16894 9.38 4 
Complement C4-B CO4B_HUMAN 193872 6.89 3 
Neutrophil elastase ELANE_HUMAN 29006 9.71 2 
Neutrophil defensin 3 DEF3_HUMAN 10514 5.71 2 
MW – theoretical molecular weight, PI – isoelectric point, peptide count – peptide identifiers   
																																																								9 Table 4.4 represents a summary of pooled salivary samples from both a healthy control, 
and a mechanically ventilated patient respectively. 
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4.3.6.2 Protein classification into protein class and biological function 
Protein classes for pooled saliva from the healthy volunteer (control) and 
mechanically ventilated patient were compared (Figure 4.11 and figure 4.12). 
Protein classes ranged from calcium-binding proteins, to defense/immunity 
proteins, proteases and transporter proteins. Generally, protein classes 
identified for the healthy individual and mechanically ventilated patient were 
similar. Certain proteins, including cell junction and transcription proteins 
were identified in saliva from the mechanically ventilated patient but were 
absent from the saliva of the healthy individual. Figures 4.13 and 4.14 
illustrate the identified proteins (genes) according to biological processes.  
 
 
 
Figure 4.11 – Grouping a total of 116 identified peptides within saliva 
collected from a healthy volunteer according to protein class (PC).  
 
	 184 
 
Figure 4.12 – Grouping 98 identified peptides from a mechanically ventilated 
patient over a period of time according to protein class (PC).  
 
 
Figure 4.13 – Comparison of biological function from 116 peptides identified 
from saliva collected from a healthy volunteer. GO – gene ontology. Gene 
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ontology (GO) is a bioinformatics initiative aiming to unify protein and gene 
classification. 
 
 
Figure 4.14 – Comparison of	biological processes of identified peptides from 
a mechanically ventilated patient.  Gene ontology (GO) is a bioinformatics 
initiative aiming to unify protein and gene classification. 
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4.3.6.3 Bacterial and fungal peptides identified in saliva 
All bacterial and fungi originating peptides isolated within saliva were 
identified with a maximum of 1 peptide match, all with a CI score >95%, 
representing a confident identification (Table 4.6). The protein pI 
representing the relative pH of the peptide suggests both acidic and basic 
peptides were present ranging from a theoretical pH of 4.45 to 10.28 from 
both the healthy individual and the mechanically ventilated patient analysed. 
 
Peptides originating from C. albicans, lactobacilli, Campylobacter concisus 
and anaerobic bacteria such as Bacteroides fragilis were identified from 
pooled healthy saliva. Similarly, peptides from oral species such as 
lactobacilli and Candida species were identified from saliva from a 
mechanically ventilated patient. Interestingly, a peptide from the potential 
respiratory pathogen Escherichia coli was detected within saliva during MV. 
This mechanically ventilated patient (PN046) exhibited respiratory pathogen 
colonisation within their dental plaque during MV. 
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4.3.7 Quantitative analysis: Protein expression during mechanical 
ventilation  
 
A total of 4 salivary samples from a healthy volunteer were labeled with a 
different iTRAQ™ label and subsequently pooled for LC-MS analysis. This 
process was repeated independently for 3 samples collected from a patient 
during MV and post-ETT extubation recovery. Raw peptide sequences were 
input into Protein Pilot™ for initial identification using Paragon™ software 
coupled with downstream quantification analysis. Identified peptides were 
quantified by expression-fold differences over time, for both healthy saliva 
and saliva collected from a mechanically ventilated patient, (Figure 4.15).  
 
Healthy saliva was compared at 3 time points over 10 d to assess protein 
compositional differences. Twenty-one proteins exhibited an expression 
change >50% from a total of 200 proteins that were identified (Table 4.7). 
Protein expression of serum albumin and cystatins noticeably increased over 
the 10 d period. Expression of Peregrin and Tripeptidyl-peptidase 2 also 
increased between 50-85 fold.  
 
For the majority of identified proteins, expression and relative quantification 
over the tested period were not noticeably different. Appendix III provides a 
full list of proteins identified from saliva of a healthy volunteer over the 10 d 
period.  
 
Differences in protein expression during MV were assessed (Table 4.8). 
Within Protein Pilot™ identified peptides (n=156) were displayed at a CI of 
95%. Proteins including complement C3, serotransferrin, antibody peptides, 
neutrophil elastase and hemoglobin were highly expressed at the time of 
intubation. Proteins including complement C4, S-100, and antibody peptides 
increased during MV (Table 4.8).  
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There were several proteins with noticeably increased expression during the 
post extubation recovery period e.g. antimicrobial proteins such as 
lactotransferrin, lysozyme and lactoperoxidase increased in expression by up 
to 10-fold. Relative expression of proteins involved in the scavenging of 
toxins and pH homeostasis, (e.g. lipocalin and carbonic anhydrase, 
respectively), increased during the post-ETT extubation period. In addition, 
expression of α-amylase increased >25-fold in the post –ETT extubation 
recovery period. Finally, proteins including cystatin-B, thioredoxin, cystatin-
SN, involucrin, and mucin-5B were expressed at similar levels to that 
encountered in saliva from the healthy individual during both MV and into the 
recovery period.  
 
 
 
Figure 4.15 – Screen shot of Protein Pilot™ software during protein 
expression and quantification analysis using iTRAQ™ multi-plex labels for 
saliva samples during mechanical ventilation (115, 116, and 117) compared 
to pooled saliva collected at multiple time points (days) from a healthy 
volunteer.  
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Table 4.7 – Peptides with expression differences >50% from the first time 
point, within a 10 d period, from healthy saliva.  
Name Accession number Peptides (95%) d1 d4 d8 
Serum albumin sp|P02768|ALBU_HUMAN 50 1.00 1.03 1.51 
Cystatin-S sp|P01036|CYTS_HUMAN 28 1.00 1.34 1.66 
Cystatin-SN sp|P01037|CYTN_HUMAN 28 1.00 1.24 1.87 
Ig lambda-2 chain C regions sp|P0CG05|LAC2_HUMAN 17 1.00 1.15 0.47 
Cystatin-SA sp|P09228|CYTT_HUMAN 16 1.00 1.47 1.71 
Prolactin-inducible protein sp|P12273|PIP_HUMAN 7 1.00 1.40 1.94 
Cystatin-D sp|P28325|CYTD_HUMAN 7 1.00 1.12 2.19 
Keratin, type I cytoskeletal 10 sp|P13645|K1C10_HUMAN 5 1.00 1.00 0.49 
Beta-2-microglobulin sp|P61769|B2MG_HUMAN 5 1.00 0.97 1.58 
Ig kappa chain V-IV region JI sp|P06313|KV403_HUMAN 3 1.00 1.34 2.52 
Keratin, type II cytoskeletal 5 sp|P13647|K2C5_HUMAN 2 1.00 0.96 0.00 
Peregrin sp|P55201|BRPF1_HUMAN 1 1.00 0.05 82.3 
Tripeptidyl-peptidase 2 sp|P29144|TPP2_HUMAN 1 1.00 1.00 52.7 
Filamin-A sp|P21333|FLNA_HUMAN 1 1.00 2.01 0.14 
Tropomyosin alpha-3 chain sp|P06753|TPM3_HUMAN 1 1.00 2.82 5.86 
EF-hand domain- protein D2 sp|Q96C19|EFHD2_HUMAN 1 1.00 0.75 1.72 
Proline-rich protein 27 sp|Q6MZM9|PRR27_HUMAN 1 1.00 2.16 2.07 
Nucleobindin-2 sp|P80303|NUCB2_HUMAN 1 1.00 2.00 8.44 
Cytidine deaminase sp|P32320|CDD_HUMAN 1 1.00 0.22 0.93 
Cathelicidin antimicrobial peptide sp|P49913|CAMP_HUMAN 1 1.00 0.66 1.62 
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Table 4.8 – Changes in salivary protein expression during mechanical 
ventilation (MV). Peptides highlighted with expression differences >50% from 
start of MV. 
 
Protein Name Accession number 
Peptides Start  Midpoint Extubation 
95% MV MV MV 
Serum albumin sp|P02768|ALBU_HUMAN 141 1.00 0.49 0.51 
Complement C3  sp|P01024|CO3_HUMAN 51 1.00 1.03 0.27 
Serotransferrin sp|P02787|TRFE_HUMAN 47 1.00 0.47 0.25 
Alpha-amylase 1 sp|P04745|AMY1_HUMAN 51 1.00 1.00 26.79 
Alpha-2-macroglobulin  sp|P01023|A2MG_HUMAN 31 1.00 0.61 0.72 
Alpha-1-antitrypsin  sp|P01009|A1AT_HUMAN 37 1.00 1.03 0.52 
Lactotransferrin sp|P02788|TRFL_HUMAN 29 1.00 3.79 3.45 
Polymeric immunoglobulin 
receptor  sp|P01833|PIGR_HUMAN 28 1.00 1.45 13.68 
Fibrinogen beta chain  sp|P02675|FIBB_HUMAN 28 1.00 1.33 0.21 
Apolipoprotein A-I sp|P02647|APOA1_HUMAN 23 1.00 0.16 0.13 
Zinc-alpha-2-glycoprotein  sp|P25311|ZA2G_HUMAN 22 1.00 1.31 15.04 
Ig gamma-2 chain C region  sp|P01859|IGHG2_HUMAN 20 1.00 0.44 0.47 
Haptoglobin  sp|P00738|HPT_HUMAN 20 1.00 13.13 1.02 
Myeloperoxidase  sp|P05164|PERM_HUMAN 13 1.00 1.36 0.36 
Alpha-1-antichymotrypsin  sp|P01011|AACT_HUMAN 15 1.00 1.55 0.98 
Actin, cytoplasmic 2  sp|P63261|ACTG_HUMAN 17 1.00 1.81 0.81 
Ig alpha-1 chain C region  sp|P01876|IGHA1_HUMAN 22 1.00 0.88 3.32 
Fibrinogen alpha chain  sp|P02671|FIBA_HUMAN 15 1.00 1.59 0.33 
Ceruloplasmin  sp|P00450|CERU_HUMAN 11 1.00 0.58 0.42 
Fibrinogen gamma chain sp|P02679|FIBG_HUMAN 13 1.00 1.49 0.11 
Complement factor B  sp|P00751|CFAB_HUMAN 11 1.00 0.85 0.21 
Antithrombin-III  sp|P01008|ANT3_HUMAN 9 1.00 0.53 0.47 
Ig mu chain C region sp|P01871|IGHM_HUMAN 12 1.00 0.64 0.27 
Leucine-rich alpha-2-glycoprotein sp|P02750|A2GL_HUMAN 9 1.00 1.09 1.43 
Hemoglobin subunit beta  sp|P68871|HBB_HUMAN 12 1.00 0.82 0.11 
Protein S100-A8  sp|P05109|S10A8_HUMAN 15 1.00 3.77 0.23 
Plastin-2  sp|P13796|PLSL_HUMAN 10 1.00 2.77 1.12 
Small proline-rich protein 3  sp|Q9UBC9|SPRR3_HUMAN 9 1.01 4.36 25.80 
Lipocalin-1  sp|P31025|LCN1_HUMAN 9 1.00 5.10 73.40 
Alpha-1-acid glycoprotein 1 sp|P02763|A1AG1_HUMAN 12 1.00 0.70 0.97 
Fibronectin sp|P02751|FINC_HUMAN 7 1.00 0.47 0.29 
Leukocyte elastase inhibitor  sp|P30740|ILEU_HUMAN 7 1.00 1.94 1.85 
Hemopexin sp|P02790|HEMO_HUMAN 7 1.00 0.82 0.87 
Ig kappa chain C region sp|P01834|IGKC_HUMAN 16 1.00 0.40 1.22 
Cystatin-S  sp|P01036|CYTS_HUMAN 11 1.00 1.00 4.00 
Vitronectin sp|P04004|VTNC_HUMAN 6 1.00 0.41 0.39 
Matrix metalloproteinase-9 sp|P14780|MMP9_HUMAN 6 1.00 3.53 1.02 
Prolactin-inducible protein sp|P12273|PIP_HUMAN 6 1.00 0.83 24.98 
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Apolipoprotein B-100  sp|P04114|APOB_HUMAN 5 1.00 0.48 0.40 
Cystatin-B  sp|P04080|CYTB_HUMAN 6 1.00 1.25 2.00 
Complement C4-A  sp|P0C0L4|CO4A_HUMAN 5 1.00 1.15 0.47 
Protein S100-A9  sp|P06702|S10A9_HUMAN 12 1.00 4.37 0.27 
Lysozyme C  sp|P61626|LYSC_HUMAN 9 1.00 3.52 33.97 
Ig gamma-1 chain C region sp|P01857|IGHG1_HUMAN 17 1.00 0.37 0.41 
Inter-alpha-trypsin inhibitor  sp|Q14624|ITIH4_HUMAN 6 1.00 0.77 0.73 
Heat shock 70 kDa protein 1A/1B  sp|P08107|HSP71_HUMAN 6 1.00 2.69 1.37 
Vitamin D-binding protein  sp|P02774|VTDB_HUMAN 6 1.00 0.79 0.32 
Immunoglobulin lambda-like 
polypeptide  sp|B9A064|IGLL5_HUMAN 12 1.00 0.56 1.10 
Gelsolin sp|P06396|GELS_HUMAN 5 1.00 1.63 0.71 
Alpha-2-HS-glycoprotein  sp|P02765|FETUA_HUMAN 5 1.00 0.38 1.48 
Alpha-enolase  sp|P06733|ENOA_HUMAN 5 1.00 2.25 0.56 
Keratin, type II cytoskeletal 1  sp|P04264|K2C1_HUMAN 5 1.00 0.77 2.39 
Alpha-1B-glycoprotein  sp|P04217|A1BG_HUMAN 5 1.00 0.71 0.34 
Plasma protease C1 inhibitor sp|P05155|IC1_HUMAN 6 1.00 0.61 0.59 
6-phosphogluconate 
dehydrogenase sp|P52209|6PGD_HUMAN 5 1.00 4.18 0.52 
Cystatin-A  sp|P01040|CYTA_HUMAN 5 1.00 1.13 8.63 
Transthyretin  sp|P02766|TTHY_HUMAN 5 1.00 0.46 0.93 
Brain acid soluble protein 1  sp|P80723|BASP1_HUMAN 5 1.00 5.30 2.74 
14-3-3 protein zeta/delta  sp|P63104|1433Z_HUMAN 5 1.00 1.00 0.49 
Immunoglobulin J chain  sp|P69905|HBA_HUMAN 6 1.00 1.44 7.44 
Hemoglobin subunit alpha sp|P26038|MOES_HUMAN 7 1.00 0.80 0.15 
Moesin sp|P22079|PERL_HUMAN 4 1.00 2.86 0.91 
Lactoperoxidase sp|P13645|K1C10_HUMAN 4 1.00 1.42 12.79 
Keratin, type I cytoskeletal 10  sp|Q01518|CAP1_HUMAN 3 1.00 0.43 1.78 
Adenylyl cyclase-associated 
protein 1  sp|P37837|TALDO_HUMAN 4 1.00 4.12 0.91 
Transaldolase sp|P10599|THIO_HUMAN 4 1.00 4.65 3.10 
Thioredoxin sp|P01037|CYTN_HUMAN 4 1.00 1.50 3.25 
Cystatin-SN  sp|P02652|APOA2_HUMAN 7 1.00 0.67 1.00 
Apolipoprotein A-II  sp|P60174|TPIS_HUMAN 3 1.00 0.16 0.12 
Triosephosphate isomerase  sp|A8K2U0|A2ML1_HUMAN 3 1.00 2.56 1.00 
Alpha-2-macroglobulin-like protein 
1  sp|P31146|COR1A_HUMAN 4 1.00 1.00 2.05 
Coronin-1A  sp|P07476|INVO_HUMAN 3 1.00 2.52 0.96 
Involucrin  sp|P08603|CFAH_HUMAN 5 1.00 2.33 4.00 
Complement factor H sp|P04075|ALDOA_HUMAN 3 1.00 0.69 0.39 
Fructose-bisphosphate aldolase A  sp|P14618|KPYM_HUMAN 3 1.00 1.78 1.10 
Pyruvate kinase PKM sp|P01042|KNG1_HUMAN 3 1.00 1.31 0.77 
Kininogen-1 sp|Q6P5S2|LEG1H_HUMAN 3 1.00 0.75 0.44 
Protein LEG1 homolog  sp|P01772|HV311_HUMAN 3 1.00 1.13 2.34 
Ig gamma-4 chain C region sp|P01861|IGHG4_HUMAN 19 1.00 0.45 0.98 
Cystatin-SA  sp|P09228|CYTT_HUMAN 8 1.00 0.60 0.00 
Apolipoprotein E sp|P02649|APOE_HUMAN 3 1.00 0.35 0.33 
Neutrophil gelatinase- lipocalin  sp|P80188|NGAL_HUMAN 3 1.00 2.57 9.87 
Beta-2-glycoprotein 1  sp|P02749|APOH_HUMAN 3 1.00 0.63 0.83 
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Ig heavy chain V-III region VH26  sp|P01764|HV303_HUMAN 3 1.00 0.48 0.94 
Ig heavy chain V-I region V35  sp|P23083|HV103_HUMAN 5 1.00 0.54 1.34 
Olfactomedin-4 sp|Q6UX06|OLFM4_HUMAN 3 1.00 1.81 1.10 
Deleted in malignant brain tumors 
1  sp|Q9UGM3|DMBT1_HUMAN 2 1.00 2.70 17.30 
Ig lambda-2 chain C regions  sp|P0CG05|LAC2_HUMAN 11 1.00 0.5 1.0 
Ig heavy chain V-III region  sp|P01767|HV306_HUMAN 2 1.00 0.8 0.8 
Ig kappa chain V-III region sp|P18136|KV313_HUMAN 4 1.19 0.9 1.2 
Alpha-actinin-1 sp|P12814|ACTN1_HUMAN 2 1.00 2.4 1.0 
Mucin-5B  sp|Q9HC84|MUC5B_HUMAN 1 1.00 1.8 1.7 
Cysteine-rich secretory protein 3  sp|P54108|CRIS3_HUMAN 2 1.00 1.09 4.76 
Superoxide dismutase [Cu-Zn] sp|P00441|SODC_HUMAN 2 1.00 1.48 4.25 
Ig kappa chain V-I region AG  sp|P01593|KV101_HUMAN 3 1.00 0.67 0.80 
Inter-alpha-trypsin inhibitor  sp|P19827|ITIH1_HUMAN 2 1.00 0.66 0.64 
Phosphoglycerate kinase 1  sp|P00558|PGK1_HUMAN 2 1.00 2.07 0.89 
Histone H2A.J sp|Q9BTM1|H2AJ_HUMAN 2 1.00 1.48 1.00 
Alpha-1-acid glycoprotein 2 sp|P19652|A1AG2_HUMAN 6 1.00 0.77 1.16 
Glucose-6-phosphate isomerase  sp|P06744|G6PI_HUMAN 2 1.00 1.70 0.75 
Ig kappa chain V-III region CLL  sp|P04207|KV308_HUMAN 2 1.00 0.70 1.06 
Peptidyl-prolyl cis-trans isomerase 
A  sp|P62937|PPIA_HUMAN 2 1.00 5.52 0.54 
Transketolase  sp|P29401|TKT_HUMAN 2 1.00 3.73 0 
Polyubiquitin-C  sp|P0CG48|UBC_HUMAN 2 1.00 1.28 1.14 
L-lactate dehydrogenase A chain sp|P00338|LDHA_HUMAN 2 1.00 2.92 1.51 
Histone H4  sp|P62805|H4_HUMAN 3 1.00 1.37 0.14 
Neutrophil defensin 3  sp|P59666|DEF3_HUMAN 2 1.00 0.86 0.94 
Protein S100-A11 sp|P31949|S10AB_HUMAN 2 1.00 4.47 2.71 
Protein S100-P  sp|P25815|S100P_HUMAN 2 1.67 2.36 0.99 
Carbonic anhydrase 6 sp|P23280|CAH6_HUMAN 2 1.00 1.08 10.41 
Neutrophil elastase sp|P08246|ELNE_HUMAN 2 1.00 0.71 0.61 
C-reactive protein  sp|P02741|CRP_HUMAN 2 1.00 0.70 0.56 
Ig kappa chain V-I region HK102  sp|P01602|KV110_HUMAN 2 1.00 0.65 1.15 
Keratin, type II cytoskeletal 6A  sp|P02538|K2C6A_HUMAN 3 1.00 0.44 0.87 
Ig lambda chain V-I region WAH  sp|P04208|LV106_HUMAN 2 1.00 0.53 0.64 
Ig gamma-3 chain C region  sp|P01860|IGHG3_HUMAN 17 1.00 0.51 0.24 
Rho GDP-dissociation inhibitor 2  sp|P52566|GDIR2_HUMAN 2 1.00 1.96 0.56 
Ig lambda chain V-III region LOI  sp|P80748|LV302_HUMAN 2 0.60 0.28 0.73 
Ig heavy chain V-III region GAL  sp|P01781|HV320_HUMAN 2 1.00 0.86 1.55 
14-3-3 protein sigma  sp|P31947|1433S_HUMAN 3 1.00 1.10 1.00 
Ig kappa chain V-II region RPMI 
6410  sp|P06310|KV206_HUMAN 2 1.00 0.50 0.92 
Ig heavy chain V-III region TEI  sp|P01777|HV316_HUMAN 2 1.00 0.55 0.99 
Keratin, type I cytoskeletal 13  sp|P13646|K1C13_HUMAN 2 1.00 0.13 0.27 
Ig alpha-2 chain C region  sp|P01877|IGHA2_HUMAN 19 1.00 1.05 4.70 
14-3-3 protein beta/alpha sp|P31946|1433B_HUMAN 3 1.00 2.59 0 
Putative V-set and immunoglobulin  sp|A6NJ16|IV4F8_HUMAN 2 1.00 0.47 1.32 
Histone H2B type 1-A  sp|Q96A08|H2B1A_HUMAN 2 1.00 1.33 2.86 
Peroxiredoxin-6  sp|P30041|PRDX6_HUMAN 1 1.00 1.38 0.44 
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Protein AMBP  sp|P02760|AMBP_HUMAN 1 1.00 0.68 1.34 
Ig lambda chain V-II region BUR  sp|P01708|LV205_HUMAN 1 1.00 0.85 1.37 
BPI fold-containing family A 
member 2  sp|Q96DR5|BPIA2_HUMAN 1 1.00 0.55 1.09 
Golgi membrane protein 1  sp|Q8NBJ4|GOLM1_HUMAN 1 1.00 1.53 12.46 
Protein S100-A12  sp|P80511|S10AC_HUMAN 1 1.00 3.40 0.75 
Actin-related protein 2/3 subunit 4  sp|P59998|ARPC4_HUMAN 1 1.00 3.38 0.42 
Serum amyloid A-4 protein sp|P35542|SAA4_HUMAN 1 1.00 0.26 0.56 
Protein S100-A4  sp|P26447|S10A4_HUMAN 1 1.00 4.47 1.10 
Cornifin-B  sp|P22528|SPR1B_HUMAN 1 1.00 1.38 7.88 
Glucose-6-phosphate 1-
dehydrogenase  sp|P11413|G6PD_HUMAN 1 1.00 1.51 0.80 
Apolipoprotein A-IV  sp|P06727|APOA4_HUMAN 1 1.00 0.58 0.19 
Serum amyloid P-component  sp|P02743|SAMP_HUMAN 1 1.00 0.88 1.20 
Ig lambda chain V-IV region Hil  sp|P01717|LV403_HUMAN 1 1.00 0.59 0.97 
Ig kappa chain V-I region Wes sp|P01611|KV119_HUMAN 1 1.00 0.48 1.27 
Ig heavy chain V-I region WOL  sp|P01760|HV105_HUMAN 1 1.00 0.73 0.79 
Fatty acid-binding protein, 
epidermal  sp|Q01469|FABP5_HUMAN 1 1.00 1.46 1.00 
Keratin, type I cytoskeletal  sp|P02533|K1C14_HUMAN 1 1.00 0.30 0.83 
E3 ubiquitin-protein ligase Arkadia  sp|Q6ZNA4|RN111_HUMAN 1 1.00 0.80 2.56 
Proline-rich protein 27 sp|Q6MZM9|PRR27_HUMAN 1 1.00 0 36.8 
Carbonic anhydrase 1  sp|P00915|CAH1_HUMAN 1 1.00 0.70 0.68 
F-actin-capping protein subunit 
alpha-1 sp|P52907|CAZA1_HUMAN 1 1.00 0.95 0 
Alpha-actinin-4  sp|O43707|ACTN4_HUMAN 1 1.00 1.06 0.87 
Myosin-13 sp|Q9UKX3|MYH13_HUMAN 1 1.00 0.16 0.23 
Cytospin-A sp|Q69YQ0|CYTSA_HUMAN 1 1.00 0.49 0.28 
CAP-Gly domain-containing linker 
2  sp|Q9UDT6|CLIP2_HUMAN 1 1.00 4.16 0.29 
Adiponectin receptor protein 2  sp|Q86V24|ADR2_HUMAN 1 1.00 0.61 0.38 
Lysyl oxidase homolog 4  sp|Q96JB6|LOXL4_HUMAN 1 1.00 0.82 0.55 
    
Decrease Decrease  
    
Increase Increase 
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4.3.8 Detection of IL-6 from plasma using ELISA  
ELISA was performed on 24 plasma samples from 8 mechanically ventilated 
patients to detect IL-6. The cytokine IL-6 was detected in 14 plasma samples 
during MV, with the highest levels recorded at the start and midpoint of MV 
(Table 4.9).  
 
 
Table 4.9 – IL-6 detection from plasma during MV.  
 
  IL-6 pg/ ml in plasma during MV 
Patient 
Number 
Start 
MV 
Midpoint 
MV 
ETT 
extubation 
PN001 15.42 7.81 23.67 
PN003 64.90 16.21 5.75 
PN026 93.10 38.27 9.41 
PN031 0.00 0.00 0.00 
PN040 0.00 0.00 1.17 
PN077 4.54 0.00 0.00 
PN088 46.32 804.90 8.11 
PN109 0.00 0.00 0.00 
Mean IL-6  28.04 108.40 6.01 
 
IL-6 was detected at all stages during MV. IL-6 ELISA was performed on 24 
plasma samples from 8 mechanically ventilated patients. 
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4.3.9 Cytokine quantification during MV using the cytometric bead array 
analysis  
4.3.9.1 Salivary cytokine analysis from healthy volunteers 
Nine saliva samples from 2 healthy volunteers were analysed for cytokine 
presence over 10 d (Figure 4.16). Levels of cytokines ranged between 0.1 
and 100-pg/ml (Table 4.10). Highest cytokine levels in healthy saliva were for 
IL-8 and IL-1β. There was a variation of ~50 pg/ml over 10 d.  
 
4.3.9.2 Plasma cytokine analysis during mechanical ventilation 
Plasma (n=105) was analysed for cytokines from 35 mechanically ventilated 
patients. The cytokines, IL-8 and IL-6 were present at >200 pg/ml, with all 
other cytokines (IL-1β, TNFα, IL-10 and IL-12p70) detected at <10 pg/ml. 
Figure 4.17 presents the detection of IL-8, IL-1β and IL-6 during MV. At the 
time of intubation the highest cytokine levels were for IL-6. There were no 
significant differences in the concentrations of IL-8 and IL-6 during MV 
(Figure 4.17). For IL-1β there was a significant increase post-ETT extubation 
period (p-<0.001). All individual cytokine quantifications are in appendix III.  
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Figure 4.16 - The CBA acquisition template for flow cytometry analysis of 
samples conjugated with cytokine beads. A; Gated population of cells, B; 
Detection of each cytokine via captured fluorescence and C; Histogram 
showing the separation peak of each pro-inflammatory cytokine. 
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Table 4.10 – Cytokine detection over 10 d in saliva from two healthy 
volunteers10. 
    Cytokine Concentration (pg/mL) 
  
IL-8 IL-1β  IL-6  IL-10 TNFα IL-12p70 
 
d1 199.38 98.01 19.93 11.13 0 13.4 
 
d3 99.05 134.72 20.76 0 14.61 0 
Volunteer 1 d8 63.5 45.31 20.76 0 0 16.16 
 
d9 13.31 30.48 0 0 0 0 
 
d10 133.58 77.46 11.72 0 18.34 17.71 
 
 
 
d1 100.18 121.63 0 0 0 13.38 
Volunteer 2 d8 56.39 112.39 14.84 0 0 0 
 
d9 53.81 96.18 24.92 18.75 0 20.29 
 
d10 160.58 166.32 19.93 0 0 29.23 
 
 
Mean 97.75 98.06 14.76 3.32 3.66 12.24 
 
SD 58.64 42.63 9.18 6.86 7.32 10.31 
  SEM 19.55 14.21 3.06 2.29 2.44 3.44 
 
 
Figure 4.17 - Plasma cytokine concentrations during MV. 
																																																								10 d – day of mechanical ventilation 
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4.3.9.3 Endotracheal tube (ETT) fluid analysis  
The fluid from 22 ETTs from 15 mechanically ventilated patients was 
analysed for cytokine presence. Cytokine’s were detected in all of the ETT 
fluids analysed. IL-8 was detected at >20,000 pg/ml in patients who had 
respiratory pathogens isolated from their dental plaque, and IL-8 was 
noticeably lower at <14,000 pg/ml for patients exhibiting predominantly 
normal oral microbiota during MV. There was no significant difference in 
cytokine levels for these two patient groups (IL-8 p=0.374, IL-1β p=0.214, IL-
6 p=0.678, IL-10 p=0.069, TNFα p=0.237 and IL-12p70 p=0.340).  
One-way ANOVA compared pro-inflammatory cytokine concentrations within 
saliva and ETT fluids. Concentrations of IL8, IL-1β, IL6, IL10 and TNFα were 
similar for both sample types. The level of IL12p70 for mechanically 
ventilated patients was significantly lower (p<0.001) in ETT fluids compared 
to saliva. Half of the ETT fluids analysed (n=11) did not contain detectable 
levels of IL12p70.  
 
4.3.9.4 Salivary cytokine levels during MV  
A total of 68 saliva samples from 22 mechanically ventilated patients were 
analysed for pro-inflammatory cytokine concentration during MV (Figure 
4.18). The salivary concentration of IL-8 was over 100-fold higher (up to 
100,000 pg/ml) than in plasma. Concentrations of IL-10, TNFα and IL-12p70 
were <500 pg/ml.  
There were no significant differences (p>0.387) in salivary cytokine levels 
during MV. An increase in IL-8 levels was noted at ETT extubation (100,000 
pg/ml relative to 70,000-pg/ml at start of MV). For IL-8 and IL-6, salivary 
levels were highest at the start of MV and were significantly reduced 
(p<0.001) post extubation. No significant difference in the levels of IL-10, 
IL12p70 and TNFα for saliva collected from mechanically ventilated patients 
and healthy volunteers (p >0.255) was found. 
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Figure 4.18 – Detection of IL-8, IL-1β and IL-6 in saliva during mechanical 
ventilation. *Denotes significant difference between cytokine concentration 
during MV and post-ETT extubation.   
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4.3.9.5 Cytokine levels and occurrence of respiratory pathogens in 
dental plaque of mechanically ventilated patients  
Patients were divided into two groups based on presence or absence of 
respiratory pathogens in dental plaque during MV (Chapters 2 and 3). Figure 
4.19 shows the cytokine levels in saliva relative to respiratory pathogens 
colonisation of dental plaque.  
The distribution of IL-6 (Figures 4.20), and IL-1β (Figure 4.22) were 
noticeably increased in saliva of patients colonised with respiratory 
pathogens (namely S. aureus and/or P. aeruginosa) in dental plaque.  In the 
case of IL-1β there was a significantly (p=0.035) higher variation in cytokine 
concentration for patients with respiratory pathogens in their dental plaque 
compared to other patients. The concentration of IL-8 (Figure 4.21) was 
however both lower in patients’ dental plaque colonised with respiratory 
pathogens and more varied (as indicated with the larger whiskers in the box 
plot). 
 
 
 
Figure 4.19 – Heat map and dendrogram showing the relationship between 
mechanically ventilated patients and relative distribution of cytokines. The 
abundance of each cytokine for each mechanically ventilated patient 
analysed is represented by a colour (blue-red). 
Normal oral microbiota 
Respiratory colonisation of dental 
plaque 
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Figure 4.20 - Box and whisker plot comparing distribution of IL-6 
concentrations between mechanically ventilated patients exhibiting normal 
oral and those exhibiting respiratory pathogens in dental plaque during 
mechanical ventilation11. 																																																								11 Within box and whisker plots, star values represent the mean value for each group of 
patients, with any noticeable outliers represented by a cross. The line within the box of the 
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Figure 4.21 - Box and whisker plot comparing distribution of IL-8 
concentrations for two patient groups; those exhibiting colonisation of dental 
plaque with potential respiratory pathogens and those in whom the plaque 
was not colonised with potential respiratory pathogens. 
 
																																																																																																																																																													
IQR represents the median value and the whiskers relate to the most extreme values when 
comparing the cytokine levels. 
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Figure 4.22 – Box and whisker plot comparing distribution of IL-1β 
concentrations for two patient groups; those exhibiting colonisation of dental 
plaque with potential respiratory pathogens and those in whom the plaque 
was not colonised with potential respiratory pathogens. 
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4.4 Discussion 	
Saliva is a complex fluid performing multiple functions, and contains several 
different antimicrobial peptides offering protection within the oral cavity (1.1). 
Although previous studies have reported reductions in salivary flow during 
hospitalisation, for example Dennesen et al., 2003 investigated salivary flow 
in intubated intensive care patients, the relationship between dental plaque 
and salivary parameters, including volume, pH and composition during 
mechanical ventilation (MV) is relatively unexplored. The main aim of this 
chapter was to evaluate whether changes in saliva volume, pH and 
composition occur both during MV and after ETT extubation, and whether 
any changes can be associated with the respiratory pathogen colonisation of 
dental plaque.  
 
Reduced salivary volumes were evident for mechanically ventilated patients 
(Figure 4.2), both during MV and into the recovery period. Dryness of the 
mouth (xerostomia) is intimately linked to lower salivary flow (O’Reilly, 2003; 
Fenoll-Palomares et al., 2004). Salivary secretion in healthy individuals 
follows natural circadian rhythm (Flink et al., 2005). Critically ill and 
mechanically ventilated patients may mirror a state of sleep, and as a 
consequence, the observed salivary flow reduction could reflect natural 
circadian rhythm patterns (Thie et al., 2002). A total of 65 of the 107 recruited 
patients were >50 years of age (2.3.2, table 2.3) and salivary flow in healthy 
individuals has been shown to decrease with age (Dodds et al., 2005), 
perhaps increasing likelihood of patients in this age group having lower saliva 
production.  
 
Dehydration of hospitalised patients, often indicated with high levels of 
sodium (hypernatraemia) (Adrogue & Madias, 2000), has been linked to 
increased length of hospital stay (Welte et al., 2012) and may further 
contribute to reduced salivary flow (Ship & Fischer, 1997), especially when 
coupled with decreased neural input from taste and chewing for mechanically 
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ventilated patients in critical care (normal activators of the salivary reflex) ( 
(Bardow et al., 2001). Due to decreased salivary flow during MV, cleansing 
and clearance actions may also be impaired, which may influence the 
abundance and composition of dental plaque (Humphrey & Williamson, 
2001).  
 
Salivary flow is often affected by medications, including those frequently 
administered to mechanically ventilated patients. Prasanthi et al., 2014 
investigated the effects of diuretics on salivary flow and oral health status. 
Diuretics are used to treat a variety of conditions including renal failure and 
congestive cardiac failure, and Prasanthi et al., 2014 reported significant 
reductions in salivary flow rates.  Medications can cause xerostomia through 
a number of mechanisms. Certain drugs (including antihistamines) compete 
with acetylcholine release at the parasympathetic effector junction, leading to 
a decreased saliva production. Diuretics however produce alterations in 
electrolyte and fluid balance, leading to fluctuations and reductions in 
stimulated whole saliva (Vinayak et al., 2013).  
 
Decreased production of saliva was evident in patients during MV and this 
would affect buffering within the oral cavity and may influence local pH levels 
(Fenoll-Palomares et al., 2004). When saliva is stimulated, for example after 
food, an increase in bicarbonate ions occurs leading to higher (more alkaline) 
salivary pH (Diaz-Arnold & Marek, 2002). Mechanically ventilated patients 
are obviously ‘nil by mouth’ and often receive a consortia of medications that 
decrease salivary flow and may therefore contribute to changes in salivary 
pH. For example, diuretics frequently used in critical care medicine, for 
controlling fluid balance (Tibor, 2007), can alter salivary buffering capability, 
again serving to reduce overall pH (Prasanthi et al., 2014). 
 
Acidic end products of saccharolytic and cariogenic bacteria may in turn 
decrease salivary pH. Streptococcus mutans can ferment carbohydrates to 
acidic end products and is tolerant of acidic conditions as low as pH 4.5. 
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Under such conditions, aciduric bacteria will have a selective advantage over 
less acid tolerant species and will out-compete these species in dental 
plaque (Ilie & Picioreanu, 2012). Dental plaque containing S. mutans are 
more resilient to acid shock tests, suggesting increased resistance to an 
environment with a lower pH (Cvitkovitch, 2010). 
 
Xerostomia during MV can contribute to the development of oral candidiasis, 
with C. albicans exploiting changes in the microenvironment of the oral cavity 
to grow at higher levels (Torres et al., 2002; Thein et al., 2007). Studies of 
microbial co-aggregation have demonstrated synergistic relationships 
between C. albicans and oral streptococci (Metwalli et al., 2013). Low 
salivary pH can influence hyphae growth of C. albicans by increasing the 
yeast-hyphae transition as a survival strategy and contribute to biofilm 
development (Xu et al., 2014). Candida albicans may also promote 
colonisation of P. aeruginosa. Azoulay et al., 2006 reported a positive 
correlation between C. albicans colonisation of the airways and P. 
aeruginosa causing VAP. The complex relationship between C. albicans and 
P. aeruginosa is further explored in biofilm in vitro development in chapter 5 
(5.3.2.2). Changes in the oral microbiome arising from lowered pH could 
have been a factor in colonisation of plaque by S. aureus and P. aeruginosa. 
In this study, S. aureus was isolated from the plaque of 43 mechanically 
ventilated patients. This species can thrive in microenvironments with a pH 
as low as 5.5 (Korting et al., 1992; Baudoux et al., 2007; Lemaire et al., 
2011). During this study, it was at the midpoint of MV when salivary pH was 
at its lowest (Figure 4.3). In addition, at midpoint of MV, respiratory pathogen 
colonisation of dental plaque was highest (demonstrated by microbial culture 
(Chapter 2) and high-throughput sequencing (Chapter 3)). 
 
For collection of the salivary proteome, Salivettes® were used. Previous 
studies have shown increased proteolytic enzyme recovery, but a reduced 
mucin recovery using Salivettes® compared with passive collection (Lundy & 
Lamey, 1995; Amado et al., 2013). Collection of saliva using passive drool is 
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often considered the ‘gold standard’ method (Topkas et al., 2012), however 
in the mechanically ventilated patient cohort in this study, such an approach 
was not practical. In addition, one advantage of lower mucin levels is that the 
resulting saliva is less viscous and this can improve resolution of proteins 
during separation and peptide identification (Amado et al., 2013). 	
 
Compositional changes in the salivary proteome during MV may be a driver 
of microbial changes, or could be a result of such changes. Proteomic 
changes in saliva were analysed during MV using gel-based and high-
throughput techniques. Analysis of whole saliva by SDS-PAGE revealed 
large proteomic differences during MV in saliva from mechanically ventilated 
patients compared with relatively stable longitudinal protein profiles observed 
in saliva from healthy individuals over 10 d (Figure 4.5 B). The saliva 
proteome is known to alter rapidly during episodes of physiological stress, 
which would be inevitably experienced by mechanically ventilated patients 
(Humphrey & Williamson, 2001).  
 
Although informative, there are several limitations to SDS-PAGE. The 
complexity of the salivary proteome limits separation on a single dimension. 
Protein identification from bands resolved by SDS-PAGE is problematic as 
such bands are likely to consist of multiple proteins due to co-migration.  
Consequently, 2-dimensonal separation is the current gel-based gold-
standard (Schwartz, 1995; Lamy et al., 2012; Amado et al., 2013). 
 
Given the occurrence of post-translational modifications (PTM) and protein 
complexes within a proteinaceous fluid such as saliva (Gharahdaghi et al., 
1999; Mata-Gómez et al., 2012), gel-based proteomics cannot truly reflect 
the salivary proteome. PTMs and protein complexes may lead to the same 
proteins being located at different positions within a single gel. Indeed, this 
was evident in this study using 2DE and colloidal coomassie blue staining 
and protein identification from gel spots by MALDI-MS coupled with 
MASCOT database searches. MASCOT provides calculated values for 
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molecular weight and pI (isoelectric point, pH) and therefore these are 
theoretical. Such calculations are for unmodified versions of peptides and do 
not take into account PTM. Identification of α-amylase at multiple locations 
within one saliva sample (Table 4.3) indicates that salivary proteins formed 
PTMs and complexes, highlighting the difficulties encountered using gel-
based approaches. The enzyme α-amylase is primarily known as a digesting 
enzyme for carbohydrates. However during MV, patients were nil-by mouth 
suggesting that α-amylase, although constitutively produced independent of 
food intake, might have more than one biological function (common attribute 
of saliva proteins). For example, α-amylase has previously been identified in 
the enamel pellicle layer, and may have an important role in microbial 
adhesion and dental plaque formation by acting as a receptor and binding 
with oral Streptococcus species (Scannapieco et al., 1993).  
 
To reveal the extent of compositional changes using a gel-based approach, 
both a colloidal coomassie blue and a silver nitrate stain were undertaken on 
the same saliva samples. Silver nitrate staining is more sensitive compared 
with colloidal coomassie blue (Gharahdaghi et al., 1999). However, when 
downstream analysis is to be undertaken, such as MALDI-MS, colloidal 
coomassie blue is often preferred. This is because silver nitrate in stained 
gels will affect any subsequent trypsin cleavage resulting in poor protein 
identification (Chevalier, 2010). For 2DE analysis, two saliva samples 
collected during MV were assessed (Figures 4.9 and 4.10). Differences in 
protein composition were evident during MV compared with saliva collected 
from a healthy individual (Figure 4.10). Results using silver nitrate staining, 
revealed that the second salivary sample collected midpoint MV had >2-
dozen additional protein spots compared with the equivalent sample at the 
start of MV (Figure 4.9).  
 
LC-MS/MS is a ‘shotgun’ bottom-up proteomic approach that can identify 
proteins in complex mixtures through a combination of chromatography and 
mass spectrometry (Lamy et al., 2012). Protein composition of saliva is 
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dynamic often changing according to age, gender, diet and status of oral 
hygiene (Fleissig et al., 2010). Identified proteins were grouped according to 
protein class and overall, were similar for both saliva collected from a healthy 
volunteer and a mechanically ventilated patient (Figures 4.11 and 4.12 
respectively). However, a number of transcription proteins were shown to be 
present in saliva from a mechanically ventilated patient, that were absent in 
the saliva from a healthy individual. 
 
Analysis of the salivary proteome during MV revealed multiple differences 
when compared to that of healthy saliva. For example complement proteins, 
and proteins associated with neutrophil recruitment were identified during MV 
(Table 4.5), but were absent from saliva at all time points for the healthy 
individual. This may suggest an initiation of innate immune responses and 
the recruitment of leukocytes for localised defense in the mechanically 
ventilated patient. Protein S-100 was identified during MV and has biological 
functions including promoting oral homeostasis in addition to regulatory roles 
for the recruitment of neutrophils and macrophages (Donato et al., 2012). 
The presence of peptides from hemoglobin in saliva collected during MV, 
may suggest an increase in localised inflammation and oral mucosal tissue 
damage during MV, perhaps as a result of dental plaque accumulation.  
Several bacterial and fungal proteins were identified in saliva from the 
healthy volunteer and a mechanically ventilated patient (Table 4.6). Proteins 
from lactobacilli, anaerobic bacteria, Candida, and Campylobacter concisus 
were identified from healthy saliva. Although C. concisus has been 
associated with gingival inflammation, there have been reports of C. concisus 
isolation in healthy individuals (Zhang et al., 2010). Alongside proteins from 
members of the normal oral microbiota, E. coli peptides were detected in 
saliva during MV. Interestingly, E. coli was also identified within dental plaque 
during MV (3.3.3.4, table 3.1 and figure 3.10).  
 
Quantitative analysis of proteins using iTRAQ™ reagents, compared protein 
expression over the course of MV. Previous studies using iTRAQ™ labeling 
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have reported success with the identification of proteins from a diverse 
abundance, isoelectric point (or pH) and molecular weight (Aggarwal et al., 
2006). It was necessary to determine relative expression changes of proteins 
in healthy saliva before quantifying changes during MV. Quantitative analysis 
on healthy volunteer saliva over 10 d allowed assessment of potential protein 
variance prior to examining changes over the course of MV (Table 4.7). 
Limited changes in salivary proteins occurred over the 10 d period for the 
healthy volunteer saliva. Out of more than 100 identified proteins, noticeable 
increases were evident only with peregrin and tripeptidyl-peptidase 2, the 
latter a multipurpose peptidase involved in metabolic pathways (Tomkinson & 
Lindås, 2005), which increased up to 50 fold.  
 
Proteomic analysis of saliva from a mechanically ventilated patient revealed 
noticeable increases in the expression of several proteins, particularly those 
associated with inflammatory responses (Table 4.8). Proteins such as 
neutrophil gelatinase, lactotransferrin, and haptoglobin were all elevated 
during MV, suggesting that the oral mucosa and gingival tissue may be 
responding to external stimuli and stress, including microbial changes and 
underlying patient condition. Protein expression was set to 1.0 at the start of 
MV, allowing calculation of the relative change in expression during MV. 
Although informative of fold-differences during MV, one such limitation of this 
approach is the investigation of highly expressed proteins at the beginning of 
MV. A drop in expression of a particular protein at midpoint of MV would 
however suggest an increased expression at intubation.  
 
Furthermore, noticeably increased levels of lysozyme and lactoperoxidase 
were evident in saliva obtained after ETT-extubation compared to during MV. 
These findings could reflect diminished expression during MV, and a return 
to normal levels of this antibacterial peptide. Lipocalin-1, is a protein 
associated with scavenging of toxic molecules (Vitorino et al., 2004; Jessie et 
al., 2010), and this was highly expressed after ETT extubation, compared 
with levels at the commencement and during MV. Saliva levels of carbonic 
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anhydrase (associated with pH homeostasis) were noticeably higher in the 
post-ETT extubation (Table 4.8). Increased concentrations of carbonic 
anhydrase VI in saliva enhances the buffering capacity of saliva (Kimoto et 
al., 2006), and could therefore have a role in increasing the salivary pH 
following discontinuation of MV. Carbonic anhydrase VI has been reported as 
a potential anti-caries protein, neutralising dental plaque acid (Kimoto et al., 
2006).  
 
Oral mucosa is comprised of stratified squamous epithelial cells, offering 
immediate continuous multi-layered protection, and cytokine production to 
recruit neutrophils to infected surfaces (Abram et al., 2000; Krisanaprakornkit 
et al., 2000; Sandros et al., 2000). Innate inflammatory responses are highly 
complex, involving combinations of mediator cells and signal cascades 
(Medzhitov, 2007; Feller et al., 2013). Cytokines are glycoproteins that 
regulate the immune responses by initiating and coordinating cell 
communication (Degré, 1996; Gemmell & Seymour, 1998; R.-Q et al., 2014). 
Interleukins (IL) facilitate communication between blood cells (including 
neutrophils and macrophages), chemokines and interferons (Kleiner et al., 
2013). Targeted cytokine levels (IL-8, IL-1β and IL-6) in saliva were 
significantly elevated during MV (Figure 4.18), with similar concentrations 
detected in fluid collected from the inner lumen of ETTs, which subsequently 
decreased post-ETT extubation to reflect levels exhibited in the saliva of 
healthy volunteers (Table 4.10). 
 
IL-8 is a pro-inflammatory chemokine involved in recruiting neutrophils and 
mediating inflammatory responses within gingival tissues. This chemokine is 
localised in increasing numbers in the gingival tissue of patients with 
periodontitis (Yumoto et al., 1999; Sandros et al., 2000; Winkler et al., 2001). 
IL-8 production in surrounding epithelial tissue may be a response to an 
acute accumulation of dental plaque (Jenkinson & Lamont, 2005; Sandros et 
al., 2000). The elevated levels of IL-8 during MV were coupled with higher 
levels of IL-6 (Figures 4.21, 4.20). IL-6 has been shown to increase during 
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episodes of oral disease and inflammation (Gemmell & Seymour, 1998; 
Peyyala et al., 2012), which is not at all surprising during MV.   
IL-1β is a pro-inflammatory cytokine generated by macrophages after 
exposure to microbial components, particularly lipopolysaccharide (LPS). An 
increase in IL-1β suggests the presence of inflammatory factors and perhaps 
an increase in Gram-negative bacteria within dental plaque (Reimann et al., 
1994). Increases in pro-inflammatory proteins such as cytokines can promote 
local tissue destruction (Ginsburg et al., 2012; Rogers H, 2013). A study by 
Wilkinson et al., 2010 has shown increased IL-8 and IL-1β within alveolar 
tissues of patients with VAP. Interestingly, the distribution of IL-1β was 
significantly (p=0.035) increased in patients in whom respiratory pathogen 
colonisation of dental plaque occurred (Figure 4.22). After extubation, a 
significant reduction in all pro-inflammatory cytokines to levels of those 
evident in the saliva of healthy individuals was apparent.  
 
Due to high levels of potential respiratory pathogens colonising dental 
plaque, oral health is an important unexplored marker for pneumonia, as 
changes to the oral microbiome may precede the translocation of potential 
pathogens into the lungs. Future work should include a clinical study 
investigating the role of cytokines circulating within saliva during MV to act as 
biomarkers for the prognosis and diagnosis of VAP. A series of adhesion 
molecules (CD62L, CD54, CD83), neutrophil elastase (Wilkinson et al., 2012; 
Hellyer et al., 2015) neutrophil receptors CD35/CR1 (Nuutila, et al., 2006) 
and cytokines (IL-6, IL-8, IL-1β and IL-12) (Conway Morris et al. 2010) could 
be quantified from saliva during MV and correlated to the respiratory 
pathogen colonisation of dental plaque. 
 
Conclusion 
During MV, there was reduced salivary flow and pH, which was particularly 
evident at the midpoint of MV, and for patients in whom respiratory 
pathogens were shown to be colonising dental plaque.  
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A series of gel-based proteomic analyses were performed to provide an 
overall picture of salivary proteins. Compared to a relatively stable saliva 
proteome expressed from a healthy individual over the course of 10 d, gel-
based proteomics revealed major compositional changes occurring during 
MV.   
LC-MS/MS analysis identified and quantified protein expression during MV in 
a high throughput manner. Initial studies indicated there were multiple protein 
changes occurring during MV, including proteins associated with 
inflammatory responses, such as lysozyme. Neutrophil elastase and 
lysozyme were among proteins identified from a mechanically ventilated 
patient with dental plaque colonisation of respiratory pathogens. Significant 
increases in salivary cytokine profiles during MV could have been instigators 
of associated microbial changes or be reflective of the changes themselves. 
 
Further studies targeting proteins such as neutrophil elastase, proteases and 
proteins involved in initiating the immune response could determine their 
involvement in the dynamics of the oral microbiome during MV. There is also 
the potential to explore the potential of salivary proteins and respiratory 
colonisation of dental plaque, as a non-invasive prognostic and diagnostic 
tool for VAP.  
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Chapter 5 
 
Effect of oral microorganisms 
and chlorhexidine on respiratory 
pathogen presence in in vitro 
biofilms
	 216 
5.1 Introduction 
 
Oral hygiene is an essential facet of care for critically ill patients, with the aim 
of reducing the risk of secondary infections such as Ventilator-Associated 
Pneumonia (VAP), as well as aiding comfort and oral lubrication (O’Reilly, 
2003; Munro et al., 2009; Johnson et al., 2012). Typically, oral wash 
interventions such as chlorhexidine are administered to enhance the physical 
removal of dental plaque (Wise et al., 2008; Ames, 2011; Gu et al., 2012). 
Before studies can accurately investigate the effectiveness of oral 
interventions, there is a need to define an optimal and universal strategy for 
measuring oral hygiene in critically ill patients via dental plaque scoring for 
example (Wise & Williams, 2013). 
 
Chlorhexidine (CHX) is an antiseptic with broad antimicrobial activity (1.7.5.5) 
and is administered widely in critical care units (Jones et al. 2004; Munro & 
Grap 2004; Pineda et al., 2006; Rello et al., 2007; Munro et al., 2009; 
Needleman et al., 2011). Depending on the outcome of oral assessments, 
CHX may be administered up to four times a day (Scannapieco et al. 2009; 
Needleman et al. 2011). Current literature shows conflicting evidence as to 
whether oral antiseptics such as CHX are effective at controlling dental 
plaque and consequently reducing VAP (Jones, 1997; Pineda et al., 2006 
Bellissimo-Rodrigues et al., 2009). Studies indicate that CHX concentrations 
as low as 0.12% (v/v) are effective against oral microbial species, especially 
when administered in conjunction with tooth brushing (Zanatta et al., 2007). 
A clinical trial by Scannapieco et al., 2009, involving 175 intubated patients, 
studied the effectiveness of 0.12% CHX in reducing the overall colonisation 
of dental plaque by oral and non-oral pathogens. Scannapieco et al., 2009 
documented the ability of CHX to reduce S. aureus in dental plaque, 
however, there was no equivalent reduction in the numbers of other 
respiratory pathogens including Pseudomonas and Acinetobacter species.  
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Changes in the microbial population during dental plaque formation and 
further colonisation by pathogenic species may influence the pH of saliva and 
dental plaque (Jakubovics & Kolenbrander, 2010). It is known that for the 
majority of critically ill patients, the level of oral hygiene frequently 
deteriorates during mechanical ventilation (MV; Fourrier et al., 1998; 
Sachdev et al., 2013), ultimately leading to accumulation of dental plaque 
and gingival inflammation (Wood et al., 2002). Decreases in local 
environmental pH can be an external pressure leading to the survival and 
growth of aciduric organisms such as S. mutans (Jakubovics & 
Kolenbrander, 2010). Increases in the abundance of aciduric and acidogenic 
streptococci will inevitably increase acidic by-products from fermentation of 
carbohydrates such as sucrose, perhaps serving to reduce the biofilm pH 
further and influence the surrounding salivary pH. Opportunistic pathogens 
such as S. aureus, P. aeruginosa and Streptococcus pseudopneumoniae 
can be predominant colonisers of dental plaque during MV. These respiratory 
pathogens may therefore exploit local environmental changes such as pH or 
oral microbial changes in dental plaque to subsequently colonise and 
possibly outcompete normal oral bacteria. Staphylococcus aureus, for 
example, will thrive under acidic conditions (as low as pH 5; Cotter & Hill, 
2003; Baudoux et al., 2007).  
 
The primary aim of the work presented in this chapter was to develop single 
and mixed species biofilm models which could be used to examine firstly, the 
interactions between selected species and secondly, the antimicrobial 
chlorhexidine and effects of different saliva pHs. 
 
More specifically the objectives were as follows- 
 
(1). To assess whether S. mutans or C. albicans would promote S. aureus 
and P. aeruginosa colonisation of biofilms on endotracheal tube (ETT) 
surfaces. This aim was assessed by both culture and imaging.  
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(2). To investigate the effect of specific oral microorganisms and oral hygiene 
interventions (as a result from the clinical investigation, chapters 2, 3 and 4) 
as drivers for respiratory pathogen colonisation of dental plaque. To assess 
this aim:  
 
i. MIC values were obtained for antimicrobial mouthwashes including 
chlorhexidine (CHX) for planktonic and biofilm organisms. 
ii. Dental plaque from healthy individuals was used to validate the 
constant depth film fermenter (CDFF) model (1.4.7) to produce oral 
biofilms for subsequent challenge experiments. 
iii. Effect of CHX (using MICs determined in 1) challenge on oral 
biofilms upon respiratory pathogen colonisation was assessed. 
iv. Effect of saliva at various different pHs upon the degree of 
respiratory pathogen viability/infiltration of dental plaque (previously 
formed in the CDFF) was assessed. 
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5.2 Materials and Methods 
5.2.1. Identification of reference strains by 16S rRNA sequencing for in 
vitro analysis 
5.2.1.1. Microbial culture and DNA extraction 
Microorganisms (Table 5.1) were cultured on 5% (v/v) blood agar (Oxoid) 
from stock isolates and incubated at 37°C for 48 h. An overnight culture was 
prepared in Brain Heart Infusion (BHI) broth (Oxoid) and incubated 
aerobically at 37°C for 24-48 h for DNA extraction. DNA extractions were 
performed according to section 2.2.3.3 (C. albicans DNA extraction was as 
described for Gram-positive bacteria), incubated overnight at 15-25°C with 
gently shaking, followed by a centrifugation of 3 min at 16,000 × g.   
 
Table 5.1 – Microbial reference strains used for in vitro analysis  
Species Source Strain reference  
 
Candida albicans 
 
American Type of 
Culture Collection 
(ATCC) 
 
90028 
Streptococcus mutans German collection of  
Microorganisms (GSM) 
 
2053t 
Staphylococcus aureus National Collection of 
Industrial Bacteria 
(NCIB) 
9518 
Pseudomonas 
aeruginosa 
American Type of 
Culture Collection 
(ATCC) 
25668 
 
5.2.1.2 Bacterial 16S rRNA PCR and gel electrophoresis 
The primers used to identify P. aeruginosa, S. mutans and S. aureus were: 
1492r (CACGGATCCTACGGGTACCTTGTTACGACTT) and 27f 
(GTGCTGCAGAGAGTTTGATCCTGGCTCAG) (Eurofins MWG Operon) 
Dalwai et al., 2007; Zuanazzi et al., 2010) (sections 3.2.2.4-3.2.2.5). The total 
volume of PCR reagents was 50 µl (25 µl PCR master mix, 2 µl DNA 
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template, 0.5 µl reverse primer, 0.5 µl forward primer, and 22 µl of nuclease 
water). PCR thermal cycling parameters consisted of an initial denaturation 
step of 95°C for 1 min, followed by 26 cycles of 94°C for 45 s, 50°C for 45 s 
and 72°C for 90 s (Thermocycler G-Storm). A final single cycle extension 
step of 72°C for 15 min was also included. Gel electrophoresis was 
performed (1.0% (w/v) agarose gel) at 70/Vcm2 for 50 min, in a 0.5× Tris 
Borate EDTA (TBE) buffer with 10% SafeView™ (NBS Biologicals NBS-SV1) 
for detection of nucleic acids alongside a 1 Kbp molecular weight ladder 
(Promega). A gel doc system was used to determine DNA presence pre-
sequencing (Gel-DocIT_UVP; Biorad). 
 
5.2.1.3 Candida albicans PCR 
To amplify DNA, rDNA sequences of C. albicans, ITS1 
(TCCGTAGGTGAACCTGCGG) and ITS2 (TCCTCCGCTTATTGATATGC) 
(Eurofins MWG Operon) primers were used (Fujita et al., 2001). PCR thermal 
cycling (G-Storm Thermocycler) consisted of an initial denaturation step of 4 
min at 95°C, and then 35 cycles of denaturation for 30 s at 95°C, annealing 
for 1 min at 62°C, and elongation for 90 s at 72°C. A final extension step was 
set at 72°C for 5 min. Gel electrophoresis was performed as described in 
section 5.2.1.2. 
5.2.1.4 DNA Sequencing  
Amplified DNA was purified for DNA sequencing using the QIAquick PCR 
purification kit (Qiagen). DNA was added to a spin column with a 1:5 ratio of 
PB buffer (binding buffer) and centrifuged at 17,900 ×g for 1 min. The DNA 
was bound to the membrane and eluted into a microcentrifuge tube using 
nuclease free water. DNA was quantified using a Nanodrop (GE Healthcare 
Bio-Sciences) and sequenced using the BigDye® Terminator v3.1 kit (Life 
Technologies) coupled with the platform 3730xl DNA Analyzer (DNA 
Sequencing Core, Molecular Biology Unit, Bio-sciences, Cardiff University). 
The primers used in the original PCR were also supplied to the sequencing 
unit at 2 pmol/µl in a 15-µl volume.  
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5.2.2 Effect of oral microorganisms on in vitro colonisation of ETT 
biofilms by respiratory pathogen  
5.2.2.1 Biofilm development on sections of ETT  
Microorganisms were cultured on selective agar and incubated as previously 
described (2.2.3). Broth cultures were prepared by inoculation of a single 
colony in 20 ml of BHI, with P. aeruginosa, S. aureus and C. albicans 
incubated aerobically at 37°C for 24 h, and Streptococcus mutans was 
incubated in 5°C carbon dioxide for 48 h. A 0.5 McFarland standard (1x 108 
CFU/ml) preparation of microorganisms was prepared from broth cultures to 
inoculate ETT sections. For single species biofilms, 1 ml of the 0.5 
McFarland preparations was added to 9 ml of BHI. For polymicrobial biofilms, 
1 ml of each organism was combined and a 1-ml volume added to 9ml of BHI 
and vortex mixed. For positive controls, serial dilutions of a 0.5 McFarland 
standard suspension were prepared for each species using a spiral-plater 
(Whitley automatic) and incubated at 37°C for 24 h for bacterial enumeration. 
 
Using a sterile scalpel, a 0.5 cm length of ETT (TaperGuard™ Evac Oral 
Tracheal Tube 8.0 mm, ID 11.8 mm OD) was cut and added aseptically to 
the universal tube. For each individual inoculum, triplicate replicates were 
prepared. The universal tubes were incubated aerobically for a total of 10 d 
at 37°C. Every 24 h, the media was decanted and replenished with 10 ml of 
fresh BHI without agitation to the biofilm. The surface area of the 0.5 cm 
section of ETT was calculated to allow results of colonisation to be 
expressed as CFU per cm2 (Figure 5.1).   
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Figure 5.1 – The total surface area of the 0.5 cm length of ETT included the 
area of the internal surface, the area of the external surface and the area of 
the top and base edges. Surface area calculation of the ETT section to allow 
expression of results as colony forming units (CFU) per cm2.  
  
= 5.265cm2 
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5.2.2.2 ETT biofilm enumeration 
After 10 d, the BHI medium was discarded and 1 ml of PBS added and the 
mixture gently rocked on a platform for 2-5 min. The PBS was discarded, 
replenished and this process was repeated three times. After the final 1 ml of 
PBS was removed, a sterile cotton swab was used to remove the biofilm 
from the ETT tube, covering all surfaces for 20 s. The cotton swab was then 
resuspended in 5 ml of PBS and vortex mixed for 20 s. Serial dilutions were 
then prepared using PBS and these were spirally plated (Don Whitley) on 
selective agars and CFU/ml determined following culture for 24 h. Colony 
counts were then extrapolated to CFU/cm2 of ETT section.  
 
5.2.2.3 ETT section preparation for microscopic imaging: Scanning 
Electron Microscopy (SEM) 
ETT biofilms were washed in PBS and sections placed in 2 ml of 10% 
formalin, and left for at least 24 h.  
After processing in pathology for wax embedded sections, a series of 20 µm 
sections were transferred onto microscope slides (Superfrost, Fisher). To de-
wax the sections for imaging, 3 incubation periods of 10 min each in xylene 
was undertaken, followed by a wash with 100% ethanol. The slides were air-
dried and sputter coated with gold for 8 min in readiness for scanning 
electron microscopy (SEM). Biofilms were viewed in a JEOL 840A SEM at 
5kV and digital images captured using SIS software (School of Medicine, 
Cardiff University).  
 
 
5.2.3 Minimum Inhibitory Concentration (MICs) determination of 
antimicrobial mouthwashes  
5.2.3.1 MIC of planktonic single and mixed species 
Staphylococcus aureus, P. aeruginosa, S. mutans and C. albicans were 
cultured on selective agar and incubated appropriately (section 2.2.3.4). In 
addition, a series of clinical isolates (n=20) obtained from dental plaque 
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during this study (2.3.2-2.3.3) were analysed. An overnight culture was 
prepared in Mueller-Hinton Broth (MHB) and a 0.5 McFarland Standard 
(1x108 CFU/ml) prepared in MHB using a spectrophotometer at 625nm. The 
McFarland standards were diluted 1:100 (1x106 CFU/ml) using MHB. Serial 
dilutions of antimicrobial mouthwashes (Listerine™ and CHX) were prepared 
in MHB, with Listerine™ starting at 50% (v/v) and CHX starting at 2% (v/v).  
A 100-µl volume of diluted antimicrobial was added to the wells of 96 well 
plates, and 100 µl of the microbial suspension was subsequently added (200 
µl total volume). Controls included sterile MHB (-VE control) and bacterial 
suspensions without antimicrobials (+VE control). The 96 well microtitre 
plates were incubated aerobically at 37°C for 24 h. After incubation the 
relative growth was estimated by a turbidity measurement of each well using 
spectrophotometric absorbance at 620nm. Readings were standardised using 
wells with antimicrobial mouthwash dilutions without microbial species. The 
MIC value was recorded as the lowest concentration of antimicrobial agent 
that showed 80% reduction in absorbance reading, compared to the positive 
control (Klepser et al., 1998). MIC ranges were determined from 3 sets of 
triplicate experiments. 
 
5.2.3.2 MICs for single and mixed species biofilms 
Artificial saliva (A/S) was prepared in dH20: 2.5 g/L porcine stomach mucin 
(Oxoid), 0.35 g/L sodium chloride (Fisher), 0.2 g/L potassium chloride 
(Fisher), 0.2 g/L calcium chloride dehydrate (CaCl2.2H20) (Fisher), 2.0 g/L 
yeast extract (Oxoid), 1.0 g/L Lab Lemco (Oxoid) and 5.0 g/L proteose 
peptone (Oxoid). The A/S mixture was aliquoted in 100 ml bottles and 
sterilised by autoclaving at 121°C for 15 min. A 125-µl volume of 40% (w/v) 
urea filter sterilised using a 0.22 µm pore size filter (Fisher) was added to 100 
ml of A/S prior to use. 
A 200-µl volume of A/S was added to each well of a 96 well plate and 
incubated for 24 h at 37°C to precondition the wells. The A/S was removed 
and 200 µl of a 1:100 diluted 0.5 McFarland standard (1x106 CFU/ml) of 
microbial species added. For multi-species inocula, the diluted preparations 
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were mixed before addition to the well. After biofilm development for 24 h at 
37°C, the medium was discarded and the biofilm washed by adding 100 µl of 
phosphate buffered saline (PBS). Two hundred µl volumes of two-fold series 
dilutions of antimicrobial mouthwashes were added to each well, and the 
biofilms incubated for a further 24 h period. Media was removed and the 
biofilm washed in 100 µl of PBS. A 200-µl volume of MHB was added to the 
wells, and the biofilm re-suspended by repeat pipetting. Absorbance readings 
were determined and the 96 well plates re-incubated for a further 6 h. The 
MIC for in vitro biofilms was determined by measuring the difference in 
absorbance over the 24 h incubation period. The MIC was the concentration 
of antimicrobial that caused an 80% absorbance reduction compared to 
positive controls (Klepser et al., 1998). For both planktonic and biofilm mixed 
species combinations, 100 µl of the sub-MIC concentration was removed for 
species-specific microbial counts, using a spiral-plater (Don Whitley). 
 
5.2.4 Dental plaque formation within the CDFF  
5.2.4.1 Ethical approval 
The collection of dental plaque required ethical approval from the Human 
Tissue Act (HTA) Governance Team at Cardiff University, and further 
approval from the School of Dentistry Research Committee (Appendix IV). 
The inclusion criteria was as follows: >18 years old, > 8 original teeth, no 
prescription medication and willing to avoid tooth brushing for 12-24 h before 
sample collection. 
5.2.4.2 Dental plaque collection 
Supragingival dental plaque was collected from recruited volunteers using 
dental instruments from 5 individuals. A dentist at the School of Dentistry 
(Paola Marino) performed the dental plaque collection once participant 
consent was obtained. Dental plaque was collected using paper points and 
initially stored in transport medium (section 2.2.3.1). Dental plaque from each 
volunteer was pooled to anonymise samples. Samples were gently inverted 
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and divided into 10x1 ml aliquots and stored in 15% (v/v) glycerol at -80°C 
until needed.  
5.2.4.3 CDFF medium preparation 
Biofilm medium (proteose peptone, 10 g/L; trypticase peptone, 5 g/L; yeast 
extract, 5 g/L, KCl, 2.5 g/L, haemin, 0.005 g/L, vitamin K1, 0.001 g/L, L-
cysteine HCl, 0.5 g/L and glucose, 10 g/L) was used to supplement the 
development of oral biofilms (McKee et al., 1985; Hill et al., 2010).  
5.2.4.4 CDFF mediated development of 5 d oral biofilms 
Oral biofilms were generated in a CDFF maintained at 37°C, on 4.75 mm 
diameter polytetrafluoroethylene (PTFE) plug inserts within a rotating 
turntable at a constant depth of 400 µm. To resemble the enamel pellicle 
formation, culture medium was initially re-circulated through the CDFF for 30 
min with a turntable speed of 20 ml/h. A 100-µl volume of dental plaque was 
added to BM medium (1 L) and re-circulated through the CDFF for 24 h to 
‘seed’ the system. After this time, the inoculum was disconnected and fresh 
un-inoculated medium fed into the CDFF, and the waste medium collected in 
a separate effluent bottle. The growth medium was delivered to the CDFF 
using a peristaltic pump (Watson–Marlow, 101U MK2) at a rate of 20 ml/h. 
The growth medium was continuously supplied to the CDFF for a period of 5 
d. A PTFE scraper blade washed incoming media over the 15 pans, each 
containing 5 PTFE plugs (Wilson 1996).  
5.2.4.5 Recovery and quantification of bacteria within the oral biofilm 
A series of viable cell counts (CFU/ml) was performed on biofilm plugs 
removed from the CDFF (before and after subsequent incubation with 
different respiratory pathogens). Plugs were aseptically removed from the 
CDFF using sterile forceps and individually immersed in 5 ml of PBS and 
vortex-mixed for 2 min to remove the biofilm. Serial dilutions were prepared 
and re-suspensions were spirally plated (Don Whitley) on to BA, FAA and 
SAB agar media. Agars were incubated aerobically for 24 h at 37°C, or in the 
case of FAA, anaerobically for 48 h at 37°C. A total of 5 PTFE pans were 
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prepared for serial dilutions for each experimental factor to allow for ANOVA 
testing (IBM SPSS v20).  
5.2.4.6 Biofilm imaging using live dead/PNA-FISH coupled with CLSM 
PTFE plugs containing biofilms for imaging were fixed in 2 ml of 10% 
formalin. Species-specific PNA probes for respiratory pathogens (S. aureus 
and P. aeruginosa) and a bacterial universal PNA probe, were added to a 
series of 20 µm sections of dental plaque biofilms after exposure to different 
experimental conditions (2.2.7.1-2.2.7.3). Biofilms were imaged on a Zeiss 
LSM 880 microscope and images were processed using Zen Lite software.  
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5.2.5 Dental plaque challenge experiments: exposure to CHX and 
altered ‘salivary’ pH 
Dental plaque biofilms formed upon CDFF PTFE pegs were subjected to 
challenge experiments including exposure to altered ‘salivary’ pH and CHX 
as outlined (Figure 5.2).  		
 
Figure 5.2 - Schematic of the challenge experiments performed on biofilms 
generated within the CDFF and further inoculated with respiratory pathogens 
and exposed to CHX/ variations in salivary pH.   
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5.2.5.1 Effects of CHX on colonisation of dental plaque by respiratory 
pathogens  
CDFF plugs were removed after 5 d and aseptically transferred to universal 
containers. CHX gluconate solution was added at sub MIC concentrations 
(previously established for P. aeruginosa and S. aureus). The plugs were 
immersed in CHX (containing respiratory pathogens 1x102 CFU/ml) and 
incubated at 37°C for 30 min, 1 h and 12 h. After incubation, biofilm bacteria 
were enumerated by culture or image analysis directly performed. 
 
5.2.5.2 Effect of ‘salivary’ pH on respiratory pathogen colonisation of 
biofilms 
The CDFF was established as outlined previously (section 5.2.3.4) to 
generate a 5 d oral biofilm using pooled dental plaque collected from 5 
healthy volunteers. Plugs were removed from the CDFF containing 5 d 
biofilms and placed in 2 ml of AS for 1 h. The pans were removed aseptically 
and transferred to a series of universals containing different AS at different 
pHs and a different composition of respiratory pathogens. The following 
conditions were used: artificial saliva at pH of 4, 5 or 6.5, inoculated with 
either S. aureus or P. aeruginosa at an inoculum level of 1x102 CFU/ ml. 
Once the plugs were immersed in AS (containing respiratory pathogens) the 
universals were incubated at 37°C for 24 h. Quantification of biofilm bacteria 
was performed as previously described (section 5.2.5.1). The pH of A/S was 
measured using a calibrated pH electrode (Fisher) following incubation with 
dental plaque biofilms. 
 
5.2.6 Statistical analysis 
All statistical analyses were performed using IBM SPSS v20. T-tests were 
used to analyse differences between MICs of CHX and Listerine™ for 
planktonic and biofilm growth of S. mutans, C. albicans, S. aureus and P. 
aeruginosa. In addition, t-tests were used to assess species viability post 
exposure of planktonic cells and biofilms to CHX. One-way ANOVA was 
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used to assess cell viability of mixed species biofilms generated within the 
CDFF post exposure to both artificial saliva at pH 4, 5 and 6.5 and post 
exposure to CHX at 30 min, 1 h and 12 h, with a Turkey HSD Post Hoc test 
for parametric analysis. To analyse differences in pH, recorded pH values 
were un-transformed to the original hydrogen ion concentration [H+], using 
the following equation H+= -log^ pH value (Boutilier & Shelton, 1979; 
Murphy, 1982). Finally, t-tests were undertaken to analyse the differences in 
enumeration between dual-species combinations of ETT biofilms. 
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5.3 Results  
5.3.1 Sequencing of microorganisms used for in vitro analyses 
Reference strain microorganisms (Table 5.2) were sequenced to confirm 
identification. DNA sequences were matched for organism identity using 
Basic Local Alignment Search Tool (BLAST; Table 5.2). BLAST uses an 
algorithmic approach to calculate a score of similar alignments. All sequence 
matches exceeded 85% coverage, confirming confident identification of 
reference organisms. 
 
 
Table 5.2 - DNA sequencing results analysed via BLAST for species-specific 
identification. The sequencing results, in addition to C. albicans were 
analysed via BLAST to give species specific identification. 	
 
Reference 
Organism 
 
Strain  
Details 
 
BLAST Identification 
best match 
 
Percentage 
(%) match 
 
P. aeruginosa 
 
ATCC 25668 
 
P. aeruginosa 
 
96 
S. aureus NCIB 9518 S. aureus 91 
S. mutans  GSM 2053t S. mutans 97 
C. albicans ATCC 90028  C. albicans  99 
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5.3.2 Effect of oral microorganisms on promotion of pathogenic ETT 
biofilms  
5.3.2.1 Single species ETT biofilm development 
Biofilms were developed on sections of ETT surfaces for 10 d. Figure 5.3 
illustrates a series of these biofilms, including monolayer of microbial cells 
(Images A, and B) and 3-dimensional structures (Images C, and D). The 
surface in image A (as identified by an arrow) is the inner lumen of the ETT. 
In this case, the biofilm has detached from the surface. The formation of 
complex biofilm structures is clearly evident (Figure 5.3, image B) with 
microbial cells aggregated together and encased in EPS. In these studies the 
lowest number of bacterial cells recovered in biofilms was for S. aureus 
(6.80x106 ± 6.89x106 CFU/cm2), and P. aeruginosa had the highest cell 
number in ETT biofilms (1.81x107 ± 1.52x107 CFU/cm2; Figure 5.4)12. To 
evaluate colonisation and relationships between microorganisms, dual 
species biofilms were also formed on sections of ETTs. 
5.3.2.2 Effect of oral microorganisms in in vitro ETT biofilm 
development by S. aureus and P. aeruginosa 
Dual species biofilms of S. mutans and S. aureus were developed and 
compared with single species controls. In single species biofilms, higher 
numbers of S. mutans (1.15x107 ± 1.02x107 CFU/cm2) were detected 
compared with S. aureus (6.80x106 ± 6.89x106 CFU/cm2). When the species 
were combined, a significantly (p=0.037) higher number of S. aureus 
(3.17x107 ± 3.29x107 CFU/cm2) were present compared with S. mutans 
(9.09x106 ± 7.94x106 CFU/cm2), with the latter showing decreased 
colonisation compared with its single species control (Figure 5.5 A). Biofilms 
were developed using Streptococcus mutans and P. aeruginosa in a similar 
way (Figure 5.5, B). In the case of single species control biofilms, P. 
aeruginosa (1.81x107 ± 1.52x107 CFU/cm2) was present in higher numbers 
than S. mutans (1.15x107 ± 1.02x107 CFU/cm2). When the two species were 
combined, a reduction in S. mutans occurred (9.43x106 ± 7.67x106 CFU/cm2) 																																																								12 Tabulated raw data in Appendix IV 
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and there was an increase in P. aeruginosa (2.02x107 ± 1.44x107 CFU/cm2), 
although these changes were not deemed significant (p=0.050).  
Biofilms involving C. albicans and S. aureus were developed (Figure 5.5, C). 
Single species biofilms had higher numbers of C. albicans (1.04x107 ± 
1.21x107 CFU/cm2) compared to S. aureus (6.80x106 ± 6.89x106 CFU/cm2). 
When C. albicans was combined in biofilm with S. aureus, a significant 
(p=0.031) reduction in C. albicans numbers occurred (3.12x106 ± 1.55x106 
CFU/cm2). The numbers of S. aureus were also lowered (3.74x106 ± 
2.88x106 CFU/cm2), but not significantly.  
Candida albicans was cultured in biofilms with P. aeruginosa (Figure 5.5, D), 
and these experiments showed that colonisation of P. aeruginosa was higher 
(2.37x107 ± 2.28x107 CFU/cm2), but not statistically significant (p=0.984) than 
C. albicans. When combined with P. aeruginosa there was a reduction in the 
numbers of C. albicans (5.23x106 ± 1.94x106 CFU/cm2), although this was 
not deemed significant (p=0.499)13. 
 
																																																								13 Tabulated raw data in Appendix IV 
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Figure 5.3 - SEM micrographs of; A and B illustrate initial stages of biofilm 
development and a monolayer of attached cells; C and D illustrate mixed 
bacterial species and C. albicans biofilms on ETT surfaces. Arrows indicate 
bacterial cells.  	
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Figure 5.4 - Colony counts for single species biofilm developed on ETT over 
10 d. 
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Figure 5.5 - Colony counts from in vitro ETT biofilms. A, S. aureus alone and 
with S. mutans; B, P. aeruginosa in mixed species biofilms with S. mutans 
compared to control data; C, single and mixed species ETT biofilm 
colonisation by S. aureus and C. albicans; D, P. aeruginosa was mixed with 
C. albicans.  
6.00 
6.50 
7.00 
7.50 
S. aureus S. mutans 
Lo
g 1
0 C
FU
/ c
m
2 
Single species Mixed species 
6.00 
6.50 
7.00 
7.50 
P. aeruginosa S. mutans 
Lo
g 1
0 C
FU
/ c
m
2 
Single species Mixed species 
B 
A * 
5.50 
6.00 
6.50 
7.00 
7.50 
S. aureus C. albicans 
Lo
g 1
0 C
FU
/ c
m
2 
Single species Mixed species 
C 
* 
6.00 
6.50 
7.00 
7.50 
P. aeruginosa  C. albicans 
Lo
g 1
0 C
FU
/c
m
2 
Single species Mixed species 
D 
	 237 
5.3.3 Minimum inhibitory concentrations (MICs) of antimicrobial 
mouthwashes against test microorganisms  
5.3.3.1 MICs against single species planktonic cells and biofilms  
MICs for CHX against planktonic oral organisms (S. mutans and C. albicans) 
and respiratory pathogen S. aureus were <0.0000586% (<the lowest 
concentration tested; Table 5.3). For planktonic P. aeruginosa the MIC was 
noticeably higher at 0.0008%. Against biofilms, the minimum biofilm inhibitory 
concentration (MBIC) values increased significantly for S. mutans (0.0049%, 
p=0.01), C. albicans (0.0039%, p=0.025) and S. aureus (0.0025%, p=0.039). 
The MIC was 0.0049% for S. mutans, 0.0039% for C. albicans and 0.0025% 
for S. aureus. The MBIC value for P. aeruginosa was elevated to 0.0076%, 
from a planktonic value of 0.0008%, although not statistically significant 
(p=0.248). 
 
A similar pattern was observed for the MICs of Listerine™ Gum Defence for 
planktonic and biofilm growth. The MIC values ranged between 2-4% for 
planktonic growth to 10-37.5% for biofilm cells. The MBICs of all 4 species 
were significantly higher than equivalent planktonic growth (S. mutans 
p=0.004, C. albicans p=<0.001, S. aureus p=0.036 and P. aeruginosa 
p=0.006)  (Table 5.3). The MICs against P. aeruginosa biofilms (37.5% ± 
2.78) were also noticeably higher compared with S. aureus (16.17% ± 0.29) 
and the oral microbial species (S. mutans (10% ± 0) and C. albicans (15.67% 
± 4.93)) (Table 5.3). 
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Table 5.3 - Planktonic and biofilm MICs of CHX and Listerine™ Gum 
Defence14 for test microorganisms. 
    CHX (% v/v) Listerine™ Gum Defence (% v/v) 
  Data set  Planktonic Biofilm Planktonic Biofilm 
  1 <0.0000586 0.0015 1.65 16.00 
S. aureus  2 <0.0000586 0.0030 1.50 16.00 
NCIB 9518 3 <0.0000586 0.0030 5.10 16.50 
 
Average <0.0000586 0.0025 2.75 16.17 
  SD 0 0.0009 2.04 0.29 
  SEM 0 0.0005 1.18 0.17 
  1 0.0007 0.0030 3.00 34.50 
 P. aeruginosa 2 0.0009 0.0038 3.13 38.00 
 ATCC 15682 3 0.0007 0.0160 6.25 40.00 
 
Average 0.0008 0.0076 4.13 37.50 
  SD 0.0001 0.0073 1.84 2.78 
  SEM 0.0001 0.0042 1.06 1.61 
  1 <0.0000586 0.0018 2.40 10.00 
S. mutans  2 <0.0000586 0.0060 2.80 10.00 
 GSM 2053t 3 <0.0000586 0.0070 2.40 10.00 
 
Average <0.0000586 0.0049 2.53 10.00 
  SD 0 0.0028 0.23 0.00 
  SEM 0 0.0016 0.13 0.00 
  1 <0.0000586 0.0040 2.40 10.00 
C. albicans  2 <0.0000586 0.0016 2.25 18.00 
ATCC 90028  3 <0.0000586 0.0060 2.40 19.00 
 
Average <0.0000586 0.0039 2.35 15.67 
  SD 0 0.0022 0.09 4.93 
  SEM 0 0.0013 0.05 2.85 
    
    
																																																								14 Each MIC value was obtained from a triplicate data set  
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5.3.3.2 MIC of CHX against mixed species planktonic and biofilms 
Dual-species combinations of S. aureus with S. mutans/C. albicans and P. 
aeruginosa with S. mutans/C. albicans were co-cultured to compare the 
planktonic MICs and mixed species biofilm MBICs. For all dual-species 
biofilms, the MBICs were significantly increased (P. aeruginosa/ S. mutans 
p=0.017, MBIC 0.008% ± 0.002; S. aureus/ C. albicans p-0.001, MBIC 
0.012% ± 0.0005; P. aeruginosa/ C. albicans p=0.007, MBIC 0.01% ± 0.002) 
when compared to planktonic MICs, with the exception of S. aureus and S. 
mutans (MBIC 0.02% ± 0.003, p=0.168) (Figure 5.6). In addition, for biofilm 
growth there was a greater variability between technical replicates as 
indicated by the larger error bars in figure 5.6. Mixed species MBICs were of 
similar values to the MBICs obtained from single species. Tabulated data in 
appendix IV. 
 
 
 
Figure 5.6 – A bar graph comparing the MIC values for dual-species 
species. A total of four combinations of oral organisms and respiratory 
pathogens isolated from dental plaque are used.  
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5.3.3.3 Species-specific recovery post-antimicrobial mouthwash 
exposure  
When compared to planktonic cultures, co-culture of S. aureus and S. 
mutans in biofilms resulted in increased CFU/ml of S. aureus (1.36x104 ± 
1.21x104 CFU/ml to 4x104 ± 1.73x103 CFU/ml) and a significant decrease in 
S. mutans CFU/ml (p=0.028, CFU/ml decrease from 2.47x103 ± 6.66x102 to 
1.46x102 ± 4.71x101 CFU/ ml) (log data table 5.4). Numbers of P. aeruginosa 
significantly increased (p=0.044) 8.8x104 ± 0 CFU/ml to 4.27x105 ± 1.27x105 
CFU/ml) when cultured with S. mutans in a biofilm compared to planktonic 
cultures. Neither S. mutans nor C. albicans were detected by microbial 
culture when co-cultured with P. aeruginosa. Finally, there were no 
significant differences in CFU/ml of S. aureus and C. albicans between 
planktonic and biofilm growth. Raw tabulated data in appendix IV.  
 
 
Table 5.4 - Total counts of cultured microorganisms after CHX exposure for 
24 h. T-tests were performed to compare enumeration difference between 
planktonic and biofilm growth post-CHX exposure. 
Dual – microbial sub-MIC15 sub-MBIC Significance 
  combination species Log10 CFU/ml 
Log10 
CFU/ml  
1 S. aureus 4.13 4.60 ns* 
  S. mutans 3.39 2.15 p=0.03 
2 P. aeruginosa 4.94 5.63 p=0.04 
  S. mutans 0.00 0.00 ns 
3 S. aureus 4.71 4.52 ns 
  C. albicans 4.37 3.93 ns 
4 P. aeruginosa  4.58 5.71 ns 
  C. albicans  0.00 0.00 ns 
counts in triplicate, *ns – not 
significant 
 
  
 
																																																								15 Sub-MIC/MBIC concentration of CHX as determined for individual species in 5.2.3.1 
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5.3.3.4 MICs of antimicrobials against clinical isolates  
The MICs of CHX and Listerine™ Gum Defence against 20 clinical isolates 
of 5x S. aureus and 5x P. aeruginosa and the oral microorganisms 5x S. 
mutans and 5x C. albicans (recovered from dental plaque of mechanically 
ventilated patients; section 2.2.3) are presented in table 5.5 and figure 5.7. 
The MBIC for CHX against clinical S. aureus isolates (MBIC 0.006% ± 0.004) 
were significantly higher compared to planktonic (MIC 0.001% ± 0.001, 
p=0.021). In addition, the mean MIC for clinical S. aureus biofilms was higher 
than for the reference strain S. aureus biofilm and this was statistically 
significant (p=0.018; Figure 5.7). 
 
The highest CHX concentration required to inhibit growth of species identified 
from dental plaque was 0.05% (v/v) for P. aeruginosa. However, there was a 
large degree of variability in MBICs of clinical isolates, 0.048% ±0.024 (also 
shown by the error bars in figure 5.7). For P. aeruginosa, the MBIC of clinical 
isolates was (0.048%) significantly higher compared to the P. aeruginosa 
reference biofilm (MBIC 0.0076%), and all planktonic P. aeruginosa isolates 
(reference, and clinical) (p=<0.0001). In addition, the MICs for CHX against 
biofilm and planktonic oral microorganisms S. mutans and C. albicans were 
determined. The MBICs for S. mutans and C. albicans were significantly 
higher, p=<0.005 (0.009% and 0.004% respectively) than against planktonic 
equivalents (0.001% and 001% respectively). 
 
The Listerine™ Gum Defence MICs against clinical isolates are shown in 
figure 5.8. For S. aureus, there was a significant difference (p<0.001) 
between planktonic MICs (3.017% ± 1.581) and biofilm MBICs (22.033% 
±6.050). This was evident using both clinical and reference isolates. Similarly 
the MBICs of clinical P. aeruginosa isolates (15.235% ±40.100) were 
significantly higher (p=<0.001) compared to planktonic isolates 2.383%± 
1.014), even considering the large variation in MBICs obtained for P. 
aeruginosa isolates. Biofilms of S mutans clinical isolates had significantly 
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higher MICs than planktonic counterparts (p=<0.001) and those of reference 
strains grown planktonically (p=<0.001) or as biofilms (p=0.004).   
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5.3.4 Dental plaque biofilms generated in the CDFF 
5.3.4.1 CDFF biofilm development  
The CDFF was used to develop complex and reproducible biofilms derived 
from supragingival and subgingival dental plaque from healthy volunteers. A 
5 d biofilm was developed on PTFE plugs as described in section 5.2.4 using 
constantly supplied BM at a pH between pH 6.77-6.89. Microbial 
enumeration of the dental plaque inocula and from the 5 d CDFF biofilms 
was undertaken (Table 5.7).  
Facultative anaerobes, aerobic bacterial species and C. albicans (budding 
cells and hyphae production identified by CLSM) were recovered from the 
CDFF generated biofilm (Figures 5.9 and 5.10). There were no significant 
differences in the recovery of aerobic and anaerobic species. There was a 
significant increase (p=<0.001) in the recovery of C. albicans following re-
culture of dental plaque biofilm formation in the CDFF (Table 5.7). 
Furthermore, potential respiratory pathogens (S. aureus and P. aeruginosa) 
were not isolated on selective media from either the dental plaque or the 5 d 
CDFF biofilms (Table 5.7) (2.2.3).  
 
5.3.4.2 Composition of dental plaque CDFF biofilms inoculated with 
respiratory pathogens 
Dental plaque derived CDFF biofilms (cultured for 5 d) were exposed to A/S 
(pH 6.5) and inoculated with S. aureus or P. aeruginosa for 24 h. Subsequent 
viable counts (CFU/ml) of aerobic and anaerobic bacteria and C. albicans 
were reduced by ~1,000 fold after culture with S. aureus and P. aeruginosa 
(Figure 5.11). 
 
The following sections report the effects of CHX treatment and exposure to 
artificial saliva at different pH upon dental plaque inoculated with respiratory 
pathogens (to mirror colonisation of dental plaque during MV). These 
investigations were undertaken to ascertain whether such environmental 
changes could promote respiratory pathogen colonisation.  
	 248 
	 249 
 
 
 
 
 
Figure 5.9 - Confocal laser scanning micrograph of microorganisms from a 5 
d dental plaque CDFF biofilm treated with A/S at pH 6.5 with a live (green) 
dead (red) stain. Cellular morphologies include yeast hyphae (as shown by 
the arrows), yeast budding cells, and smaller clusters of bacterial cells.  
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Figure 5.10 - Confocal laser scanning micrograph of microorganisms from a 
5 d dental plaque CDFF biofilm treated with A/S at pH 6.5 with a live (green) 
dead (red) stain. Live cells (predominantly Candida) are on the outer of the 
biofilm (as shown by the arrows), with bacterial aggregates within the biofilm 
(stained red). 
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Figure 5.11 - Colony counts from 5 d CDFF biofilm inoculated with A, S. 
aureus and B, P. aeruginosa for 24 h.  
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5.3.5 Effect of CHX upon dental plaque biofilms inoculated with 
respiratory pathogens  
5.3.5.1 Effect of CHX treatment on composition of CDFF dental plaque 
biofilms  	
CDFF dental plaque biofilms were treated with 0.0125% (v/v) CHX in A/S (for 
P. aeruginosa) or 0.00125% (v/v) CHX (for S. aureus) for 30 min, 1 h and 12 
h. Total aerobic species, facultative and strict anaerobic species and C. 
albicans were all quantified before and after treatment (Figure 5.12). Whilst 
the numbers of aerobic species after 30 min and 1 h CHX treatments were 
similar, there was a significant (p=<0.001) reduction in numbers after 12 h 
CHX exposure. Significant reduction in anaerobic bacteria levels occurred 
following 1 h CHX treatment (p=0.017) and further reductions were seen after 
12 h (p=0.002). No differences in numbers of C. albicans were detected for 
all durations of CHX treatment at both concentrations. Tabulated data in 
appendix IV.  
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5.3.5.2 Effect of 0.00125% (v/v) CHX on S. aureus colonisation of CDFF 
dental plaque biofilms 	
Dental plaque derived CDFF biofilms that had subsequently been seeded 
with S. aureus were analysed after 0.00125% CHX treatment. Compared 
with 30 min CHX treatment, noticeable increases in S. aureus and C. 
albicans numbers were detected following 1 h treatment. However, no 
significant differences in levels of mixed aerobic or anaerobic species were 
evident for 30 min and 1 h CHX exposures (Figure 5.13). After 12 h CHX 
treatment, S. aureus was not detected by culture, although C. albicans levels 
were similar to those after 1 h exposure (p=0.190). In addition, significant 
increases in total aerobic (p=<0.001) and anaerobic counts (p=<0.001) 
occurred following 12 h CHX treatment.  
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5.3.5.3 Effect of 0.0125% (v/v) CHX treatment on P. aeruginosa 
colonisation of CDFF dental plaque biofilms 
Figure 5.14 presents the results of CHX treatment of P. aeruginosa 
inoculated CDFF dental plaque biofilms. After 30 min CHX treatment, P. 
aeruginosa was not detected by culture, whilst log10 7.5-8.5 CFU/ml of C. 
albicans, non-P. aeruginosa aerobic bacteria and anaerobic bacteria were 
present. After 1 h CHX exposure, a significant increase in numbers of C. 
albicans and aerobic bacteria was evident (p=<0.001 and p=<0.001 
respectively), although no differences were observed for anaerobic bacteria. 
Similar to 30 min CHX exposure, no P. aeruginosa were detected after 1 h 
CHX exposure. Following CHX treatment or 12 h, numbers of P. aeruginosa 
significantly increased (p=<0.001) to log10 8.5 CFU/ml. In addition, C. 
albicans or other (non-P. aeruginosa species) aerobic bacteria were not 
detected by culture after 12 h CHX exposure. There was however, a 
significant increase in the levels of anaerobic bacteria after 12 h CHX 
exposure compared with 30 min (p=0.011) and 1 h treatments (p=0.001).  
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5.3.6 Effect of artificial saliva pH on respiratory pathogen colonisation 
of dental plaque CDFF biofilms 
5.3.6.1 Composition of CDFF dental plaque biofilms after exposure to 
artificial saliva (A/S) at different pH 
 
Dental plaque derived CDFF biofilms were exposed to artifical saliva at pH 4, 
pH 5 and pH 6.5 in the absence of respiratory pathogens and incubated for 
24 h at 37°C. For aerobic and anerobic bacteria there was no significant 
differences in numbers cultured from biofilms exposed to A/S at pH 4.5 or 6.5 
(Figure 5.15). At all A/S pHs, the numbers of C. albicans was lower 
compared with aerobic and anaerobic bacteria as shown in figure 5.14, and 
C. albicans levels were significantly lower (p=0.006) at pH 6.5 (4.07x102 ± 
1.15x101 CFU/ ml), compared with pH 5 (9.37x102 ± 2.29x102 CFU/ ml). All 
tabulated data in appendix IV. 
 
The pH of A/S was measured prior to addition to a 5 d CDFF dental plaque 
biofilm and 24 h after exposure (Table 5.8) to determine whether dental 
plaque changes the A/S pH following exposure. A significant increase 
(p=<0.001) in A/S pH occurred for the pH 4 A/S following dental plaque 
biofilm exposure (pH 4.58 ± 0.02). Similarly A/S at pH 5 showed a significant 
increase (p=0.001) to pH 5.68 ± 0.07 when added to a dental plaque biofilm. 
In addition, the pH of A/S (initially at pH 6.5) decreased significantly 
(p=0.007) pH 6.21 ± 0.03 following exposure to dental plaque biofilm for 24 h.  
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Figure 5.15 – Colony counts of aerobic and anaerobic bacteria and C. 
albicans from dental plaque 5 d CDFF biofilm after 24 h exposure with 
artificial saliva (A/S) at differing pHs, whereby ***p ≤0. 001, **p ≤0.01 and *p≤ 
0.05. 			
Table 5.8 – pH measurements of artificial saliva (A/S) before and after 
exposure to a 5d mixed species dental plaque biofilm. 
 
A/S pH 
Biofilm 
Pre-5d 
CDFF 
Post-5d 
CDFF 
Pre-5d 
CDFF 
Post-5d 
CDFF 
Pre-5d 
CDFF 
Post-5d 
CDFF 
1 4.00 4.59 5.00 5.63 6.50 6.19 
2 4.00 4.56 5.00 5.64 6.50 6.25 
3 4.00 4.59 5.00 5.76 6.50 6.20 
Mean 4.00 4.58 5.00 5.68 6.50 6.21 
SD 0.00 0.02 0.00 0.07 0.00 0.03 
SEM 0.00 0.01 0.00 0.04 0.00 0.02 
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5.3.6.2 Effect of artificial pH on dental plaque biofilms inoculated with S. 
aureus   
Dental plaque biofilms seeded with S. aureus were exposed to A/S at pH 4, 
pH 5 and pH 6.5. CLSM imaging and culture enumeration were undertaken 
to assess S. aureus colonisation of dental plaque CDFF biofilms after 24 h. 
Staphylococcus aureus were detected by FISH staining on the outer most 
layer and within the biofilm (Figure 5.16). 
 
As shown in figure 5.17, no growth of S. aureus occurred after incubation 
with aritfiical saliva at pH 4, whilst significant increases were observed at pH 
5 to 3.35x107 ± 5.82x106 CFU/ ml (p=<0.001) and at pH 6.5 to 3.22x109 ± 
2.64x108 CFU/ ml (p=<0.001). No significant differences in C. albicans levels 
were seen following treatment with A/S pH 4, pH 5 or pH 6.5 (p=0.140). A 
similar pattern was observed for both aerobic and anaerobic bacteria at the 
different A/S pHs whereby similar enueration occurred between pH 4 and 
pH5, with a significant increase in aerobic species (p=<0.001) and anaerobic 
species (p=<0.001) respectively (Figure 5.17) following exposure to pH 6.5. 
All tabulated data is in appendix IV.  
 
In addition, the pH was measured post-exposure to a 5 d dental plaque 
biofilm inouclated with S. aureus (Table 5.9). For A/S commencing at pH 4, a 
significant increase occurred after 24 h inoculation with S. aureus to pH 5.34 
± 0.20 (p=<0.001). For A/S at pH 5, a significantly higher pH of 5.86 ± 0.16 
(p=0.001) was detected 24 h after inoculation with S. aureus. Similar pH 
values  (pH 6.45 ± 0.32) were obtained for for A/S initially at pH 6.5 after 
exposure to dental plaque biofilms inoculated with S. aureus (p=0.728).  
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Figure 5.16 – Confocal laser scanning micrograph of microorganisms from a 
5 d dental plaque CDFF stained with a bacterial universal probe (Cy3, red 
staining) and coupled with a species-specific probe for S. aureus (Cy5) as 
depicted by the arrows. 
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Table 5.9 - pH of artificial saliva (A/S) pre- and post-exposure with a 5d 
dental plaque biofilm inoculated with S. aureus. 
 
        A/S pH 
S. aureus Pre-exposure 
Post-
exposure 
Pre-
exposure 
     Post-
exposure 
Pre-
exposure 
     Post-
exposure 
1 4.00 5.54 5.00 5.76 6.50 6.14 
2 4.00 5.32 5.00 6.05 6.50 6.78 
3 4.00 5.15 5.00 5.78 6.50 6.43 
Mean 4.00 5.34 5.00 5.86 6.50 6.45 
SD 0.00 0.20 0.00 0.16 0.00 0.32 
SEM 0.00 0.11 0.00 0.09 0.00 0.19 
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5.3.6.3 Effect of A/S pH on CDFF dental plaque biofilms inoculated with 
P. aeruginosa  
No P. aeruginosa were detected by culture from dental plaque CDFF biofilms 
after A/S at pH 4 exposure for 24 h. Similar counts of between 7.5-8.0 log10 
CFU/ml for C. albicans, aerobic and anaerobic bacteria were evident 
following exposure to A/S at pH 4 and pH 5 (Figure 5.18). There was a 
significant (p=<0.001) increase in P. aeruginosa numbers following 
incubation in A/S pH 6.5, compared to both pH 4 and pH 5. There was a 
reduction in numbers of C. albicans after exposure to A/S pH 6.5, however 
this was not significant (p=0.065). The presence of P. aeruginosa and C. 
albicans was evident in biofilms using CLSM imaging (Figure 5.19). Candida 
albicans hyphae were clearly detected at outermost biofilm layers. The 
highest numbers of aerobic (1.45x109 ± 3.61x108 CFU/ ml and anaerobic 
bacteria (1.04x1010 ± 1.97x109 CFU/ ml) were evident after exposure to A/S 
at pH 6.5. There was a significant (p=<0.001) increase in the numbers of 
aerobic and anaerobic bacteria at pH 6.5. All tabulated data is in appendix 
IV.  
 
The pH of A/S was measured after incubation with dental plaque biofilms 
inoculated with P. aeruginosa (Table 5.10). A significant increase in the pH of 
A/S 4, to pH 5.26 ± 0.18 was evident (p=0.007). In addition, there was a 
significant increase in the pH of A/S after a starting pH of 5 to pH 6.35 ± 0.30 
when exposed to dental plaque biofilms inoculated with P. aeruginosa 
(p=0.016). Finally, the pH of A/S initially at 6.5 remained similar following 
incubation with dental plaque biofilms inoculated with P. aeruignosa for 24 h 
with a resulting pH of 6.58 ± 0.16 (p=0.486). 
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Figure 5.19 – Confocal laser scanning micrograph of microorganisms from a 
5 d dental plaque CDFF inoculated with P. aeruginosa stained with a FITC-
labelled probe. In addition, Candida albicans was stained with a FITC-
labelled probe. The upper layers of the biofilm (bracketed in the image) 
contain extensive numbers of C. albicans hyphae (as shown by the arrows).  
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Table 5.10 – pH of artificial saliva (A/S) pre- and post-exposure with a 5d 
dental plaque biofilm inoculated with P. aeruginosa. 
 
 
 A/S pH 
P. aeruginosa Pre-exposure 
     Post-
exposure 
Pre-
exposure 
     Post-
exposure 
Pre-
exposure 
     Post-
exposure 
1 4.00 5.06 5.00 6.65 6.50 6.76 
2 4.00 5.32 5.00 6.34 6.50 6.54 
3 4.00 5.40 5.00 6.05 6.50 6.44 
Mean 4.00 5.26 5.00 6.35 6.50 6.58 
SD 0.00 0.18 0.00 0.30 0.00 0.16 
SEM 0.00 0.10 0.00 0.17 0.00 0.09 
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5.4 Discussion 	
The overarching aim of the work presented in this chapter was to determine 
the role of selected variables in the oral environment (based on results from 
chapters 2, 3 and 4) that could promote or prevent colonisation of pathogenic 
microorganisms within dental plaque and ETT biofilms. Although frequently 
overlooked in clinical practice, over 60% of bacterial infections have a biofilm 
origin (Coenye & Nelis, 2010; Römling & Balsalobre, 2012) and these biofilm 
communities are often complex and polymicrobial. The transition of 
microorganisms from free-floating (planktonic) cells to biofilm growth and 
subsequent biofilm maturation is, in part, influenced by environmental factors 
(de la Fuente-Núñez et al., 2013). Biofilm growth will be affected by a variety 
of factors including nutrient availability, dynamics of fluid flow rates, pH of 
surrounding fluids, temperature, antimicrobial presence and oxygen levels 
(Peyyala & Ebersole, 2013).  
 
Biofilms were developed on ETT surfaces over 10 d, after which the biofilm 
structure including EPS could be observed by SEM imaging (Figure 5.3). The 
majority of ETTs are composed of polyvinylchloride (PVC) material (Watson, 
1980; Gorman et al., 2001). Triandafillu et al., 2003 investigated the extent of 
P. aeruginosa adhesion to PVC using both reference strains (including PAO1 
AK44) and clinical isolates. There was a wide variation in the level of 
adhesion rates, however all strains of P. aeruginosa adhered upon contact 
with the PVC, with the greatest efficacy in adhesion observed for two clinical 
strains. Furthermore, Gorman et al., 2001 investigated biofilm formation upon 
PVC discs of re-cultured clinical P. aeruginosa isolates (originally obtained 
from ETT biofilms of mechanically ventilated patients). Atomic force 
microscopy revealed adhesion of P. aeruginosa to the PVC discs within 4h, 
and in a 5d period there was an increased formation of EPS and glycocalyx. 
During the current study, P. aeruginosa was the best biofilm former (greatest 
recovered cell number) on the PVC ETT surface (Figure 5.4), and it was not 
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significantly affected by the presence of either S. mutans of C. albicans 
presence in mixed species biofilms (Figure 5.5, B and D). 
 
In addition to single species biofilms, a series of mixed species biofilms were 
developed to assess the role of oral organisms (S. mutans and C. albicans) 
in promoting respiratory pathogen colonisation and biofilm formation within 
the ETT, as previously evident in ETTs from extubated patients (chapter 2, 
figures 2.11-2.15). Pseudomonas aeruginosa was cultured in combination 
with C. albicans (Figure 5.5). Previous literature indicates an synergistic 
relationship between P. aeruginosa and C. albicans in in vitro biofilms, 
whereby the presence of C. albicans hyphae results in the release of 
phenazine by P. aeruginosa, allowing the bacteria to exploit C. albicans 
hyphae as a growth substrate (Harriott & Noverr, 2011). Phenazines are 
important in interactions between microorganisms and are extremely toxic at 
an acidic pH, which could include the microenvironment of dental plaque 
(microbial metabolism and acidic end products) (Gibson et al., 2009). 
Phenazines will inhibit C. albicans respiration pathways via carbon growth 
impairment and lead to increased levels of fermentation products (Morales et 
al. 2013). In such situations, P. aeruginosa induces extensive hyphae 
degradation reducing overall C. albicans colony formation (Douglas, 2003). 
Whilst limiting candidal growth by accumulating within the hyphae, this can 
promote the colonisation of P. aeruginosa, and this was observed during in 
vitro investigations within this study (Figure 5.5, D). In addition, When P. 
aeruginosa was combined with C. albicans for biofilm formation upon the 
ETT surface, although a slight reduction in the numbers of C. albicans 
occurred, there was no significant decrease, and this is perhaps due to a lack 
of hyphae. Although disruption of the biofilm composition may occur, P. 
aeruginosa does not degrade yeast forms of C. albicans (McAlester et al. 
2008), which contributes to Candida’s pathogenesis (Naglik et al. 2011; Méar 
et al. 2013) 
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In vivo interactions are likely to be more complex, largely due to the presence 
of the host immune response. Dectin-1, a C-type lectin receptor expressed 
on epithelial cells and macrophages, is an important pathogen recognition 
molecule in host defence against fungal pathogens, including C. albicans 
(Gantner et al., 2005). The ligand for Dectin-1 is β-glucan, which is highly 
abundant within yeast cells. The magnitude of the immune response is 
dependent on the balance of yeast to hyphal transition, as filamentous C. 
albicans can avoid immune activation via recognition of the Dectin-1 receptor 
on macrophages (Naglik et al., 2011). Nevertheless, this relationship 
between P. aeruginosa and C. albicans may be important when considering 
the possiblity of this pathogen exploiting the presence of oral commensal 
microorganisms in colonisation processes (Avila et al., 2009; Wade, 2013b). 
 
A further key finding of mixed-species biofilm formation upon the ETT surface 
was the ability of S. mutans to enhance attachment and biofilm development 
of S. aureus compared to when cultured alone. Streptococcus mutans forms 
complex glucan-binding proteins, ultimately enabling S. mutans to adhere to 
surfaces, initiating biofilm formation (Lynch et al., 2013). Invertase catalyzes 
the hydrolysis of sucrose into fructose and glucose. At this stage, the 
glycolytic pathway can convert glucose into lactic acid. Additionally, glucose 
can be converted into a polymer known as a glucan, by glucosyltransferase 
(Gtf) enzymes (Loesche, 1996). In vivo, after medical devices (catheters and 
ETTs for example) are inserted, they quickly become coated with protein rich 
fluids, enhancing the attachment and rapid biofilm formation of opportunistic 
pathogens including S. aureus (Otto, 2008). During in vitro investigations 
within this project, S. aureus was cultured in nutrient and protein-rich culture 
media encouraging biofilm formation upon the ETT. The presence of S. 
mutans end products from metabolism may further promote and enhance the 
competitive growth of S. aureus. Lactic acid for example, ultimately produced 
by S. mutans, may stimulate the growth of S. aureus (Kao & Frazier, 1966). 
Recent work by Nair et al, 2014 explains that when exposed to lactic acid, S. 
aureus can deploy defense strategies towards the competing bacteria to 
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thrive in the same ecological niche (in this case, the surface of the ETT). Oral 
organisms including S. mutans promote biofilm formation, and enhance 
pathogenic attachments, and may as a consequence, contribute in the 
translocation of microorganisms towards the lower airways and the 
development of VAP (Perkins et al., 2010; Vandecandelaere & Coenye, 
2015).  
 
Antimicrobial mouthwashes are an important tool in promoting oral hygiene, 
and the effectiveness that these have against microbial species and oral 
biofilms has been extensively studied (Zanatta et al., 2007; Wise et al., 2008; 
Marsh, 2010; Hooper et al., 2011; Malic et al., 2013; Sands et al., 2014). 
Chlorhexidine and Listerine™ are frequently used mouthwashes and are 
effective against most oral microbiota. Chlorhexidine is key in many current 
oral intervention programs in an attempt to control the oral biofilm during MV 
(Jones 1997; Bellissimo-Rodrigues et al. 2009; Scannapieco et al. 2009; 
Klompas et al. 2014; Niazi et al. 2015). Listerine™ however is ineffective at 
both reducing dental plaque (potentially colonised by respiratory pathogens) 
and the incidence of VAP in mechanically ventilated patients (Berry 2013; 
Kollef 2015). Berry et al., 2013 revealed that Listerine™ was no more 
effective than the control group of sterile water in reducing the colonisation of 
dental plaque (n=398). 
 
If bacteria that are not normally able to colonise dental plaque have reduced 
susceptibility to such antimicrobials compared with the existing oral bacteria 
then this selective pressure could facilitate subsequent colonisation of the 
oral biofilm following displacement of susceptible species. To test the 
hypothesis that those species with reduced susceptibility to administered 
antimicrobials would subsequently have an enhanced ability to colonise 
dental plaque biofilms, it was first necessary to establish the MICs of the 
antimicrobials against test organisms and then assess whether exposure of 
biofilms to sub-MIC environments promoted colonisation. 
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Importantly, the MIC of CHX against P. aeruginosa (both planktonic and in 
biofilm formation) was notably higher compared with that for S. aureus, S. 
mutans and C. albicans (Table 5.3). Additionally MICs of CHX against single 
species biofilms were all significantly higher compared to planktonic values 
(Table 5.3). Although an interesting observation, it is worth noting that direct 
comparison of the MIC/MBIC values between planktonic and biofilm culture 
is not strictly fair.  While the numbers of organisms for each test was 
measured initially, it is likely that biofilm growth resulted in fewer cell 
replications.  The antimicrobial activity of CHX was also determined against 
dual-species cultures. Microbial counts (CFU/ml) at sub-MIC CHX (0.0025- 
0.0076% CHX) revealed significant (p=0.03) reduction in oral 
microorganisms (S. mutans and C. albicans) when combined with S. aureus, 
and this was most evident in biofilms (Table 5.4). Once cultured into a biofilm 
and exposed to CHX at the sub-MIC concentration, P. aeruginosa was 
significantly increased when combined with S. mutans compared to levels 
exhibited during mixed species planktonic analysis. 
 
It was also apparent that when cultured with S. mutans, P. aeruginosa 
numbers were enhanced (Table 5.4). In addition, after exposure of S. mutans 
and P. aeruginosa to sub-MIC CHX, S. mutans was not subsequently 
detected by culture. In vitro P. aeruginosa growth is rapid and this could have 
been a key factor in reduced levels of S. mutans (LaBauve & Wargo, 2012). 
Baldan et al. 2014 revealed that within mixed species biofilms, P. aeruginosa 
was able to outcompete other opportunistic pathogens including S. aureus, 
(pathogens associated in cystic fibrosis and respiratory infection). Both 
laboratory reference strains of P. aeruginosa (PA14 and PAO1) and isolates 
from early stage respiratory infection during the study by Baldan et al., 2014, 
successfully outcompeted S. aureus growth. Mucoidal P. aeruginosa from 
late stage infection did not however express the same ability to out compete 
growth of S. aureus. Within this current study, the MIC of CHX against S. 
mutans was lower than that of P. aeruginosa and as a consequence the 
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selective pressure of CHX would have been of greater detriment to S. 
mutans.  
 
Clinical isolates generally exhibited similar MIC ranges compared to the 
reference strains used. Notably, the MICs of CHX were greater at 0.0480% ± 
0.024 for clinical P. aeruginosa biofilms (Table 5.5) (compared to P. 
aeruginosa reference biofilms with an MIC 0.0076%). This relatively higher 
tolerance of P. aeruginosa biofilms to CHX could represent a limitation of 
such oral hygiene interventions in mechanically ventilated patients. Although 
studies have reported outcomes in the reduction in VAP (Munro et al., 2009) 
mortality and bacterial counts using 0.12% CHX (a concentration >2x MIC 
obtained against biofilms of clinical isolates of P. aeruginosa within this 
study), respiratory pathogens are colonising the dental plaque during MV 
(Balamurugan et al., 2012; Kusahara et a., 2012). Scannapieco et al., 2009 
specifically reported a decrease in the numbers of S. aureus following 
decontamination with CHX, but not an overall reduction in the number of 
respiratory pathogens including Gram-negative species such as P. 
aeruginosa and Klebsiella species.  
 
Antibacterial agents at sub-MIC levels may influence and promote biofilm 
formation. An in vitro investigation using S. mutans strain UA159 by Dong et 
al., 2012 found that exposure to sub-MIC levels of chlorhexidine (MIC was 
detected at 2.5mg/L) (amongst other antibacterial agents) resulted in the up 
regulation of biofilm formation genes including gtfB, comD, and comE. Future 
work investigating the expression of biofilm related genes of respiratory 
pathogens isolated from dental plaque of mechanically ventilated patients, 
(and following exposure to sub-MIC concentrations of CHX in vitro), could 
elucidate the extent at which CHX promotes biofilm formation of respiratory 
pathogens.  
 
To further assess the influence of healthy dental plaque microbiota on 
respiratory pathogen integration into biofilms, the CDFF was used to 
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construct dental plaque biofilms >300µm employing pooled dental plaque 
from healthy volunteers (maturity of dental plaque between 12-24 h) (Figures 
5.9 and 5.10). Using the CDFF, mixed species dental plaque biofilms were 
formed over 5 d. Live dead staining revealed a large quantity of cells stained 
with propidium iodide. Although this can be an indication of staining dead 
cellular material via intercalating with DNA, in a biofilm setting this may 
reflect the presence of eDNA within the EPS. Figure 5.10 reveals the extent 
of propidium iodide staining within the dental plaque biofilm. The presence of 
non-specific staining (staining outside the intact cells) may further indicate 
staining of the eDNA within the biofilm formed EPS. Confocal imaging of 5 d 
biofilms revealed a large proportion of C. albicans were in hyphal formation. 
Interestingly, C. albicans was not viable from dental plaque culture before 
supplementation into BM medium containing 1% glucose (Hill et al., 2010). 
Glucose is a source of energy for C. albicans proliferation and may further 
promote exaggerated colonisation triggering such morphological changes to 
hyphal form, usually observed as a virulence factor in invasive candidiasis 
(Brown et al. 2006; Vylkova et al., 2011). Candida albicans may be 
influenced to undergo morphogenesis by variation in extracellular pH 
although morphogenesis tends to occur at a greater rate with higher alkaline 
pH as opposed to acidic, C. albicans is tolerant to pH variation (Nadeem et 
al., 2013). 
 
Established CDFF biofilms were inoculated with S. aureus and/or P. 
aeruginosa and treated with CHX (routinely administered as part of oral 
hygiene protocols during MV, to mirror clinical administration). The main aim 
of this work was to assess whether chlorhexidine, currently applied during 
MV as part of an oral intervention strategy, can promote further respiratory 
colonisation within the mixed species oral biofilm. Using the CDFF to 
generate biofilms was performed to confirm the results generated through the 
96 well plate biofilm model and the MIC investigations (Tables 5.3 and 5.4). 
Chlorhexidine absorbs to the mucosal surface and the enamel pellicle via 
salivary proteins, with limited absorption upon formed dental plaque (Jones 
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1997). The concentration of active CHX may vary according to the amount of 
CHX being adsorbed upon the various surfaces within the oral cavity and this 
may have differential lasting antimicrobial activity, especially upon microbial 
biofilms. After a 12 h exposure period to CHX in suspension (as opposed to 
coated onto a surface) to mirror the clinical application in the oral cavity, S. 
aureus was not detected within the oral biofilm via microbial culture (Figure 
5.13), however P. aeruginosa was detected amongst oral microorganisms 
after the same exposure periods to CHX (Figure 5.14). Gram-positive 
bacteria, such as S. aureus are perhaps exhibiting increased sensitivity to 
chlorhexidine due to the structure of the cell wall (Toté et al., 2010). 
 
Dental plaque inoculated with respiratory pathogens was also subjected to 
variations of artificial saliva pH, to mirror the altered salivary pH evident in 
mechanically ventilated patients (whereby >25% of mechanically ventilated 
patients exhibited a decrease in salivary pH, and were also colonised with 
respiratory pathogens within their dental plaque during MV, Chapter 4, 4.3.3). 
The pH of saliva will directly modulate dental plaque pH (Marsh, 2006). An 
increase in the number and activity of acidophilic/acidogenic bacteria such as 
S. mutans in dental plaque may conversely lead to a reduction in the pH of 
saliva (Cvitkovitch, 2010). Changes in salivary flow and/or salivary pH will 
inevitably add ecological pressure to the dental plaque community resulting 
in changes in the overall composition. This phenomenon is referred to as the 
ecological plaque hypothesis, a term coined by Philip Marsh (Marsh, 1994). 
A relevant example is dental caries whereby an increased exposure to 
dietary sugars resulted in a caries-low pH, modulating the plaque over time 
eventually leading to aciduric organisms such as S mutans and lactobacilli 
species dominating the plaque community (Takahashi, 2005; Marsh, 2006).  
 
In CDFF dental plaque biofilms, the pH of the A/S medium changed 
significantly after exposure to respiratory pathogens. From a starting salivary 
pH of 4 or 5, noticeable increases were observed post exposure to the CDFF 
dental plaque biofilm (Table 5.9). Biofilms, of mixed species, may both adapt 
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to the pH of saliva by entering a stationary growth phase if necessary, as 
fluctuations in the pH can have biocidal effects (Garrett et al., 2008). 
Pseudomonas aeruginosa was detected from an artificial saliva (A/S) pH of 
6.5, however absent from an A/S of pH 4 and 5 respectively. If P. aeruginosa 
can exploit the dental plaque in the early stages of MV, and integrate in the 
biofilm, P. aeruginosa cells may be protected within the EPS against 
changes in internal and external pH levels.  
 
At an A/S pH of 5, S. aureus was detected at a relatively lower abundance 
compared to normal oral microbiota, and P. aeruginosa was absent by 
culture. This is not surprising as S. aureus is known to be more tolerant than 
P. aeruginosa at pH 5 environments (Korting et al., 1992). Under these acidic 
conditions S. aureus would theoretically be better suited to colonising dental 
plaque biofilms, whilst P. aeruginosa would prefer a higher pH of 6-7.5 
(Charyulu & Gnanamani, 2010). 
 
In situations where saliva is not able to perform its buffering functions 
optimally, for example when saliva flow and pH decreases (as seen during 
MV, chapter 4; mirrored in challenge experiments 5.2.5) the pH of the dental 
plaque will decrease concurrently due to selective pressure from variations in 
the pH shifting the microbial community of dental plaque. Acid tolerant 
organisms including S. mutans, Lactobacillus species and late anaerobic 
colonisers will predominate within dental plaque. Acid-sensitive organisms 
may be competitively outcompeted, enhancing the ability of opportunistic 
respiratory pathogens (for example S. aureus) to survive and thrive within 
dental plaque. 
 
Conclusion 
Single and mixed species biofilm models were developed to examine the 
interactions between selected organisms, chlorhexidine and salivary pH. The 
ETT biofilm model of mixed-species colonisation revealed that oral 
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organisms including S. mutans enhance the colonisation of S. aureus, an 
important pathogen in the aetiology of VAP. 
 
The application of CHX may be effective against oral biofilms in critically ill 
patients, reducing the overall bio-load in the oral cavity however this may not 
reduce all respiratory pathogens to the same extent. Pseudomonas 
aeruginosa exhibited the largest MIC towards chlorhexidine, especially once 
in biofilm formation and a total of 25 mechanically ventilated patients became 
colonised with P. aeruginosa during MV (2.3.3). Chlorhexidine applications 
may therefore alter both the abundance and composition of dental plaque, 
potentially allowing more respiratory pathogens to thrive and out-compete 
residual oral biofilm members and free-floating microorganisms within the 
oral cavity.  
 
In addition, decreases in salivary pH significantly influenced the ability of 
respiratory pathogen colonisation and integration within dental plaque. 
Staphylococcus aureus was detected at a pH of 5 and 6.5, whereas P. 
aeruginosa was only detected via microbial culture within a salivary pH of 6. 
5.  
 
Using in vitro investigations, this experimental chapter highlights the potential 
limitations faced by current oral care practices within this patient population, 
whilst also emphasising the possible role of commensal oral microorganisms 
in promoting and enhancing respiratory pathogen colonisation and 
pathogenic biofilm formation within the dental plaque and the ETT biofilms. 
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6. General Discussion 	
VAP, a pneumonia occurring more than 48h after the initiation of mechanical 
ventilation, is the most frequently occurring hospital-acquired infection of 
patients who are in receipt of critical care (Joseph et al., 2010). It has a 
global prevalence estimated at 15% (Kollef, 2015) and a mortality rate 
between 20 and 70% (Joseph et al., 2010), although Kollef has suggested 
attributable mortality is likely to be towards the lower estimate (Kollef, 2015). 
A meta-analysis analysing individual patient data from 6284 patients from 24 
different trials further revealed the attributable mortality rate of VAP at ~13% 
(Melsen et al., 2013). The prognosis of VAP is adversely influenced when the 
there is involvement of multidrug resistant biofilms (Raad et al., 2011; Grap 
et al., 2012; Seguin et al., 2014; Branch-Elliman et al., 2015).  
 
Since the oral cavity is anatomically linked directly to the lower airways, 
associations between the oral microbial community and respiratory infection 
seem plausible. In the case of VAP, it has been suggested that commensal 
oral microorganisms can facilitate the colonisation of dental plaque and the 
lumens of endotracheal biofilms by respiratory pathogens (Doré et al., 1996; 
Bahrani-Mougeot et al., 2007). A study by Zuanzazzi et al., 2010, examined 
the colonisation of dental plaque and saliva by respiratory pathogens, pre 
and post surgery of 30 hospitalised patients (not all patients were ventilated). 
Zuanzazzi et al., 2010 documented colonisation by P. aeruginosa and 
Acinetobacter species in 25% and 60 % of dental plaque samples, 
respectively.  
 
One of the aims of this research was to establish the factors involved in 
dental plaque colonisation by respiratory pathogens in mechanically 
ventilated critically ill patients. Initial experiments sought to analyse the 
extent of colonisation in mechanically ventilated patients using culture 
independent methods. Additionally, the persistence of respiratory pathogens 
in dental plaque for up to 3-months after cessation of mechanical ventilation 
was examined and this had never been investigated before. Persistence of 
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respiratory pathogens into the period of patient recovery may also be 
indicative of higher risk of future respiratory infection by acting as a future 
reservoir of infection.  
Most previous studies have studied mechanically ventilated patients for only 
a short period following liberation from the ventilator. Scannapieco et al., 
2009 measured the effect of chlorhexidine (CHX) on oral bacterial pathogens 
in mechanically ventilated patients. Using selective microbial culture, this 
comprehensive study simultaneously assessed the colonisation of the dental 
plaque by certain respiratory pathogens. Dental plaque was sampled every 
48 h up to a period of two weeks, however there was no additional analysis 
following extubation. Although Scannapieco et al., 2009 did not publish 
dental plaque colonisation of respiratory pathogens at multiple time points 
during MV, they found dental plaque colonisation by S. aureus, P. 
aeruginosa, Acinetobcater species and Enterobacteriaceae.  
 
Should dental plaque provide a reservoir of potential VAP pathogens, then it 
is desirable to understand the dynamics of the oral microbiome during MV 
and how this relates to contamination of both the endotracheal tube and lung 
parenchyma. Based on the results of microbial culture, the composition of 
dental plaque altered in one third of mechanically ventilated patients with 
inclusion of at least one respiratory pathogen (S. aureus and/or P. 
aeruginosa). Importantly, these bacterial species are considered to be the 
causative bacteria in up to 50% of VAP cases and frequently exhibit 
multidrug resistant genes, potentially limiting the efficacy of antibiotic 
treatment (Hunter, 2006; Parker et al., 2008; Bouza et al., 2012).  
 
For the first time, this research has comprehensively analysed dental plaque 
microbiota of mechanically ventilated patients using high throughput 
sequencing. High-throughput sequencing generates a large amount of high 
quality and accessible data. Using this approach, over 100 microbial species, 
representing 40 bacterial genera were identified in dental plaque microbial 
communities during MV, highlighting high species richness and diversity. 
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Wang et al., 2013 performed metagenomic sequencing on dental plaque of 
16 individuals (7 healthy and 9 patients with chronic periodontitis), identifying 
over 30 different genera. Wang et al., 2013 revealed large differences 
occurring in the composition of dental plaque between healthy control 
subjects and patients with chronic periodontitis. Bacteriodes was the most 
abundant phylum in all samples of periodontitis, whereas Actinobacteria and 
Proteobacteria were significantly increased in the healthy control plaque. At 
the genera level, Prevotella was most dominant in periodontitis plaque, (up to 
45% of total bacterial communities), whereas, interestingly, not one genera 
was deemed most dominant in healthy dental plaque. Several different 
genera, including streptococci were present at similar levels. Comparably, 
during the current study, a substantial microbial change in the composition of 
dental plaque was evident during the course of MV and was noted by the 
detection of several potential respiratory pathogens, including 
Staphylococcus aureus, Streptococcus pseudopneumoniae and Escherichia 
coli.  
 
Opportunistic pathogens in dental plaque contribute to the pathogenesis of 
both oral and systemic infections. Although not generally considered a 
permanent member of healthy dental plaque, S. aureus has been isolated 
from many areas of the oral cavity and nasal regions. Ohara-Nemoto et al., 
2008 analysed the saliva, dental plaque and nasal cavity of 56 healthy 
adults; Staphylococcus aureus was the species most frequently isolated from 
saliva (50%, n=26). Interestingly during their study, S. aureus was isolated in 
over one-third of individuals’ dental plaque (=n19). Whilst studies have 
shown the prevalence of S. aureus colonisation in the oral cavity of healthy 
individuals, there is little evidence in the literature to suggest Streptococcus 
pseudopneumoniae colonisation. Streptococcus pseudopneumoniae, a 
relatively new species genetically and morphologically different from 
Streptococcus pneumoniae was originally isolated from a lower respiratory 
tract infection. Although implicated in respiratory infections, the clinical 
importance of S. pseudopneumoniae is still to be fully determined (Keith et 
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al., 2006). Escherichia coli, another pathogen isolated within dental plaque 
during MV, is a commensal coloniser of the human large intestine and a 
frequent pathogen of urinary tract infections (Katouli, 2010). Previous studies 
have however reported the isolation of E. coli from saliva and oral tissues in 
hospitalised (non-ventilated) patients (Ewan et al., 2015), but currently there 
is little evidence for colonisation within dental plaque.  
Interestingly, after ETT-extubation, both the prevalence and abundance of 
respiratory pathogens decreased. For the majority of patients, a loss of the 
colonising respiratory pathogen occurred and this was most apparent with S. 
aureus. However, for some patients, persistence of the targeted respiratory 
pathogens in dental plaque occurred highlighting that plaque remained a 
reservoir for potential recurrent infection. Pseudomonas aeruginosa was 
more persistent than S. aureus in dental plaque post ETT extubation. 
Nevertheless, whilst dental plaque provides a source of infectious bacteria 
during intubation, it would generally appear that its microbial composition 
quickly reverts back to one usually associated with health. These findings are 
important as they strongly indicate that dynamic changes to dental plaque 
composition occur in response to critical illness and treatment As such, 
identifying the factors involved in driving these microbial changes could 
facilitate the development of preventative and management   strategies or 
serve as prognostic and diagnostic markers.  
The ETT provides an essential interface between the lower airways of the 
patient and the ventilator. However, it also provides a conduit for microbial 
movement from the oral cavity to the lower airways (Cairns et al., 2011). This 
process typically would involve microbial aspiration from the oral cavity to the 
inflated retention cuff of the ETT. In the majority of ETTs, the thin 
polyurethane cuff material will contain folds, which form during inflation as 
the fully inflated cuff is larger than the tracheal diameter. This is because 
tracheal diameters vary between individuals and ETT cuffs have to be of a 
size to accommodate the tracheal size ranges. The microchannels that 
develop in a cuff provide pathways for microbial leakage. The effect also 
arises when a loss of cuff pressure occurs. Once below the cuff, subglottic 
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secretions can either enter the lungs or be drawn into the ETT lumen, which 
leads to biofilm formation. 
Microbial culture, characterisation of the ETT biofilm microbiome and use of 
species-specific PNA probes (in situ hybridisation) coupled with confocal 
microscopy revealed that ETT biofilms of 47 mechanically ventilated patients, 
were colonised with members of the oral microbiota including S. mutans and 
strictly anaerobic species including P. gingivalis. Members of the oral 
microbiota colonising within the ETT may therefore contribute to the 
pathogenesis of VAP by acting as a reservoir for respiratory pathogens or 
indirectly by increasing pathogenic biofilm development in the ETT (Gil-
Perotin et al., 2012). 
In this study, the ETT biofilm from 21 patients was culture positive for 
respiratory pathogens. Within these 21 patients, dental plaque was colonised 
by respiratory pathogens (either S. aureus and/or P. aeruginosa) during MV 
in 18. It has been suggested that as ETT biofilms accumulate, there may be 
an increase in resistance to gas flow through the ETT and the biofilm can 
become displaced to the lower airways, increasing the risk of respiratory 
infection (Coppadoro et al., 2013). Aggregates of respiratory pathogens 
including S. aureus and P. aeruginosa identified (2.3.12) were indeed evident 
in ETT biofilms from patients using fluorescence in situ hybridisation and 
species-specific PNA probes. The fact that biofilm aggregates would be 
transferred to the lower airway might mean that the bacteria present would 
immediately be in an already resistant state to host defences and 
administered antimicrobials. Use of in vitro ETT biofilm model (5.3.2) further 
revealed that S. mutans significantly increased colonisation and biofilm 
formation by S. aureus. By-products of S. mutans metabolism, including 
lactic acid, may be influencing S. aureus growth, to outcompete the biofilm 
formation of S. mutans on the surface of the ETT (5.4).  
Having established that microbiological composition changes occurred in the 
dental plaque of patients receiving MV and also after extubation, establishing 
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the underlying reasons for this is important. If the mechanistic basis for the 
acquisition of respiratory pathogens in dental plaque could be determined, 
then preventative approaches could be developed. Many factors could 
potentially serve as drivers for changes in the oral microbiome in 
mechanically ventilated patients, including underlying illness and effects of 
treatment. However, the research undertaken was primarily based on the 
hypothesis that changes in saliva would instigate alterations in the dental 
plaque community. To this end, the salivary factors assessed were flow, pH 
and proteomic composition on a longitudinal basis during MV. This is the first 
time that such an investigation has been undertaken.  
It has been shown that mechanically ventilated patients develop dryness in 
the mouth (xerostomia) (Munro & Grap, 2004; Berry & Davidson, 2006; 
Prendergast et al., 2013). Xerostomia may arise in mechanically ventilated 
patients simply by the mouth being partially held open by the presence of the 
ETT. Administered medications, including diuretics (often prescribed to 
critically ill patients), and an absence of mechanical and chemical oral 
stimulation may also reduce the quantity of saliva produced. A reduced 
salivary flow rate during intubation was evident, with 52 out of 107 
mechanically ventilated patients showing a reduction in saliva volume during 
MV (4.3.2). 
A reduced salivary volume will promote plaque accumulation since there 
would be an associated reduction in the physical removal of plaque 
organisms by the flushing action of saliva, and a concurrent lowering of host 
antimicrobial components (Devine, 2003; Gorr & Abdolhosseini, 2011). 
Neither salivary flow nor salivary composition is typically measured during 
hospital stay. Although salivary flow rates vary significantly with age, gender 
and diet and flow rates range between 0.1-2 ml/min (Fenoll-Palomares et al., 
2004), salivary reduction will inevitably influence dental plaque composition. 
Patients suffering with xerostomia, common in elderly individuals, may 
therefore develop dental oral dysbiosis leading to oral diseases including 
caries. A reduction in saliva (including a reduction in salivary antimicrobial 
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proteins and pH buffering systems) will inevitably lead to gradual dental 
plaque changes, specifically to caries associated microorganisms, able to 
tolerate an acidic environment (Turner et al., 2007; Su et al., 2011). 
Additionally, individuals with xerostomia often see increases in Candida 
colonisation within the oral cavity (Shinozaki et al., 2012). 
A reduced salivary pH was also apparent during mechanical ventilation and 
this was most evident when microbial changes in plaque were detected 
(Figure 4.3). The reasons for this change are unclear, however, it is possible 
that a more acidic oral environment promotes respiratory pathogen 
colonisation. Marsh (Marsh, 1994) has described a mechanistic basis with 
relevant examples of dental caries and periodontal disease as to how 
changes in dental plaque and saliva pH may affect the composition of dental 
plaque (4.4). By in vitro modeling studies, this current research has 
demonstrated that S. aureus is more acid-tolerant (pH 5) than P. aeruginosa. 
This was evident from dental plaque challenge experiments using the CDFF, 
in which the growth of S. aureus was not inhibited at a pH of 5  (5.3.6.2). 
Respiratory pathogens may be better suited to an acidic environment and 
able to exploit this environment out competing other members of the 
community. Alternatively, it is possible that a reduction in saliva secretion will 
lead to a reduction in bicarbonate (primary pH buffer of saliva) (Hicks et al., 
2003) resulting in a decreased ability to maintain salivary pH. Prasanthi et al., 
2014 reported a correlation between reductions in stimulated saliva 
secretion, and reductions in buffering capacity and pH as a result of diuretic 
medications. In turn, a reduction in both salivary volume and pH could also 
promote increased colonisation by respiratory pathogens. 
 
Proteomic analysis of saliva revealed changes in salivary proteins both 
during MV and into the post-ETT extubation period (Table 4.8). Particularly 
evident was the increased concentration of a spectrum of antimicrobial 
peptides including lysozyme, lactoperoxidase and cystatin in the post-ETT 
extubation period, compared with levels found during MV (Table 4.8). 
Several bacterial groups, predominantly Gram negative bacilli, that enter the 
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oral cavity after the early plaque colonisers can exploit these bacteria to 
adhere to the tooth surface indirectly (Perkins et al., 2010). Dental plaque 
colonisation of respiratory pathogens during MV may provoke a localised 
immune response. Proteomic and cytokine analysis during MV appeared to 
support this, significant increases in salivary levels of pro-inflammatory 
cytokines, including IL-8 and IL-1β occurred compared to healthy volunteers. 
Interestingly, levels of these cytokines reduced post extubation to levels 
similar to those of the healthy volunteers.  	
In vitro models of dental plaque and ETT biofilms were developed and used 
to assess the effect of an antimicrobial on respiratory pathogen colonisation 
of biofilms. Oral antiseptics, such as chlorhexidine have been used in general 
dentistry and critical care since the 1970s (Jones, 1997). Over the years 
there have been several studies assessing the effects of chlorhexidine in 
reducing VAP incidence and mortality (O’Reilly, 2003; Grap et al., 2011; 
Balamurugan et al., 2012). The CDFF modeling system was used to create 
robust dental plaque biofilms. Biofilm analysis revealed that the minimum 
biofilm inhibitory concentration was considerably higher, up to 1000-fold, than 
planktonic cell susceptibility (Malic et al., 2013; Smith et al., 2013). Following 
in vitro dental plaque biofilm inoculation with S. aureus and exposure to 
chlorhexidine for 12 h, growth of S. aureus was successfully inhibited. In 
contrast, a significant increase in numbers of P. aeruginosa was evident 
following a similar challenge with chlorhexidine, and only the highest 
chlorhexidine concentration tested was shown to inhibit the growth of this 
species.  
 
Further studies 
Based on this research, a number of areas have been identified for future 
work. Given that a number of salivary changes were found to occur during 
MV and in patients with microbial alteration in their dental plaque, it would be 
beneficial to assess specific salivary proteins for use as biomarkers to 
identify patients at higher risk of VAP, VAP prognosis and to assess 
effectiveness of interventions. Diagnostic biomarkers within saliva are an 
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emerging area of proteomic research (Thomadaki et al., 2011). Studies have 
investigated fluid collected from the lower airways of mechanically ventilated 
patients for proteomic content and potential biomarkers to aid the diagnosis 
of VAP (Wu et al., 2003). Antibacterial proteins including neutrophil 
proteases were expressed at significantly higher concentrations in those 
patients diagnosed with VAP (Lu et al. 2008; Wilkinson et al. 2012). 
Investigating the proteomic composition of saliva during MV has highlighted 
certain protein profiles, with elevated levels of antibody peptides and highly 
expressed antimicrobial peptides into the recovery period, warranting further 
clinical investigations. 
 
Reductions in both salivary flow and salivary pH were evident during MV. 
Investigating therapeutic interventions involving salivary supplementation 
with antimicrobial peptides or the use of artificial saliva could be beneficial in 
reducing respiratory pathogen colonisation of dental plaque. 
 
Further areas for investigation are as follows: 
- Biomarkers that can predict VAP. Table 4.5 has provided a short list of 
proteins to focus on in future clinical investigations.  
- Clinical water testing to ascertain the aetiology and origins of P. 
aeruginosa colonisation. 
- Routine nasal swabbing for the detection of S. aureus in mechanically 
ventilated patients. In addition, in those patients with nasal S. aureus 
colonisation bacterial strain typing could be performed to match 
isolates recovered from dental plaque.  
- Further biofilm modeling with the CDFF could use human saliva, 
adding the benefit of the complex proteomic composition. Larger 
quantities would be collected to allow for repeat experiments and 
generation of data capable of statistical analysis.  
- Future work to enhance the biofilm CDFF model to allow viability of 
anaerobes and therefore creating PNA probes allowing multiplex 
images could further track certain species within the biofilm. 
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- Bacterial strain typing and further genomic analysis of biofilm-related 
genes would elaborate on whether patients’ who remain colonised in 
the post-ETT extubation period harbor the same strain.  
- Developing a co-culture model to look at antibacterial and anti-
inflammatory/proinflammatory response at same time. Can you mimic 
the recorded microbial shift that occurs during mechanical ventilation 
to detect biomarkers to predict the onset of VAP? 
 
Research Summary 
Dental plaque of mechanically ventilated patients was shown to become 
colonised by a range of potential respiratory pathogens. Also during 
ventilation changes were observed in saliva volume, pH and concentration. 
These changes were accompanied by an increase in salivary pro-
inflammatory cytokines. Following extubation, dental plaque colonisation by 
respiratory pathogens was not detected (for most patients) and levels of 
salivary cytokines were seen to be reduced to levels similar to those of 
healthy volunteers. Whilst the patient is mechanically ventilated, dental 
plaque does serve as a reservoir for respiratory pathogens. There were 
several salivary parameters, including reduced salivary flow, pH and the 
salivary proteome, that changed, and were associated with the presence of 
these respiratory pathogens in dental plaque.  
 
VAP remains an important hospital acquired infection in critically ill patients 
(Kollef, 2015) and is associated with increased mortality, duration of stay and 
cost (Bahrani-Mougeot et al., 2007; Sundar et al., 2012). Performing 
longitudinal microbial culture coupled with high-throughput sequencing of the 
dental plaque microbiome revealed extensive changes occurring during MV. 
In over one-third of mechanically ventilated patients reductions in salivary 
volume and/or pH were also evident. Approaches that maintain adequate 
salivary flow and at a suitable pH for example the administration of artificial 
saliva, could prove inhibitory to respiratory pathogens colonising dental 
plaque and consequently could limit the translocation of pathogenic 
	 289 
microorganisms to the lower airways. In addition, the observed changes in 
salivary cytokines explored through high-throughput proteomic analysis might 
be of future value as diagnostic markers that reflect either the inflammatory 
responses of the lower airway, or accumulation of respiratory pathogens in 
the plaque. Such an approach would be highly beneficial as it would be a 
non-invasive tool for VAP diagnosis, and this is a feature lacking with most 
other approaches. 
Key findings include: 
• This is the largest study of oral microbial changes during MV and 
recovery from critical illness. During MV, dental plaque was shown to 
become heavily colonised with respiratory pathogens, including Gram-
positive and Gram-negative species such as S. aureus, P. aeruginosa, 
E. coli and S. pseudopneumoniae. 
• Analyses revealed that 70% and 55% of mechanically ventilated 
patients that demonstrated colonization of dental plaque with S. 
aureus and P. aeruginosa, respectively, were shown to have “lost” 
these species post-extubation. 
• For the first time, the dental plaque microbial community of 
mechanically ventilated patients has been comprehensively analysed 
using high throughput sequencing.  
• The full diversity of dental plaque during MV was demonstrated with 
40 genera, and over 100 identified species with 8 species of potential 
respiratory pathogens detected.  
• Decreases (a trend) in salivary volume were evident in over a third of 
mechanically ventilated patients. Reduced salivary pH was also 
observed, and was especially significant in patients where respiratory 
pathogens occurred in dental plaque during MV. 
• The salivary proteomic concentration and composition differed during 
MV compared with that at commencement of MV. Significant 
increases in pro-inflammatory cytokines IL-6, IL-1β and IL-8 were also 
evident during MV in comparison to healthy volunteers. Post ETT-
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extubation these levels reduced to those observed in healthy 
volunteers. 
• In vitro biofilm model systems were successfully developed to allow 
the modeling of the changes in vivo and study the effects of bacterial 
challenges and antimicrobial interventions. 
• The presence of Streptococcus mutans increased the numbers of S. 
aureus within in vitro ETT biofilms models.  
• In vitro dental plaque biofilms inoculated with respiratory pathogens 
(S. aureus and/or P. aeruginosa), exhibited significant changes when 
challenged at different pH. Staphylococcus aureus remained viable at 
a pH of 5, whilst P. aeruginosa was only viable at a higher salivary pH 
of 6.5.  
• Chlorhexidine challenge of in vitro oral biofilms inoculated with 
respiratory pathogens had differential effects on respiratory 
pathogens. Whilst able to limit the numbers of S. aureus within the 
oral biofilm, chlorhexidine was not effective at inhibiting P. aeruginosa.  
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Appendix I 
Clinical study additional information and data 
 
 
 
 
 
- NHS ethics letter 
- Critical care oral assessment plan 
- Individual DMFT scores  
- Individual patient demographics 
- Individual patient target/selective microbial culture results 
- Pseudomonas aeruginosa isolate PCR amplicons 
- Staphylococcus aureus isolate PCR amplicons 
- Pseudomonas aeruginosa isolate sensitivities 
- Staphylococcus aureus isolate sensitivities 
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NHS ethics letter: 
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Critical Care Oral plan: 
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Individual DMFT scores: 
 
DMFT	score	
	 	 	 	 	 	 	Age	 PN	 DMFT	complete	 D	 M	 F	 Total	
	 	 	 	 	 	 	51	 1	 ✓ 0	 3	 5	 8	
33	 2	 ✓ 0	 4	 0	 4	
31	 3	 ✓ 1	 1	 7	 9	
55	 4	 ✓ 3	 12	 4	 19	
62	 5	 ✓ 1	 6	 14	 21	
34	 6	 ✓ 0	 0	 0	 0	
54	 7	 ✓ 1	 6	 4	 11	
63	 8	 ✓ 0	 9	 3	 12	
77	 9	 ✓ 9	 13	 1	 23	
30	 10	 ✗	
	 	 	 	73	 11	 ✓ 1	 9	 6	 16	
68	 12	 ✓ 2	 5	 6	 13	
50	 13	 ✓ 0	 5	 9	 14	
44	 14	 ✓ 0	 0	 11	 11	
49	 15	 ✓ 2	 5	 4	 11	
28	 16	 ✓ 0	 4	 0	 4	
51	 17	 ✓ 1	 18	 4	 23	
39	 18	 ✗	
	 	 	 	69	 19	 ✓ 1	 11	 10	 22	
29	 20	 ✓ 0	 2	 1	 3	
18	 21	 ✓ 0	 0	 0	 0	
72	 22	 ✓ 0	 1	 11	 12	
19	 23	 ✓ 1	 0	 4	 5	
40	 24	 ✓ 0	 4	 10	 14	
27	 25	 ✓ 0	 2	 2	 4	
63	 26	 ✗	
	 	 	 	41	 27	 ✓ 0	 3	 2	 5	
55	 28	 ✓ 1	 9	 5	 15	
76	 29	 ✓ 1	 9	 5	 15	
58	 30	 ✓ 0	 14	 5	 19	
31	 31	 ✗	
	 	 	 	67	 32	 ✓ 0	 5	 6	 11	
85	 33	 ✓ 2	 14	 1	 17	
57	 34	 ✓ 1	 7	 10	 18	
58	 35	 ✓ 9	 8	 2	 19	
60	 36	 ✗	
	 	 	 	37	 37	 ✓ 3	 5	 7	 15	
37	 38	 ✓ 0	 0	 0	 0	
86	 39	 ✓ 0	 14	 3	 17	
60	 40	 ✓ 0	 18	 3	 21	
58	 41	 ✓ 0	 21	 5	 26	
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74	 42	 ✓ 0	 8	 7	 15	
59	 43	 ✓ 3	 1	 2	 6	
22	 45	 ✗	
	 	 	 	48	 46	 ✓ 0	 2	 10	 12	
53	 47	 ✓ 0	 9	 3	 12	
57	 48	 ✓ 3	 1	 3	 7	
75	 49	 ✓ 0	 1	 15	 16	
39	 50	 ✓ 3	 2	 6	 11	
73	 51	 ✓ 0	 2	 6	 8	
65	 52	 ✓ 2	 10	 4	 16	
66	 53	 ✓ 0	 6	 5	 11	
66	 54	 ✓ 0	 3	 10	 13	
60	 55	 ✓ 0	 0	 8	 8	
49	 56	 ✓ 2	 8	 7	 17	
53	 57	 ✓ 0	 6	 5	 11	
38	 58	 ✓ 0	 0	 6	 6	
86	 59	 ✓ 8	 10	 10	 28	
39	 60	 ✓ 0	 1	 8	 9	
36	 61	 ✓ 0	 7	 7	 14	
21	 62	 ✓ 0	 0	 1	 1	
58	 63	 ✗	
	 	 	 	44	 64	 ✓ 4	 19	 0	 23	
42	 65	 ✓ 3	 2	 8	 13	
73	 66	 ✓ 0	 0	 0	 0	
68	 67	 ✓ 1	 14	 4	 19	
52	 68	 ✓ 0	 0	 8	 8	
82	 69	 ✓ 0	 9	 11	 20	
18	 70	 ✓ 0	 0	 2	 2	
26	 71	 ✓ 0	 5	 2	 7	
67	 72	 ✓ 0	 7	 3	 10	
59	 73	 ✓ 0	 14	 5	 19	
51	 74	 ✓ 1	 12	 4	 17	
75	 75	 ✓ 0	 12	 8	 20	
49	 76	 ✓ 1	 5	 10	 16	
70	 77	 ✓ 3	 13	 2	 18	
75	 78	 ✓ 7	 11	 6	 24	
51	 79	 ✗	
	 	 	 	71	 80	 ✓ 2	 2	 2	 6	
74	 81	 ✓ 1	 12	 5	 18	
45	 82	 ✓ 0	 1	 0	 1	
47	 83	 ✓ 1	 0	 0	 1	
58	 84	 ✓ 0	 5	 12	 17	
75	 85	 ✓ 0	 1	 13	 14	
74	 86	 ✓ 1	 3	 1	 5	
80	 87	 ✓ 0	 4	 7	 11	
40	 88	 ✓ 19	 0	 3	 22	
38	 89	 ✓ 9	 4	 2	 15	
	 334 
66	 90	 ✓ 4	 9	 4	 17	
55	 92	 ✓ 2	 4	 7	 13	
42	 93	 ✓ 1	 2	 4	 7	
60	 94	 ✓ 3	 5	 5	 13	
41	 95	 ✓ 1	 0	 8	 9	
27	 96	 ✓ 0	 1	 0	 1	
77	 97	 ✓ 0	 5	 17	 22	
58	 99	 ✓ 0	 4	 5	 9	
26	 100	 ✓ 2	 0	 4	 6	
29	 101	 ✓ 12	 8	 5	 25	
30	 102	 ✓ 0	 3	 5	 8	
80	 103	 ✗	
	 	 	 	56	 104	 ✓ 0	 10	 8	 18	
67	 105	 ✓ 0	 8	 6	 14	
60	 106	 ✓ 1	 6	 12	 19	
47	 107	 ✓ 0	 2	 10	 12	
74	 108	 ✗	
	 	 	 	38	 109	 ✓ 0	 1	 6	 7	
60	 110	 ✗	
	 	 	 	
	
		 Total	DMFT	 D	 M	 F	
DMFT	
Score	
	
Average	 96	 1.46	 5.70	 5.39	 12.54	
	 	 	 	 	 	 	
	 	 	 	 	 	 	Key:	
	 	 	 	 	 	DMF	 Group	
	 	 	 	 	0-5	 1	
	 	 	 	 		6-10	 2	
	 	 	 	 		11-15	 3	
	 	 	 	 		16-20	 4	
	 	 	 	 		21-25	 5	
	 	 	 	 		25+	 6	
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Recruited patients Patient NO. Gender Age Admission details (reason for MV) DFMT 
1 PN001 M 51 Respiratory failure 8 
2 PN002 M 33 Stroke/brain injury/seizures 4 
3 PN003 M 31 Overdose/suicide attempt 9 
4 PN004 F 55 Stroke/brain injury/seizures 19 
5 PN005 M 62 Stroke/brain injury/seizures 21 
6 PN006 F 34 Respiratory failure 0 
7 PN007 F 54 Stroke/brain injury/seizures 11 
8 PN008 M 63 Respiratory failure 12 
9 PN009 F 77 Other 23 
10 PN010 F 30 Stroke/brain injury/seizures  -  
11 PN011 F 73 Respiratory failure 16 
12 PN012 M 68 Respiratory failure 13 
13 PN013 F 50 Stroke/brain injury/seizures 14 
14 PN014 M 44 Respiratory failure 11 
15 PN015 F 49 Stroke/brain injury/seizures 11 
16 PN016 M 28 Other 4 
17 PN017 F 51 OOHCA 23 
18 PN018 M 39 Overdose/suicide attempt  -  
19 PN019 M 69 Poly-trauma  22 
20 PN020 F 29 Poly-trauma  3 
21 PN021 F 18 Stroke/brain injury/seizures 0 
22 PN022 M 72 OOHCA 12 
23 PN023 M 19 Stroke/brain injury/seizures 5 
24 PN024 M 40 Stroke/brain injury/seizures 14 
25 PN025 F 27 Stroke/brain injury/seizures 4 
26 PN026 F 63 General surgery - Stomach  -  
27 PN027 M 41 Stroke/brain injury/seizures 5 
28 PN028 F 55 Respiratory failure 15 
29 PN029 M 76 Respiratory failure 15 
30 PN030 F 58 Stroke/brain injury/seizures 19 
31 PN031 F 31 Other  -  
32 PN032 M 67 Stroke/brain injury/seizures 11 
33 PN033 F 85 Respiratory failure 17 
34 PN034 M 57 Other 18 
35 PN035 M 58 OOHCA 19 
36 PN036 M 60 OOHCA  -  
37 PN037 M 37 Stroke/brain injury/seizures 15 
38 PN038 M 37 Stroke/brain injury/seizures 0 
39 PN039 F 86 Respiratory failure 17 
40 PN040 F 60 Respiratory failure 21 
41 PN041 F 58 Respiratory failure 26 
42 PN042 M 74 Stroke/brain injury/seizures 15 
43 PN043 M 59 Stroke/brain injury/seizures 6 
	 336 
44 PN045 F 22 Stroke/brain injury/seizures  -  
45 PN046 M 48 OOHCA 12 
46 PN047 M 53 Stroke/brain injury/seizures 12 
47 PN048 M 57 Stroke/brain injury/seizures 7 
48 PN049 F 75 General surgery - Stomach 16 
49 PN050 M 39 Stroke/brain injury/seizures 11 
50 PN051 F 73 Stroke/brain injury/seizures 8 
51 PN052 M 65 Other 16 
52 PN053 F 66 Respiratory failure 11 
53 PN054 M 66 Other 13 
54 PN055 F 60 Other 8 
55 PN056 F 49 Stroke/brain injury/seizures 17 
56 PN057 M 53 Respiratory failure 11 
57 PN058 F 38 Stroke/brain injury/seizures 6 
58 PN059 M 86 General surgery - Stomach 28 
59 PN060 M 39 Stroke/brain injury/seizures 9 
60 PN061 M 36 Poly-trauma  14 
61 PN062 M 21 Poly-trauma  1 
62 PN063 M 58 Respiratory failure  -  
63 PN064 M 44 OOHCA 23 
64 PN065 F 42 General surgery - Stomach 13 
65 PN066 F 73 Respiratory failure 0 
66 PN067 M 68 Respiratory failure 19 
67 PN068 M 52 OOHCA 8 
68 PN069 F 82 General surgery - Stomach 20 
69 PN070 M 18 Poly-trauma  2 
70 PN071 M 26 Poly-trauma  7 
71 PN072 M 67 Respiratory failure 10 
72 PN073 M 59 Other 19 
73 PN074 F 51 Stroke/brain injury/seizures 17 
74 PN075 M 75 Stroke/brain injury/seizures 20 
75 PN076 M 49 Respiratory failure 16 
76 PN077 M 70 Stroke/brain injury/seizures 18 
77 PN078 M 75 Respiratory failure 24 
78 PN079 F 51 Respiratory failure  -  
79 PN080 F 71 Respiratory failure 6 
80 PN081 M 74 Other 18 
81 PN082 F 45 Stroke/brain injury/seizures 1 
82 PN083 M 47 Respiratory failure 1 
83 PN084 M 58 Poly-trauma  17 
84 PN085 F 75 Respiratory failure 14 
85 PN086 M 74 Stroke/brain injury/seizures 5 
86 PN087 M 80 OOHCA 11 
87 PN088 F 40 Dental/Oral cavity 22 
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88 PN089 M 38 Poly-trauma  15 
89 PN090 M 66 Respiratory failure 17 
90 PN092 M 55 Stroke/brain injury/seizures 13 
91 PN093 F 42 Stroke/brain injury/seizures 7 
92 PN094 M 60 Respiratory failure 13 
93 PN095 M 41 Stroke/brain injury/seizures 9 
94 PN096 F 27 Other 1 
95 PN097 F 77 Poly-trauma  22 
96 PN099 M 58 Other 9 
97 PN100 M 26 Overdose/suicide attempt 6 
98 PN101 M 29 Respiratory failure 25 
99 PN102 M 30 Respiratory failure 8 
100 PN103 F 80 Respiratory failure  -  
101 PN104 M 56 OOHCA 18 
102 PN105 M 67 OOHCA 14 
103 PN106 F 60 Respiratory failure 19 
104 PN107 F 47 Stroke/brain injury/seizures 12 
105 PN108 M 74 OOHCA  -  
106 PN109 M 
 
Respiratory failure 7 
107 PN110 M 60 Other   
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Individual patient  dental plaque microbial culture results: 			
PN	 Dental	Plaque	
	
		
	
S.aureus	
S.	
mutans	 C.ablicans	 P.aeruginosa	
	 	 	 	
		
1	 No	 Yes	 Yes	 No	
2	 No	 No	 Yes	 No	
3	 No	 Yes	 Yes	 No	
4	 No	 Yes	 Yes	 No	
5	 Yes	 Yes	 Yes	 No	
6	 No	 Yes	 Yes	 Yes	
7	 Yes	 Yes	 Yes	 Yes	
8	 Yes	 No	 Yes	 Yes	
9	 Yes	 Yes	 Yes	 No	
10	 No	 Yes	 No	 No	
11	 No	 Yes	 Yes	 No	
12	 Yes	 Yes	 Yes	 No	
13	 Yes	 Yes	 No	 No	
14	 No	 Yes	 Yes	 No	
15	 Yes	 Yes	 Yes	 No	
16	 No	 No	 No	 No	
17	 No	 Yes	 Yes	 No	
18	 Yes	 No	 Yes	 Yes	
19	 No	 Yes	 Yes	 No	
20	 No	 Yes	 Yes	 No	
21	 Yes	 Yes	 No	 No	
22	 No	 Yes	 No	 No	
23	 No	 No	 No	 No	
24	 Yes	 Yes	 Yes	 No	
25	 Yes	 Yes	 No	 No	
26	 No	 No	 Yes	 No	
27	 Yes	 Yes	 Yes	 No	
28	 Yes	 Yes	 Yes	 No	
29	 No	 Yes	 No	 No	
30	 No	 Yes	 Yes	 Yes	
31	 No	 Yes	 Yes	 No	
32	 No	 No	 Yes	 No	
33	 No	 No	 Yes	 No	
34	 No	 Yes	 Yes	 No	
35	 No	 Yes	 Yes	 No	
36	 No	 No	 No	 No	
37	 Yes	 Yes	 Yes	 No	
38	 No	 No	 Yes	 Yes	
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39	 No	 No	 Yes	 No	
40	 No	 No	 Yes	 No	
41	 No	 No	 Yes	 No	
42	 Yes	 Yes	 Yes	 No	
43	 Yes	 No	 No	 No	
44	 EXEMPT	 		 		 		
45	 Yes	 Yes	 Yes	 No	
46	 Yes	 No	 Yes	 No	
47	 No	 No	 Yes	 Yes	
48	 Yes	 No	 Yes	 No	
49	 Yes	 Yes	 Yes	 Yes	
50	 Yes	 No	 Yes	 Yes	
51	 Yes	 Yes	 Yes	 Yes	
52	 Yes	 No	 Yes	 No	
53	 No	 No	 Yes	 No	
54	 Yes	 Yes	 No	 No	
55	 No	 Yes	 Yes	 No	
56	 Yes	 No	 Yes	 No	
57	 No	 Yes	 Yes	 No	
58	 No	 No	 Yes	 No	
59	 No	 No	 Yes	 No	
60	 No	 Yes	 Yes	 Yes	
61	 No	 No	 No	 No	
62	 No	 No	 No	 Yes	
63	 No	 No	 No	 No	
64	 Yes	 Yes	 Yes	 No	
65	 No	 No	 Yes	 No	
66	 No	 No	 No	 No	
67	 Yes	 No	 Yes	 No	
68	 Yes	 No	 Yes	 No	
69	 No	 No	 No	 No	
70	 No	 No	 Yes	 No	
71	 No	 Yes	 Yes	 No	
72	 No	 No	 Yes	 No	
73	 No	 Yes	 Yes	 No	
74	 No	 No	 Yes	 Yes	
75	 No	 No	 Yes	 No	
76	 No	 No	 Yes	 No	
77	 Yes	 No	 Yes	 No	
78	 No	 No	 Yes	 No	
79	 No	 No	 Yes	 Yes	
80	 Yes	 No	 Yes	 No	
81	 Yes	 Yes	 Yes	 No	
82	 No	 No	 Yes	 No	
83	 No	 Yes	 Yes	 Yes	
84	 No	 Yes	 Yes	 No	
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85	 No	 No	 Yes	 No	
86	 No	 No	 Yes	 No	
87	 Yes	 No	 Yes	 No	
88	 No	 No	 No	 No	
89	 Yes	 Yes	 Yes	 No	
90	 Yes	 No	 Yes	 No	
91	 		 		 		 		
92	 Yes	 No	 Yes	 No	
93	 No	 No	 Yes	 No	
94	 Yes	 Yes	 Yes	 No	
95	 Yes	 No	 Yes	 Yes	
96	 No	 No	 No	 No	
97	 No	 Yes	 No	 No	
98	 WITHDRAW	 		 		 		
99	 Yes	 No	 Yes	 No	
100	 No	 No	 Yes	 No	
101	 No	 Yes	 Yes	 No	
102	 Yes	 No	 Yes	 Yes	
103	 No	 No	 Yes	 No	
104	 Yes	 Yes	 Yes	 Yes	
105	 Yes	 No	 No	 Yes	
106	 Yes	 No	 Yes	 Yes	
107	 Yes	 Yes	 No	 Yes	
108	 Yes	 No	 Yes	 No	
109	 Yes	 No	 Yes	 Yes	
110	 Yes	 No	 No	 Yes					
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Pseudomonas aeruginosa isolates: 
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Staphylococcus aureus isolates: 
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Pseudomonas aeruginosa isolate sensitivities: 
 
Patient Antibiotics 
Patient  Sample Ceftazidime Ciprofloxacin Gentamicin Meropenem Piperacillin 
Piperacillin-
Tazobactam Tobramycin 
PN006 DP 22 30 20 27 24 27 19 
PN007 DP 22 30 20 28 24 27 22 
PN008 DP 24 30 26 28 24 27 21 
PN018 DP 22 30 19 27 24 28 21 
PN018 NBL 23 30 18 32 25 27 20 
PN030 DP 19 30 19 28 23 27 20 
PN030 NBL 20 30 19 29 24 27 20 
PN030 SUB 21 29 20 30 24 27 19 
PN030 NBL 22 29 20 30 24 29 19 
PN030 ETT 23 30 18 32 20 26 20 
PN030 DP 19 31 19 31 18 26 20 
PN038 DP 22 30 24 0 18 20 20 
PN045 NBL 22 30 22 0 17 21 22 
PN047 DP 22 29 19 20 21 26 24 
PN047 DP 19 28 21 27 22 29 22 
PN047 DP 22 30 19 27 23 26 19 
PN047 DP 21 30 20 27 19 27 20 
PN048 NBL 22 30 20 28 23 27 21 
PN049 DP 21 30 19 28 17 18 19 
PN049 DP 22 30 18 18 23 26 21 
PN051 DP 21 30 20 27 23 28 21 
PN060 DP 23 30 21 27 21 25 22 
PN060 DP 22 30 21 18 14 19 21 
PN060 DP 21 30 19 29 21 28 19 
PN062 DP 22 31 21 29 22 27 19 
PN062 NBL 22 28 21 28 22 27 19 
PN062 DP 22 30 20 0 23 25 20 
PN075 DP 20 30 20 29 21 26 19 
PN078 NBL 21 30 20 28 20 28 20 
PN079 SUB 22 30 18 30 21 26 20 
PN079 DP 22 30 21 28 0 14 19 
PN079 NBL 23 30 21 29 19 28 22 
PN079 DP 22 27 19 6 11 15 21 
PN079 DP 22 27 19 0 12 17 21 
PN081 DP 23 30 20 0 21 26 20 
PN083 NBL 23 30 21 10 19 27 21 
PN095 SUB 22 29 20 29 20 29 19 
PN095 DP 20 29 21 29 21 28 22 
PN095 ETT 22 29 21 29 19 29 19 
PN095 DP 22 30 21 0 18 29 18 
PN095 NBL 21 30 18 10 22 29 19 
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PN095 SUB 21 30 23 28 23 27 20 
PN102 DP 21 30 20 30 24 28 20 
PN104 DP 20 30 19 30 21 28 20 
PN105 ETT 24 30 19 28 24 27 21 
PN105 NBL 25 30 19 29 24 29 21 
PN105 DP 21 29 21 29 21 28 21 
PN106 DP 19 29 21 27 23 27 19 
PN107 DP 22 30 21 30 22 28 20 
PN108 ETT 16 7 17 19 11 19 14 
PN109 DP 20 30 21 31 23 28 20 
PN109 DP 23 30 21 27 23 29 20 
PN109 DP 22 29 21 29 25 28 19 
PN110 DP 22 28 20 28 21 25 20 
PN110 NBL 23 27 21 28 22 26 19 
PN110 ETT 22 30 21 29 22 26 21 
       
Resistant 
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Staphylococcus aureus isolate sensitivities: 
 
 
Patient Antibiotic 
Patient  Sample Cefepime Cefoxitin Ceftazidime Ciprofloxacin Clindamycin Erythromycin 	 		 	 	 	 	 	 	PN004 SUB 25 0 20 35 0 0 
PN005 DP 28 29 16 28 0 0 
PN005 DP 27 29 19 28 0 0 
PN007 DP 27 30 20 20 27 26 
PN007 DP 28 29 18 21 36 25 
PN007 DP 24 28 18 21 22 26 
PN007 DP 27 0 28 35 0 0 
PN009 DP 24 29 18 27 20 24 
PN009 NBL 22 28 17 24 30 24 
PN009 DP 23 29 16 22 30 18 
PN015 DP 28 0 27 35 0 0 
PN021 ETT 26 31 14 21 29 21 
PN021 DP 27 29 17 20 30 24 
PN021 NBL 28 30 18 20 30 25 
PN021 DP 24 29 17 22 28 21 
PN024 SUB 26 30 19 21 28 26 
PN024 NBL 25 29 19 22 27 26 
PN024 ETT 24 29 18 22 27 23 
PN024 DP 23 30 19 26 30 23 
PN024 NBL 27 28 16 28 29 22 
PN025 DP 25 30 17 27 28 24 
PN025 NBL 27 30 18 28 30 24 
PN025 NBL 27 29 17 27 28 25 
PN025 ETT 26 29 18 26 27 25 
PN027 NBL 28 29 28 34 29 23 
PN027 NBL 25 29 16 0 29 24 
PN027 ETT 23 30 18 0 22 0 
PN028 ETT 0 9 0 24 23 0 
PN028 SUB 0 10 0 12 29 0 
PN028 NBL 0 11 0 0 31 0 
PN037 DP 24 30 18 26 28 18 
PN037 NBL 25 30 19 27 24 27 
PN037 NBL 31 30 20 25 28 26 
PN037 NBL 24 30 17 24 28 22 
PN042 DP 24 30 18 24 28 23 
PN042 NBL 24 30 18 25 24 23 
PN042 SUB 16 0 0 25 13 26 
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PN042 ETT 24 30 18 25 28 22 
PN043 DP 24 30 18 24 28 22 
PN045 DP 22 29 19 23 30 23 
PN046 DP 24 30 18 25 28 22 
PN046 NBL 24 30 18 25 28 22 
PN046 DP 25 30 19 24 28 22 
PN046 NBL 27 30 20 27 25 19 
PN046 ETT 24 30 18 24 28 22 
PN046 DP 22 30 20 23 30 22 
PN048 NBL 25 30 18 24 24 18 
PN049 DP 22 30 19 25 21 20 
PN049 NBL 20 30 20 24 21 23 
PN049 DP 25 0 18 11 10 22 
PN050 DP 22 30 19 25 28 20 
PN050 NBL 22 29 20 24 28 19 
PN050 ETT 23 30 20 22 29 19 
PN051 DP 23 30 19 0 28 0 
PN051 DP 20 30 20 22 21 19 
PN052 DP 24 31 18 24 0 0 
PN052 NBL 23 30 19 24 30 23 
PN052 ETT 21 30 19 22 21 22 
PN054 NBL 23 30 20 24 22 23 
PN056 DP 23 30 20 22 29 19 
PN056 NBL 23 30 20 22 29 19 
PN056 DP 19 29 21 22 22 23 
PN056 NBL 20 30 19 22 29 23 
PN056 SUB 19 30 21 22 21 23 
PN056 SUB 19 30 21 23 21 22 
PN057 NBL 19 29 20 23 22 22 
PN057 ETT 20 30 18 23 22 19 
PN058 SUB 19 29 20 21 22 22 
PN063 NBL 20 29 18 22 22 19 
PN068 DP 21 30 20 0 9 0 
PN068 NBL 22 30 20 22 28 0 
PN068 DP 22 30 19 21 28 28 
PN077 NBL 22 29 19 21 27 22 
PN077 DP 22 30 19 26 28 22 
PN077 NBL 21 30 20 22 28 22 
PN080 SUB 0 14 0 10 28 0 
PN080 DP 0 13 0 0 32 0 
PN080 DP 0 15 0 0 33 0 
PN081 NBL 0 0 0 0 28 23 
PN081 SUB 0 0 0 0 32 26 
PN081 DP 0 9 0 0 33 29 
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PN081 DP 0 8 0 0 30 27 
PN086 NBL 23 30 19 23 28 22 
PN087 ETT 21 30 19 23 28 19 
PN087 NBL 25 20 16 21 29 8 
PN087 SUB 24 30 19 24 22 0 
PN087 DP 23 30 20 22 28 0 
PN089 NBL 23 30 20 24 28 22 
PN089 SUB 23 29 21 22 21 22 
PN089 NBL 25 30 22 23 28 24 
PN089 DP 21 30 21 24 28 22 
PN092 DP 23 30 22 0 21 23 
PN092 NBL 21 30 20 23 21 24 
PN094 NBL 24 29 21 22 28 23 
PN095 DP 21 29 21 22 0 0 
PN095 NBL 29 32 17 22 0 0 
PN095 SUB 26 30 14 24 0 0 
PN095 DP 22 30 18 24 0 0 
PN097 NBL 23 30 21 24 24 23 
PN099 DP 20 29 23 24 28 22 
PN099 DP 23 30 19 22 27 19 
PN102 DP 23 30 19 23 25 22 
PN102 DP 20 29 22 21 0 0 
PN104 DP 21 30 24 23 28 24 
PN104 NBL 21 30 21 23 21 25 
PN104 DP 20 30 22 24 21 23 
PN105 NBL 20 30 21 20 28 23 
PN105 ETT 24 30 22 21 21 24 
PN106 ETT 22 30 23 21 28 23 
PN108 DP 20 30 22 23 21 23 
PN108 NBL 24 30 19 23 28 22 
PN108 ETT 21 30 16 23 29 22 
PN109 DP 20 30 17 24 24 22 
PN110 NBL 0 0 0 10 32 0 	 	 	 	 	 	 	 		 	 	 	 	 	 Resistant   	 	 	 	 	 	 	 		 	 	 	 	 	 	 		 	 	 	 	 	 	 	Patient Antibiotic 
Patient  Sample 
Fusidic 
Acid Gentamicin Meropenem Penicillin Tobramycin Vancomycin  	 		 	 	 	 	 	 	PN004 SUB 0 26 26 0 22 0 
PN005 DP 30 24 34 16 22 16 
PN005 DP 36 24 38 17 23 16 
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PN007 DP 30 22 34 40 22 17 
PN007 DP 36 22 36 16 22 16 
PN007 DP 31 24 32 29 21 16 
PN007 DP 24 23 35 0 22 0 
PN009 DP 33 23 36 42 20 18 
PN009 NBL 33 23 33 33 23 16 
PN009 DP 32 22 31 28 22 16 
PN015 DP 0 23 36 0 25 0 
PN021 ETT 35 24 36 17 21 16 
PN021 DP 36 23 39 16 19 16 
PN021 NBL 35 22 36 15 23 16 
PN021 DP 30 22 32 29 21 17 
PN024 SUB 30 23 31 15 21 16 
PN024 NBL 30 22 30 17 22 16 
PN024 ETT 29 23 33 30 22 18 
PN024 DP 31 22 30 39 20 18 
PN024 NBL 32 23 33 36 21 19 
PN025 DP 30 23 32 30 21 16 
PN025 NBL 31 22 31 34 22 17 
PN025 NBL 30 22 30 40 22 16 
PN025 ETT 32 23 32 29 21 18 
PN027 NBL 30 24 31 40 21 17 
PN027 NBL 30 22 30 30 23 17 
PN027 ETT 30 22 10 0 21 17 
PN028 ETT 30 25 0 0 19 14 
PN028 SUB 33 22 13 7 22 16 
PN028 NBL 30 22 12 0 22 17 
PN037 DP 31 25 30 17 20 18 
PN037 NBL 30 23 30 17 21 17 
PN037 NBL 30 24 30 19 19 18 
PN037 NBL 30 24 30 20 20 20 
PN042 DP 30 24 30 20 20 20 
PN042 NBL 30 24 30 20 19 18 
PN042 SUB 30 24 18 0 14 15 
PN042 ETT 30 22 30 30 19 19 
PN043 DP 30 24 30 18 18 18 
PN045 DP 30 22 32 21 22 19 
PN046 DP 30 22 30 28 19 19 
PN046 NBL 30 22 30 28 19 19 
PN046 DP 30 22 30 28 18 14 
PN046 NBL 29 22 29 21 22 18 
PN046 ETT 28 23 30 28 18 21 
PN046 DP 29 0 31 18 20 18 
PN048 NBL 30 22 30 28 20 20 
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PN049 DP 30 19 29 19 22 20 
PN049 NBL 29 25 32 29 24 0 
PN049 DP 19 20 30 20 14 0 
PN050 DP 30 22 30 28 19 20 
PN050 NBL 29 19 30 19 20 20 
PN050 ETT 29 23 30 28 20 20 
PN051 DP 29 19 30 28 24 20 
PN051 DP 30 22 29 22 24 21 
PN052 DP 29 22 30 28 22 19 
PN052 NBL 29 22 30 29 21 4 
PN052 ETT 29 22 30 20 20 11 
PN054 NBL 30 22 30 21 19 19 
PN056 DP 29 22 30 19 22 19 
PN056 NBL 30 24 30 29 19 21 
PN056 DP 30 18 30 29 21 19 
PN056 NBL 30 24 29 28 21 19 
PN056 SUB 30 18 30 28 22 20 
PN056 SUB 30 18 28 21 21 21 
PN057 NBL 30 22 30 19 21 22 
PN057 ETT 29 23 30 21 21 21 
PN058 SUB 29 18 30 30 22 0 
PN063 NBL 29 18 30 30 22 0 
PN068 DP 30 20 30 30 20 0 
PN068 NBL 26 21 29 28 0 28 
PN068 DP 11 21 30 29 21 19 
PN077 NBL 29 20 21 22 19 19 
PN077 DP 30 20 32 23 20 0 
PN077 NBL 30 20 30 29 21 19 
PN080 SUB 30 10 20 0 10 21 
PN080 DP 30 10 21 0 10 21 
PN080 DP 33 11 21 0 0 21 
PN081 NBL 10 27 30 0 20 0 
PN081 SUB 29 23 7 0 20 9 
PN081 DP 31 24 14 0 23 18 
PN081 DP 21 24 9 0 22 17 
PN086 NBL 29 22 29 21 22 20 
PN087 ETT 30 24 29 21 24 20 
PN087 NBL 29 22 29 17 23 20 
PN087 SUB 30 22 30 28 22 20 
PN087 DP 30 22 29 29 21 20 
PN089 NBL 30 24 30 29 21 19 
PN089 SUB 29 22 30 28 20 21 
PN089 NBL 29 23 29 31 20 20 
PN089 DP 29 23 29 28 21 19 
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PN092 DP 30 22 27 24 21 20 
PN092 NBL 29 23 29 29 22 20 
PN094 NBL 30 22 29 29 21 19 
PN095 DP 29 22 29 32 21 20 
PN095 NBL 17 25 35 29 22 19 
PN095 SUB 19 24 33 29 18 18 
PN095 DP 19 23 29 18 21 0 
PN097 NBL 30 21 31 31 22 18 
PN099 DP 30 23 30 28 21 21 
PN099 DP 29 23 30 29 21 18 
PN102 DP 29 22 33 29 19 19 
PN102 DP 30 22 34 30 21 20 
PN104 DP 30 24 30 21 21 17 
PN104 NBL 30 24 30 29 22 18 
PN104 DP 30 23 30 28 20 21 
PN105 NBL 30 23 30 31 22 19 
PN105 ETT 30 23 29 29 20 18 
PN106 ETT 29 23 30 30 21 19 
PN108 DP 30 23 30 28 19 20 
PN108 NBL 29 22 29 28 21 20 
PN108 ETT 31 24 30 28 20 19 
PN109 DP 32 22 32 30 20 17 
PN110 NBL 25 12 0 0 12 20 	 	 	 	 	 	 	 		 	 	 	 	 	 Resistant   
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Appendix II 
Community profiling data 
 
 
 
 
 
- Mothur output 
- Raw sequencing data 
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Mothur output:  
 
#Mothur commands 
make.contigs(file=Sands3242.files, processors=25) 
summary.seqs(fasta=Sands3242.trim.contigs.fasta, processors=25) 
screen.seqs(fasta=Sands3242.trim.contigs.fasta, group=Sands3242.contigs.groups, 
summary=Sands3242.trim.contigs.summary, maxn=0, maxambig=0, maxhomop=6, 
minlength=310, maxlength=339) 
unique.seqs(fasta=Sands3242.trim.contigs.good.fasta) 
count.seqs(name=Sands3242.trim.contigs.good.names, 
group=Sands3242.contigs.good.groups) 
align.seqs(fasta=Sands3242.trim.contigs.good.unique.fasta, 
reference=../../silva.bacteria.fasta, flip=t, processors=25) 
summary.seqs(fasta=Sands3242.trim.contigs.good.unique.align, 
count=Sands3242.trim.contigs.good.count_table, processors=25) 
screen.seqs(fasta=Sands3242.trim.contigs.good.unique.align, 
count=Sands3242.trim.contigs.good.count_table, 
summary=Sands3242.trim.contigs.good.unique.summary, start=1044, end=6333, 
maxhomop=5) 
filter.seqs(fasta=Sands3242.trim.contigs.good.unique.good.align, vertical=T, trump=.) 
unique.seqs(fasta=Sands3242.trim.contigs.good.unique.good.filter.fasta, 
count=Sands3242.trim.contigs.good.good.count_table) 
pre.cluster(fasta=Sands3242.trim.contigs.good.unique.good.filter.unique.fasta, 
count=Sands3242.trim.contigs.good.unique.good.filter.count_table, diffs=2, processors=25) 
chimera.uchime(fasta=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.fast
a, count=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.count_table, 
dereplicate=t) 
remove.seqs(fasta=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.fasta, 
accnos=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.uchime.accnos) 
classify.seqs(fasta=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.pick.fa
sta, 
count=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.uchime.pick.count_t
able, reference=../../trainset9_032012.rdp.fasta, taxonomy=../../trainset9_032012.rdp.tax, 
cutoff=80, processors=25) 
remove.lineage(fasta=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.pick
.fasta, 
count=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.uchime.pick.count_t
able, 
taxonomy=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.pick.rdp.wang.t
axonomy, taxon=Chloroplast-Mitochondria-unknown-Archaea-Eukaryota) 
cluster.split(fasta=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.pick.pick
.fasta, 
count=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.uchime.pick.pick.co
unt_table, 
taxonomy=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.pick.rdp.wang.p
ick.taxonomy, splitmethod=classify, taxlevel=4, cutoff=0.15) 
make.shared(list=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.pick.pick
.an.unique_list.list, 
count=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.uchime.pick.pick.co
unt_table, label=0.03) 
classify.otu(list=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.pick.pick.a
n.unique_list.list, 
count=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.uchime.pick.pick.co
unt_table, 
taxonomy=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.pick.rdp.wang.p
ick.taxonomy, label=0.03) 
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sub.sample(shared=Sands3242.trim.contigs.good.unique.good.filter.unique.precluster.pick.pi
ck.an.unique_list.shared, size=1016) 
dist.seqs(fasta=Sands3242.final.fasta, output=phylip, processors=25) 
clearcut(phylip=Sands3242.final.phylip.dist) 
collect.single(shared=Sands3242_final_subsample.shared, calc=chao-invsimpson-shannon, 
freq=5) 
rarefaction.single(shared=Sands3242_final_subsample.shared, calc=sobs, freq=5) 
summary.single(calc=nseqs-sobs-chao-ace-invsimpson-npshannon-coverage) 
unifrac.weighted(tree=Sands3242.final.phylip.tre, name=Sands3242.final.names, 
group=Sands3242.final.groups, distance=square, processors=25, random=F, 
subsample=1016) 
get.oturep(phylip=Sands3242.final.phylip.dist, list=Sands3242.final.list, 
fasta=Sands3242.final.fasta, label=0.03) 
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Raw sequencing data (Species level 97%):  
 
 
 
Species 97% 1 2 3 4 6 7 8 9 10 
Veillonella_parvula 107 9 300 158 537 377 963 44 8 
Escherichia/Shigella_flexneri 0 0 0 0 0 0 3 0 0 
Streptococcus_pseudopneumoniae 2 0 0 101 12 1 0 155 766 
Enterococcus_villorum 623 983 135 0 0 0 0 0 0 
Staphylococcus_aureus 11 2 35 0 0 0 0 1 241 
Lactobacillus_gasseri 9 0 0 0 0 5 0 0 0 
Prevotella_nanceiensis 0 0 0 0 24 0 0 0 0 
Granulicatella_adiacens 0 0 26 17 55 3 9 44 0 
Prevotella_melaninogenica 3 4 42 27 22 238 0 1 0 
Prevotella_oris 0 3 9 72 0 0 0 82 0 
Haemophilus_influenzae 3 0 0 0 0 0 0 0 0 
Unclassified 4 0 138 59 1 6 4 102 1 
Lactobacillus_salivarius 0 0 0 0 0 0 0 0 0 
Lactobacillus_rhamnosus 17 0 0 0 106 285 0 1 0 
Enterococcus_faecalis 0 1 20 0 0 0 0 0 0 
Haemophilus_parainfluenzae 0 0 0 4 0 0 0 0 0 
Prevotella_salivae 0 0 33 49 62 41 0 0 0 
Parvimonas_micra 0 1 33 195 4 0 0 173 0 
Streptococcus_parasanguinis 10 0 26 29 4 1 10 0 0 
Neisseria_flavescens 0 0 0 0 0 0 0 0 0 
Streptococcus_cristatus 0 0 1 37 26 13 16 159 0 
Peptostreptococcus_stomatis 0 0 0 0 0 0 0 22 0 
Gemella_haemolysans 0 0 0 3 0 0 0 1 0 
Streptococcus_vestibularis 0 0 0 0 7 22 0 0 0 
Lactobacillus_crispatus 0 0 0 0 0 0 0 0 0 
Streptococcus_gordonii 0 0 0 9 142 12 0 7 0 
Streptococcus_infantis 0 0 0 0 0 0 0 0 0 
Streptococcus_constellatus 0 2 0 10 0 0 0 17 0 
Prevotella_aurantiaca 0 0 0 0 0 0 0 0 0 
Streptococcus_anginosus 0 0 15 4 0 0 1 7 0 
Solobacterium_moorei 0 4 0 0 0 0 0 2 0 
Prevotella_histicola 0 0 0 70 0 2 0 0 0 
Megasphaera_micronuciformis 0 0 0 8 0 1 0 5 0 
Streptococcus_peroris 0 0 0 6 0 0 0 46 0 
Dialister_invisus 0 0 0 7 0 0 0 4 0 
Selenomonas_sputigena 0 0 0 1 0 0 0 7 0 
Prevotella_denticola 0 0 0 11 0 0 0 9 0 
Eikenella_corrodens 0 0 0 1 0 0 0 1 0 
Abiotrophia_defectiva 0 0 0 0 0 0 0 0 0 
Streptococcus_agalactiae 0 0 0 0 0 0 0 0 0 
Selenomonas_infelix 0 0 0 1 0 0 0 0 0 
Aggregatibacter_segnis 0 0 0 0 0 0 0 4 0 
Aggregatibacter_aphrophilus 0 0 0 0 0 0 0 0 0 
Streptococcus_sanguinis 0 0 0 0 1 0 0 0 0 
Prevotella_tannerae 0 0 0 0 0 0 0 25 0 
Actinomyces_meyeri 6 0 0 6 0 0 2 3 0 
Lactobacillus_paracasei 0 0 0 0 4 4 0 0 0 
Granulicatella_elegans 0 0 0 0 0 0 0 0 0 
Prevotella_loescheii 0 0 0 3 0 0 0 6 0 
Oribacterium_sinus 0 0 0 3 0 0 0 2 0 
Finegoldia_magna 0 0 0 0 0 0 0 0 0 
Gemella_morbillorum 0 0 0 0 0 0 0 1 0 
Dialister_pneumosintes 0 0 45 5 0 0 0 4 0 
Prevotella_nigrescens 0 0 0 0 0 0 0 0 0 
Serratia_nematodiphila 214 0 30 0 0 0 0 1 0 
Selenomonas_artemidis 0 0 0 2 0 0 0 0 0 
Clostridium_bolteae 0 0 0 0 0 0 0 0 0 
Anaeroglobus_geminatus 0 0 0 1 0 0 0 0 0 
Tannerella_forsythia 2 0 41 0 0 0 0 0 0 
Streptococcus_lactarius 0 0 0 0 0 0 0 0 0 
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Streptococcus_oralis 0 0 0 0 0 0 0 0 0 
Staphylococcus_devriesei 0 0 0 0 0 0 0 0 0 
Neisseria_bacilliformis 0 0 0 2 0 0 0 0 0 
Selenomonas_noxia 0 0 0 16 0 0 0 0 0 
Actinomyces_viscosus 0 0 1 2 1 0 0 0 0 
Streptococcus_mutans 0 0 0 6 0 2 0 0 0 
Stenotrophomonas_pavanii 0 0 0 0 0 0 0 0 0 
Prevotella_oulorum 0 0 0 2 0 0 0 0 0 
Catonella_morbi 0 0 0 4 0 0 0 4 0 
Kingella_oralis 0 0 0 0 0 0 0 1 0 
Bacteroides_dorei 0 0 0 0 0 0 0 0 0 
Filifactor_alocis 0 0 0 11 0 0 0 18 0 
Prevotella_veroralis 0 0 0 1 0 0 0 2 0 
Robinsoniella_peoriensis 0 0 0 0 0 0 0 0 0 
Prevotella_maculosa 0 0 0 1 0 0 0 0 0 
Prevotella_pleuritidis 0 0 45 4 0 0 0 11 0 
Treponema_denticola 0 0 0 0 0 0 0 4 0 
Eubacterium_yurii 0 0 0 0 0 0 0 0 0 
Prevotella_intermedia 0 0 0 24 0 0 0 0 0 
Eubacterium_saphenum 0 0 0 0 0 0 0 1 0 
Gemella_asaccharolytica 0 0 0 0 0 0 0 0 0 
Gemella_sanguinis 0 0 0 0 0 0 0 0 0 
Prevotella_zoogleoformans 0 0 0 0 0 0 0 0 0 
Prevotella_oralis 0 0 7 0 0 0 0 1 0 
Bacillus_niacini 0 0 9 0 0 0 0 0 0 
Eubacterium_infirmum 0 0 0 0 0 0 0 11 0 
Treponema_maltophilum 0 0 0 0 0 0 0 1 0 
Phocaeicola_abscessus 0 0 0 0 0 0 0 0 0 
Actinomyces_dentalis 0 0 0 0 0 0 0 0 0 
Porphyromonas_gingivalis 0 0 0 0 0 0 0 0 0 
Treponema_amylovorum 0 0 0 0 0 0 0 16 0 
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Appendix III 
Additional information: Salivary analysis during mechanical 
ventilation 
 
 
 
- Ethics approval documents for saliva collection from healthy 
volunteers 
- Full breakdown of salivary parameters for all patients 
- Protein identification from healthy saliva 
- Protein identification from patient saliva 
- Cytokine quantification from saliva, ETT fluid and plasma
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Ethical approval documents for saliva collection from healthy volunteers: 
 
 
(Version 1, 20th March 2014) 
 
CONSENT FORM    
 
COLLECTION OF SALIVA FOR PROTEOMIC RESEARCH PURPOSES 	
Name of Researchers: Kirsty M Sands, Professor David W Williams, Dr Melanie J Wilson, 
Dr Matthew P Wise and Professor Michael AO Lewis 
                    
Please initial 		
 
1. I confirm that I have read and understood the study information 
sheet and have had an opportunity to ask any questions and 
had sufficient time to come to my decision. 
 
2. I give permission that the saliva be collected and stored within 
the Cardiff School of Dentistry only for use in salivary proteomics 
in this study and then discarded via autoclaving. 	
3. I understand that my participation is voluntary and that I am free 
to withdraw at any time prior to my samples being used in the 
study without giving any reason, without my medical care or legal 
rights being affected.  
 
4. I understand that results from this study may be used in 
medical/scientific journals and/or publications, but donated 
saliva will not be identifiable. 	
5. I understand that the sample is given as a “gift” and that I will 
have no right to a share of any profits which might arise from 
research using it (e.g. as part of a new medical treatment or 
test). 
 
 
_________________  ________________  _________________  
Name of Cardiff  
University volunteer  Date  Signature  
 
_________________  ________________  ___________________  
Name of Person  Date  Signature   
taking consent  
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Ethical approval documents for saliva collection from healthy volunteers  
 
 
Version 2, 14th April 2014 
 
 
Information Sheet 
 
Cardiff School of Dentistry 
 
Collection of saliva for proteomic research purposes 
 
 
Study title 
Collection of saliva for proteomic research purposes 
 
Invitation 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it 
will involve. Please	take	time	to	read	the	following	information	carefully.	Please	feel	free	to	ask	us	any	questions	if	anything	is	unclear,	in	order	to	help	you	decide	whether	you	wish	to	take	part.	
 
1. What is the purpose of the salivary proteomic study? 
 
Saliva contains hundreds of proteins, several of which contain antimicrobial 
peptides. In critically ill patients, it is accepted that salivary flow may be reduced 
as a direct consequence of mechanical ventilation (MV) i.e. a direct result from 
the apparatus leading to the patient’s mouth remaining open. Understanding the 
salivary flow, pH, and composition of proteins in critically ill patients can provide 
an insight into the involvement salivary peptides can have in dental plaque 
biofilm formation. This may be important when dental plaque changes are 
associated with those bacteria that can cause pneumonia. If any changes in the 
salivary protein composition are established, these proteins can then be targeted 
for specific and quantitative analysis. Healthy volunteers will be used to provide 
comparable data to critically ill patients. 
 
This research project has been considered and accepted by the Research 
Ethics Committee within the School of Dentistry. 
 
2. Why have I been chosen 
You have been chosen as you meet the required inclusion/exclusion criteria and 
are deemed able to readily donate a small volume of saliva. A total of 5 
individuals will contribute to this study. 
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3. Do I have to take part? 
 
There is no obligation for you to take part in this study 
 
 
4. How can I contribute and what will happen if I take part? 
 
If you decide to contribute you will be requested to chew gently on a cotton swab 
specifically designed to collect saliva, a total of 5 samples will be collected over 
a period of 14 days. Your saliva will be stored in the -80°C until processed for 
the extracellular proteins. Your name will not be written on the microcentrifuge 
tube, or used at any time throughout the analysis. A number will be generated 
and used from point of collection, analysis and until saliva discarded. The saliva 
sample will be subject to a protein assay and analysis via SDS-PAGE. Any 
remaining sample will be discarded via autoclaving at 121°C for 50 min. You will 
not be contacted after regarding the results of the sampling, and no results will 
affect the future health/knowledge of the individual. No genetic testing will be 
carried out on any samples. 
 
If at any stage you choose to withdraw consent, no future contact will be 
necessary. Any samples already collected to that date would have been used in 
proteomic analysis (pooling of samples at time of collection). 
Samples that have been processed and used will not be able to be removed 
from the study and will continue to remain part of the study results. 
 
Any complaints can be made via contact with Dr Fiona Gagg – the Laboratory 
Manager. 
 
5. What about confidentiality? 
 
Your sample will be collected in a numbered receptacle and will be 
pseudoanonymised to the research team.  Prior to use your saliva will be pooled 
with the saliva collected from other volunteering individuals. Your identity will not 
be disclosed in any results or publications arising from this study. 
 
6. What do I have to do? 
 
You will be requested to chew gently on a cotton swab specifically designed to 
collect saliva. This cotton swab will then be returned to the researcher for saliva 
collection. 
 
7. Are there any risks? 
 
There are no obvious risks to you in taking part in this study. 
 
 
8. What are the benefits of taking part and what will happen to the 
results? 
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Whilst there is no personal benefit from taking part in this study, participation will 
provide healthy volunteer control data for extracellular human salivary proteins. 
The control data can then be referred to in comparison from data obtained from 
critically ill patients. The results of the study will be used to compare data 
findings from a patient study. 
 
9. Who is organising and funding the research? 
 
The research is being organised by Miss Kirsty Sands and Professor David Williams 
(School of Dentistry, Cardiff University). The funder of the study is GlaxoSmithKline 
(as a result of a small grant success). 
 
 
 
10. Contact for Further Information 
Further information on this study can be obtained from Miss Kirsty Sands, 
PhD Student Sandsk1@cardiff.ac.uk 
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Full breakdown of salivary volume for all patients: 
 
PN 
Sample 
date 
Saliva 
volume 
Time 
collection  protein conc 
Saliva 
flow 
protein content per 
volume 
    (ml) (s) (mg/ml) (ml/min)  collected (mg) 
PN002 30/07/13 0.3 45 s 28.5 0.40 8.55 
PN002 05/08/13 0.02 45 s 16.8 0.03 0.34 
PN003 02/08/13 0.5 45 s 7.95 0.67 3.98 
PN003 06/08/13 0.1 45 s 4.40 0.13 0.44 
PN003 08/08/13 0.1 45 s 3.60 0.13 0.36 
PN004 04/08/13 1.7 45 s 7.60 2.27 12.92 
PN004 09/08/13 0.04 45 s 5.25 0.05 0.21 
PN004 10/08/13 0.01 45 s 5.10 0.01 0.05 
PN004 17/08/13 0.45 45 s 4.50 0.60 2.03 
PN004 23/08/13 0.7 45 s 2.40 0.93 1.68 
PN004 26/08/13 0.72 45 s 2.50 0.96 1.80 
PN004 31/08/13 0.4 45 s 1.05 0.53 0.42 
PN004 16/05/14 0.35 45 s 10.95 0.47 3.83 
PN004 20/05/14 0.05 45 s 3.15 0.07 0.16 
PN005 17/08/13 0.1 45 s 11.55 0.13 1.16 
PN005 19/08/13 0.5 45 s 6.3 0.67 3.15 
PN006 17/08/13 0.01 45 s 18 0.01 0.18 
PN006 04/10/13 0.06 45 s 4.05 0.08 0.24 
PN007 20/08/13 0.4 45 s 7.65 0.53 3.06 
PN007 22/09/13 0.2 45 s 0.9 0.27 0.18 
PN008 20/08/13 0.05 45 s 6.45 0.07 0.32 
PN008 29/08/13 0.4 45 s 4.4 0.53 1.76 
PN010 25/08/13 1 45 s 3.1 1.33 3.10 
PN010 11/09/13 0.2 45 s 2.2 0.27 0.44 
PN012 30/08/13 0.35 45 s 17.25 0.47 6.04 
PN012 02/09/13 0.05 45 s 6 0.07 0.30 
PN012 09/09/13 0.3 45 s 16.5 0.40 4.95 
PN013 26/08/13 0.01 45 s 29.25 0.01 0.29 
PN013 02/09/13 0.3 45 s 37.50 0.40 11.25 
PN014 01/09/13 0.2 45 s 45.00 0.27 9.00 
PN015 28/08/13 0.065 45 s 16.5 0.09 1.07 
PN015 30/08/13 0.15 45 s 18.6 0.20 2.79 
PN016 03/09/13 0.44 45 s 9.90 0.59 4.36 
PN016 11/09/13 0.1 45 s 2.00 0.13 0.20 
PN017 04/10/13 0.15 45 s 4.65 0.20 0.70 
PN018 03/10/13 0.7 45 s 14.19 0.93 9.93 
PN019 16/10/13 0.18 45 s 19.95 0.24 3.59 
PN020 08/10/13 0.15 45 s 18.75 0.20 2.81 
PN021 07/10/13 0.40 45 s 9.3 0.53 3.72 
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PN021 09/10/13 0.05 45 s 8.4 0.07 0.42 
PN022 09/10/13 0.50 45 s 11.4 0.67 5.70 
PN022 12/10/13 1.10 45 s 9.6 1.47 10.56 
PN023 13/10/13 0.03 45 s 5.25 0.04 0.16 
PN024 12/10/13 0.9 45 s 10.05 1.20 9.05 
PN025 19/10/13 0.05 45 s 15.9 0.07 0.80 
PN028 31/10/13 0.9 45 s 15.23 1.20 13.71 
PN028 03/11/13 0.1 45 s 10 0.13 1.00 
PN028 10/11/13 0.9 45 s 5.9 1.20 5.31 
PN033 12/11/13 0.05 45 s 15.90 0.07 0.80 
PN033 17/11/13 0.25 45 s 6.60 0.33 1.65 
PN035 15/11/13 0.05 45 s 9.30 0.07 0.47 
PN036 21/11/13 1 45 s 5.55 1.33 5.55 
PN037 05/01/14 0.02 45 s 20.7 0.03 0.41 
PN037 25/01/14 0.4 45 s 5.7 0.53 2.28 
PN038 13/01/14 0.1 45 s 5.7 0.13 0.57 
PN039 29/01/14 0.12 45 s 2.70 0.16 0.32 
PN040 14/01/14 0.26 45 s 18.00 0.35 4.68 
PN040 17/01/14 0.3 45 s 7.35 0.40 2.21 
PN041 17/01/14 1.3 45 s 3.00 1.73 3.90 
PN042 28/01/14 0.08 45 s 6.8 0.11 0.54 
PN042 04/02/14 0.12 45 s 3.3 0.16 0.40 
PN043 17/01/14 0.04 45 s 10.2 0.05 0.41 
PN043 20/01/14 0.15 45 s 5.4 0.20 0.81 
PN045 03/02/14 0.045 45 s 4.8 0.06 0.22 
PN045 15/02/14 0.28 45 s 4.625 0.37 1.30 
PN046 06/02/14 0.35 45 s 30 0.47 10.50 
PN046 08/02/14 0.15 45 s 11.55 0.20 1.73 
PN046 18/02/14 0.035 45 s 37.125 0.05 1.30 
PN046 03/03/14 0.35 45 s 3.75 0.47 1.31 
PN046 18/03/14 0.05 45 s 33 0.07 1.65 
PN046 25/03/14 0.075 45 s 28.5 0.10 2.14 
PN047 11/02/14 0.25 45 s 20.55 0.33 5.14 
PN048 11/02/14 1.4 45 s 5.7 1.87 7.98 
PN050 18/02/14 0.1 45 s 20.25 0.13 2.03 
PN051 19/02/14 0.02 45 s 30 0.03 0.60 
PN052 23/02/14 0.01 45 s 16.5 0.01 0.17 
PN052 27/02/14 1.2 45 s 12 1.60 14.40 
PN054 26/02/14 0.35 45 s 5.1 0.47 1.79 
PN054 28/02/14 0.035 45 s 24 0.05 0.84 
PN054 11/04/14 0.065 45 s 1.65 0.09 0.11 
PN055 01/03/14 0.05 45 s 16.5 0.07 0.83 
PN057 05/03/14 0.1 45 s 9.3 0.13 0.93 
PN058 10/03/14 0.33 45 s 4.2 0.44 1.39 
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PN060 12/03/14 0.08 45 s 18 0.11 1.44 
PN060 20/03/14 0.075 45 s 18.3 0.10 1.37 
PN060 27/03/14 1.08 45 s 25.05 1.44 27.05 
PN061 14/03/14 0.12 45 s 17.7 0.16 2.12 
PN062 17/03/14 0.04 45 s 18.45 0.05 0.74 
PN064 28/03/14 0.04 45 s 3.9 0.05 0.16 
PN066 10/04/14 0.05 45 s 18.15 0.07 0.91 
PN068 14/04/14 0.13 45 s 11.55 0.17 1.50 
PN070 24/04/14 0.05 45 s 4.5 0.07 0.23 
PN075 07/05/14 0.2 45 s 4.8 0.27 0.96 
PN075 09/05/14 1.5 45 s 4.8 2.00 7.20 
PN077 06/05/14 0.3 45 s 3.9 0.40 1.17 
PN079 21/05/14 0.08 45 s 20.25 0.11 1.62 
PN082 29/05/14 0.2 45 s 5.55 0.27 1.11 
PN082 31/05/14 0.45 45 s 9.9 0.60 4.46 
PN083 26/05/14 0.25 45 s 12.45 0.33 3.11 
PN083 29/05/14 0.1 45 s 4.2 0.13 0.42 
PN086 05/06/14 0.05 45 s 8.7 0.07 0.44 
PN089 09/06/14 0.03 45 s 10.5 0.04 0.32 
PN093 25/06/14 0.25 45 s 20.25 0.33 5.06 
PN094 05/07/14 0.1 45 s 14.85 0.13 1.49 
PN094 30/07/14 0.1 45 s 9.75 0.13 0.98 
PN095 13/07/14 0.1 45 s 36 0.13 3.60 
PN097 10/07/14 0.03 45 s 24 0.04 0.72 
PN097 13/07/14 0.02 45 s 18 0.03 0.36 
PN099 10/07/14 1.85 45 s 19.65 2.47 36.35 
PN099 12/07/14 0.4 45 s 2.85 0.53 1.14 
PN099 14/07/14 0.7 45 s 4.5 0.93 3.15 
PN099 21/07/14 1.6 45 s 9.75 2.13 15.60 
PN099 04/08/14 0.05 45 s 6.6 0.07 0.33 
PN102 25/07/14 0.1 45 s 2.85 0.13 0.29 
PN102 03/08/14 0.2 45 s 2.1 0.27 0.42 
PN104 18/07/14 0.4 45 s 25.05 0.53 10.02 
PN105 21/07/14 0.08 45 s 25.5 0.11 2.04 
PN106 19/07/14 0.1 45 s 25.35 0.13 2.54 
PN106 15/08/14 0.1 45 s 2.7 0.13 0.27 
PN107 27/07/14 0.2 45 s 17.25 0.27 3.45 
PN107 30/07/14 0.1 45 s 16.5 0.13 1.65 
PN107 08/08/14 0.1 45 s 24.9 0.13 2.49 
PN108 31/07/14 0.4 45 s 1.8 0.53 0.72 
PN109 02/08/14 0.5 45 s 1.8 0.67 0.90 
PN109 05/08/14 0.5 45 s 1.7 0.67 0.85 
PN109 07/08/14 0.1 45 s 1.6 0.13 0.16 
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Protein identification from healthy saliva: 
 
 
Peptide 
no' Protein Name 
Accession 
Number Protein MW 
Protein 
PI 
Peptide 
Count 
1 Serum albumin  ALBU_HUMAN 70931.0625 5.92 23 
2 Alpha-2-macroglobulin-like protein 1  A2ML1_HUMAN 162153.75 5.5 21 
3 Serotransferrin   TRFE_HUMAN 78853.14063 6.81 15 
4 Polymeric immunoglobulin receptor PIGR_HUMAN 84197.39063 5.58 14 
5 Heat shock 70 kDa protein 1A/1 HSP71_HUMAN 70238.96875 5.48 13 
6 Complement C3 CO3_HUMAN 188271.5469 6.02 13 
7 Alpha-enolase  ENOA_HUMAN 47415.23828 7.01 13 
8 Alpha-amylase 2B AMY2B_HUMAN 58178.87109 6.64 12 
9 Actin, cytoplasmic 2  ACTG_HUMAN 42041.71875 5.31 12 
10 Mucin-5B MUC5B_HUMAN 608560.75 6.2 12 
11 Ig alpha-1 chain C region  IGHA1_HUMAN 38320.44922 6.08 11 
12 Keratin, type II cytoskeletal 1  K2C1_HUMAN 66136.96094 8.15 11 
13 Ig alpha-2 chain C region IGHA2_HUMAN 37146.82813 5.71 10 
14 Fructose-bisphosphate aldolase A  ALDOA_HUMAN 39763.21094 8.3 10 
15 14-3-3 protein sigma  1433S_HUMAN 27848.66992 4.68 10 
16 Involucrin  INVO_HUMAN 68529.17969 4.62 9 
17 Heat shock cognate 71 kDa protein HSP7C_HUMAN 71038.17188 5.37 9 
18 Ezrin  EZRI_HUMAN 69461.71094 5.94 9 
19 Protein disulfide-isomerase  PDIA1_HUMAN 57402.58984 4.76 9 
20 Pyruvate kinase PKM  KPYM_HUMAN 58359.89844 7.96 9 
21 Phosphoglycerate kinase 1  PGK1_HUMAN 44908.03906 8.3 9 
22 Lactotransferrin TRFL_HUMAN 79649.50781 8.5 8 
23 Zinc-alpha-2-glycoprotein  ZA2G_HUMAN 34421.05078 5.71 7 
24 6-phosphogluconate dehydrogenase, decarboxylating  6PGD_HUMAN 53519.83984 6.8 7 
25 14-3-3 protein zeta/delta 1433Z_HUMAN 27865.68945 4.73 7 
26 Small proline-rich protein 3 SPRR3_HUMAN 18510.13086 8.86 7 
27 Peroxiredoxin-1  PRDX1_HUMAN 22280.23047 8.27 6 
28 Heat shock 70 kDa protein 6 HSP76_HUMAN 71352.13281 5.81 6 
29 Cystatin-A  CYTA_HUMAN 10999.66016 5.38 6 
30 Leukocyte elastase inhibitor  ILEU_HUMAN 42806.67969 5.9 6 
31 Moesin MOES_HUMAN 67869.75781 6.08 6 
32 Gelsolin  GELS_HUMAN 85966.10156 5.9 6 
33 Transaldolase  TALDO_HUMAN 37654.42188 6.36 6 
34 Haptoglobin  HPT_HUMAN 45728.42188 6.13 6 
35 Cystatin-S CYTS_HUMAN 16433.90039 4.95 5 
36 Thioredoxin  THIO_HUMAN 11959.67969 4.82 5 
37 Profilin-1  PROF1_HUMAN 15182.51953 8.44 5 
38 Ig gamma-3 chain C region IGHG3_HUMAN 42088.14063 8.23 5 
39 Immunoglobulin lambda-like polypeptide 5 IGLL5_HUMAN 23324.56055 9.08 5 
40 Triosephosphate isomerase TPIS_HUMAN 31001.63086 5.65 5 
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41 Immunoglobulin J chain  IGJ_HUMAN 18454.90039 5.12 5 
42 Prolactin-inducible protein  PIP_HUMAN 16791.73047 8.26 5 
43 Macrophage-capping protein  CAPG_HUMAN 38704.41016 5.82 5 
44 Fatty acid-binding protein, epidermal  FABP5_HUMAN 15430.48047 6.6 5 
45 78 kDa glucose-regulated protein GRP78_HUMAN 72380.40625 5.07 5 
46 Transketolase TKT_HUMAN 68386.57813 7.58 5 
47 Serpin B3  SPB3_HUMAN 44582.53125 6.35 5 
48 Coronin-1A  COR1A_HUMAN 51545.64844 6.25 5 
49 Cystatin-SN  CYTN_HUMAN 16561.28906 6.73 4 
50 Heme-binding protein 2  HEBP2_HUMAN 22861.18945 4.58 4 
51 Cystatin-SA CYTT_HUMAN 16664.15039 4.85 4 
52 Ig lambda-3 chain C regions  LAC3_HUMAN 11368.46973 6.92 4 
53 14-3-3 protein beta/alpha  1433B_HUMAN 28156.81055 4.76 4 
54 Ig gamma-4 chain C region IGHG4_HUMAN 36331.75 7.18 4 
55 Ig gamma-2 chain C region IGHG2_HUMAN 36383.62109 7.66 4 
56 Alpha-1-antitrypsin  A1AT_HUMAN 46844.98047 5.37 4 
57 Glutathione S-transferase P GSTP1_HUMAN 23524.9707 5.43 4 
58 Keratin, type I cytoskeletal 10  K1C10_HUMAN 58975.64063 5.13 4 
59 Ig mu chain C region IGHM_HUMAN 49827.37891 6.35 4 
60 UPF0762 protein C6orf58  CF058_HUMAN 38177.48047 5.78 4 
61 Kallikrein-1 KLK1_HUMAN 29376.74023 4.68 4 
62 Peptidyl-prolyl cis-trans isomerase A   PPIA_HUMAN 18184.83984 7.68 4 
63 Desmoglein-1  DSG1_HUMAN 114503.6406 4.9 4 
64 14-3-3 protein theta 1433T_HUMAN 27976.69922 4.68 4 
65 L-lactate dehydrogenase A chain  LDHA_HUMAN 36895.30078 8.44 4 
66 Phosphatidylethanolamine-binding protein 1  PEBP1_HUMAN 21135.64063 7.01 4 
67 Aldehyde dehydrogenase, dimeric NADP-preferring  AL3A1_HUMAN 50684.76172 6.11 4 
68 Protein DJ-1  PARK7_HUMAN 20016.44922 6.33 4 
69 Peroxiredoxin-6  PRDX6_HUMAN 25111.16016 6 4 
70 Malate dehydrogenase, cytoplasmic MDHC_HUMAN 36586.96875 6.91 4 
71 Ig kappa chain C region  IGKC_HUMAN 11739.62988 5.58 3 
72 Cystatin-B CYTB_HUMAN 11178.58008 6.96 3 
73 Phosphoglycerate mutase 1  PGAM1_HUMAN 28877.81055 6.67 3 
74 Ig heavy chain V-III region BRO  HV305_HUMAN 13310.37012 6.45 3 
75 Beta-2-microglobulin B2MG_HUMAN 13797.88965 6.06 3 
76 Interleukin-1 receptor antagonist protein  IL1RA_HUMAN 20317.88086 5.83 3 
77 Transthyretin TTHY_HUMAN 15969.01953 5.52 3 
78 Deleted in malignant brain tumors 1 protein  DMBT1_HUMAN 266593.1875 5.18 3 
79 Ubiquitin-40S ribosomal protein S27a  RS27A_HUMAN 18229.41992 9.68 3 
80 Glyceraldehyde-3-phosphate dehydrogenase G3P_HUMAN 36168.35938 8.57 3 
81 14-3-3 protein gamma  1433G_HUMAN 28422.88086 4.8 3 
82 Alpha-actinin-4  ACTN4_HUMAN 105156.3672 5.27 3 
83 Superoxide dismutase [Cu-Zn]  SV=2 SODC_HUMAN 16109.84961 5.7 3 
84 Protein S100-A8  S10A8_HUMAN 10873.63965 6.51 3 
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85 Cellular retinoic acid-binding protein 2 RABP2_HUMAN 15820.98047 5.42 3 
86 Cornulin CRNN_HUMAN 53685.58984 5.73 3 
87 Cystatin-D  CYTD_HUMAN 16299.87988 6.7 2 
88 Keratin, type II cytoskeletal 2 epidermal K22E_HUMAN 65623.14844 8.07 2 
89 Ig kappa chain V-I region EU  KV106_HUMAN 11872.74023 8.62 2 
90 Transgelin-2  TAGL2_HUMAN 22515.14063 8.41 2 
91 Desmoglein-3  DSG3_HUMAN 108569.0703 4.86 2 
92 Heat shock protein beta-1  HSPB1_HUMAN 22814.48047 5.98 2 
93 Ig kappa chain V-III region WOL KV305_HUMAN 11830.87988 9.07 2 
94 Rho GDP-dissociation inhibitor 2   GDIR2_HUMAN 23019.58984 5.1 2 
95 Cystatin-C  CYTC_HUMAN 15973.03027 9 2 
96 Phosphoglucomutase-1  PGM1_HUMAN 61640.46875 6.3 2 
97 Cysteine-rich secretory protein 3 CRIS3_HUMAN 28347.81055 8.09 2 
98 Ig heavy chain V-III region CAM  HV307_HUMAN 13751.15039 9.65 2 
99 Catalase CATA_HUMAN 59902.69922 6.9 2 
100 Ig kappa chain V-IV region Len  KV402_HUMAN 12724.16992 7.92 2 
101 Ig kappa chain V-IV region JI KV403_HUMAN 14715.2998 6.15 2 
102 Protein S100-A6  S10A6_HUMAN 10219.33008 5.33 2 
103 Neutrophil gelatinase-associated lipocalin NGAL_HUMAN 22711.67969 9.02 2 
104 ERO1-like protein alpha  ERO1A_HUMAN 55047.87109 5.48 2 
105 Protein S100-A2 S10A2_HUMAN 11293.30957 4.68 2 
106 Alpha-actinin-1  ACTN1_HUMAN 103452.5078 5.25 2 
107 Carbonic anhydrase 6  CAH6_HUMAN 35436.57031 6.51 2 
108 Galectin-3-binding protein  LG3BP_HUMAN 66025.09375 5.13 2 
109 Desmocollin-2 DSC2_HUMAN 101048.4297 5.19 2 
110 Lactoperoxidase PERL_HUMAN 80972.67969 8.89 2 
111 Leukotriene A-4 hydrolase LKHA4_HUMAN 69747.10156 5.8 2 
112 Plastin-2 PLSL_HUMAN 70703.77344 5.29 2 
113 Transcobalamin-1  TCO1_HUMAN 48589.91016 4.96 2 
114 Glycogen phosphorylase, liver form  PYGL_HUMAN 97408.9375 6.71 2 
115 BPI fold-containing family B member 2  BPIB2_HUMAN 49233.69922 8.82 2 
116 Glycogen phosphorylase, brain form  PYGB_HUMAN 97186.36719 6.4 2 
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Protein identification from mechanically ventilated patient saliva: 
 
Peptide 
no' Protein Name 
Accession 
Number Protein MW 
Protein 
PI Peptide Count 
1 Serum albumin ALBU_HUMAN 70931.0625 5.92 36 
2 Complement C3  CO3_HUMAN 188271.5469 6.02 29 
3 Serotransferrin TRFE_HUMAN 78853.14063 6.81 28 
4 Alpha-2-macroglobulin  A2MG_HUMAN 164337.5781 6.03 20 
5 Polymeric immunoglobulin  PIGR_HUMAN 84197.39063 5.58 15 
6 Alpha-amylase 2B AMY2B_HUMAN 58178.87109 6.64 14 
7 Alpha-1-antitrypsin A1AT_HUMAN 46844.98047 5.37 14 
8 Haptoglobin HPT_HUMAN 45728.42188 6.13 13 
9 Fibrinogen beta chain  FIBB_HUMAN 56444.10938 8.54 13 
10 Lactotransferrin TRFL_HUMAN 79649.50781 8.5 12 
11 Apolipoprotein APOA1_HUMAN 30758.92969 5.56 11 
12 Actin, cytoplasmic 2  ACTG_HUMAN 42041.71875 5.31 11 
13 Zinc-alpha-2-glycoprotein ZA2G_HUMAN 34421.05078 5.71 10 
14 Ig gamma-1 chain C region  IGHA1_HUMAN 38320.44922 6.08 9 
15 Ig gamma-2 chain C region  IGHM_HUMAN 49827.37891 6.35 9 
16 Ig gamma-3 chain C region  IGHG3_HUMAN 42088.14063 8.23 9 
17 Hemoglobin subunit beta HBB_HUMAN 16080.26953 6.75 8 
18 Alpha-1-antichymotrypsin AACT_HUMAN 47758.5 5.33 8 
19 Ig gamma-1 chain C region IGHG1_HUMAN 36497.05859 8.46 8 
20 Ig gamma-2 chain C region  IGHG2_HUMAN 36383.62109 7.66 8 
21 Ceruloplasmin  CERU_HUMAN 122817.3984 5.44 8 
22 Complement factor B  CFAB_HUMAN 86582.22656 6.67 8 
23 Ig alpha-2 chain C region  IGHA2_HUMAN 37146.82813 5.71 7 
24 Fibrinogen alpha chain  FIBA_HUMAN 95512.25 5.7 7 
25 Protein S100-A8  S10A8_HUMAN 10873.63965 6.51 7 
26 Myeloperoxidase  PERM_HUMAN 84596.63281 9.19 7 
27 Ig gamma-4 chain C region  IGHG4_HUMAN 36331.75 7.18 6 
28 Alpha-1-acid glycoprotein 1  A1AG1_HUMAN 23680.71094 4.93 6 
29 Small proline-rich protein 3  SPRR3_HUMAN 18510.13086 8.86 6 
30 Fibrinogen gamma chain  FIBG_HUMAN 51984.73047 5.37 6 
31 Leucine-rich alpha-2-glycoprotein  A2GL_HUMAN 38338.05859 6.45 6 
32 Fibronectin FINC_HUMAN 265357.3125 5.46 6 
33 Lysozyme C  LYSC_HUMAN 16894.18945 9.38 6 
34 Lipocalin-1  LCN1_HUMAN 19375.7793 5.39 5 
35 Cystatin-B  CYTB_HUMAN 11178.58008 6.96 5 
36 Alpha-enolase ENOA_HUMAN 47415.23828 7.01 5 
37 Alpha-1B-glycoprotein A1BG_HUMAN 54679.42188 5.56 5 
38 14-3-3 protein zeta/delta 1433Z_HUMAN 27865.68945 4.73 5 
39 Cystatin-S CYTS_HUMAN 16433.90039 4.95 5 
40 Protein S100-A9  S10A9_HUMAN 13279.5 5.71 5 
41 Hemopexin HEMO_HUMAN 52241.10938 6.55 5 
42 Alpha-2-HS-glycoprotein  FETUA_HUMAN 39943.53906 5.43 5 
43 Matrix metalloproteinase-9 MMP9_HUMAN 79282.11719 5.69 5 
44 
Immunoglobulin lambda-like 
polypeptide 5 IGLL5_HUMAN 23324.56055 9.08 4 
45 Immunoglobulin J chain IGJ_HUMAN 18454.90039 5.12 4 
46 Hemoglobin subunit alpha  HBA_HUMAN 15293.91016 8.72 4 
47 Transthyretin TTHY_HUMAN 15969.01953 5.52 4 
48 Leukocyte elastase inhibitor  ILEU_HUMAN 42806.67969 5.9 4 
49 Transaldolase  TALDO_HUMAN 37654.42188 6.36 4 
50 Antithrombin-III  ANT3_HUMAN 52936.76172 6.32 4 
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51 Plasma protease C1 inhibitor IC1_HUMAN 55303.33984 6.09 4 
52 Alpha-1-acid glycoprotein 2  A1AG2_HUMAN 23817.57031 5.03 4 
53 
6-phosphogluconate 
dehydrogenase 6PGD_HUMAN 53519.83984 6.8 4 
54 Complement C4-B  CO4B_HUMAN 193872.2031 6.89 4 
55 Keratin, type II cytoskeletal 1 K2C1_HUMAN 66136.96094 8.15 4 
56 Ig lambda-3 chain C regions  LAC3_HUMAN 11368.46973 6.92 3 
57 Cystatin-SN  CYTN_HUMAN 16561.28906 6.73 3 
58 Triosephosphate isomerase TPIS_HUMAN 31001.63086 5.65 3 
59 Coronin-1A COR1A_HUMAN 51545.64844 6.25 3 
60 Thioredoxin THIO_HUMAN 11959.67969 4.82 3 
61 Keratin, type I cytoskeletal 10 K1C10_HUMAN 58975.64063 5.13 3 
62 14-3-3 protein beta/alpha  1433B_HUMAN 28156.81055 4.76 3 
63 Ig heavy chain V-III region CAM HV307_HUMAN 13751.15039 9.65 3 
64 Heat shock 70 kDa protein 1A/1B HSP71_HUMAN 70238.96875 5.48 3 
65 Prolactin-inducible protein PIP_HUMAN 16791.73047 8.26 3 
66 Kininogen-1 KNG1_HUMAN 72785.92188 6.34 3 
67 Vitamin D-binding protein VTDB_HUMAN 54216.67969 5.4 3 
68 Beta-2-glycoprotein 1 APOH_HUMAN 39330.37891 8.34 3 
69 Vitronectin  VTNC_HUMAN 54914.98828 5.55 3 
70 Cystatin-SA  CYTT_HUMAN 16664.15039 4.85 3 
71 Plastin-2 PLSL_HUMAN 70703.77344 5.29 3 
72 14-3-3 protein sigma 1433S_HUMAN 27848.66992 4.68 3 
73 Keratin, type II cytoskeletal 6B  K2C6B_HUMAN 60260.23047 8.09 3 
74 Ig kappa chain C region IGKC_HUMAN 11739.62988 5.58 2 
75 Ig kappa chain V-I region EU  KV106_HUMAN 11872.74023 8.62 2 
76 
Inter-alpha-trypsin inhibitor heavy 
chain H4  ITIH4_HUMAN 103476.9297 6.51 2 
77 Moesin  MOES_HUMAN 67869.75781 6.08 2 
78 Ig heavy chain V-III region BRO  HV305_HUMAN 13310.37012 6.45 2 
79 Involucrin INVO_HUMAN 68529.17969 4.62 2 
80 Protein S100-P S100P_HUMAN 10439.20996 4.75 2 
81 Histone H4 H4_HUMAN 11360.37988 11.36 2 
82 Lactoperoxidase PERL_HUMAN 80972.67969 8.89 2 
83 
Deleted in malignant brain tumors 
1 protein  DMBT1_HUMAN 266593.1875 5.18 2 
84 Transketolase TKT_HUMAN 68386.57813 7.58 2 
85 Ig kappa chain V-III region WOL KV305_HUMAN 11830.87988 9.07 2 
86 Ig heavy chain V-III region TIL HV304_HUMAN 12440.03027 9.24 2 
87 Ig heavy chain V-III region VH26 HV303_HUMAN 12712.17969 8.49 2 
88 Olfactomedin-4  OLFM4_HUMAN 57473.73047 5.5 2 
89 Cystatin-A CYTA_HUMAN 10999.66016 5.38 2 
90 Ig heavy chain V-III region GAL  HV320_HUMAN 12814.17969 8.7 2 
91 Apolipoprotein A-II APOA2_HUMAN 11259.87012 6.26 2 
92 Carbonic anhydrase 6  CAH6_HUMAN 35436.57031 6.51 2 
93 
Neutrophil gelatinase-associated 
lipocalin  NGAL_HUMAN 22711.67969 9.02 2 
94 Neutrophil defensin 3  DEF3_HUMAN 10514.08984 5.71 2 
95 
Interleukin-1 receptor antagonist 
protein  IL1RA_HUMAN 20317.88086 5.83 2 
96 Brain acid soluble protein 1 BASP1_HUMAN 22680.00977 4.64 2 
97 
Peptidyl-prolyl cis-trans isomerase 
A PPIA_HUMAN 18184.83984 7.68 2 
98 Gelsolin  GELS_HUMAN 85966.10156 5.9 2 
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Saliva, plasma and ETT cytokine quantification: 
 
 
 
	 	 	 	 	 	 	 	
Sample  PN Date  
Respiratory 
pathogen 
Sample 
time  IL-8  IL-1β  IL-6 
 in dental plaque point 
SAL PN002 30/07/13 x d1 118008.2 2884.96 21780.46 
SAL PN002 02/08/13 x d4 233.66 5569.67 13.46 
SAL PN002 05/08/13 x d7 576716.92 15310.08 10326.68 
SAL PN004 04/08/13 x d1 99636.88 4148.64 5465.98 
SAL PN004 09/08/13 x d5 2589.68 491.7 58.43 
SAL PN004 11/08/13 x d7 6747.93 755.25 517.73 
SAL PN004 23/08/13 x WARD 49.61 29.41 0 
SAL PN004 26/08/13 x WARD 121.82 107.46 24.92 
SAL PN004 31/08/13 x WARD 17.56 45.31 0 
SAL PN004 04/10/13 x WARD 18.42 46.53 0 
SAL PN004 16/05/14 x d1* 1555.03 5394.17 46.87 
SAL PN004 22/05/14 x d6* 2134 6365.93 368.13 
SAL PN007 20/08/13 Y d3 42072.25 8338.68 418.51 
SAL PN007 22/09/13 Y WARD 24.02 18.87 22.41 
SAL PN010 23/08/13 x d1 738.07 1121.46 26.63 
SAL PN010 25/08/13 x d3 113.13 208.93 14.84 
SAL PN010 11/09/13 x WARD 21.7 45.92 20.34 
SAL PN012 30/08/13 Y d5 13048.92 17168.84 38.09 
SAL PN012 02/09/13 Y d8 5129 4003.84 173.11 
SAL PN012 09/09/13 Y d15 42525.48 60147.49 12275.72 
SAL PN021 07/10/13 Y d1 1336.8 4678.3 47.5 
SAL PN021 09/10/13 Y d3 375.33 462.17 41.59 
SAL PN022 09/10/13 x d1 20023.6 287.4 134.2 
SAL PN022 12/10/13 x d4 17872.5 3797.3 1137.7 
SAL PN028 31/10/13 Y d3 8863.14 2741.7 96.06 
SAL PN028 03/11/13 Y d6 6747.93 1380.56 56 
SAL PN028 10/11/13 Y d13 256.19 139.29 11.72 
SAL PN038 13/01/14 x d4 236.15 141.61 19.93 
SAL PN045 15/02/14 x d13 890.3 886.58 213.97 
SAL PN046 06/02/14 Y d1 502664.5 75386.85 341237.95 
SAL PN046 08/02/14 Y d3 11631.89 25218.47 3076.35 
SAL PN046 10/02/14 Y d5 1865.44 4212.16 585.16 
SAL PN046 11/02/14 Y d6 123297.02 59232.76 51413.34 
SAL PN046 18/02/14 Y d13 610341.51 31131.69 8685.59 
SAL PN046 03/03/14 Y d26 806.13 259.12 75.76 
SAL PN046 18/03/14 Y d41 335666.18 11527.93 26681.68 
SAL PN046 28/03/14 Y d51 397793.19 63957.67 57809.31 
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SAL PN050 18/02/14 x d1 4146.05 3507.56 101.21 
SAL PN051 19/02/14 Y d1 13749.03 5052.41 1690.26 
SAL PN060 12/03/14 Y d3 29605.76 5875.1 599.53 
SAL PN060 20/03/14 Y d11 22501.02 5934.37 1616.99 
SAL PN060 27/03/14 Y d18 2255.99 1639.81 179.67 
SAL PN062 17/03/14 Y d1 1723.35 2274.42 110.23 
SAL PN079 21/05/14 Y d8 7734.73 742.25 66.75 
SAL PN083 26/05/14 Y d1 3745.01 9635.92 3810.54 
SAL PN083 29/05/14 Y d4 1217.9 569.07 17.44 
SAL PN099 10/07/14 Y d1 2661.64 123.75 34.72 
SAL PN099 12/07/14 Y d3 464.4 555.5 72.91 
SAL PN099 14/07/14 Y d5 511.23 522.78 96.06 
SAL PN099 21/07/14 Y d12 2182.05 1037.65 44.72 
SAL PN099 04/08/14 Y d26 1337.8 148.73 220.15 
SAL PN104 18/07/14 Y d1 378870.73 927.61 460.05 
SAL PN106 19/07/14 Y d1 46839.8 38079.77 530.64 
SAL PN106 15/08/14 Y WARD 160.58 66.74 0 
SAL PN107 27/07/14 Y d1 22032.61 3805.47 6138.83 
SAL PN107 30/07/14 Y d4 13464.57 13451.2 636.83 
SAL PN109 02/08/14 Y d1 13324.56 5476.11 278.72 
SAL PN109 05/08/14 Y d4 126.97 90.83 0 
SAL PN109 08/08/14 Y d7 54477.45 10383.36 11288.71 
SAL B1 29/04/14 Healthy control d1 199.38 98.01 19.93 
SAL B2 01/05/14 Healthy control d3 99.05 134.72 20.76 
SAL B3 06/05/14 Healthy control d8 63.5 45.31 20.76 
SAL B4 07/05/14 Healthy control d9 13.31 30.48 0 
SAL B5 14/05/14 Healthy control d16 133.58 77.46 11.72 
SAL D1 29/04/14 Healthy control d1 100.18 121.63 0 
SAL D2 06/05/14 Healthy control d8 56.39 112.39 14.84 
SAL D3 07/05/14 Healthy control d9 53.81 96.18 24.92 
SAL D4 14/05/14 Healthy control d16 160.58 166.32 19.93 
PL	 PN002 30/07/13 x d1 295.83 0 223.35 
PL	 PN002 01/08/13 x d3 199.83 1.38 1528.78 
PL	 PN002 03/08/13 x d5 898.65 7.32 951.05 
PL	 PN002 05/08/13 x d7 486.04 2.56 292.97 
PL	 PN007 18/08/13 Y d1 308.14 4.58 103.36 
PL	 PN007 20/08/13 Y d3 305.41 3.37 65.63 
PL	 PN007 23/08/13 Y d6 1317.57 12.78 61.43 
PL	 PN004 04/08/13 x d1 74.56 3.24 405.41 
PL	 PN004 06/08/13 x d3 123.98 4.31 252.13 
PL	 PN004 09/08/13 x d6 223.61 3.91 78.38 
PL	 PN004 10/08/13 x d7 89.86 3.51 96.93 
PL	 PN004 23/08/13 x d20 280.66 6.27 37.3 
PL	 PN010 23/08/13 x d1 48.58 4.04 38.46 
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PL	 PN010 25/08/13 x d3 45.96 3.24 9.67 
PL	 PN012 26/08/13 Y d1 196.39 0 201.79 
PL	 PN012 28/08/13 Y d3 74.56 3.91 63.8 
PL	 PN012 30/08/13 Y d5 106.73 4.04 188.32 
PL	 PN012 02/09/13 Y d8 48.05 3.64 22.62 
PL	 PN012 09/09/13 Y d15 51.31 2.56 28.57 
PL	 PN012 16/09/13 Y d22 94.3 39.26 31.78 
PL	 PN012 23/09/13 Y d29 39.17 6.12 23.81 
PL	 PN019 05/10/13 x d1 128.67 2.05 151.79 
PL	 PN019 07/10/13 x d3 157.42 3.77 139.79 
PL	 PN019 09/10/13 x d5 134.74 4.04 141.08 
PL	 PN021 07/10/13 Y d1 65.37 17.38 350.9 
PL	 PN021 09/10/13 Y d3 27.7 4.58 31.61 
PL	 PN021 11/10/13 Y d5 76.82 11.24 51.22 
PL	 PN022 09/10/13 x d1 99.4 3.37 196.28 
PL	 PN022 12/10/13 x d3 123.98 7.48 539.12 
PL	 PN022 15/10/13 x d7 131.07 3.37 166.35 
PL	 PN028 29/10/13 Y d1 79.92 4.44 65.01 
PL	 PN028 31/10/13 Y d3 36.93 4.04 34.01 
PL	 PN028 03/11/13 Y d6 16.56 5.69 25.19 
PL	 PN028 10/11/13 Y d13 38.72 5.13 34.9 
PL	 PN030 02/11/13 Y d1 132.28 3.77 127.58 
PL	 PN030 05/11/13 Y d4 163.24 4.31 156.02 
PL	 PN030 07/11/13 Y d6 206.32 6.56 315.99 
PL	 PN030 14/11/13 Y d13 556.57 7.63 310.06 
PL	 PN038 09/01/14 Y d1 54.14 2.5 63.2 
PL	 PN038 13/01/14 Y d4 54.14 5.34 72.75 
PL	 PN038 19/01/14 Y d10 84.77 4.31 136.64 
PL	 PN038 26/01/14 Y d17 44.95 4.04 33.66 
PL	 PN045 03/02/14 x d1 30.71 4.51 84.41 
PL	 PN045 05/02/14 x d3 33.11 3.91 29.98 
PL	 PN045 08/02/14 x d6 92.5 10.68 137.26 
PL	 PN045 15/02/14 x d13 53 4.44 15.19 
PL	 PN045 22/02/14 x d20 44.44 3.51 15.59 
PL	 PN046 06/02/14 Y d1 12614.68 25.22 6748.59 
PL	 PN046 08/02/14 Y d3 83.13 3.91 158.9 
PL	 PN046 10/02/14 Y d5 100.83 3.44 247.47 
PL	 PN046 11/02/14 Y d6 175.49 4.04 716.16 
PL	 PN046 18/02/14 Y d13 531.94 7.63 549.99 
PL	 PN046 25/02/14 Y d20 105.73 4.04 47.85 
PL	 PN046 03/03/14 Y d26 108.77 4.17 139.79 
PL	 PN046 11/03/14 Y d34 72.35 4.31 57.47 
PL	 PN049 09/02/14 Y d1 248.88 3.51 128.75 
PL	 PN049 11/02/14 Y d3 145.01 3.24 110.21 
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PL	 PN050 18/02/14 x d1 43.7 4.04 86.78 
PL	 PN050 21/02/14 x d3 115.07 2.84 298.55 
PL	 PN050 24/02/14 x d6 101.79 2.91 10.97 
PL	 PN050 03/03/14 x d13 47 1.97 40.04 
PL	 PN051 19/02/14 Y d1 97.99 3.37 219.3 
PL	 PN051 22/02/14 Y d4 86.44 4.31 51.22 
PL	 PN051 25/02/14 Y d7 100.83 4.04 70.08 
PL	 PN051 03/03/14 Y d13 114 3.84 22.49 
PL	 PN056 05/03/14 x d1 210.04 4.58 94.29 
PL	 PN056 07/03/14 x d3 92.5 5.27 174.16 
PL	 PN056 10/03/14 x d6 920.03 16.1 47.85 
PL	 PN056 17/03/14 x d13 69.49 5.76 48.32 
PL	 PN060 10/03/14 Y d1 89.86 2.42 61.43 
PL	 PN060 12/03/14 Y d3 239.52 4.52 119.21 
PL	 PN060 20/03/14 Y d11 244.53 0 102.19 
PL	 PN060 27/03/14 Y d18 79.75 1.51 154.04 
PL	 PN062 17/03/14 Y d1 104.7 1.71 191.27 
PL	 PN062 20/03/14 Y d4 252.23 3.36 566.92 
PL	 PN062 23/03/14 Y d7 99.96 1.23 147.78 
PL	 PN079 14/05/14 Y d1 140.43 2.5 205.47 
PL	 PN079 21/05/14 Y d8 209.13 2.05 256.95 
PL	 PN004 16/05/14 x d1 129.92 3.22 319.14 
PL	 PN004 18/05/14 x d3 555.68 0 278.58 
PL	 PN004 20/05/14 x d5 42.79 0 78.81 
PL	 PN083 26/05/14 Y d1 148.37 0 455.3 
PL	 PN083 29/05/14 Y d4 103.5 0 36.22 
PL	 PN083 01/06/14 Y d7 484.51 3.08 11.58 
PL	 PN083 06/06/14 Y d12 99.38 0 15.31 
PL	 PN099 10/07/14 x d1 129.92 0 19.01 
PL	 PN099 12/07/14 x d3 75.03 0 31.02 
PL	 PN099 14/07/14 x d5 70.53 0 19.82 
PL	 PN099 21/07/14 x d12 196.3 0 93.78 
PL	 PN099 27/07/14 x d18 247.08 4.82 83.24 
PL	 PN099 04/08/14 x d26 104.7 2.79 72.16 
PL	 PN104 18/07/14 Y d1 409.65 5.28 1861.79 
PL	 PN104 20/07/14 Y d3 257.48 0 92.78 
PL	 PN104 23/07/14 Y d6 260.16 0 66.01 
PL	 PN104 30/07/14 Y d13 479.77 1.88 126.33 
PL	 PN106 19/07/14 Y d1 184.18 1.71 134.53 
PL	 PN106 21/07/14 Y d3 202.63 3.36 83.24 
PL	 PN106 23/07/14 Y d5 109.64 0 86 
PL	 PN106 01/08/14 Y d13 88.86 0 103.29 
PL	 PN107 27/07/14 Y d1 110.9 0 32.62 
PL	 PN107 30/07/14 Y d4 102.31 1.88 95.82 
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PL	 PN107 01/08/14 Y d6 41.6 1.51 32.21 
PL	 PN109 02/08/14 Y d1 61.78 14.3 36 
PL	 PN109 05/08/14 Y d4 544.93 28.63 75.42 
PL	 PN109 07/08/14 Y d6 86.77 22.89 34.27 
ETT PN002 07/08/13 x d9 28098.81 100.49 30.15 
ETT PN007 20/08/13 Y d6 22722.69 1187.11 2.64 
ETT PN010 27/08/13 x d5 3432.2 193.02 26.27 
ETT PN012 27/08/13 Y d2 3000.32 17.15 23.18 
ETT PN012 09/09/13 Y d13 18916.02 18188.25 671.44 
ETT PN021 10/10/13 Y d4 27800.64 13027.32 15.54 
ETT PN022 15/10/13 x d8 14685.34 1079.76 6.44 
ETT PN028 04/11/13 Y d33 349.21 2.79 2.36 
ETT PN030 19/11/13 Y d17 34673.58 1842.13 7.19 
ETT PN038 11/01/14 Y d3 1878.55 17.15 14.2 
ETT PN038 23/01/14 Y d14 29646.68 1673.36 664.8 
ETT PN045 11/02/14 x d8 4411.53 34.43 2.27 
ETT PN045 18/02/14 x d15 9596.89 243.86 122.4 
ETT PN046 11/02/14 Y d5 38039.51 11064.98 684.94 
ETT PN046 11/03/14 Y d34 20889.85 765.03 125 
ETT PN046 23/03/14 Y d47 39310.19 3654.07 23.65 
ETT PN046 24/03/14 Y d48 32315.17 1789.71 12.95 
ETT PN049 14/02/14 Y d6 22016.03 661.1 420.35 
ETT PN050 20/02/14 x d3 27214.29 8380.95 6.91 
ETT PN050 06/03/14 x d15 11046.76 444.92 292.98 
ETT PN051 05/03/14 Y d14 8100.58 203.71 493.11 
ETT PN056 13/03/14 x d14 18050.96 305.69 1116.09 
ETT PN056 19/03/14 x d20 9501.3 436.58 503.04 	 	 	 	 	 	 	 		 	 	 	 	 	 	 		 	 	 	   No detection 	 		 	 	 	   Near out of detection limits 	 	 	 	   In acceptable range 	 	 	 	   Over detection limit >than 	 		 	 	 	 	 	 	 	
Sample  PN Date  
Respiratory 
pathogen 
Sample 
time   IL-10  TNFα  IL-12p70 
 in dental plaque point 
SAL PN002 30/07/13 x d1 44.13 986.11 0 
SAL PN002 02/08/13 x d4 9.12 7.21 8.77 
SAL PN002 05/08/13 x d7 27.24 872.78 0 
SAL PN004 04/08/13 x d1 25.19 0 39.81 
SAL PN004 09/08/13 x d5 0 0 27.3 
SAL PN004 11/08/13 x d7 0 15.58 18.34 
SAL PN004 23/08/13 x WARD 11.57 0 31.18 
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SAL PN004 26/08/13 x WARD 0 0 32.81 
SAL PN004 31/08/13 x WARD 0 0 0 
SAL PN004 04/10/13 x WARD 0 0 20.29 
SAL PN004 16/05/14 x d1* 0 0 19.68 
SAL PN004 22/05/14 x d6* 0 0 0 
SAL PN007 20/08/13 Y d3 0 0 15.23 
SAL PN007 22/09/13 Y WARD 0 0 0 
SAL PN010 23/08/13 x d1 0 0 0 
SAL PN010 25/08/13 x d3 0 0 15.23 
SAL PN010 11/09/13 x WARD 0 0 23.68 
SAL PN012 30/08/13 Y d5 13.06 0 27.3 
SAL PN012 02/09/13 Y d8 11.13 0 0 
SAL PN012 09/09/13 Y d15 18.44 24.59 23.68 
SAL PN021 07/10/13 Y d1 0 0 14.1 
SAL PN021 09/10/13 Y d3 0 0 20.29 
SAL PN022 09/10/13 x d1 0 13.7 11.4 
SAL PN022 12/10/13 x d4 0 0 0 
SAL PN028 31/10/13 Y d3 18.13 11.79 11.44 
SAL PN028 03/11/13 Y d6 0 0 37.97 
SAL PN028 10/11/13 Y d13 0 0 11.44 
SAL PN038 13/01/14 x d4 0 0 23.68 
SAL PN045 15/02/14 x d13 0 0 18.34 
SAL PN046 06/02/14 Y d1 142.22 6074.83 0 
SAL PN046 08/02/14 Y d3 0 14.96 17.08 
SAL PN046 10/02/14 Y d5 0 0 16.16 
SAL PN046 11/02/14 Y d6 0 14.61 20.29 
SAL PN046 18/02/14 Y d13 20 11.75 51.81 
SAL PN046 03/03/14 Y d26 0 0 15.23 
SAL PN046 18/03/14 Y d41 29.71 40.24 36.21 
SAL PN046 28/03/14 Y d51 119.39 605.96 0 
SAL PN050 18/02/14 x d1 11.57 0 29.23 
SAL PN051 19/02/14 Y d1 46.4 10.9 54.01 
SAL PN060 12/03/14 Y d3 14.38 0 22.99 
SAL PN060 20/03/14 Y d11 0 0 17.08 
SAL PN060 27/03/14 Y d18 0 0 0 
SAL PN062 17/03/14 Y d1 0 0 20.29 
SAL PN079 21/05/14 Y d8 0 25.5 11.44 
SAL PN083 26/05/14 Y d1 0 0 18.34 
SAL PN083 29/05/14 Y d4 0 14.61 0 
SAL PN099 10/07/14 Y d1 0 0 0 
SAL PN099 12/07/14 Y d3 0 0 15.23 
SAL PN099 14/07/14 Y d5 0 0 27.3 
SAL PN099 21/07/14 Y d12 0 0 0 
SAL PN099 04/08/14 Y d26 0 0 22.3 
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SAL PN104 18/07/14 Y d1 0 25.04 0 
SAL PN106 19/07/14 Y d1 14.38 24.59 20.29 
SAL PN106 15/08/14 Y WARD 0 0 0 
SAL PN107 27/07/14 Y d1 0 0 0 
SAL PN107 30/07/14 Y d4 0 17.43 17.08 
SAL PN109 02/08/14 Y d1 0 20.12 21.97 
SAL PN109 05/08/14 Y d4 0 21.9 0 
SAL PN109 08/08/14 Y d7 13.74 0 0 
SAL B1 29/04/14 Healthy control d1 11.13 0 13.4 
SAL B2 01/05/14 Healthy control d3 0 14.61 0 
SAL B3 06/05/14 Healthy control d8 0 0 16.16 
SAL B4 07/05/14 Healthy control d9 0 0 0 
SAL B5 14/05/14 Healthy control d16 0 18.34 17.71 
SAL D1 29/04/14 Healthy control d1 0 0 13.38 
SAL D2 06/05/14 Healthy control d8 0 0 0 
SAL D3 07/05/14 Healthy control d9 18.75 0 20.29 
SAL D4 14/05/14 Healthy control d16 0 0 29.23 
PL	 PN002 30/07/13 x d1 11.03 0 1.99 
PL	 PN002 01/08/13 x d3 6.62 0 0 
PL	 PN002 03/08/13 x d5 17.32 2.98 4.15 
PL	 PN002 05/08/13 x d7 30.74 0 0 
PL	 PN007 18/08/13 Y d1 5.54 0 0 
PL	 PN007 20/08/13 Y d3 5.29 0 0 
PL	 PN007 23/08/13 Y d6 4.32 0 2.99 
PL	 PN004 04/08/13 x d1 4.92 0 0 
PL	 PN004 06/08/13 x d3 12.26 0 2.54 
PL	 PN004 09/08/13 x d6 6.56 0 4.44 
PL	 PN004 10/08/13 x d7 6.82 0 4.15 
PL	 PN004 23/08/13 x d20 5.17 0 3.93 
PL	 PN010 23/08/13 x d1 2.28 0 0 
PL	 PN010 25/08/13 x d3 3.62 0 3.43 
PL	 PN012 26/08/13 Y d1 6.95 0 0 
PL	 PN012 28/08/13 Y d3 5.41 0 0 
PL	 PN012 30/08/13 Y d5 8.62 0 0 
PL	 PN012 02/09/13 Y d8 6.69 0 0 
PL	 PN012 09/09/13 Y d15 3.97 0 0 
PL	 PN012 16/09/13 Y d22 8.91 0 2.54 
PL	 PN012 23/09/13 Y d29 3.97 0 2.99 
PL	 PN019 05/10/13 x d1 3.62 3.62 2.54 
PL	 PN019 07/10/13 x d3 3.38 0 2.22 
PL	 PN019 09/10/13 x d5 4.32 0 5.77 
PL	 PN021 07/10/13 Y d1 10.76 2.77 4.29 
PL	 PN021 09/10/13 Y d3 3.32 0 2.99 
PL	 PN021 11/10/13 Y d5 4.56 3.62 5.32 
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PL	 PN022 09/10/13 x d1 3.62 0 2.22 
PL	 PN022 12/10/13 x d3 5.66 5.73 0 
PL	 PN022 15/10/13 x d7 4.09 0 0 
PL	 PN028 29/10/13 Y d1 3.03 0 0 
PL	 PN028 31/10/13 Y d3 0 0 3.43 
PL	 PN028 03/11/13 Y d6 2.54 0 2.99 
PL	 PN028 10/11/13 Y d13 4.32 0 2.54 
PL	 PN030 02/11/13 Y d1 5.05 0 0 
PL	 PN030 05/11/13 Y d4 5.41 0 0 
PL	 PN030 07/11/13 Y d6 25.7 0 2.54 
PL	 PN030 14/11/13 Y d13 15.78 0 5.47 
PL	 PN038 09/01/14 Y d1 2.54 0 0 
PL	 PN038 13/01/14 Y d4 4.09 0 0 
PL	 PN038 19/01/14 Y d10 2.15 0 2.22 
PL	 PN038 26/01/14 Y d17 0 0 4.73 
PL	 PN045 03/02/14 x d1 2.28 0 2.54 
PL	 PN045 05/02/14 x d3 3.03 0 2.99 
PL	 PN045 08/02/14 x d6 8.48 8.7 10.26 
PL	 PN045 15/02/14 x d13 4.32 0 0 
PL	 PN045 22/02/14 x d20 5.66 0 0 
PL	 PN046 06/02/14 Y d1 45.73 0 4.73 
PL	 PN046 08/02/14 Y d3 0 0 0 
PL	 PN046 10/02/14 Y d5 5.41 0 0 
PL	 PN046 11/02/14 Y d6 8.48 0 1.97 
PL	 PN046 18/02/14 Y d13 13.49 0 0 
PL	 PN046 25/02/14 Y d20 4.8 0 0 
PL	 PN046 03/03/14 Y d26 6.95 0 0 
PL	 PN046 11/03/14 Y d34 3.97 0 2.54 
PL	 PN049 09/02/14 Y d1 18.51 0 0 
PL	 PN049 11/02/14 Y d3 15.48 0 0 
PL	 PN050 18/02/14 x d1 2.66 0 0 
PL	 PN050 21/02/14 x d3 4.44 0 0 
PL	 PN050 24/02/14 x d6 2.6 0 0 
PL	 PN050 03/03/14 x d13 2.54 0 5.77 
PL	 PN051 19/02/14 Y d1 5.29 4.46 3.71 
PL	 PN051 22/02/14 Y d4 5.66 0 3.71 
PL	 PN051 25/02/14 Y d7 4.92 2.98 0 
PL	 PN051 03/03/14 Y d13 14.23 0 4.44 
PL	 PN056 05/03/14 x d1 4.86 0 3.43 
PL	 PN056 07/03/14 x d3 8.62 0 4.44 
PL	 PN056 10/03/14 x d6 7.91 0 0 
PL	 PN056 17/03/14 x d13 0 3.62 0 
PL	 PN060 10/03/14 Y d1 3.26 0 0 
PL	 PN060 12/03/14 Y d3 6.51 0 0 
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PL	 PN060 20/03/14 Y d11 3.48 0 2.09 
PL	 PN060 27/03/14 Y d18 1.64 0 3.61 
PL	 PN062 17/03/14 Y d1 2.11 0 0 
PL	 PN062 20/03/14 Y d4 2.98 0 3.61 
PL	 PN062 23/03/14 Y d7 2.74 0 1.44 
PL	 PN079 14/05/14 Y d1 3.14 0 1.78 
PL	 PN079 21/05/14 Y d8 5.18 0 0 
PL	 PN004 16/05/14 x d1 40.4 0 10.81 
PL	 PN004 18/05/14 x d3 66.28 0 8.76 
PL	 PN004 20/05/14 x d5 33.61 0 9.11 
PL	 PN083 26/05/14 Y d1 3.92 0 1.78 
PL	 PN083 29/05/14 Y d4 1.8 0 2.09 
PL	 PN083 01/06/14 Y d7 2.74 0 3.61 
PL	 PN083 06/06/14 Y d12 2.58 0 2.09 
PL	 PN099 10/07/14 x d1 3.66 0 0 
PL	 PN099 12/07/14 x d3 3.31 0 0 
PL	 PN099 14/07/14 x d5 3.35 0 1.78 
PL	 PN099 21/07/14 x d12 4.11 0 0 
PL	 PN099 27/07/14 x d18 4.58 0 1.78 
PL	 PN099 04/08/14 x d26 8.84 0 1.61 
PL	 PN104 18/07/14 Y d1 50.52 0 3.05 
PL	 PN104 20/07/14 Y d3 5.08 0 3.84 
PL	 PN104 23/07/14 Y d6 12.9 2.26 1.78 
PL	 PN104 30/07/14 Y d13 23.72 0 1.44 
PL	 PN106 19/07/14 Y d1 3.83 0 0 
PL	 PN106 21/07/14 Y d3 3.66 0 0 
PL	 PN106 23/07/14 Y d5 5.5 0 2.09 
PL	 PN106 01/08/14 Y d13 3.14 0 2.62 
PL	 PN107 27/07/14 Y d1 3.92 0 2.94 
PL	 PN107 30/07/14 Y d4 3.66 0 1.44 
PL	 PN107 01/08/14 Y d6 2.34 0 0 
PL	 PN109 02/08/14 Y d1 3.14 16.84 3.05 
PL	 PN109 05/08/14 Y d4 3.7 29.25 0 
PL	 PN109 07/08/14 Y d6 3.66 25.71 1.44 
ETT PN002 07/08/13 x d9 0 5.18 0 
ETT PN007 20/08/13 Y d6 0 2.42 0 
ETT PN010 27/08/13 x d5 0 3.16 0 
ETT PN012 27/08/13 Y d2 1.8 0 2.09 
ETT PN012 09/09/13 Y d13 1.38 2184.73 0 
ETT PN021 10/10/13 Y d4 1.17 5.32 0 
ETT PN022 15/10/13 x d8 0 2.42 2.09 
ETT PN028 04/11/13 Y d33 2.27 0 3.38 
ETT PN030 19/11/13 Y d17 2.9 11.71 3.61 
ETT PN038 11/01/14 Y d3 1.29 0 0 
	 378 
ETT PN038 23/01/14 Y d14 0 70.83 4.02 
ETT PN045 11/02/14 x d8 0 0 0 
ETT PN045 18/02/14 x d15 0 0 1.44 
ETT PN046 11/02/14 Y d5 1.88 25.33 0 
ETT PN046 11/03/14 Y d34 0 1.76 0 
ETT PN046 23/03/14 Y d47 1.56 11.26 0 
ETT PN046 24/03/14 Y d48 2.11 4.76 2.09 
ETT PN049 14/02/14 Y d6 0 13.63 1.44 
ETT PN050 20/02/14 x d3 0 24.23 0 
ETT PN050 06/03/14 x d15 0 0 2.09 
ETT PN051 05/03/14 Y d14 0 2.72 4.2 
ETT PN056 13/03/14 x d14 1.64 2.72 0 
ETT PN056 19/03/14 x d20 1.17 2.42 0 
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Appendix IV 
In vitro biofilm development analysis 
 
 
 
 
- Ethical approval documents for dental plaque collection from healthy 
volunteers 
- ETT biofilm enumeration (CFU/cm2) for single and mixed species  
- Mixed species MIC and MBIC tabulated data: 
- Mixed species enumeration post CHX exposure 
- CFU/ml counts for aerobic and anaerobic species, and C. albicans 
after exposure to CHX for 30 min, 1 h and 12 h (relation to figure 5.13, 
section 5.3.5.1) 
- CFU/ml counts for aerobic and anaerobic species, and C. albicans 
after exposure to salivary pHs  (relation to figure 5.16, section 5.3.6.1) 
- CFU/ml counts of S. aureus inoculated CDFF biofilms after exposure 
to different salivary pHs 
- CFU/ml counts of P. aeruginosa inoculated CDFF biofilms after 
exposure to different salivary pHs 
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Ethical approval documents for dental plaque collection from healthy 
volunteers: 
 
 
(Version 3, 30th January 2015) 
CONSENT FORM 
EVALUATING THE EFFECTS OF RESPIRATORY PATHOGENS WITHIN 
ORAL BIOFILMS 
Name of Researchers: Kirsty M Sands, Professor David W Williams, Dr Melanie J Wilson, 
Dr Matthew P Wise and Professor Michael AO Lewis 
Sandsk1@cardiff.ac.uk 
            
Please initial 
 
A. I confirm that I have read and understood the study information 
sheet (Version 3, 30th January) and have had an opportunity to ask 
any questions and had sufficient time to come to my decision. 
 
B. I give permission that the dental plaque be collected and stored 
within the Cardiff   School of Dentistry only for microbial biofilm 
analysis  	
C. I understand that my participation is voluntary and that I am free to 
withdraw at any time prior to my samples being taken in the study 
without giving any reason, without my medical care or legal rights 
being affected.  
 
D. I understand that results from this study may be used in 
medical/scientific journals and/or publications, but donated plaque 
will not be identifiable. 	
E. I understand that the sample is given as a “gift” and that I will have 
no right to a share of any profits which might arise from research 
using it (e.g. as part of a new medical treatment or test). 
 
F. I understand that during the collection of dental plaque there will be 
inadvertent collection of human tissue, and furthermore the storage 
of human tissue. Any tissue collected will not be used in this study 
and will be destroyed in the experimental process.   
_________________  ________________  _________________  
Name of Cardiff Uni  
volunteer  Date  Signature  
 
_________________  ________________  ___________________  
Name of Person  Date  Signature   
taking consent  
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Version 3, 30th January 2015  
 
 
PARTICIPANT INFORMATION SHEET 
Cardiff School of Dentistry 
 
EVALUATING THE EFFECTS OF RESPIRATORY 
PATHOGENS WITHIN ORAL BIOFILMS 
 
You are being invited to take part in a research study.  Before you decide it is important for 
you to understand why the research is being done and what it will involve.  Please take time 
to read the following information carefully and discuss it with others if you wish.  Ask us if 
there is anything that is not clear or if you would like more information.  Take time to decide 
whether or not you wish to take part. Thank you for reading this. 
 
1. What is the purpose of the study? 
 
Dental plaque is an oral biofilm, containing aggregates of several microbial species including 
both bacteria and fungi. To date over 800 bacterial species have been identified within the 
oral cavity, representing one of the largest human microbiome’ alongside the gastrointestinal 
tract. Studies have suggested that the dental plaque community can change to include 
respiratory pathogens (not usually present in the plaque of healthy individuals) once a 
patient undergoes mechanical ventilation in critical care (to assist breathing). Using an in 
vitro model to recreate the microbial shift determined from the patient study (introducing 
respiratory pathogens into the oral biofilm) allows the investigation into reasons behind this 
significant microbial shift, and also to explore the effects of antimicrobial mouthwashes such 
as Chlorhexidine. 
 
This study will involve using pooled dental plaque (a type of mixed species or polymicrobial 
biofilm) from 10 volunteers to develop oral biofilms using a constant depth film fermenter (an 
in vitro biofilm model). The aim of this study is to first create complex oral biofilms using 
healthy samples of dental plaque. Once biofilms have been developed a small inoculum of 
respiratory pathogens (P. aeruginosa) will be added to represent the changes that occur 
within the oral cavity within mechanically ventilated patients. Once the analysis and cell 
counting of P. aeruginosa and oral bacteria is complete, the experiment will be repeated 
changing parameters each time, including pH change, protein conditioning, adapting protein 
composition within artificial saliva and the use of a clinically relevant mouthwash 
(Chlorhexidine). The overall aim of this study is to evaluate the effects of certain conditions 
on the numbers of respiratory pathogens within the oral biofilm. The duration of the study is 
3 months. The research has been considered and accepted by the Research Ethics 
Committee within the School of Dentistry. The inclusion criteria to be followed are: >18 years 
of age, and the volunteer must not be taking any antibiotics.  
 
2. Why have I been chosen? 
 
You have been chosen as you meet the required inclusion/exclusion criteria (outlined above) 
and are deemed able to readily donate a sample of dental plaque. A total of 10 individuals 
will contribute to this study.   
 
3. Do I have to take part? 
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It is up to you to decide whether or not to take part.  If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to 
take part you are still free to withdraw without giving a reason any time before the sample is 
collected. After the samples have been collected, they will be pooled and anonymous and 
the volunteer can no longer withdraw their sample so it must remain in the study. Deciding 
not to take part or withdrawing will not affect any current or future treatment. Samples for 10 
volunteers will (ideally) be collected within the same session to prevent repeated sample 
freeze-thaw cycles and immediately pooled for storage. 
 
 
4. What will happen to me if I take part? 
 
One sample of dental plaque will be collected, which will take no longer than 5 minutes of 
your time. Dental instruments will be used to collect the sample, performed by a dentist. This 
procedure will be similar to the scraping performed in a routine dental exam.  
 
5.      What about confidentiality? 
 
Samples collected from a total of 10 volunteers will be pooled together. No personal 
identification data will be collected or used within this study. After the study any remaining 
aliquots will be destroyed via autoclaving at 121C for 15 min followed by sample incineration. 
During dental plaque collection it is likely the plaque sample will be contaminated with blood 
from the gums and some gingival crevicular fluid, therefore human tissue will be 
inadvertently collected.  Any human tissue inadvertently collected as ‘contaminant’ in this 
study will be stored with the pooled dental plaque samples but will not be used within the 
study. The pooled plaque will be collected via centrifugation and the supernatant autoclaved. 
Only microbial species will have adequate nutrients for growth and therefore upon use of 
dental plaque any human tissue will be destroyed. No personal identification will be 
recorded; the dental plaque is serving as a reservoir to be inserted into liquid media to grow 
microbial biofilms. Results of the study will be available at the end of the study for brief 
discussion. 
 
 
6. What do I have to do? 
 
The participant will be required to donate a sample of dental plaque in the morning of sample 
collection (Date to be confirmed) before lunchtime. Dental plaque from individuals will be 
pooled together and further divided into aliquots allowing for multiple repetitions of 
experiments. To comply with HTA guidelines aliquots of dental plaque will be stored in 
the -80C freezer, 4th Floor, room 404 freezer 2.  
 
 
7.         Are there any risks? 
 
There are no obvious risks to you in taking part in this study, however you may experience 
some minor bleeding and pain/discomfort of the gums around the collection site. This should 
however cease within a few minutes of collection 
 
8. What will happen to the results of the research study? 
 
Results from this study may form part of a publication (to be published at a later stage) A 
copy of the publication, if successful will be available within the School of Dentistry. No 
identification of individuals will occur within any written results from this study. Samples will 
be used for biofilm growth and autoclaved after cell counting and biofilm imaging using both 
scanning electron microscopy (SEM) and Confocal Laser Scanning Microscopy (CLSM) 
coupled with molecular fluorescent probes for species identification of respiratory pathogens. 
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9. Who is organising and funding the research? 
 
This study is organised within the School of Dentistry, with Professor David Williams and Dr 
Melanie Wilson as leading supervisors. The research is funded by The School of Dentistry, 
Cardiff University. 
 
 
10.    Contact for Further Information 
 
Miss Kirsty Sands 
Sandsk1@cardiff.ac.uk 
Mobile: 07703467561 
 
Any complaints can be made via contact with Dr Fiona Gagg – the Laboratory Manager 
(WhiteFs@cf.ac.uk 02920742546). 	
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ETT biofilm enumeration (CFU/cm2) for single species: 
 
 
Single species biofilm development on ETTs: 
       S. aureus  S. mutans P. aeruginosa C. albicans  
1 1.75E+07 1.75E+07 3.26E+07 1.86E+07 
2 4.78E+06 1.63E+07 1.86E+07 2.56E+07 
3 3.96E+06 4.78E+06 2.10E+07 1.52E+07 
4 1.98E+07 2.33E+06 2.10E+07 1.98E+07 
5 1.17E+06 2.91E+07 1.63E+07 1.75E+07 
6 4.55E+06 6.41E+06 2.68E+07 1.86E+07 
7 4.43E+06 2.21E+07 3.03E+07 2.21E+07 
8 5.22E+06 1.12E+07 3.56E+07 1.88E+07 
9 1.17E+07 2.68E+07 1.86E+07 2.68E+07 
Mean 8.12E+06 1.52E+07 2.45E+07 2.03E+07 
SD 6.60E+06 9.69E+06 6.97E+06 3.82E+06 
SEM  2.20E+06 3.23E+06 2.32E+06 1.27E+06 
 
  
	 385 
 
ETT biofilm enumeration (CFU/cm2) for mixed species: 
 
S. aureus and S. mutans mixed biofilms: P. aeruginosa and S. mutans mixed biofilms: 
         S. aureus  S. mutans 
 
  S. mutans P.aeruginosa 
1 7.69E+06 1.52E+06 
 
1 2.10E+06 4.31E+06 
2 3.26E+07 1.63E+06 
 
2 2.10E+06 1.63E+07 
3 5.48E+06 1.52E+06 
 
3 1.52E+06 2.68E+07 
4 2.68E+07 8.28E+06 
 
4 8.28E+06 1.17E+06 
5 2.91E+07 1.63E+07 
 
5 1.63E+07 3.61E+07 
6 8.51E+06 1.86E+07 
 
6 1.86E+07 3.15E+07 
7 2.80E+06 7.93E+05 
 
7 1.96E+06 4.90E+06 
8 8.28E+07 1.86E+07 
 
8 1.86E+07 3.96E+07 
9 8.98E+07 1.45E+07 
 
9 1.45E+07 2.10E+07 
Mean 3.17E+07 9.09E+06 
 
Mean 9.34E+06 2.02E+07 
SD 3.29E+07 7.94E+06 
 
SD 7.67E+06 1.44E+07 
SEM 1.10E+07 2.65E+06 
 
SEM 2.56E+06 4.81E+06 
       
 
      S. aureus and C. albicans mixed biofilms: P. aeruginosa and C. albicans mixed biofilms: 
         S.aureus C.albicans 
 
  P. aeruginosa C. albicans  
1 3.38E+06 3.85E+06 
 
1 3.38E+06 2.33E+06 
2 9.09E+05 3.26E+06 
 
2 5.36E+06 1.52E+07 
3 1.03E+06 4.78E+06 
 
3 7.58E+07 4.78E+06 
4 8.39E+06 2.10E+06 
 
4 7.23E+06 6.99E+06 
5 2.56E+06 2.80E+06 
 
5 2.80E+07 1.75E+07 
6 2.80E+06 3.50E+06 
 
6 3.61E+07 3.15E+07 
7 3.85E+06 7.58E+05 
 
7 2.68E+07 2.56E+07 
8 2.10E+06 5.59E+06 
 
8 2.21E+07 7.32E+06 
9 8.65E+06 1.43E+06 
 
9 8.51E+06 6.76E+06 
Mean 3.74E+06 3.12E+06 
 
Mean 2.37E+07 1.31E+07 
SD 2.88E+06 1.55E+06 
 
SD 2.28E+07 1.01E+07 
SEM 9.59E+05 5.16E+05 
 
SEM 7.59E+06 3.36E+06 
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Mixed species MIC and MBIC tabulated data: 
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Mixed species planktonic (CFU/ml) counts following CHX exposure at sub-
MIC level in microtitre wells: 
 
Mixed species planktonic counts 
    S. aureus  S. mutans  
1 1.30E+04 2.30E+03 
2 2.60E+04 3.20E+03 
3 1.90E+03 1.90E+03 
Mean 1.36E+04 2.47E+03 
SD 1.21E+04 6.66E+02 
     P. aeruginosa S. mutans 
1 8.80E+04 0.00E+00 
2 8.80E+04 0.00E+00 
3 8.80E+04 0.00E+00 
Mean 8.80E+04 0.00E+00 
SD 0.00E+00 0.00E+00 
     S. aureus C. albicans 
1 6.60E+04 1.70E+04 
2 3.80E+04 2.10E+04 
3 5.10E+04 3.20E+04 
Mean 5.17E+04 2.33E+04 
SD 1.40E+04 7.77E+03 
     P. aeruginosa C. albicans 
1 3.80E+04 0.00E+00 
2 3.80E+04 0.00E+00 
3 3.80E+04 0.00E+00 
Mean 3.80E+04 0.00E+00 
SD 0.00E+00 0.00E+00 
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Mixed species biofilm (CFU/ml) counts following CHX exposure at sub-MIC 
level in microtitre wells: 
 
Mixed species biofilm counts 
     S. aureus S. mutans 
1 3.90E+04 1.99E+02 
2 3.90E+04 1.09E+02 
3 4.20E+04 1.30E+02 
Mean 4.00E+04 1.46E+02 
SD 1.73E+03 4.71E+01 
     P. aeruginosa S. mutans 
1 5.10E+05 0.00E+00 
2 4.90E+05 0.00E+00 
3 2.80E+05 0.00E+00 
Mean 4.27E+05 0.00E+00 
SD 1.27E+05 0.00E+00 
     S. aureus C. albicans 
1 3.20E+04 1.30E+04 
2 3.90E+04 2.90E+03 
3 2.90E+04 9.90E+03 
Mean 3.33E+04 3.93E+00 
SD 5.13E+03 5.17E+03 
     P. aeruginosa C. albicans 
1 4.50E+05 0.00E+00 
2 7.88E+05 0.00E+00 
3 2.90E+05 0.00E+00 
Mean 5.09E+05 0.00E+00 
SD 2.54E+05 0.00E+00 
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Total CFU/ml counts for aerobic and anaerobic species, and C. albicans after 
exposure to CHX for 30 min, 1 h and 12 h (relation to figure 5.13, section 
5.3.5.1): 
 
 
  30 min CHX exposure 
  Aerobic spp. Anaerobic spp. C. albicans 
1 4.61 4.79 2.68 
2 4.70 4.89 2.89 
3 4.88 4.95 3.04 
Mean 4.73 4.88 2.87 
SD 0.14 0.08 0.18 
SEM 0.08 0.05 0.10 
      1 h CHX exposure 
  Aerobic spp. Anaerobic spp. C. albicans  
1 4.58 4.71 2.60 
2 4.70 4.00 2.83 
3 4.69 4.95 2.94 
Mean 4.66 4.55 2.79 
SD 0.07 0.50 0.17 
SEM 0.04 0.29 0.10 
      12 h CHX exposure 
  Aerobic spp. Anaerobic spp. C. albicans  
1 3.28 3.48 2.60 
2 3.26 3.65 2.45 
3 3.48 3.08 2.48 
Mean 3.34 3.40 2.51 
SD 0.12 0.29 0.08 
SEM 0.07 0.17 0.05 
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Total CFU/ml counts of CDFF biofilms after exposure to different salivary 
pHs (relation to figure 5.16, section 5.3.6.1): 
 
  pH 4 
  Aerobic spp. Anaerobic spp. C. albicans  
1 5.30E+04 3.00E+04 8.00E+02 
2 2.70E+04 5.10E+04 5.00E+02 
3 3.50E+04 8.10E+04 6.20E+02 
Mean 3.83E+04 5.40E+04 6.40E+02 
SD 1.33E+04 2.56E+04 1.51E+02 
SEM 7.70E+03 1.48E+04 8.73E+01 
    
      pH 5 
  Aerobic spp. Anaerobic spp. C. albicans  
1 2.50E+04 3.80E+04 1.20E+03 
2 3.00E+04 3.90E+04 8.20E+02 
3 4.90E+04 3.40E+04 7.90E+02 
Mean 3.47E+04 3.70E+04 9.37E+02 
SD 1.27E+04 2.65E+03 2.29E+02 
SEM 7.32E+03 1.53E+03 1.32E+02 
  
 
 
   pH 6.5 
  Aerobic spp. Anaerobic spp. C. albicans  
1 2.30E+04 7.70E+04 4.00E+02 
2 1.30E+04 7.90E+04 4.20E+02 
3 1.90E+04 6.10E+03 4.00E+02 
Mean 1.83E+04 5.40E+04 4.07E+02 
SD 5.03E+03 4.15E+04 1.15E+01 
SEM 2.91E+03 2.40E+04 6.67E+00 
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CFU/ml counts of S. aureus inoculated CDFF biofilms after exposure to 
different salivary pHs: 
 
pH 4    S. aureus  C. albicans Aerobic sp. Anaerobic sp. 
 
1 0.00E+00 9.10E+07 1.30E+08 8.00E+07 
 
2 0.00E+00 1.10E+08 8.90E+07 8.90E+07 
 
3 0.00E+00 1.20E+08 9.90E+07 9.00E+07 
 
4 0.00E+00 1.30E+08 1.40E+08 9.90E+07 
 
5 0.00E+00 9.60E+07 1.50E+08 1.30E+08 
 
6 0.00E+00 9.80E+07 1.20E+08 1.40E+08 
 
Mean 0.00E+00 107500000 121333333.3 104666666.7 
 
SD 0.00E+00 15254507.53 23627667.4 24459490.32 
  SEM 0.00E+00 6.23E+06 9.65E+06 9.99E+06 
       pH 5   S. aureus  C. albicans Aerobic sp. Anaerobic sp. 
 
1 3.00E+07 7.30E+07 1.20E+08 1.40E+08 
 
2 3.30E+07 6.10E+07 9.80E+07 9.00E+07 
 
3 3.00E+07 7.70E+07 8.10E+07 1.10E+08 
 
4 4.50E+07 7.00E+07 9.00E+07 8.90E+07 
 
5 3.30E+07 4.90E+07 1.10E+08 9.00E+07 
 
6 3.00E+07 5.00E+07 1.10E+08 1.30E+08 
 
Mean 3.35E+07 6.33E+07 1.02E+08 1.08E+08 
 
SD 5.82E+06 1.19E+07 1.45E+07 2.25E+07 
  SEM 2.38E+06 4.88E+06 5.92E+06 9.17E+06 
      pH 6.5    S. aureus  C. albicans Aerobic sp. Anaerobic sp. 
 
1 3.30E+09 3.00E+07 1.10E+10 1.90E+10 
 
2 3.60E+09 4.70E+07 1.20E+10 1.10E+10 
 
3 2.90E+09 5.90E+08 9.90E+09 1.20E+10 
 
4 3.40E+09 5.00E+06 1.10E+10 2.00E+10 
 
5 3.00E+09 3.80E+08 1.00E+09 1.10E+10 
 
6 3.10E+09 4.00E+08 8.90E+09 1.20E+10 
 
Mean 3.22E+09 2.42E+08 8.97E+09 1.42E+10 
 
SD 2.64E+08 2.47E+08 4.05E+09 4.17E+09 
  SEM 1.08E+08 1.01E+08 1.65E+09 1.70E+09 
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CFU/ml counts of P. aeruginosa inoculated CDFF biofilms after exposure to 
different salivary pHs: 
 
pH 4   P. aeruginosa  C. albicans 
Aerobic 
spp. Anaerobic spp. 
 
1 8.77E+00 7.48E+00 9.28E+00 9.94E+00 
 
2 8.80E+00 7.48E+00 9.11E+00 9.94E+00 
 
3 8.90E+00 7.48E+00 9.18E+00 9.98E+00 
 
4 8.78E+00 7.52E+00 9.26E+00 1.00E+01 
 
5 8.79E+00 7.54E+00 8.96E+00 1.01E+01 
 
6 8.76E+00 7.71E+00 9.11E+00 1.00E+01 
 
Mean 8.80E+00 7.53E+00 9.15E+00 1.00E+01 
 
SD 4.98E-02 8.96E-02 1.15E-01 7.65E-02 
  SEM 2.03E-02 3.66E-02 4.68E-02 3.12E-02 
      
pH 5   P. aeruginosa  C. albicans 
Aerobic 
spp. Anaerobic spp. 
 
1 0.00E+00 7.48E+00 7.91E+00 7.63E+00 
 
2 0.00E+00 7.57E+00 8.00E+00 8.11E+00 
 
3 0.00E+00 7.85E+00 8.00E+00 8.08E+00 
 
4 0.00E+00 7.56E+00 8.00E+00 8.00E+00 
 
5 0.00E+00 7.89E+00 8.59E+00 8.08E+00 
 
6 0.00E+00 7.89E+00 8.00E+00 7.83E+00 
 
Mean 0.00E+00 7.70E+00 8.08E+00 7.95E+00 
 
SD 0.00E+00 1.89E-01 2.52E-01 1.89E-01 
  SEM 0.00E+00 7.71E-02 1.03E-01 7.70E-02 
      
pH 6.5   P. aeruginosa  C. albicans 
Aerobic 
spp. Anaerobic spp. 
 
1 8.77E+00 7.48E+00 9.28E+00 9.94E+00 
 
2 8.80E+00 7.48E+00 9.11E+00 9.94E+00 
 
3 8.90E+00 7.48E+00 9.18E+00 9.98E+00 
 
4 8.78E+00 7.52E+00 9.26E+00 1.00E+01 
 
5 8.79E+00 7.54E+00 8.96E+00 1.01E+01 
 
6 8.76E+00 7.71E+00 9.11E+00 1.00E+01 
 
Mean 8.80E+00 7.53E+00 9.15E+00 1.00E+01 
 
SD 4.98E-02 8.96E-02 1.15E-01 7.65E-02 
  SEM 2.03E-02 3.66E-02 4.68E-02 3.12E-02 
 
 		
